{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "outputs": [],
   "source": [
    "#!/usr/bin/env python\n",
    "\n",
    "\"\"\"clip_classes.py: Contains the CLIPDataset and CLIPTrainer wrapper\"\"\"\n",
    "\n",
    "__author__ = \"Christoper Alexander\"\n",
    "__copyright__ = \"Copyright 2023\"\n",
    "__credits__ = [\"Andrew D'Amico\", \"Christoper Alexander\", \"Katya Nosulko\", \"Vivek Chamala\", \"Matthew Conger\"]\n",
    "__license__ = \"\"\n",
    "__version__ = \"0.0.1\"\n",
    "__maintainer__ = \"Andrew Damico\"\n",
    "__email__ = \"andrew.damico@u.northwestern.edu\""
   ],
   "metadata": {
    "collapsed": false
   }
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0f9343d9",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "import unicodedata\n",
    "\n",
    "from Bio import Entrez\n",
    "from bs4 import BeautifulSoup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "aea08597",
   "metadata": {},
   "outputs": [],
   "source": [
    "def strip_html_tags_from_string(my_string: str) -> str:\n",
    "    soup = BeautifulSoup(my_string, 'html.parser')\n",
    "    return soup.get_text()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "a1856c93",
   "metadata": {},
   "outputs": [],
   "source": [
    "def remove_tags_and_content(text):\n",
    "    # This regular expression pattern will match both opening and closing HTML/XML tags,\n",
    "    # as well as their content (including nested tags).\n",
    "    pattern = r'<[^>]*>[^<]*</[^>]*>|<[^/>]+/>'\n",
    "\n",
    "    # Use the re.sub function to replace all matches of the pattern with an empty string.\n",
    "    cleaned_text = re.sub(pattern, '', text)\n",
    "\n",
    "    return cleaned_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "900f6227",
   "metadata": {},
   "outputs": [],
   "source": [
    "def remove_tags_and_content2(text):\n",
    "    soup = BeautifulSoup(text, 'html.parser')\n",
    "\n",
    "    # Find all tags in the soup\n",
    "    for tag in soup.find_all(True):\n",
    "        # Extract the tag's parent and replace the tag with an empty string\n",
    "        tag.extract()\n",
    "\n",
    "    # Get the cleaned text\n",
    "    cleaned_text = soup.get_text()\n",
    "\n",
    "    return cleaned_text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "d506f716",
   "metadata": {},
   "outputs": [],
   "source": [
    "url_pattern = r\"http\\S+\"\n",
    "url_regexp = re.compile(url_pattern)\n",
    "\n",
    "\n",
    "def replace_urls_in_string(my_string: str) -> str:\n",
    "    # Replace a URL with the string \"URL\" \n",
    "    return url_regexp.sub(\"URL\", my_string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "67d9c05a",
   "metadata": {},
   "outputs": [],
   "source": [
    "def remove_special_chars(text):\n",
    "    # Replace newline characters and carriage returns with spaces\n",
    "    text = re.sub(r'[\\n\\r]', ' ', text)\n",
    "\n",
    "    # Remove non-standard UTF elements (e.g., \"\\xa0\", \"\\u2009\") by replacing them with a space\n",
    "    text = re.sub(r'[\\u00A0\\u2009\\xa0]', ' ', text)\n",
    "\n",
    "    # Replace multiple consecutive spaces with a single space\n",
    "    text = re.sub(r'\\s+', ' ', text).strip()\n",
    "\n",
    "    return text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "c98c4418",
   "metadata": {},
   "outputs": [],
   "source": [
    "def strip_corrupt_utf_from_string(my_string: str) -> str:\n",
    "    return ''.join([c if unicodedata.is_normalized('NFC', c) else ' ' for c in my_string])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "d70f9fc1",
   "metadata": {},
   "outputs": [],
   "source": [
    "punctuation_pattern = r'[-.,:;,!?\\'\"\\[\\]\\(\\)\\{\\}|\\\\`#\\$%@^&*_+<>“”—’‘/]+'\n",
    "punctuation_regexp = re.compile(punctuation_pattern)\n",
    "\n",
    "\n",
    "def strip_punctuation_from_string(my_string: str) -> str:\n",
    "    return punctuation_regexp.sub(\"\", my_string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "940ec169",
   "metadata": {},
   "outputs": [],
   "source": [
    "numbers_pattern = r'\\d+'\n",
    "numbers_regexp = re.compile(numbers_pattern)\n",
    "\n",
    "\n",
    "def strip_numbers_from_string(my_string: str) -> str:\n",
    "    return numbers_regexp.sub(\"\", my_string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "1719c315",
   "metadata": {},
   "outputs": [],
   "source": [
    "articles_pattern = '(\\s+)(a|an|the)(\\s+)'\n",
    "articles_regexp = re.compile(articles_pattern, re.IGNORECASE)\n",
    "\n",
    "\n",
    "def strip_articles_from_string(my_string: str) -> str:\n",
    "    return articles_regexp.sub(\" \", my_string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "52c9eb3a",
   "metadata": {},
   "outputs": [],
   "source": [
    "prepositions_pattern = '(\\s+)(about|above|across|after|against|along|among|around|at|away|before|behind|below|between|by|during|for|from|in|into|like|out|since|than|through|to|toward|under|until|upon|with|within|without)(\\s+)'\n",
    "prepositions_regexp = re.compile(prepositions_pattern, re.IGNORECASE)\n",
    "\n",
    "\n",
    "def strip_prepositions_from_string(my_string: str) -> str:\n",
    "    return prepositions_regexp.sub(\" \", my_string)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "cfc1f00f",
   "metadata": {},
   "outputs": [],
   "source": [
    "def clean_doc(document: str) -> str:\n",
    "    doc = remove_tags_and_content2(document)\n",
    "    doc = doc.strip()\n",
    "    doc = remove_special_chars(doc)\n",
    "    doc = replace_urls_in_string(doc)\n",
    "    doc = strip_corrupt_utf_from_string(doc)\n",
    "    doc = strip_punctuation_from_string(doc)\n",
    "    doc = strip_numbers_from_string(doc)\n",
    "    doc = strip_articles_from_string(doc)\n",
    "    doc = strip_prepositions_from_string(doc)\n",
    "    return doc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "dda15504",
   "metadata": {},
   "outputs": [],
   "source": [
    "BASE_QUERY = 'medline[sb] AND \"open access\"[filter]'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "7a1dbbb3",
   "metadata": {},
   "outputs": [],
   "source": [
    "def search(query, db=\"pmc\"):\n",
    "    Entrez.email = \"christopheralexander2023@u.northwestern.edu\"\n",
    "    new_query = f\"{query} AND {BASE_QUERY}\"\n",
    "    handle = Entrez.esearch(db=db,\n",
    "                            sort=\"relevance\",\n",
    "                            retmax=\"20\",\n",
    "                            retmode=\"xml\",\n",
    "                            term=new_query,\n",
    "                            usehistory=\"y\")\n",
    "    results = Entrez.read(handle)\n",
    "    return results\n",
    "\n",
    "\n",
    "def fetch_details(results):\n",
    "    ids = ','.join(results[\"IdList\"])\n",
    "    Entrez.email = \"christopheralexander2023@u.northwestern.edu\"\n",
    "    handle = Entrez.efetch(db=\"pmc\",\n",
    "                           rettype=\"full\",\n",
    "                           retmode=\"xml\",\n",
    "                           id=ids,\n",
    "                           webenv=results[\"WebEnv\"],\n",
    "                           query_key=results[\"QueryKey\"])\n",
    "    docs = Entrez.read(handle)\n",
    "    return docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "e452ab92",
   "metadata": {},
   "outputs": [],
   "source": [
    "def process_section(section):\n",
    "    if not section.get(\"sec\", []):\n",
    "        return [section]\n",
    "\n",
    "    result = []\n",
    "    subs = section[\"sec\"]\n",
    "    if isinstance(subs, list):\n",
    "        for sub in section[\"sec\"]:\n",
    "            result.extend(process_section(sub))\n",
    "    else:\n",
    "        return [subs]\n",
    "\n",
    "    return result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "0d643835",
   "metadata": {},
   "outputs": [],
   "source": [
    "def process_query(query):\n",
    "    results = search(query)\n",
    "    docs = fetch_details(results)\n",
    "\n",
    "    processed_docs = []\n",
    "\n",
    "    for i, doc in enumerate(docs):\n",
    "        doc_dict = {}\n",
    "        counter = 0\n",
    "        for section in process_section(doc[\"body\"]):\n",
    "            title = section.get(\"title\", \"no_title\")\n",
    "            if not title:\n",
    "                title = \"no_title\"\n",
    "            sec_id = section.attributes.get(\"id\", \"no_id\")\n",
    "            string_elements = section[\"p\"]\n",
    "            if isinstance(string_elements, list):\n",
    "                for string_element in section[\"p\"]:\n",
    "                    text = str(string_element)\n",
    "                    sub_id = string_element.attributes.get(\"id\", \"no_sub_id\")\n",
    "                    doc_dict[(title, sec_id, sub_id, counter)] = clean_doc(text)\n",
    "                    counter += 1\n",
    "        processed_docs.append(doc_dict)\n",
    "        print(f\"processed {i + 1} docs\")\n",
    "\n",
    "    return processed_docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "7e2d21ff",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "processed 1 docs\n",
      "processed 2 docs\n",
      "processed 3 docs\n",
      "processed 4 docs\n",
      "processed 5 docs\n",
      "processed 6 docs\n",
      "processed 7 docs\n",
      "processed 8 docs\n",
      "processed 9 docs\n",
      "processed 10 docs\n",
      "processed 11 docs\n",
      "processed 12 docs\n",
      "processed 13 docs\n",
      "processed 14 docs\n",
      "processed 15 docs\n",
      "processed 16 docs\n",
      "processed 17 docs\n",
      "processed 18 docs\n",
      "processed 19 docs\n",
      "processed 20 docs\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/opt/homebrew/Caskroom/miniforge/base/envs/biomed/lib/python3.10/site-packages/bs4/__init__.py:435: MarkupResemblesLocatorWarning: The input looks more like a filename than markup. You may want to open this file and pass the filehandle into Beautiful Soup.\n",
      "  warnings.warn(\n"
     ]
    }
   ],
   "source": [
    "test = process_query(\"cancer\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "7dcd90d4",
   "metadata": {},
   "outputs": [],
   "source": [
    "results = search(\"cancer\")\n",
    "docs = fetch_details(results)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "731e634b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'sec': DictElement({'title': {}, 'p': DictElement({}, attributes={'id': 'para430'})}, attributes={'id': 'cesec80'})}"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "docs[0][\"body\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "2d0e1f8b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{},\n",
       " {('Introduction',\n",
       "   'Sec1',\n",
       "   'Par94',\n",
       "   0): 'Malignant neoplasms or any neoplasm central nervous system occurring children and adolescents age of  years are defined as childhood cancer IARC  Despite extensive research on this topic risk factors sporadic childhood cancer remain largely unknown Thun et al  Inherited genetic predispositions only account of childhood cancer cases Saletta et al  Such predispositions can affect pathways that are needed radiationresponse course of treatment first primary neoplasm Saletta et al  Vogelstein et al  Genotoxic cancer therapies using cytostatic drugs and ionizing radiation IR high doses HDIR ≥  Gray Gy radiation therapy are established risk factors development of second primary neoplasms later life Spector et al  Tukenova et al  ScholzKreisel et al  Travis et al  Ron et al  Inskip et al  Meadows et al  Tucker et al  Young age exposure is additional and important risk factor iatrogenic second primary neoplasms Hodgson et al  Of all survivors of first primary neoplasm occurring age of  years Germany  develop second primary neoplasm years of first diagnosis ScholzKreisel et al incidence and survival rates of childhood cancer are increasing worldwide number of second primary neoplasms is expected increase as well ScholzKreisel et al  Kutanzi et al  Kaatsch et al  Contrary established cancer risk associated exposure HDIR carcinogenic potential of low doses of IR LDIR   Gy is still being discussed and controversial Inskip et al  Spycher et al  Cardarelli et al  Sutou  Ji et al  Luckey  Graupner et al  Ma et al  Velegzhaninov et al children studies suggest elevated leukemia risk association diagnostic applications of LDIR such as computed tomography Berrington de Gonzalez et al  Little et al  Despite potential risk not being fully understood LDIR are increasingly used medical diagnostics SmithBindman et al  Linet et al Germany diagnostic applications account about  of total radiation deposited organs per person and year  of  millisievert Claudia Hachenberger et al  Also radiation therapy unwanted but inevitable exposure LDIR outside primary radiation beam is regarded as additional risk factor second primary neoplasms besides impact of HDIR deposited tumor volume Diallo et al ',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par95',\n",
       "   1): 'Irrespective its dosage exposure IR causes variety of cellular responses primarily based on potent induction of deoxyribonucleic acid DNA damage Nikitaki et al  On cellular level radiationinduced DNA damage activates complex signaling cascades of DNA repair cell cycle regulation apoptosis senescence and immunogenic responses Mavragani et al induction of these signaling pathways is dosedependent Graupner et al  Velegzhaninov et al  Ghandhi et al  Tilton et al  Helm et al  whereby signaling pathways inactivation of cells apoptosis or premature senescence predominate HDIR Sokolov et al  Ding et al  Such mechanisms of radiationresponse can be measured changes gene expression Wahba et al  and ribonucleic acid RNAsequencing has shown be potent and precise method transcriptome analysis replacing probebased tools such as microarrays Kukurba et al  Studies that examined molecular response IR via transcriptome analysis have been conducted using vastly different cell types irradiation doses time points of extraction of messenger RNA mRNA and sequencingmethods depending on their research intent Sokolov et al  Ding et al  Ray et al  Yunis et al  Warters et al  Stecca et al previous work we have reported downregulation of  and nonirradiated Victor et al  and irradiated  Gy Weis et al  fibroblasts of former childhood cancer patients at least one second primary neoplasm N compared former childhood cancer patients first primary neoplasm only N Both of these genes are associated cellular response and repair of radiationinduced DNA damages These findings indicate compromised radiationresponse N that might be associated increased risk their second primary malignancies Additionally we hypothesize that former childhood cancer patients show differences transcriptional radiationresponse their skin fibroblasts compared those of cancerfree controls N date changes gene expression induced IR have not been examined and results have not been compared N and N using nextgeneration sequencing and subsequent pathway analysis',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par96',\n",
       "   2): 'The present study aimed unravel molecular mechanisms of susceptibilities sporadic cancer early childhood and therapyassociated second primary neoplasms related genotoxic radiationresponse this purpose we explored gene expression profiles using Illuminabased nextgeneration sequencing and N n =  N n =  and N n = exposure low and high dose of IR',\n",
       "  ('Study design and participants',\n",
       "   'Sec3',\n",
       "   'Par97',\n",
       "   3): 'The KiKme study is nested case–control study emphasis on interplay hereditary dispositions cellular reaction IR risk sporadic childhood cancer as well as therapyrelated second primary neoplasms to   participants were included study study population data collection and strategies recruitment were described elsewhere Marron et al experiments this project primary skin fibroblasts obtained skin biopsies of  participants KiKmestudy were used Table  Former childhood cancer patients registered German Childhood Cancer Registry ScholzKreisel et al  provided basis recruitment of cancer patients at least one second primary neoplasm and first primary neoplasms only Participants had be least  years old and diagnosed one first primary neoplasm childhood first primary neoplasm had be one of three most common childhood cancers including leukemia lymphoma or tumor of central nervous system second primary neoplasm had occur anatomic site potentially exposed radiation therapy such as thyroid carcinoma breast cancer skin carcinoma malignant melanoma leukemia or ependymomas and choroid plexus tumors Dracham et al addition  cancerfree controls were recruited patients undergoing elective surgery unrelated cancer Department of Orthopedic Surgery University Medical Center Mainz One longterm childhood cancer survivor at least one second primary neoplasm one second primary neoplasm and one cancerfree control were matched according age sampling as well as sex and then processed as triplets longterm cancer survivors of triplet were also matched according tumor entity as well as age and year of diagnosis of first primary neoplasm',\n",
       "  ('Samples and experiments',\n",
       "   'Sec4',\n",
       "   'Par98',\n",
       "   4): 'The acquisition of biosamples establishment of primary fibroblasts radiation experiments RNA extraction and processing as well as analysis differentially expressed genes DEGs have been described depth elsewhere Marron et al  Brackmann et al summary fibroblasts were obtained via skin biopsies former childhood cancer patients as mm punch biopsy inside of cubital region Samples cancerfree controls were taken scar region of surgery Primary fibroblasts were expanded biopsies – days and cryopreserved radiation experiments cells were thawed cultured and synchronized G confluency overview of experimental workflow is provided as Fig  Cells were exposed room temperature dose of  Gy kilovolt Xrays dose rate of  Gy per minute or Gy kilovolt Xrays dose rate of  Gy per minute using D Xray Therapy System Gulmay Medical Ltd Byfleet UK This was achieved reducing voltage kilovolt and sourcetotarget distance of  cm Thus exposure times were  and  min HDIR and LDIR respectively Shamirradiated cells were kept same conditions radiation device control room Cells matched triplets were cultivated and treated simultaneously prevent batch effects groups mRNA was extracted four hours radiation exposure previous work we showed highest number of DEGs fibroblasts this time point overall observational period of  min h postexposure IR Brackmann et al mRNAsequencing RNASeq libraries were processed on HiSeq instrument Illumina San Diego California USA set highoutput mode Singleend reads length of  base pairs were generated using Illumina San Diego California USA and Illumina San Diego California USA Base calling was performed Version  and resulting data were converted FASTQ format using Version  Illumina San Diego California USA',\n",
       "  ('Processing of RNA-Seq data',\n",
       "   'Sec5',\n",
       "   'Par99',\n",
       "   5): 'To detect DEGs and conduct pathway analysis RNASeq data were processed Marron et al  First was employed clean adapter sequences raw reads Bolger et al  Here quality of less was defined as threshold remove bases reads average quality less over  bases were trimmed Processed reads were aligned human reference genome GRCh using STARc Dobin et al number of aligned reads per gene seen as equal expression per gene was quantified using Liao et al  Data were then normalized using method Law et al ',\n",
       "  ('Analysis of differential gene expression',\n",
       "   'Sec6',\n",
       "   'Par100',\n",
       "   6): 'DEGs dependent on radiation dose were detected using linear models implemented package Ritchie et al  accounting individual donor as block variable as well as factors and differential gene expression irradiation was computed comparing measurements of fibroblasts of each participant measurements shamirradiation eg counts of transcripts cells of each individual Gy versus counts Gy Additional files   Differential expression was detected using three different models  crude model  considering age and sex model  and  considering age sex age and year of diagnosis of first neoplasm and tumor type model latter was used analysis N and N data only values were computed interaction effect of radiation and donor group as well as effect of radiation alone Genes value adjusted false discovery rate FDR Benjamini–Hochberg procedure Benjamini et al were flagged as significant further analyses multiple pairwise comparisons were calculated values separate analysis each donor group have be regarded as explorative',\n",
       "  ('Quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR)',\n",
       "   'Sec7',\n",
       "   'Par101',\n",
       "   7): 'Total RNAs were prepared treated and untreated fibroblast cultures using Nucleo Spin RNA Plus Kit Macherey–Nagel Düren Germany  µg of RNA samples were reversely transcribed complementary DNA using SuperScript IV FirstStrand random hexamer Synthesis System Invitrogen Waltham United States Exonspanning forward and reverse primers were designed PrimerBLAST Ye et al  or purchased Qiagen Hilden Germany depending on availability of primers Qiagen Additional file Transcripts of gene were used as endogenous reference gene control Each  µl reaction volume contained  ng complementary DNA or DNA template µl SybrGreen Master Mix Biozym  µl ribonucleasefree PCR graded water MN and  µl each of forward and reverse primer  µM All reactions were performed triplicate and two stages one cycle of  °C min first stage and  cycles of  °C s  s primerspecific melting temperature and  °C s second stage using LightCycler II Roche Amplification qualities were assayed using melting curves and agarose gel analysis qRTPCR amplification efficiency was calculated using LinReg program Ruijter et al  and cycle threshold values were corrected using mean amplification efficiency Relative quantification was carried with comparative cycle threshold method using endogenous control gene and control Gy calibration',\n",
       "  ('Ingenuity pathway and gene ontology analysis',\n",
       "   'Sec8',\n",
       "   'Par102',\n",
       "   8): 'Pathway analyses were conducted via Content Version  QIAGEN Inc  Krämer et al  As input lists of DEGs and corresponding genewise values adjusted FDR procedure as well as log foldchange LFC retrieved analysis of differential expression were used cutoff FDR was set settings were selected as Additional file Fishers Exact Test is employed compute significance of overlap of list of DEGs and gene list representing pathway Negative logarithms log of resulting values are reported and value of least  ≙ value = Benjamini–Hochberg correction was regarded as here Such pathways were marked as activation zscore threshold was set z ≥ Krämer et al zscore indicates pathway activation or inactivation comparing given expressional directions of pathway components information data set entered analysis If z ≥ pathway was marked as  Moreover pathways negative zscore ≤ − were marked as  pathways zscore ≥  were marked as ratio calculated as number of DEGs k per number of postulated genes pathway database K was documented as well some pathways zscore calculation was not possible z = Not number NaN This was either because of insufficient data database lack of information on expected direction of differential expression or information provided our data was not sufficient these pathways either activity prediction is not useful due its circular or multicellular nature or data are not sufficient proper calculation of zscore complete output analyses can be found Additional file all experiments molecular networks were extracted sake of legibility only networks network score   were included main body of this work as all data sets showed only – networks score of this magnitude next networks per donor group and dose combination reaching scores range of – full list can be found Additional file d was also employed predict upstream regulators These are transcription factors that are likely have induced DEGs and direction of differential expression Again Fishers Exact Test was used calculate value significance of overlap of DEGs and genes known be regulated specific transcription factor As described zscore prediction of activation state was calculated where applicable This method was also applied prediction of downstream functions and diseases Additional file c As pathway analyses results upstream and downstream analyses were adjusted using Benjamini–Hochberg procedure adjust FDR All results of pathway analyses model  are displayed heat maps Additional file comparison of differential expression values of genes per donor group and treatment analyzed pathways was also plotted as heat maps Additional file all analyzed pathways molecule activity prediction of was used Additional file  Moreover genes found network analysis were displayed heat map as well Additional file account even small effects interaction of radiation and donor group results of interaction analysis were filtered top  genes per donor group comparison regard value irrespective of significance threshold These gene sets were then analyzed overrepresentation using ConsensusPathDB Additional file e Kamburov et al gene background provided Additional file f resulting Gene Ontology GO terms were then summarized as well as displayed tree maps using REVIGO Supek et al allowed semantic similarity of  and organism set Additional file and b Moreover we filtered genes per comparison those lowest values of each respective data set value   or LFC additional sensitivity analyses DEGs and subsequent analyses were also computed data  stratified sex and adjusted age Additional file  and exclusion of selfreported nonCaucasian participants n =  prior computing DEGs using model  Additional file addition that we repeated analyses using only genes showing absolute changes larger compared expression levels Gy Additional file ',\n",
       "  ('Study participants',\n",
       "   'Sec10',\n",
       "   'Par103',\n",
       "   9): 'Primary fibroblasts of  donors were analyzed  N  N and  N Table median age of participants was  and  years sampling longterm survivors of childhood cancer at least one second primary neoplasm and respectively interquartile range IQR – years and  years IQR – years cancerfree controls each donor group   of participants were female longterm childhood cancer survivors median age diagnosis first primary neoplasm was  years IQR – years IQR – years median age diagnosis second primary neoplasm was  years IQR – years',\n",
       "  ('Differential gene expression after exposure to LDIR',\n",
       "   'Sec11',\n",
       "   'Par104',\n",
       "   10): 'In fibroblasts of all donor groups and all adjustment models crude modelmodel model  more genes were down upregulated exposure LDIR Fig The total number of DEGs was three times higher both N model   and N model   compared N model detailed list of DEGs LDIR is provided Additional file The amount of DEGs was similar adjusted models each group of donors Less half of all DEGs were upregulated all three groups all adjustment models reaction LDIR Fig N showed highest fraction of upregulated genes  model  albeit lowest amount n =  model  of total upregulated genes followed N  model  and N  model LDIR Compared female N and N and male N male N and N showed larger number of DEGs LDIR Additional file These were mostly centered value threshold of significance top genes regard value main analysis were differentially expressed all groups nevertheless Additional file b removal of selfreported nonCaucasian participants did not change results of differential expression analysis LDIR Additional file Moreover upregulated genes LDIR showed higher peaks concerning logvalue volcano plots Fig b Only upregulated genes showed value donor groups LDIR top  genes regard value LDIR are shown stratified donor group and LFCdirection Fig c All of highestranking upregulated genes were present all groups LDIR these topranking genes that were downregulated       and  were observed be only downregulated N and N  was only downregulated N Nevertheless qPCR conducted on subsample n =  per group did not confirm differential expression LDIR Additional file b previous work collective of KiKme study n =  per group Brackmann et al  we showed that groups  is upregulated LDIR Additional file c',\n",
       "  ('Differential gene expression after exposure to LDIR',\n",
       "   'Sec11',\n",
       "   'Par105',\n",
       "   11): 'Analysis interactions of effect of radiation dose and donor group was used identify genes showing differential reaction radiation exposure donor groups Only one gene showed differential reaction exposure LDIR Comparing N and N  was upregulated borderline significant value LFC  value =  crude model LDIR Table  All genes that were differentially expressed LDIR more one donor group showed same direction of differential expression Additional files b and b Comparing fibroblasts of cancer survivors N      and  were of interest based on extended criteria LDIR Table  Fig Comparing N N nine genes of interest were observed LDIR     uncharacterized     and  Due multiple occurrences of identical values filtering top  genes regard value per donor group comparison use GO enrichment analysis resulted more genes two instances n = NN vs N and n = N vs N All of these were used GO analyses',\n",
       "  ('Functional analysis of DEGs after exposure to LDIR',\n",
       "   'Sec12',\n",
       "   'Par106',\n",
       "   12): 'The overrepresentation analysis resulted distinct GO terms all comparisons of interactions radiation dose and donor group and can be found Additional files e and b Noteworthy N compared N showed large cluster of seven GO terms subsumed term  Comparing NN N and including  were largest clusters of GO terms three terms each',\n",
       "  ('Functional analysis of DEGs after exposure to LDIR',\n",
       "   'Sec12',\n",
       "   'Par107',\n",
       "   13): 'Data of DEGs per donor group radiation dose and adjustment model were used upstream analyses Fig  Additional file b We observed  as common predicted upstream regulator fibroblasts of all donor groups LDIR Additional file N and N showed be additional upstream regulator LDIR which was not significant correction false discovery',\n",
       "  ('Functional analysis of DEGs after exposure to LDIR',\n",
       "   'Sec12',\n",
       "   'Par108',\n",
       "   14): 'Correspondingly pathway analysis showed that was affected and activated LDIR however only N crude model and model  and N crude model and model  but not N Fig  Additional file b Here  and  were not differentially expressed N  and  only N Additional file b Using only DEGs LFC higher was not activated any donor group and only affected all donor groups and models but N model  Additional file this analysis and were inactivated all models of N sensitivity analysis were only affected N LDIR Downstream functions reaction LDIR N were predicted as well Fig  Additional file c These were   and   and   and  and   and  Except latter all of these were only present data of crude model whereas was also found model ',\n",
       "  ('Functional analysis of DEGs after exposure to LDIR',\n",
       "   'Sec12',\n",
       "   'Par109',\n",
       "   15): 'In each donor group and adjustment model one network score over  was identified in data LDIR treatment Fig  Additional files d and annotated functions of network N were   and crude model and model N annotations crude model and model  were  and LDIR model network included and LDIR N top diseases and functions were   and all models Together we observed trend towards activation of cell cycle control and DNA repair N and cell death and cancerassociated signaling pathways N following LDIR',\n",
       "  ('Differential gene expression after exposure to HDIR',\n",
       "   'Sec13',\n",
       "   'Par110',\n",
       "   16): 'As treatment LDIR there were more downregulated upregulated DEGs fibroblasts of all donor groups exposure HDIR Fig Additional file The total number of DEGs was slightly higher N and N compared N all adjustment models and number of DEGs per group differed only slightly adjustment models HDIR As reaction LDIR upregulated genes HDIR showed lower values compared downregulated genes Fig b model  only detail only upregulated genes showed value range of in all donor groups All of highestranking up and downregulated genes were found all groups HDIR Fig c model  only Here qRTPCR conducted for subsample n =  per group did confirm differential expression HDIR N Additional file b Also upregulation of and all groups present study has been previously confirmed us using qRTPCR Brackmann et al  Additional file c Neither stratifying sex nor prior removal of selfreported nonCaucasian participants did change results of differential expression main analysis exposure HDIR Contrary reaction LDIR several genes were differentially expressed when comparing response HDIR donor groups Table  Fig b Additional file b      and  were differentially expressed comparing fibroblasts of both cancer groups N HDIR model  Additionally  was differentially expressed comparing N N model  As gene expression LDIR general direction of gene expression HDIR genes that were commonly differentially expressed more one donor group was identical Additional files b and b additional filtering nonsignificant genes value smaller lowest values of respective data or LFC larger found five genes of interest comparison of cancer survivor groups HDIR uncharacterized locus and  Table  Fig b',\n",
       "  ('Functional analysis of DEGs after exposure to HDIR',\n",
       "   'Sec14',\n",
       "   'Par111',\n",
       "   17): 'Comparing reaction HDIR donor groups analysis GO term enrichment resulted several groupspecific differences Additional files e and b\\ufeff Comparing reaction of N N and N largest GO term clusters were and HDIR Comparing N and N largest cluster  terms was and comparing N N largest cluster  terms was comparison cancer groups N and N resulted two GO terms  and ',\n",
       "  ('Functional analysis of DEGs after exposure to HDIR',\n",
       "   'Sec14',\n",
       "   'Par112',\n",
       "   18): 'Fibroblasts of all donor groups had as predicted upstream regulator reaction HDIR Fig  Additional file main analysis Moreover was predicted be upstream regulator all adjustment models of N and N HDIR sensitivity analysis using LFC threshold of  was predicted be active upstream regulator zscore all models of N and N but not N Additional file  Additionally   Chromobox homolog   and  were inactivated  was activated upstream regulator all donor groups and all models HDIR based on prediction Only all models of N  was active upstream regulator',\n",
       "  ('Functional analysis of DEGs after exposure to HDIR',\n",
       "   'Sec14',\n",
       "   'Par113',\n",
       "   19): 'In pathway analysis of main analysis was found be affected HDIR Contrary LDIR it was affected all groups and models Moreover it was activated all groups and models except N crude model HDIR was inactivated all donor groups but not affected any model N Here  and  were only downregulated all models of N and N Additional file sensitivity analysis was activated both models N and affected all models of N and N Additional file  Here pathway was inactivated all models of all groups Moreover only sensitivity analysis   and were inactivated all models of all donor groups HDIR main analysis there were five pathways where zscore calculation was not possible that were affected at least one group pathway was affected all donor groups and models was affected N crude model and model all models of N and N all models N and N crude model and model HDIR',\n",
       "  ('Functional analysis of DEGs after exposure to HDIR',\n",
       "   'Sec14',\n",
       "   'Par114',\n",
       "   20): 'In analysis downstream diseases and bio functions Fig  Additional file c senescence  and  showed trend activation N and both crude model and model  N  all models and crude model inactivation HDIR N transformation  and  showed trend inactivation was found N all models trend inactivation N and N HDIR was found be downstream function N and N though not significant',\n",
       "  ('Functional analysis of DEGs after exposure to HDIR',\n",
       "   'Sec14',\n",
       "   'Par115',\n",
       "   21): 'Following HDIR associated functions network N all adjustments were   and Fig  Additional files d and N networks both adjustment models showed associated functions be  and HDIR N we observed two networks model  and model both adjustment models associated functions first respective network were and N second network N differed and was  and model  and and model ',\n",
       "  ('Exposure to LDIR',\n",
       "   'Sec16',\n",
       "   'Par117',\n",
       "   22): 'is most prominent pathway activated genotoxic stress eg shown irradiation of whole blood variety of doses and dose rates Ghandhi et al  Furthermore predicted downstream activities are line previous findings on response LDIR Ding et al our data activity prediction N and N was similar cell cycle progression apoptosis and DNA repair were increased cell survival being inactivated\\ufeff This pathway not being affected any model N and being only weakly affected N is important finding personalized risk assessment of application of LDIR diagnostics',\n",
       "  ('Exposure to LDIR',\n",
       "   'Sec16',\n",
       "   'Par119',\n",
       "   23): 'Results pathway analysis were further supported corresponding molecular networks and their attributed functions and diseases where N and N had as associated function while only N included LDIR key molecule others network of N was important functions excision repair and cell fate decision Sugasawa et al  Stoyanova et al  Additionally downstream functions and were only found N This implies that if insufficient or no apoptotic response occurs induced genomic mutations may be transmitted following generations carrying potential carcinogenic risk inducing resistance and increased DNA damage tolerance Multiple exposures LDIR could then amplify this effect Martin et al ',\n",
       "  ('Exposure to LDIR',\n",
       "   'Sec16',\n",
       "   'Par120',\n",
       "   24): 'We additionally hypothesize that high difference number of DEGs following LDIR N and NN may implicate undirected reaction N and N including expression of genes necessity radiationresponse while N react more precise manner Interestingly stratifying sex this was found only male N and N whereas number of DEGs female N and N was similar those male and female N LDIR Sexspecific differences radiationresponse have been proposed Alsbeih et al  Nevertheless further research is needed elaborate on such differences fibroblasts of childhood cancer survivors LDIR',\n",
       "  ('Exposure to HDIR',\n",
       "   'Sec17',\n",
       "   'Par121',\n",
       "   25): 'After HDIR our most important finding was that was affected and activated all models of N and N but not activated crude model or N When we applied LFCthreshold only N showed activation of this pathway inactivation of pathway HDIR N and N was line radiationinduced G arrest as Pololike kinases are amongst others responsible GStransition Zitouni et al notable difference N was upregulation of HDIR N and N donors that has been previously described various pathological conditions Zuehlke et al  and stabilization of Pololike kinase  Future efforts are needed investigate this signal detail order validate our findings was affected all donor groups HDIR and cell survival was inactivated via radiationtriggered activation of a welldocumented mechanism Pordanjani et al N and N cell cycle progression was inactivated and apoptosis was activated HDIR Remarkably we observed inverse response HDIR N that was mediated upregulation of different isoforms of protooncogene promote radiation resistance fostering DNA repair survival and proliferation Sahlberg et al  Hollander et al  Here activation of cell cycle progression and inactivation of apoptosis may lead accumulation of DNAdamage that is subsequently carried on further cellular generations',\n",
       "  ('Comparison of the reactions to LDIR and HDIR',\n",
       "   'Sec18',\n",
       "   'Par122',\n",
       "   26): 'In reaction LDIR limited subset of genes has been found be consistently upregulated other studies Sokolov et al  which is activated dependent manner and plays pivotal role cell cycle arrest Sokolov et al  Maier et al  Kabacik et al  proposed set of genes be positively associated radiation response and  h following HDIR  and  Gy cultured lymphocytes and peripheral whole blood them       and results upregulation of these genes LDIR or HDIR were confirmed present work all donor groups Comparing prediction of pathwayspecific downstream activity of  results were similar LDIR and HDIR both treatments activation of apoptosis and downregulation of cell survival was inferred However was activated LDIR and inactivated HDIR which may be rooted cellular effort rather repair induce apoptosis lower genotoxic insult that LDIR entails compared HDIR',\n",
       "  ('Interactions between radiation dose and donor groups',\n",
       "   'Sec19',\n",
       "   'Par123',\n",
       "   27): ' only gene borderline significant value when comparing groupspecific differential expression reaction LDIR comparing N and N crude model has been shown be involved cancer Luan et al  stress reaction species Mollet et al  and cardiac hypertrophy Song et al genes differentially expressed HDIR N N vs N and N vs N were associated regulation of apoptosis  Pan et al  survival chronic lymphocytic leukemia  Plešingerová et al  Plesingerova et al  prevention of accumulation of reactive oxygen species  Wang et al  cell growthproliferation heat shock response and tumorigenesis  also known as  which is methylated Vera et al  Liu et al ',\n",
       "  ('Strengths and limitations',\n",
       "   'Sec20',\n",
       "   'Par124',\n",
       "   28): 'To best of our knowledge this is first study that examined genomewide transcriptome response IR primary fibroblasts of large group of former childhood cancer patients compared cancerfree controls Moreover participants were carefully matched sex age sampling as well as age and type of first cancer diagnosis account largest sources of variation addition cases were matched year of diagnosis account differences treatment Following our previous work we used fibroblasts skin biopsies that were collected large welldefined pool of cell donors n =  Marron et al  Unlike other studies we chose not use commercial cell lines Velegzhaninov et al  Ding et al  Mezentsev et al  Hou et al  Ghandhi et al  Jen et al  Although commercial cell lines may be well researched they do not adequately depict intrinsic individual biological variability Therein also lies limitation as this unknown variation might have influenced our results Our study controlled this aforementioned careful matching of subjects accounting variation R software package  and adjustment of differential expression factors that introduce most variation such as age and sex Despite other cell types being more accessible such as lymphocytes via venipuncture we chose fibroblasts perform our radiation experiments on because survival and cultivation of lymphocytes immortalization EpsteinBarr virus transformation is very limited Neitzel  Additionally untransformed fibroblasts keep intact cell cycle that may provide more complete analysis of gene expression even confluency Moreover as some of our participating longterm childhood cancer survivors have received bone marrow transplants blood samples would have contained foreign blood cells of bone marrow donors Victor et al  This would have precluded analysis of germline mutations which was our main aim Finally pathways were analyzed using  This steadily updated and curated database allows analysis of complex RNAsequencing data It gives insight beyond expression of single genomic features incorporating measurements and inferring further information transcriptional patterns provided Moreover we conducted sensitivity analyses such as exclusion of selfreported nonCaucasian participants which did not change results of this study LDIR or HDIR This came unsurprisingly as date there is no data that reports on disparities radiationresponse based on ethnicity Despite strengths mentioned important issues radiation carcinogenesis such as systemic or nontargeted radiation effects bystander effect or genomic instability Mavragani et al  were not addressed our work We aimed provide initial results future studies using primary cells and performing radiation experiments vitro It was essential examine basic cellular events accounting highly complex intercellular or systemic effects As this is important factor radiationrelated adverse effects and carcinogenesis we aim address these important issues future works tissues cellular networks and different cell types particular regard involvement of immune responsesystem Mavragani et al  ElSaghire et al  As design of study allowed only inclusion of longterm cancer survivors aggressive tumor entities high mortality rates could not be taken account However most cancers share constitutive characteristics such as autonomous and unlimited proliferation evasion of cell death or invasion of normal tissues Spector et al  This work investigated impact of two different radiation doses single time point postexposure low and high dose were chosen simulate clinically relevant exposure radiologic examinations or radiation therapy respectively Pearce et al  Seidlitz et al  Even though gene expression patterns LDIR show dynamic transient response h postradiation Albrecht et al  Berglund et al  we Brackmann et al  and others Yunis et al  Chaudhry et al  observed highest amount of DEGSs – h irradiation compared shamirradiated cells and we hence chose this time point of analysis our investigations Although dose rate effects transcriptome level are known radiation exposures such studies usually compare acute and very protracted irradiations latter is usually performed dose rates of few mGy per minute several hours desired cumulative dose is reached present study however both exposure scenarios very short irradiation times represent acute exposures Thus difference absolute dose is expected dominate impact on transcriptome but influence of varying dose rates HDIR and LDIR cannot be ruled In irradiation experiments human lymphocytes different dose rates  Gymin vs  Gymin had no effect on activation of same cumulative doses Ghandhi et al ',\n",
       "  ('Conclusion',\n",
       "   'Sec21',\n",
       "   'Par125',\n",
       "   29): 'In this study we report alterations radiationresponse primary fibroblasts of former childhood cancer patients compared cancerfree donors that were most pronounced reaction low dose of IR longterm survivors which developed subsequent second primary neoplasm Mechanisms directed genotoxic stress were activated same extent high dose all donor groups However radiation response was impaired low dose fibroblast of childhood cancer survivors This suggests increased risk adverse effects accumulation of DNAdamage following genotoxic insult that may subsequently lead carcinogenesis particularly fibroblasts of donors at least one second primary neoplasm This work provides foundation further projects and facilitates guided validatory works on proposed differences molecular mechanisms coping IR',\n",
       "  ('no_title', 'Sec22', 'no_sub_id', 30): ''},\n",
       " {('Methods',\n",
       "   'S1',\n",
       "   'P5',\n",
       "   0): 'We convened consensus conference of experts fields of cancer evolution and cancer ecology lay groundwork development of evolutionary and ecological classification system initial participants Maley Aktipis Graham Sottoriva Boddy Janiszewska Silva Gerlinger Anderson Brown and Shibata were faculty Evolution and Ecology of Cancer summer school funded Wellcome and held Wellcome Genome Campus Hinxton UK July of  Input all participants was solicited and discussion we identified areas of consensus Afterwards other leaders field were invited join effort coediting and discussing developing statement All authors reviewed and approved final statement Wellcome Genome Campus Advanced Courses and Scientific Conferences provided financial support consensus meeting We have named classification system their permission appreciation of Wellcomes support Please note that statement reflects opinions of authors and not necessarily those of Wellcome',\n",
       "  ('Goals and guiding principles',\n",
       "   'S2',\n",
       "   'P6',\n",
       "   1): 'Our development of this framework has been guided several goals and principles We agreed that ideal classification system should have following properties First it must be able alter clinical decision point Second it should be simple enough be easily remembered and applied Third it should also align our current understanding of dynamics of neoplasms Fourth classification system should be general enough be applied different types of neoplasm recognizing that types of measurement may need be individualized given type of cancer',\n",
       "  ('Goals and guiding principles',\n",
       "   'S2',\n",
       "   'P7',\n",
       "   2): 'This framework is based on fundamental theoretical principles underlying evolutionary and ecological dynamics It is not based on any particular assay or parameter but rather captures fundamental drivers of tumour evolution This is necessary first step that we hope will lead many methodological and measurement innovations quantify key components of tumour evolution and ecology that we identify here Because evolution of cancer is still relatively new field there is still uncertainty best ways measure and describe evolution and ecology of tumour',\n",
       "  ('Goals and guiding principles',\n",
       "   'S2',\n",
       "   'P8',\n",
       "   3): 'There are also practical considerations construction of classification system If tumour could be classified based on single biopsy standard assays such as those that can be done on formalinfixed paraffinembedded FFPE tissue or standard radiological images translation clinic would be relatively easy However studies have not yet been done test whether measures of evolvability of tumour single biopsy sample are sufficient or whether multiple samples substantially improve predictions of clinical outcomes We hypothesize that we will need extensively sample neoplasms over both space and time order accurately quantify their evolvability but this remains open question It is clear however that evolutionary analyses are limited if clonal structure of primary tumour is unknown use of cellfree DNA cfDNA liquid biopsy samples should facilitate longitudinal studies although deconvoluting clones such mixed sample remains challenge',\n",
       "  ('Framework for classifying tumour evolution',\n",
       "   'S3',\n",
       "   'P9',\n",
       "   4): 'There are many wellestablished ways classify tumours largely based on extent of spread and morphological appearances example stage and grade evolutionary classification system would augment current schemes further capturing evolvability of tumour How much intrinsic genetic instability does it have How likely is it respond quickly new selective pressure such as therapeutic intervention example rapid progression chemotherapy is probably driven preexisting resistant variants and therefore failure is more likely tumours more subclonal diversity intratumoural heterogeneity Moreover it would be useful classify evolution time example second biopsy same patient therapy may reveal minimal diversity indicating recurrent tumour derived single clone or substantial diversity suggesting intrinsic resistance majority of tumour cells There was widespread agreement consensus conference that both evolutionary dynamics of neoplastic cells themselves cancer cell intrinsic factors and microenvironment that defines ecology of those cells cancer cell extrinsic factors are important predicting future behaviour and response of tumour capture this we have developed framework both evolutionary index Evoindex that describes intrinsic evolvability of neoplastic cell population and ecological index Ecoindex that describes potential selective pressures imposed surrounding microenvironment',\n",
       "  ('Diversity',\n",
       "   'S5',\n",
       "   'P11',\n",
       "   5): 'The heterogeneity that is currently present population defines its capacity respond population level selective pressures This diversity is fuel engine of natural selection There are different forms of diversity including genetic diversity epigenetic diversity phenotypic diversity and functional diversity Genetic diversity can predict progression invasive cancers as well as recurrence and survival relationship diversity and clinical outcomes is not universally consistent different cancer types and can be complicated ',\n",
       "  ('Diversity',\n",
       "   'S5',\n",
       "   'P12',\n",
       "   6): 'Diversity can be proxy likelihood that resistant clone is present neoplasm We currently do not know all mutations and epigenetic alterations that make neoplastic cell resistant particular therapy and even those we do know are difficult detect if they are present only small region of tumour Compared homogeneous neoplasms diverse neoplasms are more likely harbour resistant clones and are also probably more likely evolve resistance future',\n",
       "  ('Diversity',\n",
       "   'S5',\n",
       "   'P13',\n",
       "   7): 'Multiple forms of diversity neoplasm may be clinically important not only as fuel natural selection but also as biomarkers of clinically targetable dynamics example if high levels of genetic diversity are indicative of high levels of moderately deleterious passenger mutations then suppressing mechanisms cell that buffer those deleterious effects such as chaperone proteins should preferentially harm neoplastic cells Alternatively diversity may be indicative of cooperation clones mechanisms such as cross feeding These mechanisms of cooperation are themselves potential therapeutic targets Theory suggests that targeting cancer cell cooperation should provide weaker selection resistance cytotoxic therapies',\n",
       "  ('Diversity',\n",
       "   'S5',\n",
       "   'P14',\n",
       "   8): 'It is likely that not all forms of diversity are equal and future work must test which are clinically relevant It may be case that measures of functional diversity or even phenotypic diversity are better predictors of clinical outcomes measures of genetic diversity as many genetic mutations will have no phenotypic consequence and ideal measures may vary tumour types',\n",
       "  ('Measuring diversity',\n",
       "   'S6',\n",
       "   'P15',\n",
       "   9): 'Of four components of classification framework largest number of methods has been developed measuring diversity intratumoural heterogeneity  There is large literature ecology on quantification of diversity overall diversity of large area or landscape gamma diversity can be broken down diversity local regions alpha diversity and differences regions beta diversity Inherent this definition is concept that measuring diversity requires defining spatial scale that one is examining One might define withinregion diversity as diversity measured biopsy sample while betweenregion diversity would account differences biopsy samples multi region sampling studies Alternatively one could take sample entire tumour perhaps using cfDNA and estimate diversity of entire population Most of studies date have focused on withinregion diversity or diversity of entire tumour use of ecological statistics measuring betweenregion diversity tumours remains relatively unexplored Established measures of differences microbial communities could possibly be applied measuring differences biopsy samples',\n",
       "  ('Measuring diversity',\n",
       "   'S6',\n",
       "   'P16',\n",
       "   10): 'There are many ways measure diversity and number of challenges measuring diversity neoplasms as discussed In Barrett oesophagus Merlo and colleagues tested many of those measures of diversity and found that high levels of diversity were predictive of progression cancer regardless of measure Because evolution is driven fitness outliers and it may take only one resistant cell diagnosis eventually cause drug resistance or relapse therapy much of predictive value of measuring diversity may lie long tail of rare clones Because of this we recommend using either count of number of clones species richness or Shannon index which equally weights number and relative abundance of clones quantify diversity',\n",
       "  ('Measuring diversity',\n",
       "   'S6',\n",
       "   'P17',\n",
       "   11): 'The feasibility of obtaining complete picture of diversity of neoplasm multiregion sampling or cfDNA varies tumour types Barrett oesophagus bladder cancer and prostate cancer multiregion sampling is part of current standard of care wellmixed neoplasm such as blood cancer single sample may be sufficient but it requires singlecell assays which have their own challenges other tumours that are difficult sample such as pancreatic cancers we are lucky get more one biopsy sample main challenge using cfDNA is detecting it serum cancers that have not yet metastasized although level of tumour cfDNA serum varies cancer types recent study was able detect tumour cfDNA of earlystage lung squamous cell carcinomas but only  of earlystage lung adenocarcinomas',\n",
       "  ('Measuring diversity',\n",
       "   'S6',\n",
       "   'P18',\n",
       "   12): 'The interpretation of diversity of neoplasm depends on context of its history neoplasm that has just been homogenized therapy that killed most of clones that neoplasm is different neoplasm that is homogeneous because it has very low mutation rate and has not had enough time accumulate many clones contrast high level of diversity neoplasm that has just passed therapeutic bottleneck may be sign that therapy selected mutator phenotype Because of this complication we agreed that we must measure how neoplasms are changing over time as well as diversity',\n",
       "  ('Change over time',\n",
       "   'S7',\n",
       "   'P19',\n",
       "   13): 'There are variety of ways that neoplastic cell population changes over time These include mutations natural selection and genetic drift One important parameter of change over time is mutation rate which describes how fast lineage accumulates new mutations Of course there are different mutation rates induced each mechanism genetic and epigenetic alteration including mutation signatures induced specific agents as well as telomere erosion nonhomologous recombination other forms of chromosomal instability CpG methylation and histone modifications Which mechanisms are relevant will depend on individual tumours and may vary different clones same tumour',\n",
       "  ('Change over time',\n",
       "   'S7',\n",
       "   'P20',\n",
       "   14): 'When we talk and measure mutation rates we are implicitly assuming that mutations happen regular rate Evolutionary biologists call these molecular clocks REF  However catastrophic mitosis can generate chromosomal alterations genome single event There is continuum regular gradual clocklike small alterations sporadic punctuated large alterations example lineage may evolve different mutation rates its history as happens evolution of mutator phenotype If cell lineage can change suddenly what used be called macromutation generating hopeful monster REF  then that tumour may have different capacity evolution compared tumour that is constrained evolve slow accumulation of mutations small phenotypic effects There is large cancer literature on genetic instability that is relevant here and evidence has shown that tumours extremely high mutation rates may have better prognosis tumours moderate rates High levels of genomic instability may make it difficult cell lineages maintain adaptive information encoded their genomes generating nonviable daughter cells and may also produce abundance of neoantigens that stimulate antitumour immune response Furthermore high mutation rates of single nucleotide variants can generate deleterious mutations leading fitness decline of neoplastic cell lineages form of Mullers ratchet This may even cause tumour regression some cases',\n",
       "  ('Change over time',\n",
       "   'S7',\n",
       "   'P21',\n",
       "   15): 'The genetic composition of population changes over time not only rate which mutations arise and genetic drift of those alleles but also action of natural selection Natural selection leads adaptations such as drug resistance that are clinically relevant Detecting and measuring natural selection is likely be important component of our future clinical management of cancers',\n",
       "  ('Change over time',\n",
       "   'S7',\n",
       "   'P22',\n",
       "   16): 'The classification of neoplasms change over time Δ will probably need take account both speed which tumour acquires genetic or epigenetic alterations or changes phenotypically including how fast clones spread natural selection as well as tempo of that change gradual punctuated appropriate intervals longitudinal sampling will depend on rate of change over time Note that neutral or passenger mutations should not be ignored these calculations because selective pressures change over time particularly onset of therapy Thus resistance mutations which may be deleterious or neutral absence of therapy can become selectively advantageous neoplastic cells exposed therapy',\n",
       "  ('Measuring change over time',\n",
       "   'S8',\n",
       "   'P23',\n",
       "   17): 'Measuring change over time is complicated whether it is genetic or phenotypic change  illustrates simple version of how Evoindex can describe evolutionary changes tumour cell populations It is possible there be change over time but diversity remain stable dynamic equilibrium of clones appearing and going extinct single samples past genetic changes over time can be indirectly inferred based on mutation frequencies Sottoriva and Graham have pioneered methods infer mutation rate and distinguish tumours that are dominated genetic drift versus those evidence of natural selection transformation absence of selection mutations that occur first cell division transformation should appear approximately onehalf of all cancer cells mutations that occur second round of cell division should appear onequarter of all cancer cells and so on',\n",
       "  ('Measuring change over time',\n",
       "   'S8',\n",
       "   'P24',\n",
       "   18): 'There are number of measures of genetic change over time population genetics that might be used on neoplasms including Neis standard genetic distance and Jaccard similarity coefficient as well as measures of beta diversity that can also quantify changes community over time such as UniFrac or fixation index degree of genetic divergence samples called nucleotide diversity molecular population genetics provides indirect information on degree of change over time Genetic divergence is often defined as percentage of genome that is different pairs of samples This statistic provides predictive power independent of number of clones predicting progression supporting framework of including both diversity and change over time Evoindex Note that same clonal structure can have radically different degrees of genetic divergence  Maley and colleagues have calculated mean pairwise divergence score all pairs of samples neoplasm As chance that two samples come same clone and so have minimal divergence depends on size of clone mean pairwise divergence blends degree of divergence clone size measures and so blends D Δ',\n",
       "  ('Measuring change over time',\n",
       "   'S8',\n",
       "   'P25',\n",
       "   19): 'One of primary tools measuring change over time evolutionary biology is phylogenetic inference which reconstructs history of neoplasm Phylogenetic methods can be used describe and quantify diversity patterns as well as rates of evolution both space and time Multiple phylogenetic approaches have been developed recent years study tumour evolution patient both bulk and singlecell data and variety of data types These methods depend on evolutionary models likelihood of molecular alterations occurring neoplastic cell lineages although development of these models is still its infancy',\n",
       "  ('Measuring change over time',\n",
       "   'S8',\n",
       "   'P26',\n",
       "   20): 'All of measures discussed so far can be calculated single timepoint Of course degree and nature of change over time can be better measured directly longitudinal samples Minimally invasive assays such as sequencing cfDNA longitudinal blood samples could reveal action of natural or artificial selection patients',\n",
       "  ('Measuring change over time',\n",
       "   'S8',\n",
       "   'P27',\n",
       "   21): 'Incorporation of Evoindex clinical trials can better describe evolutionary terms why interventions fail Most human tumours time of clinical presentation contain multiple large clones and probably many more small clones and relapse reduction diversity would probably imply intrinsic resistance or perhaps that intervention resulted increased mutagenesis contrast relapse less diversity D implies bottleneck effect where only minority of tumour cells survived intervention probably indicating selection one or few resistant clones',\n",
       "  ('Hazards',\n",
       "   'S10',\n",
       "   'P30',\n",
       "   22): 'There are multiple sources of hazards neoplastic cells including immune cells toxins waste products microorganisms and anticancer therapies There is good evidence that immune predation is associated improved cancer prognosis Furthermore there is emerging evidence linking high mutation loads that result formation of neoantigens immune predation and better survival patients treated immune checkpoint blockade therapies addition high subclonal neoantigenic burden is associated worse outcomes lung cancer when patients are treated checkpoint inhibitors These data suggest that subclonal neoantigens might impede cytotoxic immune responses neoantigens that are present every tumour cell',\n",
       "  ('Hazards',\n",
       "   'S10',\n",
       "   'P31',\n",
       "   23): 'Other hazards faced neoplastic cells include accumulation of waste products their microenvironments This may include lactic acid and lactate buildup glycolysis as well as reactive oxygen species excessive cellular proliferation Methylglyoxal nitric oxide and advanced glycation end products have also been implicated as toxic waste products cancer microenvironments',\n",
       "  ('Hazards',\n",
       "   'S10',\n",
       "   'P32',\n",
       "   24): 'The role of microbiome cancer is complicated and largely unknown While some microorganisms may promote tumours others have antitumour effects enhancing efficacy of chemotherapy Thus microorganisms may act as both resources and hazards neoplastic cells',\n",
       "  ('Measuring hazards',\n",
       "   'S11',\n",
       "   'P33',\n",
       "   25): 'The current best measures of hazards neoplastic cell depend on measures of immune predation  There is large literature on association infiltrating lymphocytes and favourable prognosis cancer addition pancancer analysis revealed T cell signatures be broadly favourable prognostic markers cancer types Galon and colleagues have found that signature of activated T cells bulk tumour samples is also strongly predictive of favourable survival Yuan and colleagues have shown that haematoxylin and eosin images can be computationally analysed identify neoplastic cells fibroblasts and lymphocytes and furthermore that patients breast cancer who show colocalization of neoplastic cells lymphocytes tumour have better prognosis patients tumours which lymphocytes are separated neoplastic cells This is based on standard ecological statistic Morisita–Horn index quantifying statistically significant colocalization order detect ecological interactions this case predation These results suggest that immune predation is major form of hazard neoplastic cell and measures of that predation should be central component of ecological index',\n",
       "  ('Measuring hazards',\n",
       "   'S11',\n",
       "   'P34',\n",
       "   26): 'While much research has investigated potentially toxic effects of low pH REFS  fewer studies have examined fitness consequences cancer cells various metabolites Future research should determine effects of different concentrations of putative toxic metabolites on cancer cell survival and proliferation both cell culture experiments and mouse models Measurements of anticancer drug concentrations tumour are also likely quantify important hazards neoplastic cells addition microbiome including virome of tumours can be surveyed reveal microbial hazards neoplastic cells',\n",
       "  ('Resources',\n",
       "   'S12',\n",
       "   'P35',\n",
       "   27): 'Resources including oxygen glucose micronutrients survival signals growth signals and space are also critical future behaviour of tumour Surprisingly little is known interactions cell metabolism and availability of key resources which ecologists term organisms foraging ecology Almost all cancers rely on glycolytic as opposed aerobic metabolism suggesting that resources can select tumour phenotypes nature we know that selection favours feeding behaviours that balance speed efficiency and safety There must be strong selection cancer cells do same example upregulation of transporters such as glucose transporter type  erythrocytebrain GLUT also known as SLCA Measuring which resources limit population size and proliferation of neoplastic cells would allow researchers identify some of strongest selective pressures on tumour and predict how it will change future This approach would also provide targets further reducing evolvability of neoplasm lowering carrying capacity of its microenvironment',\n",
       "  ('Resources',\n",
       "   'S12',\n",
       "   'P36',\n",
       "   28): 'In broader ecological literature consumer–resource theory shows that resource supply depletion and availability affect population growth rates population sizes and competition different species that is distinct clonal lineages Resource supply represents rate which new resources enter system this case tumour and rate which resources become available nutrient cycling system aggregate consumption of all cells depletes resources typically levels much lower experienced normal tissues fact glucose becomes depleted levels detectable most analyses However some cases immune predation and fluctuations resource supply can prevent complete exploitation of resources leaving patches of residual resources available future exploitation',\n",
       "  ('Resources',\n",
       "   'S12',\n",
       "   'P37',\n",
       "   29): 'The potential resources tumour include contents of plasma and metabolites synthesized and secreted normal cells of tumour and its microenvironment Hence list includes proteins albumins globulins and fibrinogens glucose amino acids fatty acids hormones electrolytes oxygen and trace elements functional response and value of resources consumer are dictated nutritional relationships some cases lack of resource may trigger stasis but others it may lead cell death or dispersal moment there are many open questions intratumoural cycle of critical nutrients other carbon and nitrogen that is phosphate iron copper etc These nutrient cycles may contain valuable therapeutic targets',\n",
       "  ('Resources',\n",
       "   'S12',\n",
       "   'P38',\n",
       "   30): 'Some resources particularly growth and survival signals may be provided neighbouring stromal cells Nutrients may also be provided stroma Pyruvate and lactate can be supplied cancer cells activated fibroblasts and fatty acids may be supplied activated adipocytes Tumour and stroma only come physical contact when basement membrane is breached malignant neoplastic cells this stage cancer cells can directly interact cancerassociated fibroblasts which are known play key role regulation and development of tumours especially solid tumours this secretory reactive state fibroblasts facilitate not only cancer growth and progression but also treatment resistance addition their presence tumour has been correlated poor outcomes',\n",
       "  ('Resources',\n",
       "   'S12',\n",
       "   'P39',\n",
       "   31): 'Other resources must be delivered vasculature Folkman made crucial link angiogenesis and tumour invasion and metastasis realizing that preventing new vessels forming could be simple way inhibit further tumour growth presence many tumours of necrosis and hypoxia which are major drivers of angiogenesis attests importance of resource limitation tumours Furthermore there is evidence that necrosis is prognostic factor many cancers',\n",
       "  ('Resources',\n",
       "   'S12',\n",
       "   'P40',\n",
       "   32): 'The effects of resources on evolution of tumour are not defined simply their supply depletion and availability Resource diversity may also be important Whether resources are uniform space or heterogeneous patchy or exhibiting gradients makes difference Patchy resources and hazards create multiple habitats example rich and sparse regions that may select different clones that can survive those regions and may be differentially responsive and differentially exposed therapies Furthermore we and others have shown that if those patchy resources change over time then there is selective pressure on cells move escape regions of scarce resources and exploit transient regions of more plentiful resources Thus ecological theory predicts that heterogeneous resources should select invasion and metastasis and there is evidence support that prediction cancer Verduzco and colleagues found that intermittent exposure of some cell lines hypoxia selected increased resistance variety of chemotherapies including etoposide docetaxel and methotrexate compared unselected controls addition resource gradients often lead rapid evolution as organisms that are able invade more stressful environments can escape competition and flourish Much needs be learned resource heterogeneity consumer–resource dynamics and foraging ecology of neoplastic cells',\n",
       "  ('Measuring resources',\n",
       "   'S13',\n",
       "   'P41',\n",
       "   33): 'Measuring resources and hazards requires consideration of relevant spatial and temporal scales It is not yet clear how combine measures of level of resources their spatial variance and their stability over time single statistic',\n",
       "  ('Measuring resources',\n",
       "   'S13',\n",
       "   'P42',\n",
       "   34): 'There are various resources and methods measure them that may be prognostically relevant proportion of tumour that is necrotic or poorly perfused may be read standard positron emission tomography and computed tomography PET–CT images and other measures of blood vessel density degree and patchiness of hypoxia can also be assayed FFPE samples antibodies carbonic anhydrase  CA or hypoxiainducible factor α HIFα or via intravenous introduction of nitroHimidazolyl pentafluoropropyl acetamide EF and subsequent measurement of its binding tumour tissue EF binding and related techniques have proved useful clinic detecting regions of hypoxia determining prognosis and measuring response therapy While it is difficult measure glucose concentration directly indirect measure may be made via immunohistochemistry staining expression of GLUT Measures of ATP may also be good indirect measure of amount of resources available neoplastic cells Glutamine pyruvate lactate fatty acids calcium potassium phosphorus and various trace metals may also be limiting and important measure but this appears be unexplored Most of these measures will be limited biopsy samples analysed and thus will suffer problems of spatial heterogeneity and sampling error',\n",
       "  ('Measuring resources',\n",
       "   'S13',\n",
       "   'P43',\n",
       "   35): 'In some cases problem of spatial heterogeneity and sampling error can be avoided gross measures of resources radiological images Radiographic images such as those obtained using PET–CT and magnetic resonance imaging MRI can provide valuable habitat data natural systems there is usually tight correlation habitat and types and characteristics of species inhabiting habitat Similarly simply knowing different habitat types tumour may be prognostic of community of cancer cells and therapeutic outcomes instance glioblastoma measures of fluidattenuated inversion recovery FLAIR T and T MRI examinations gadolinium administration identified distinct habitats that correlated therapeutic outcome independent of tumour size Texture analysis of MRI scans has been used identify spatial heterogeneity and regional variations that are associated microenvironmental conditions including cell density tissue stiffness blood flow and nutrient dispersion These may also be used measure functional diversity D tumours Geographic information systems GIS and ecology provide rich literature and source of tools analysing spatial resource information but these are rarely utilized cancer research',\n",
       "  ('Measuring resources',\n",
       "   'S13',\n",
       "   'P44',\n",
       "   36): 'Standard histopathology can provide measures of T cell infiltration and vascular and lymphatic density Using digital pathology Lloyd investigated spatial distributions of oestrogen receptor ER expression relation vascular density and tissue necrosis breast cancer histology specimens revealing considerable regional variations cancer proliferation phenotypes accompanied vascularity and immune response Yuan and colleagues also used digital pathology analyse spatial relationships fibroblasts and neoplastic cells We have summarized statistics and assays measuring diversity change over time hazards and resources ',\n",
       "  ('A roadmap for improvements',\n",
       "   'S15',\n",
       "   'P47',\n",
       "   37): 'We are not yet position specify which measures and thresholds should be used determine DΔ or HR type of tumour Initial studies should test if these classifications significantly predict clinical outcomes and which evolutionary and ecological measures provide independent predictive value They should also test if there are measures that can apply cancer types or if they have be uniquely defined specific organs or tumour subtypes Future studies should test alternative measures of diversity change over time  hazards and resources help standardize useful metrics classifications They should also quantify improvements prognosis gained sampling multiple regions multiple timepoints',\n",
       "  ('A roadmap for improvements',\n",
       "   'S15',\n",
       "   'P48',\n",
       "   38): 'The ecology of tumour affects its evolution and evolution of cells tumour change their ecology Neoplastic cells evolve genomic instability generating neoantigens as well as adaptations such as recruitment of resources activating fibroblasts and neoangiogenesis Evolution of neoantigens triggers immune predation which may reduce diversity and select immune evasion High levels of extrinsic mortality and resources select rapid proliferation little investment somatic maintenance These interactions imply that not all possible combinations of ecological and evolutionary measurements are equally likely We will probably be able drop some of possible tumour types and focus on subset of classes that present clinic',\n",
       "  ('A roadmap for improvements',\n",
       "   'S15',\n",
       "   'P49',\n",
       "   39): 'The framework classification system that we have proposed could be incorporated clinical trials which could allow us gather data on how different types of evolving tumour respond different types of intervention  Clinical trials could then be developed stratify treatment of patients based on Evo and Ecoindices of their tumours We could use results develop guidelines best practice managing cancers',\n",
       "  ('Vision of the future',\n",
       "   'S16',\n",
       "   'P50',\n",
       "   40): 'In future pathology report neoplasm could include its Evoindex and Ecoindex classifications Ideally these classifications would provide chessboardlike scenarios where based on current evolutionary class of tumour one could anticipate how tumour type will change different possible therapeutic moves  Clinicians would then be able choose appropriate interventions evolvability of those neoplasms and would also be able track whether neoplasms change substantially response interventions DΔ tumour or even DΔ tumour would be prime candidate aggressive therapy curative intent fact DΔ tumour may be so evolutionarily indolent as not require any form of intervention On other hand DΔ tumour is likely have multiple resistant subclones present diagnosis and future clinical trials should test if such tumour can be managed strategies that minimize expansion of resistant subclones exploiting their disadvantage competition sensitive subclones legitimate clinical strategy might be downstage tumour highly evolvable one much more clinically manageable class that could be contained nonlethal state indefinitely  If validated Evo and Ecoindices could be used as surrogate measures overall survival or diseasefree survival',\n",
       "  ('Conclusions',\n",
       "   'S17',\n",
       "   'P51',\n",
       "   41): 'The evolutionary biology of cancer is clinically similar state psychiatry nineteenth century that time there was no standard classification system mental illness used practitioners such classification system it was difficult even talk illness let alone make progress as common language was lacking American Medical Associations Standard Classified Nomenclature of Disease published REF  and first Diagnostic and Statistical Manual of Mental Disorders published REF  no matter how flawed they were diagnoses of mental disorders became standardized which facilitated studies refine both classifications as well as treatment of those disorders Studies based on same classification system were then comparable which further facilitated metaanalyses and overall progress field',\n",
       "  ('Conclusions',\n",
       "   'S17',\n",
       "   'P52',\n",
       "   42): 'We have diagnostic categories types of tumour based on their tissue of origin and staging as well as some molecular markers but we have lacked system classifying evolvability and ecology of tumour which help determine how it will respond interventions and how it might best be managed Evolutionary oncology requires shared lexicon which base discovery We reached consensus on proposed framework classification system characterize evolutionary differences tumours that is applicable all cancer types Importantly evolutionary classification system will facilitate future efforts study this fundamental property of tumours reveal implications treatment'},\n",
       " {('1. Introduction',\n",
       "   'sec1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   0): 'The glycemic index GI is index of carbohydrate foods which indicates how quickly food causes increase blood glucose levels  High GI foods have fastrelease carbohydrates and higher blood glucose concentrations leading increased insulin secretion Low GI foods are digested absorbed and metabolized more slowly thus resulting more gradual rise blood glucose glycemic load GL is product of GI and total available carbohydrate content given amount of food It reflects both quality ie GI and quantity of carbohydrates ',\n",
       "  ('1. Introduction',\n",
       "   'sec1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   1): 'Postprandial glycaemia and consequently dietary GI and GL have been related diabetes coronary heart disease CHD and obesity ',\n",
       "  ('1. Introduction',\n",
       "   'sec1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   2): 'A possible role development of selected cancers has been also suggested  but evidence is yet weak  Longterm consumption of high GIGL diet results chronically high blood glucose and hence chronically elevated insulin concentration Insulin increases bioactive IGF which promote cancer development inhibiting apoptosis and stimulating cell proliferation addition hyperglycemia insulin resistance diabetes and obesity which are linked glucose metabolism may affect risk of cancer ',\n",
       "  ('1. Introduction',\n",
       "   'sec1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   3): 'In  we systematically reviewed data epidemiological reports addressing association dietary GI and GL and risk of cancer over  cancer cases  Seventytwo studies were included metaanalyses cancer sites summary relative risks RR of hormonerelated cancers highest versus lowest studyspecific category ranged confidence interval CI – breast cancer CI – endometrial cancer GI and CI – prostate cancer CI – ovarian cancer GL significantly increased colorectal cancer risk emerged high GI summary RR =   CI – Other summary RRs were not significantly unity',\n",
       "  ('1. Introduction',\n",
       "   'sec1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   4): 'After that review  reports  have been published accounting distinct original studies and almost  additional cancer cases These included EPICItaly cohort investigating multiple cancer sites Framingham Offspring cohort on adiposityrelated cancers pooled analysis of two studies on esophageal and gastric cardia adenocarcinoma  three studies on colorectal cancer  one combined analysis of two North European cohorts on cancer of biliary tract  two studies on lung cancer  including combined analysis of two Asian cohorts  one on melanoma  four on breast cancer  including update of Nurses Health Study II NHSII  two on endometrial cancer  one on ovarian cancer  one on bladder cancer  one on kidney cancer  and one on thyroid cancer ',\n",
       "  ('1. Introduction',\n",
       "   'sec1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   5): 'A few metaanalyses have recently reported on GIGL and single cancer  but no study has provided updated comprehensive quantification of association of GIGL wide range of cancer types single report',\n",
       "  ('1. Introduction',\n",
       "   'sec1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   6): 'Given new original data we updated our systematic review and metaanalysis derive more precise estimation of associations Specifically we reviewed most recent up May  epidemiological data on association dietary GI and GL and cancer risk updated summary RRs stomach colorectal pancreatic breast endometrial ovarian and prostate cancers and addressed issues of heterogeneity and complexities of interpretation  Moreover we calculated metaanalytic estimates kidney and first time lung and bladder neoplasms',\n",
       "  ('2.1. Search Strategy and Selection Criteria',\n",
       "   'sec2dot1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   7): 'We conducted systematic review and series of metaanalyses on dietary GI and dietary GL and cancer risk following recognized reporting guidelines  We included relevant studies selected our prior systematic review and metaanalysis on GIGL intake and cancer risk search up January   and updated search using same search strategy May  Briefly following string was used MedlinePubmed no language or other restriction cancer OR neoplasm OR carcinoma AND glycemic index OR glycemic load OR glycaemic index OR glycaemic load electronic search was supplemented hand searching of references of selected publications and previous reviews',\n",
       "  ('2.1. Search Strategy and Selection Criteria',\n",
       "   'sec2dot1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   8): 'We selected original cohort or casecontrol studies that assessed association dietary GI andor GL intake and incidence of or mortality specific cancer  Studies analyzing cancer overall were excluded be included quantitative metaanalyses studies had report estimates of RRs ie odds ratios ORs or RRs or hazard ratios HRs and corresponding  CI categories of GIGL intake or information needed their calculation studies providing only RR increment of one unit of GIGL were reviewed but not considered metaanalyses  We conducted metaanalyses cancer sites investigated at least four studies',\n",
       "  ('2.1. Search Strategy and Selection Criteria',\n",
       "   'sec2dot1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   9): 'Two reviewers independently identified eligible studies screening titles abstract and when appropriate fulltexts of articles Any discrepancy was discussed and resolved consensus If there were multiple publications same study population we used data longest followup cohorts or larger database casecontrol studies',\n",
       "  ('2.1. Search Strategy and Selection Criteria',\n",
       "   'sec2dot1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   10): 'From each selected publication we extracted details on study design country sex of participants tumor site number of enrolled subjects cases and controls or cohort size period of enrolment casecontrol studies or followup cohort studies methods dietary assessment type number of food items and whether it had been validated reference food GIGL white bread or glucose comparison levels of GI andor GL RR estimates ie odds ratioshazard ratiosRRs comparison highest versus lowest category of GIGL intake and confounding factors which adjustment was made When RR estimates models different covariates were provided we extracted RRs adjusted largest number of confounding factors',\n",
       "  ('2.2. Statistical Analysis',\n",
       "   'sec2dot2-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   11): 'We conducted quantitative metaanalyses of GI and GL intake association risk of cancer current analysis we considered cancer sites investigated at least four studies and which new epidemiological data have become available previous review  ie breast endometrium ovary and prostate hormonerelated cancers stomach colorectum and pancreas digestive tract cancers and lung bladder and kidney other cancer sites Although new data on liver cancer have been made available EPICItaly cohort  we did not update metaanalysis on liver cancer as that data partially overlapped those reported by Fedirko et al  which analyzed overall EPIC cohort',\n",
       "  ('2.2. Statistical Analysis',\n",
       "   'sec2dot2-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   12): 'We derived summary estimates of RR combining studyspecific ORs or RRs or HRs highest versus lowest category of GI and GL intake using randomeffects models which account heterogeneity RR estimates Heterogeneity was evaluated χ test and quantified and statistic ',\n",
       "  ('2.2. Statistical Analysis',\n",
       "   'sec2dot2-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   13): 'We updated subgroup analyses breast cancer according menopausal status and body mass index BMI  kgm and BMI ≥  kgm One study showing RR of breast cancer according GI and GL women BMI ≥  kgm was excluded subgroup analysis ',\n",
       "  ('2.2. Statistical Analysis',\n",
       "   'sec2dot2-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   14): 'Publication bias was assessed funnel plots and Egger tests ',\n",
       "  ('2.2. Statistical Analysis',\n",
       "   'sec2dot2-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   15): 'All statistical analyses were performed using STATA software version  StataCorp College Station TX USA',\n",
       "  ('3.1.1. Multiple Cancer Sites',\n",
       "   'sec3dot1dot1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   16): 'The EPICItaly cohort provided results different cancer types median followup of years  incident cancers occurred including  colon  rectal  pancreatic  lung  breast  endometrial  ovarian  prostate  bladder and  kidney cancers most cancer sites no association was found either dietary GI or GL High GI was associated increased risk of colon HR fifth versus first quintile   CI – and bladder cancer HR   CI – and high GL increased risk of colon HR   CI  and diabetesrelated cancers HR   CI – but decreased risk of rectal cancer HR   CI – Framingham Offspring cohort found no association GI GL and adiposityrelated cancers based on total of  incident cancers of gastrointestinal tract reticuloendothelial system blood bone and spleen female reproductive tracts genitourinary organs and thyroid gland analyses cancer type no significant associations were found breast colorectal and prostate cancers HRs third versus first tertile were   CI – GI and   CI – GL breast cancer  cases   CI – GI and   CI – GL colorectal cancer  cases and   CI – GI and   CI – GL prostate cancer  cases',\n",
       "  ('3.1.2. Hormone-Related Cancers',\n",
       "   'sec3dot1dot2-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   17): 'As breast cancer update of NHSII which included  additional years of followup and almost four times number of cases compared report  found null association GI and GL and breast cancer risk HRs fifth versus first quintile of   CI – GI and   CI – GL based on  invasive cases  Similar null results were observed pre HR GI  HR GL  and postmenopause HR GI  HR GL  as well as normo HR GI  HR GL  and overweight women HR GI  HR GL  not significant secondary analysis framework of PREDIMED trial based on  incident cases dietary GI and GL were not related breast cancer postmenopausal women high risk of cardiovascular diseases HR third versus first tertile   CI – GI and   CI – GL  No association breast cancer was also reported Mexican populationbased casecontrol study including  women breast cancer ORs fourth versus first quartile being   CI – GI and   CI – GL that study null association was also observed subgroups defined menopausal status and BMI further Mexican casecontrol study including  cases matched age population controls found positive association GI and breast cancer overall OR unit increase   CI – and luminal HER and TN molecular subtypes no association emerged GL regardless of subtype ',\n",
       "  ('3.1.2. Hormone-Related Cancers',\n",
       "   'sec3dot1dot2-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   18): 'Two studies investigating GIGL relation endometrial cancer found both absence of association HRs were   CI – GI and   CI – GL fourth versus first quartile US Cancer Prevention Study II CPSII Nutrition Cohort which included  incident cases occurred median followup of years addition Canadian casecontrol study over  cases and  population controls found OR of   CI – fourth versus first quartile of dietary GL no effect modification BMI ',\n",
       "  ('3.1.2. Hormone-Related Cancers',\n",
       "   'sec3dot1dot2-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   19): 'As ovarian cancer casecontrol study AfricanAmericans USA enrolling cases and  population controls found no association GI OR fourth versus first quartile   CI – but suggestion of positive association GL ORs were   CI – per  units of GL kcal continuous analysis and   CI – highest versus lowest quartile of GL when variable was considered categories latter analysis however clear doserisk relationship did not emerge ORs subsequent quartiles   significant  p trend =  ',\n",
       "  ('3.1.3. Cancers of the Digestive Tract',\n",
       "   'sec3dot1dot3-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   20): 'Two casecontrol  and one cohort study  on colorectal cancer have become available previous metaanalysis Japan Public Health Centerbased prospective Study JPHC Study provided first time data on GIGL and colorectal cancer risk Japanese population  Based on  incident cases population of over  subjects followed years on average JPHC study found overall nonsignificant results GI as well as GL HRs of colorectal cancer fourth versus first quartile were   CI – men and   CI – women GI and   CI men and   CI – women GL However nonsignificantly reduced risk of proximal colon cancer high GL consumption was observed men HRs proximal colon cancer   CI – and nonsignificantly reduced risk of rectal cancer high GI HRs   CI – and GL HR   CI – was found women Chinese casecontrol study including  cases and  communityderived or hospital controls reported positive association GI and colorectal OR fourth versus first quartile   CI – as well as colon  cases and rectal cancer  cases similar men and women  High GL was not associated colorectal OR fourth versus first quartile   CI – colon or rectal cancer However increased risk of colorectal cancer highest versus lowest quartile of GL was found women only OR   CI – casecontrol study Argentina and based on  cases of colorectal cancer and  populationbased controls showed significant positive associations GI and GL women only OR third versus first tertile   CI – GI OR   CI – GL ',\n",
       "  ('3.1.4. Other Neoplasms',\n",
       "   'sec3dot1dot4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   21): 'A pooled analysis of two US populationbased casecontrol studies ie US MultiCenter Study and Los Angeles MultiEthnic Study including overall  esophageal adenocarcinomas  gastric cardia adenocarcinomas and  controls reported increased risk of esophageal adenocarcinoma fifth versus first quintile of GI intake OR   CI – absence however of clear doserisk relationship p trend  Such positive association was evident only subjects BMI ≥  kgm No relation emerged GI and esophageal adenocarcinoma OR fifth versus first quintile   CI – as well as GL intake and esophageal OR   CI – and gastric cardia adenocarcinoma OR   CI – ',\n",
       "  ('3.1.4. Other Neoplasms',\n",
       "   'sec3dot1dot4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   22): 'Dietary GI and GL were positively related risk of biliary tract cancer combined analysis of Swedish Mammography Cohort and cohort of Swedish Men which included  extrahepatic and  intrahepatic cancer cases developed population of over  individuals mean followup of  years HRs fourth versus first quartile of dietary GI was   CI – extrahepatic and   CI – intrahepatic biliary tract cancer corresponding values GL were respectively   CI – and   CI – ',\n",
       "  ('3.1.4. Other Neoplasms',\n",
       "   'sec3dot1dot4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   23): 'Two reports gave results on GIGL and lung cancer  Data Shanghai Womens and Mens Health Studies including  incident lung cancers women and men developed average followup of years indicated no association of GI or GL lung cancer HRs fourth versus first quartile of GI was   CI – women and   CI – men corresponding figures GL were   CI women and   CI – men Null findings were also found strata of BMI smoking family history of cancer and menopausal status women populationbased casecontrol study USA based on  incident cases and  controls significant positive association lung cancer risk was found GI OR fifth versus first quintile   CI – trend   but not GL OR   CI – positive association GI was more evident never smokers OR fifth quintile   CI – and squamous cell carcinoma histologic subtype OR   CI – ',\n",
       "  ('3.1.4. Other Neoplasms',\n",
       "   'sec3dot1dot4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   24): 'An Italian populationbased casecontrol study including  cases of melanoma and  age and sexmatched controls reported positive association GL women OR   CI highest versus lowest quintile trend =  but not men OR   CI – and lack of relation GI either sex ',\n",
       "  ('3.1.4. Other Neoplasms',\n",
       "   'sec3dot1dot4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   25): 'A positive association GL and bladder cancer risk was found casecontrol study Italy including  cases and  hospitalcontrols risk of bladder cancer was significantly increased second quartile onwards and subjects fourth quartile had approximately doubled risk of bladder cancer compared those first one OR   CI –  No association emerged GI',\n",
       "  ('3.1.4. Other Neoplasms',\n",
       "   'sec3dot1dot4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   26): 'One casecontrol study USA investigated renal cell carcinoma and found positive association GI and absence of association GL  Based on total of  cases and  populationbased controls ORs fourth versus first quartile were   CI – trend = GI and   CI – GL',\n",
       "  ('3.1.4. Other Neoplasms',\n",
       "   'sec3dot1dot4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   27): 'An analysis based on  welldifferentiated thyroid cancers EPIC cohort found overall no association GI HR fourth versus first quartile   CI – and GL HR   CI – stratified analysis significant positive relation overweight HR   CI – trend =  and inverse one normoweight subjects HR   CI – trend =  emerged GI ',\n",
       "  ('3.2.1. Hormone-Related Cancers',\n",
       "   'sec3dot2dot1-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   28): 'Summary RR of hormonerelated cancers were all unity but nonsignificant both GI and GL all cancer sites  They were   CI – GI  studies  casesPanel and   CI – GL  studies  casesPanel B breast cancer   CI – GI  studies  cases and   CI – GL  studies  cases endometrial cancer   CI – GI eight studies  cases and   CI – GL eight studies  cases ovarian cancer and   CI – GI eight studies  cases and   CI – GL seven studies  cases prostate cancer Significant heterogeneity studies was observed all metaanalyses',\n",
       "  ('3.2.2. Digestive-Tract Cancers',\n",
       "   'sec3dot2dot2-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   29): 'There was positive significant association high GI intake and colorectal cancer risk No other significant associations were detected  Summary RRs were   CI GI seven studies  casesPanel and   CI – GL seven studies  cases–Panel B stomach cancer   CI – GI  studies  cases and   CI – GL  studies  cases colorectal cancer   CI – GI  studies  cases and   CI – GL  studies  cases pancreatic cancer Significant heterogeneity studies was detected all metaanalyses except that on GI and pancreatic cancer sensitivity analysis summary RR of colorectal cancer according high GI remained statistically significant exclusion of each study turn',\n",
       "  ('3.2.3. Other Neoplasms',\n",
       "   'sec3dot2dot3-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   30): 'There was no association high GI or GL intake and lung cancer risk summary RRs being   CI – GI six studies  cases and   CI – GL five studies  cases significant positive association was found high GI and bladder cancer summary RR of   CI – four studies  cases corresponding summary RR GL was   CI – four studies  cases Summary RRs kidney cancer were   CI – GI five studies  cases and   CI – GL five studies  cases Heterogeneity studies was lowtomoderate most of metaanalyses I ranging to  except those on GI and lung cancer I =  and GL and kidney cancer I = sensitivity analyses positive association high GI and bladder cancer remained significant when any study was removed metaanalysis while summary RR of kidney cancer high GI was no longer significant exclusion of each study turn except that George et al ',\n",
       "  ('3.2.4. Subgroup Analyses for Breast Cancer',\n",
       "   'sec3dot2dot4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   31): 'In subgroup analyses menopausal status summary RRs of breast cancer highest versus lowest category of GI were   CI –  studies heterogeneity =  I= premenopausal breast cancer and   CI –  studies heterogeneity =  I= postmenopausal breast cancer heterogeneity strata = corresponding figures GL were   CI –  studies heterogeneity =  I = premenopausal breast cancer and   CI –  studies heterogeneity   I = postmenopausal breast cancer heterogeneity strata = ',\n",
       "  ('3.2.4. Subgroup Analyses for Breast Cancer',\n",
       "   'sec3dot2dot4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   32): 'Summary RRs of breast cancer strata of BMI indicated null association GI and GL normoweight as well as overweight women As GI RRs highest versus lowest intake were   CI – six studies heterogeneity =  I = BMI   kgm and   CI – six studies heterogeneity =  I = BMI ≥  kgm heterogeneity strata =  Values GL were   CI – seven studies heterogeneity =  I = BMI   kgm and   CI – seven studies heterogeneity =  I = BMI ≥  kgm heterogeneity strata = ',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   33): 'The present work based on  reports represents most updated comprehensive quantification of relation of GI and GL intake cancer risk It updates and expands previous analysis published and provides metaanalytic results kidney and first time lung and bladder cancers present results largely confirm those of previous metaanalysis  summary RRs are similar those previously reported but general they are more precise providing more confidence results We found significant but small unfavorable effects of high versus low GI diets colorectal and possibly bladder and kidney cancers and possible modest positive association high GL and endometrial cancer Most of summary RRs were weakly and nonsignificantly or most marginally significantly increased indicating no major role of GIGL intake etiology of most cancer types',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   34): 'Possible biological mechanisms explain modest associations observed include impact of GI and GL on blood glucose HbAc and hence insulin and IGF These may also impact on body weight Although body weight was allowed in most of analyses considered residual confounding may be present However GI and GL are correlated other aspects of carbohydrate quality such as cereal fibers  Confounding these factors may also partly explain observed associations',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   35): 'Our findings are broadly similar other metaanalyses addressing role of dietary GI dietary GL and cancer risk particular no associations stomach  prostate  and pancreatic cancers  were reported others metaanalysis on kidney cancer based on same study sample yielded essentially identical results  ie positive but weak significant association high GI and no association GL Although absence of appreciable heterogeneity studies supports robustness of findings on GI and kidney cancer still limited number of studies and null association GL need be considered interpretation of findings addition exclusion GIkidney cancer metaanalysis of each study turnwith exception of study George et al gave nonsignificant summary RR estimates',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   36): 'According World Cancer Research FundAmerican Institute Cancer Research WCRFAICR high dietary GL but not GI is probably cause of endometrial cancer while evidence on other cancer sites including colorectal pancreatic liver and breast cancers is inconclusive conclusion on endometrial cancer was based on doseresponse metaanalysis based on six cohort studies published up which estimated significant  increased risk per  unitsday of GL summary RR of endometrial cancer high versus low GL was   CI – our previous metaanalysis based on  studies  and   CI – current update inclusion of two additional studies Although only marginally significant such  increased risk was not contrast WCRF result thought different methods of analyses ie doseresponse versus extreme quantile inclusion criteria eg only cohort versus both cohort and casecontrol studies and search updates do not allow direct comparison positive association high GL but not GI and risk of endometrial cancer was reported other previous metaanalyses  while recent high profile publication Reynold et al which provided systematic reviews and metaanalyses of prospective studies on relationship most widely studied indicators of carbohydrate quality and incidence of and mortality wide range of noncommunicable diseases did not find any relation GI and GL both doseresponse and extreme quantile analyses that report high GI was associated marginally significant  increased risk of colorectal cancer summary RR   CI – and each  unitsday of GI increased risk of borderline significance summary RR   CI – while no association was reported GL  Excess risks of colorectal cancer less for high versus low GI were found previous metaanalyses of prospective studies excess risk was slightly higher – but essentially comparablein metaanalyses based on both cohort and casecontrol studies  including present one',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   37): 'We found modest nonsignificant association of GIGL and breast cancer Other metaanalyses generally showed no or small  increased risks highest versus lowest GI or GL metaanalyses Reynolds et al summary RRs of breast cancer were   CI – high versus low GI but   CI – unitday increase and   CI – high versus low GL another metaanalysis updated association GIbut not GLwas slightly stronger postmenopausal premenopausal women but difference was not significant addition BMI did not influence association GI GL and breast cancer  This is line current results showing comparable estimates of GIGLbreast cancer association pre and postmenopausal women as well as normoweight and overweight women',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   38): 'No metaanalysis has previously systematically addressed association of GIGL ovarian lung or bladder cancers our study GI and GL did not significantly influence risk of lung and ovarian cancer We found significant  increased risk of bladder cancer high versus low GI intake and association remained significant when excluding each study turn no relation was observed GL Conditions related chronic hyperinsulinemia and hyperglycemia such as diabetes and metabolic syndrome have been associated bladder cancer  Urinary tract infections influence risk of bladder cancer and may be associated diet promoting large increase blood glucose addition insulin can increase expression of epidermal growth factors and protein kinase and induced bladder cancer cell proliferation in vitro studies ',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   39): 'Part of different associations of dietary GI and dietary GL on selected cancer types may be explained differences underlying dietary patterns Some studies indeed suggested that while overall GL of diet is mostly associated highcarbohydrate foods and hence closely correlates total carbohydrate intake GI is associated not only high consumption of highcarbohydrate foods but also low consumption of some lowcarbohydrate foods and related nutrients including fruit dairy  vegetables and legumes  Thus dietary GI unlike GL may reflect more dimensions of diet just carbohydrates  This could partly explain least positive association of GI colorectal cancera cancer potentially related various aspects of dietin absence of any relation GL any case scientific consensus statement international experts on carbohydrate research recognized that GI is valid and reproducible measure express glycemic response of foods ',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   40): 'The heterogeneity studies results observed most metaanalyses may be due several reasons including dietary habits of studied populations ie low carbohydrate diets which include high animal proteins and fats eg North American populations versus high carbohydrate diets eg populations southern Europe number and type of carbohydrate items FFQs and GI values attributed FFQ items consequent different ranges of GIGL particularly GL various studies Moreover studies used different methods of GIGL categorization analyses eg tertiles quartiles quintiles therefore there is heterogeneity highest and lowest absolute levels of GIGL study design and selection of adjustment factors may also contribute observed heterogeneity',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   41): 'In epidemiologic studies high dietary GI and GL were consistently associated greater risks of diabetes and CHD When restricting our analyses on colorectal and breast cancers large wellrecognized cohorts which reported on GIGL and such other health outcomes ie Swedish Mammography Cohort and cohort of Swedish Men Shanghai Womens and Mens studies Health Professional Followup Study NHSI and NHSII EPIC cohort Women Health Study and Womens Health Initiative results were essentially unchanged while heterogeneity decreased GIbreast cancer I =  =  GIcolorectal cancer I =  =  and GLbreast cancer I =  =  metaanalyses but not appreciably metaanalysis on GL and colorectal cancer I =  = ',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   42): 'Most studies adjusted most relevant confounders ie BMIphysical activity energy intake tobacco and social class but some residual confounding is still possible GIGL are positively associated diabetes and diabetes increases risk of colorectal pancreatic endometrial and perhaps breast cancer  and possibly decreases risk of prostate cancer addition diabetic patients are often advised change their diet lower carbohydrate intake and this could underestimate any positive association Therefore careful consideration of subjects diabetes condition is necessary when examining relation of GI and GL diabetesrelated neoplasms most studies on colorectal endometrial and prostate cancer authors either  excluded diabetics analyses  gave RRs adjusted diabetes  reported that adjustment diabetes or restricting analyses nondiabetic subjects did not influence results or  reported that observed association was independent diabetes However excluding women diabetes slightly strengthened association GI and colorectal cancer risk Swedish Mammography Cohort  and higher GL was positively associated endometrial cancer nondiabetic women only Iowa Womens Health Study ',\n",
       "  ('4. Discussion',\n",
       "   'sec4-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   43): 'Major strengths of present study are consideration of many studies and cancer cases which provided statistical power detect moderate associations most cancer sites use of rigorous and systematic methodology identifying and pooling evidence previous studies and ability examine GI and GL association several types of cancer cohort and casecontrol studies single report',\n",
       "  ('5. Conclusions',\n",
       "   'sec5-nutrients-11-02342',\n",
       "   'no_sub_id',\n",
       "   44): 'The present analysis provides most comprehensive and updated quantification of relation GI GL and cancer risk It indicates moderate unfavorable effects of high versus low GI on colorectal and possibly bladder and kidney cancers and possible modest positive association GL and endometrial cancer Such small excess risks may however be relevant population level due high incidence of selected cancers namely colorectal and breast cancer'},\n",
       " {('Introduction',\n",
       "   'sec005',\n",
       "   'no_sub_id',\n",
       "   0): 'Over past two decades Korea incidence of childhood cancer has increased substantially recent nationwide childhood cancer study Korea showed that agestandardized incidence rate all cancers children aged years was  per million children – agestandardized incidence rate increased per million children to  per million children with annual percentage change of  However survival rate of childhood cancer has also increased  which may be result of improved treatment and health infrastructure ',\n",
       "  ('Introduction',\n",
       "   'sec005',\n",
       "   'no_sub_id',\n",
       "   1): 'On other hand increase of childhood cancer survivors has resulted substantial increase incidence of second malignant neoplasms SMNs childhood cancer occurrence of SMNs childhood cancer survivors reduces their life expectancy and negatively impacts their quality of life  Overall childhood cancer survivors have longer life expectancy adult cancer survivors and SMN and secondary chronic health problems life span will influence patient patients family and society  Second neoplasms have been known be major contributors excess total cumulative burden of chronic health conditions  SMN has also been reported be significant factor related financial or other hardships experienced childhood cancer survivors ',\n",
       "  ('Introduction',\n",
       "   'sec005',\n",
       "   'no_sub_id',\n",
       "   2): 'A proper surveillance program childhood cancer patients is needed detect other malignant diseases and provide more preemptive management Research has consistently demonstrated that incidence of neoplasms patients who have previously had cancer is higher that general population  – Early detection and appropriate management of these patients would influence their total survival rate',\n",
       "  ('Introduction',\n",
       "   'sec005',\n",
       "   'no_sub_id',\n",
       "   3): 'According previous studies it has been reported that risk of SMN increases followup time and that cancer treatment determines risk of secondary cancer – risk of developing SMNs is unequal different types of cancer   Possible reasons this difference have been explained as follows difference onset age of primary cancer prevalence of secondary cancer risk factors including primary cancer treatments environmental exposures and genetic susceptibility  Further study of SMN incidence would help clarify characteristics of group highest risk developing SMNs as well as elucidate proper surveillance methods atrisk patients and better understanding of time period which SMNs develop',\n",
       "  ('Introduction',\n",
       "   'sec005',\n",
       "   'no_sub_id',\n",
       "   4): 'The total number of childhood cancer survivors Korea is estimated be approximately  however recent statistics SMNs Korea are not yet available previous retrospective multicenter study involving  centers Korea reported that  cases of second malignant neoplasm childhood cancer were treated and   However there has been no nationwide study SMN childhood cancer Korea',\n",
       "  ('Introduction',\n",
       "   'sec005',\n",
       "   'no_sub_id',\n",
       "   5): 'Thus present study we aimed evaluate incidence and survival outcomes of SMNs that occurred childhood cancer survivors Korea analysis of national registry data',\n",
       "  ('Data sources',\n",
       "   'sec007',\n",
       "   'no_sub_id',\n",
       "   6): 'Registrybased data on childhood cancer patients aged – years old diagnosed and  were obtained Korea National Cancer Incidence Database KNCIDB of Korea Central Cancer Registry KCCR KCCR is populationbased cancer registry that was begun by Korean Ministry of Health and Welfare and which has covered entire Korean population KNCIDB includes information sex age date of first diagnosis primary tumor site and method of diagnosis Detailed information KCCR data has been reported previously  Mortality data was earned cancer mortality database of Statistics Korea',\n",
       "  ('Data sources',\n",
       "   'sec007',\n",
       "   'no_sub_id',\n",
       "   7): 'We considered that primary malignancy treatment did not affect second cancer diagnosis that was established months of first cancer diagnosis Therefore patients who developed second malignancy first  months of followup were excluded study  As result total of  patients were analyzed childhood cancer and institutional review board National Cancer Center approved this study NCC',\n",
       "  ('Statistical methods',\n",
       "   'sec008',\n",
       "   'no_sub_id',\n",
       "   8): 'Childhood cancer patients this study were classified according diagnosis of SMN using main diagnostic groups of International Classification of Childhood Cancers  edition  SMNs included all observed cases of subsequent cancer accordance Surveillance Epidemiology and End Results Program SEER expected number of cancers was estimated multiplying number of personyears risk PYR age sex and calendar periodspecific cancer incidence rates general population As measure of risk developing SMNs standardized incidence ratios SIRs were calculated as observed number of SMNs divided expected number of malignant neoplasms general population confidence intervals CIs were calculated assuming Poisson distribution observed cases this study midyear population obtained Statistics Korea  was used as general reference population measure overall burden of SMN excess absolute risks EARs of SMN were calculated dividing difference observed number and expected number PYR and were presented as numbers per  PYR number of PYR was defined months date of first childhood cancer diagnosis date of death or end of this study whichever occurred first addition we calculated cumulative incidence of second primary cancer which was defined time of first cancer diagnosis',\n",
       "  ('Statistical methods',\n",
       "   'sec008',\n",
       "   'no_sub_id',\n",
       "   9): 'KaplanMeier survival analyses were done primary cancer patients and SMN patients Survival differences primary cancer patients and SMN patients were estimated using logrank test All statistical tests were twosided and considered statistically significant values  All calculations of SIR and EAR were performed using SEERStat software version  National Cancer Institute Bethesda MD cumulative incidence rates and survival curves were generated and logrank tests were performed SAS version  SAS Institute Cary NC and Stata ',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   10): 'Malignant neoplasm was diagnosed patients aged – years men and  women who contributed total of  PYR over year study period – these patients  cases of subsequent malignant neoplasms were observed patients including  patients who developed third cancers ',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   11): 'The median age initial diagnosis was  years old and median followup period was  years most common type of SMN was other malignant epithelial neoplasms and malignant melanomas Group XI diagnosed cases This group is composed of adrenocortical carcinomas thyroid carcinomas nasopharyngeal carcinomas malignant melanomas skin carcinomas and other and unspecified carcinomas Thyroid carcinoma  cases  was most common type of neoplasm this group ',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   12): 'Following other malignant epithelial neoplasms and malignant melanomas second third fourth and fifth most commonlyobserved types of SMNs were leukemias myeloproliferative diseases and myelodysplastic diseases Group I  cases soft tissue and other extraosseous sarcomas Group IX  cases malignant bone tumors Group VIII  cases and central nervous system CNS and miscellaneous intracranial and intraspinal neoplasms Group III  cases respectively overall SIR was following group of cancers showed high SIR as SMNs other and unspecified malignant neoplasms  soft tissue and other extraosseous sarcomas  and other malignant epithelial neoplasms and malignant melanomas ',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   13): 'The SIR was higher women SIR =   CI – compared men SIR =   CI – but difference was not statistically significant ',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   14): 'According primary malignant neoplasm types soft tissue and other extraosseous sarcomas showed highest SIR developing SMN  Patients who had soft tissue and extraosseous sarcoma as primary cancer often developed soft tissue and other extraosseous sarcomas as secondary cancer  of  SMNs followed leukemias myeloproliferative diseases and myelodysplastic diseases  of  SMNs',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   15): 'On comparing incidence of primary and secondary cancers types all  retinoblastoma patients SMN developed secondary malignant bone tumors addition leukemias myeloproliferative diseases and myelodysplastic diseases was most common type of SMN primary malignant bone tumor  of  cases absolute value of SMN cases each cancer was not indicated because of small number of cases',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   16): 'Almost half  n =  of SMNs occurred years of diagnosis of primary cancer while  cases  occurred – years diagnosis of primary cancer and  cases  occurred more years diagnosis of primary cancer  According latency period diagnosis of primary cancer overall SIR was highest years initial cancer diagnosis SIR = ',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   17): 'The overall EAR was  per  PYR  EAR was highest other malignant epithelial neoplasms and malignant melanomas group  When EAR was analyzed based on time of SMN diagnosis soft tissue and other extraosseous sarcomas group had highest EAR of  per  PYR – months primary cancer diagnosis – months primary cancer diagnosis leukemias had highest EAR of  per  PYR other malignant epithelial neoplasms and malignant melanomas group had highest EAR and  per  PYR – and ≥ months primary cancer diagnosis respectively This suggests that greater increase incidence corresponds longer time period primary and SMN diagnosis',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   18): 'The median latency first and second cancers was  years which was shortest secondary lymphomas and reticuloendothelial neoplasms  years and neuroblastoma and other peripheral nervous cell tumors  years On contrary carcinomas of breast  years and thyroid carcinomas  years had longest median latency median age SMN was  years while development of hepatic tumors occurred oldest age  years cumulative incidence of SMNs was years years and years ',\n",
       "  ('Results',\n",
       "   'sec009',\n",
       "   'no_sub_id',\n",
       "   19): 'The year overall survival rates were patients only one primary cancer and patients second malignant neoplasms year overall survival rate of patients SMN was  lower overall survival rate of patients SMN but statistically nonsignificant year and year overall survival rates onset of SMNs were  and  respectively particular patients SMN year survival rate was highest those whose SMN was categorized as other malignant epithelial neoplasm and malignant melanoma and lowest those diagnosed leukemia addition year survival rates of common SMNs were  soft tissue and other extraosseous sarcomas  malignant bone tumors and  CNS and miscellaneous intracranial and intraspinal neoplasms data not shown',\n",
       "  ('Discussion',\n",
       "   'sec010',\n",
       "   'no_sub_id',\n",
       "   20): 'Through this study we concluded that risk of SMN childhood was fold greater childhood cancer survivors risk of developing malignant neoplasm general population SIR and EAR of SMN childhood cancer survivors this cohort were  and  respectively When compared previous reports various nations SIR this study was higher in others which reported values –   – This difference may be associated shorter follow up period our study as SIR is known be highest first – years and decreases longer duration of follow up   This can be explained low incidence of cancer general population aged – years old and relatively much higher incidence of SMN cancer survivors Cumulative incidence of SMN childhood cancer this study was years and years which is similar previous studies One Japanese study reported  and  of CIR years and  years childhood cancer respectively  Data Childhood Cancer Survivor Study CCSS showed year and year cumulative incidence of SMN be  and  respectively  while recent US study reported that cumulative incidence of new subsequent neoplasm and SMNs occurring age  was  and  respectively  Longer follow up is needed measure cumulative incidence of SMN Korean childhood cancer survivors',\n",
       "  ('Discussion',\n",
       "   'sec010',\n",
       "   'no_sub_id',\n",
       "   21): 'When divided according primary malignant neoplasm breast cancer showed particularly high SIR this study high proportion of breast cancer cases occurred diagnosis of malignant bone tumor soft tissue sarcoma germ cell tumor or other malignant epithelial neoplasm ICCC group XI median age diagnosis of breast cancer Korean women is approximately  years younger that of women United States and this difference may be associated different environmental and genetic backgrounds ethnicities addition possible genetic or environmental factors treatments sarcomas germ cell tumors and other malignant epithelial neoplasms may have influenced early occurrence of breast cancer this study recent study has shown that prevalence of BRCA mutations Korean familial breast cancer patients is similar that Western cohorts but more studies are needed concrete conclusion can be drawn ',\n",
       "  ('Discussion',\n",
       "   'sec010',\n",
       "   'no_sub_id',\n",
       "   22): 'In our study risk of SMN was higher females in males concordant previous studies     Females demonstrated higher SIR SMNs other malignant neoplasm group which includes thyroid carcinomas and carcinomas of breast and soft tissue sarcoma group higher risk of SMNs female survivors of childhood cancer may part be influenced breast cancer risk',\n",
       "  ('Discussion',\n",
       "   'sec010',\n",
       "   'no_sub_id',\n",
       "   23): 'In this study primary cancer highest SMN risk was soft tissue sarcoma and malignant bone tumor Due lack of data treatment our data set it is impossible identify relationship treatment and results SMN However previous studies have shown possible relationship treatment and SMNs sarcoma patients high incidence of SMN these groups could be partially related treatment including alkylators anthracyclines or epipodophyllotoxins  Radiation therapy is also known increase risk of secondary sarcoma development previous sarcoma patients  Therefore efforts modify treatment lowrisk sarcoma patients could lower risk of SMN sarcoma survivors second possible reason high SMN rate soft tissue sarcoma and malignant bone tumors may be associated cancerprone mutations example mutation or mutation osteosarcoma Newly discovered mutations have been reported various types of sarcomas  Expansion of knowledge these mutations will provide more information of pathophysiology and tumorigenesis of SMNs Genetic study is not routinely done childhood cancer patients Korea but future extended trials of genetic study will provide information not only cancer treatment but also SMN surveillance and family management',\n",
       "  ('Discussion',\n",
       "   'sec010',\n",
       "   'no_sub_id',\n",
       "   24): 'Several studies showed high incidence of SMN treatment of Hodgkin lymphoma   However this study we could not find higher tendency of SMN lymphoma possibly because we did not divide diagnosis of lymphoma according subtypes Known common SMNs childhood Hodgkin Lymphoma are breast cancer thyroid cancer or sarcoma and as latency of these SMNs are long these could not be detected short follow up duration of our study',\n",
       "  ('Discussion',\n",
       "   'sec010',\n",
       "   'no_sub_id',\n",
       "   25): 'According this study secondary leukemia or lymphoma mostly occurred years of primary diagnosis and carcinoma of thyroid or breast was found years of latency Based on these results routine blood test is needed at least  years cancer treatment screen secondary hematologic malignancy Beyond  years surveillance of thyroid and breast cancers physical examinations or imaging studies would be beneficial short our results indicate need of clinical follow up more years and emphasizing continued surveillance patients is of particular importance As many cancer survivors do not realize health risks that are related their childhood cancer many do not undergo regular medical followup that is recommended secondary cancer screening ',\n",
       "  ('Discussion',\n",
       "   'sec010',\n",
       "   'no_sub_id',\n",
       "   26): 'In this study year overall survival rate of patients and SMN were  and  respectively Although there are several longterm studies of childhood cancer survivors only few studies reported overall survival of patients who developed SMN childhood cancer recent Japanese study showed overall survival of survivors who developed secondary cancer and years primary cancer diagnosis be  and  respectively ',\n",
       "  ('Discussion',\n",
       "   'sec010',\n",
       "   'no_sub_id',\n",
       "   27): 'This study has several limitations First as data was extracted populationbased cancer registry database it lacks detailed information individual treatment methods such as radiotherapy chemotherapy and surgical therapy Several studies have reported that secondary cancer risk is increased treatment received first cancer particular emphasis on effects of radiotherapy   Hematopoietic stem cell transplantation is also known increase risk of SMN due conditioning regimen or total body irradiation graftversushost disease and posttransplant lymphoproliferative disorder – Further study treatment data is needed provide recommendations cancer treatment that consider risk of SMN Second follow up period of this study was shorter in previous studies     although comparable some national studies   Several previous studies have shown that breast thyroid bone tumor colorectal and lung cancer risk increases Hodgkin disease and average time second neoplasm has been reported be  years   As follow up time was shorter current study risk of Hodgkin lymphoma this study could have been underestimated and longer follow up could provide different data reported this study Further study and longterm follow up of childhood cancer survivors is needed more detailed and reliable data Lastly this study included only small number of cases some diagnostic groups study should thus be interpreted caution Particularly caution is required when interpreting SIR values small number of cases because these values could be statistically unstable',\n",
       "  ('Discussion',\n",
       "   'sec010',\n",
       "   'no_sub_id',\n",
       "   28): 'In spite of these limitations this study retains its significance as many studies concerning SMNs childhood cancer do not provide survival data Furthermore this study is valuable as first Korean nationwide populationbased study of SMN childhood cancer This study will be helpful planning cancer control program strategies such as screening surveillance and treatment decrease incidence of SMNs and improve childhood SMN survival rates Korea',\n",
       "  ('Conclusion',\n",
       "   'sec011',\n",
       "   'no_sub_id',\n",
       "   29): 'Our findings suggest that childhood cancer survivors risk of SMN is increased fold when compared risk general population Due this increased risk continued surveillance of SMN is recommended childhood cancer survivors Additionally attempts should be made reduce treatment intensity and select proper treatment modalities Further studies longer follow up time periods are needed clarify pattern of SMN reveal etiology and risk factors SMN childhood primarycancer survivors and provide advanced follow up guide childhood cancer survivors'},\n",
       " {('Introduction',\n",
       "   's1',\n",
       "   'no_sub_id',\n",
       "   0): 'Both genetic and environmental factors play role causes of earlyonset cancer Several welldefined genetic syndromes contribute earlyonset cancer risk with wider array of common alleles that influence risk marginally and detected population level As example of former Li–Fraumeni syndrome caused mutations tumor suppressor gene is associated increased risk of spectrum of cancers diagnosed early ages example of low penetrance common genetic variations associated cancer risk includes and genes pediatric acute lymphoblastic leukemia ALL  Both of these classes of variants may vary frequency raceethnic group and cluster families    Examination of cancer predisposition requires investigation ethnic strata particularly where cancer incidence rates are known differ as they do many pediatric cancer types such as leukemia  and brain cancer ',\n",
       "  ('Introduction',\n",
       "   's1',\n",
       "   'no_sub_id',\n",
       "   1): 'In addition primary cancers incidence patterns of second independent malignancies may also provide perspective of underlying genetic predisposition childhood cancer survivors more second primary malignancy SPM cases are observed nonLatino Whites NLW Latino subjects  This is also reflected adult cancers where Latino breast cancer survivors had lower risk of second cancers NLW and NL Black women ',\n",
       "  ('Introduction',\n",
       "   's1',\n",
       "   'no_sub_id',\n",
       "   2): 'Germline pathogeniclikely pathogenic variants cancer predisposition genes are found approximately  of pediatric cancer patients     and may be inherited or arise de novo Highly penetrant inherited variants will contribute clustering of cancer cases family Shared environments family unit may also be considered alongside genetic risk as potential causes familybased cancer concordance',\n",
       "  ('Introduction',\n",
       "   's1',\n",
       "   'no_sub_id',\n",
       "   3): 'Familial concordance of wide variety of cancers has been assessed using Swedish FamilyCancer Database leading deep understanding of familial relative risks Victorian Paediatric Cancer Family Study Australia also explored cancer risks relatives of children cancer small population United States Utah Population database may be bestknown population studying familial risk      Importantly these studies largely comprise families of European ancestry and therefore have not examined potential ethnicspecific familial risks Here we utilized linked population registries over  individuals quantify familial risks siblings and mothers and risks of earlyonset SPMs highly diverse and large population of California Risk patterns suggest that raceethnic minority subjects United States may harbor higher burden of familial risks some types of cancers compared majority population – NLW',\n",
       "  ('Source of data',\n",
       "   's2-1',\n",
       "   'no_sub_id',\n",
       "   4): 'We used linked populationbased registries California evaluate relative risks of earlyonset cancers – years age of onset siblings and mothers of children adolescents and young adults AYA aged – diagnosed cancer as well as relative risks of earlyonset SPMs proband patients dataset was created linking information California Cancer Registry CCR and California Birth Statistical Master File allowing capture of siblings and parents of cancer probands with their cancer incidence linked dataset comprehensively encompassed all cancer cases – years old as well as their sibling and mother cancers diagnosed to California Our upper age limit of  was set based on available age range covered this relatively young cohort Overall dataset included total of  individuals information on healthy siblings and mothers was available whole study period whereas information on fathers was not available in birth files and therefore is not included current analysis',\n",
       "  ('Source of data',\n",
       "   's2-1',\n",
       "   'no_sub_id',\n",
       "   5): 'For analysis of cancer familial risks we included all primary incident cancer cases diagnosed to patients aged – years patient ageatdiagnosis limited study time period which California maintained statewide SEER goldstandard cancer registry analysis of secondary cancer risks we included all SPMs diagnosed over same years and patient age ranges Although CCR only records primary malignancies some misclassification of relapsed or recurrent disease is possible physician EN reviewed diagnosis codes of all cases diagnosed first primary case prevent misclassification of relapsed first primary malignancies FPMs as SPMs both analyses we classified cancers broad groups and subgroups as defined International Classification of Childhood Cancer Third edition ICCC November abbreviations cancer types are included We also grouped cancers hematologic or solid categories analyses Hematologic cancers were defined as leukemias and lymphomas Solid cancers were defined as central nervous system CNS tumors neuroblastomas retinoblastomas renal tumors hepatic tumors bone tumors sarcomas germ cell tumors epithelial neoplasms and other and unspecified malignant neoplasms',\n",
       "  ('Statistical analysis',\n",
       "   's2-2',\n",
       "   'no_sub_id',\n",
       "   6): 'We quantified relative risks siblings and mothers and relative risks of SPMs calculating standardized incident ratios SIRs of given cancer or of SPMs healthy siblings and SIRs of given cancer healthy mothers of probands using previous published method  We defined proband as pediatric or AYA patient given cancer Only one childAYA each family can be proband so that families two or more cases proband is defined as patient earliest date of diagnosis Given proband cancer we calculated SIRs sibling or mother same family all types of cancers Separately we calculated SIRs sibling same type of cancer as proband We also stratified analyses selfidentified raceethnicity of mother each family SIRs siblings mothers or of SPMs can be denoted aswhere N is number of families n is number of nonproband individuals of interest siblingsSPMsmothers family i and Kmax is total number of age intervals data each individual includes disease indicator D and number of years risk kth age interval t given individual is defined be risk beginning their age when proband their family is diagnosed and ending either when they become affected themselves or when they are censored due end of study followup siblings and mothers age was stratified seven groups as  – – – – – and – years calculation of SIRs given race group is race sex and agespecific incidence rate of given cancer We compared SIRs raceethnic groups approximate chisquare tests approximate chisquare method compares probability of occurrence of events one group another based on binomial distribution This comparison is not related confidence intervals CIs SIRs We designated that all events occurred right middle point of each calendar year We also stratified analysis year age groups CIs were calculated assuming Poisson distribution categories less observed cases categories more observed cases we adopted method as indicated to calculate CIs as suggested Washington State Department of Health   Statistical analyses were performed using R software v  Any twosided pvalue less was considered statistically significant supplement is included this manuscript more information on statistical tests and computational codes used Please access more information',\n",
       "  ('Demographics of the study population',\n",
       "   's3-1',\n",
       "   'no_sub_id',\n",
       "   7): 'From we identified total of  pediatric and AYA patients primary malignancy comprising  probands  affected siblings families and  affected mothers All siblings were diagnosed probands diagnosis as defined and   of mothers were diagnosed probands diagnosis We also identified  SPMs all pediatric and AYA probands ',\n",
       "  ('Familial relative risks of early-onset cancers',\n",
       "   's3-2',\n",
       "   'no_sub_id',\n",
       "   8): 'Overall we found fold  CI – increased relative risk of any cancer siblings and mothers who have proband cancer same family Briefly we found fold  CI – increased relative risk of any cancer given proband hematologic cancers and fold  CI – increased relative risk of any cancer given proband solid cancers When stratified cancer type higher relative risks siblings and mothers were observed given probands leukemias lymphomas CNS tumors retinoblastomas renal tumors sarcomas germ cell tumors GCTs epithelial neoplasms and other unspecified neoplasms ',\n",
       "  ('Familial relative risks of early-onset cancers',\n",
       "   's3-2',\n",
       "   'no_sub_id',\n",
       "   9): 'For relative risk of specific cancer types we found fold  CI – increased risk of hematologic cancers siblings and mothers of proband hematologic cancer and fold  CI – increased relative risk of solid cancers siblings and mothers of proband solid cancer  Furthermore leukemias lymphomas CNS tumors retinoblastoma sarcomas GCT and epithelial neoplasms exhibited statistically significantly increased relative risk same type of cancer as proband  and ',\n",
       "  ('Familial relative risks of early-onset cancers',\n",
       "   's3-2',\n",
       "   'no_sub_id',\n",
       "   10): 'When stratified more finely defined cancer subtypes increased relative risks of any cancer siblings and mothers were observed given proband lymphoid leukemia acute myeloid leukemia Hodgkin lymphomas nonHodgkin lymphomas astrocytomas intracranial and intraspinal embryonal tumors certain gliomas certain specified intracranial and intraspinal neoplasms nephroblastoma and other nonepithelial renal tumors rhabdomyosarcomas fibrosarcomas peripheral nerve sheath tumors and other fibrous neoplasms certain specified soft tissue sarcomas malignant gonadal germ cell tumors and certain unspecified carcinomas ',\n",
       "  ('Familial relative risks of early-onset cancers',\n",
       "   's3-2',\n",
       "   'no_sub_id',\n",
       "   11): 'When stratified raceethnicity relative risk of any cancer siblings and mothers given proband solid cancer was significantly higher Latino and nonLatino black subjects NLW subjects Latino SIR =   CI – NLW SIR =   CI – p=  NonLatino AsiansPacific Islanders API had higher SIRs NLW given proband hematologic cancer SIR =   CI – p= compared NLW and nonLatino Blacks had higher SIRs NLW given proband any cancer SIR =   CI – p= compared NLW or solid cancer SIR =   CI – p= compares NLW  and relative risk of category of cancers given proband that type of cancer Latino subjects also showed higher relative risk of solid cancers NLW subjects Latino SIR =   CI – NLW SIR =   CI – p=  and  Data on other minority groups Asians nonLatino Blacks were too sparse make this comparison',\n",
       "  ('Relative risks of SPMs',\n",
       "   's3-3',\n",
       "   'no_sub_id',\n",
       "   12): 'Overall SPMs all childhood patients were enriched families that exhibited familial risks that is those families two or more primary cancer patients We found  SPMs of  members families that exhibited familial risks two or more primary cancers and  SPMs of  members families that did not exhibit familial risk p= ',\n",
       "  ('Relative risks of SPMs',\n",
       "   's3-3',\n",
       "   'no_sub_id',\n",
       "   13): 'For relative risks we found fold increased risk of SPMs relative general population childrenAYAs FPM SIR =   CI – Most primary cancer types were associated elevated relative risk of SPMs  When stratified raceethnicity similar relative risk of all SPMs given proband cancer was observed Latino subjects and NLW subjects Latino SIR =   CI – NLW SIR =   CI – p= relative risk of all SPMs given proband any cancer and solid cancers were higher nonLatino API subjects compared NLW subjects any cancer nonLatino API SIR =   CI – p hematologic cancers nonLatino API SIR =   CI – p ',\n",
       "  ('Relative risks of SPMs',\n",
       "   's3-3',\n",
       "   'no_sub_id',\n",
       "   14): 'For relative risks of SPMs of same cancer types as FPM we found elevated risks both hematologic and solid cancers When stratified raceethnicity similar relative risks were observed NLW subjects compared Latino subjects given proband hematologic or solid cancer  numbers were too sparse compare Asian and nonLatino Blacks',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   15): 'To our knowledge this is first study quantify familial clustering risks and risks of SPMs earlyonset cancer patients emphasis on racialethnic differences Using linked population registry data California population we found that risk sibling childAYA or mother have earlyonset cancer was elevated once proband was identified earlyonset cancer Likewise relative risks SPMs were elevated childrenAYAs who contracted first primary cancer Due rarity of childhood cancers absolute risk of earlyonset cancer is very small but still higher young siblings and mothers current study  compared general population  calculated SEER of same age group findings were consistent raceethnic groups however magnitude was different Latinos and nonLatino Blacks had higher siblingmaternal relative risks compared NLWs solid cancers and APIs exhibited higher risk of hematologic neoplasms',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   16): 'Consistent our results rich literature primary focus on European ancestry populations has reported excessive familial risks of hematologic malignancies  lymphomas    brain tumors   neuroblastomas  retinoblastomas   germ cell tumors  sarcomas  and melanomas terms of secondary cancers studies have reported excessive risks of SPMs of survivors of hereditary retinoblastoma  chronic myeloid leukemia  chronic lymphocytic leukemia  Hodgkins lymphoma  nonHodgkins lymphoma  and neuroblastoma excessive familial risks of certain cancers are highly likely be associated genetic predisposition archetypic examples are germline lossoffunction mutations which are found ~ of retinoblastoma cases  and adrenal cortical cancer germline mutations accounting most familial cases  Low penetrance common genetic variations instance and genes ALL are associated cancer risk and may also contribute familial concordance as combinations of lowfrequency alleles or polygenic risk scores have been shown be as impactful as single strong predisposition mutations adult cancers   however their contribution cancer clustering children and their families has not yet been studied',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   17): 'Our data demonstrate higher degree of familialbased clustering of solid cancers Latinos and nonLatino Blacks compared nonLatino Whites and hematologic cancers AsianPacific Islanders This familial concordance is likely due both shared genetic and environmental causes and appears affect some cancer types differentially raceethnicity Latinos are admixed population comprising ancestral mixture Native American European and African sources likewise nonLatino Blacks are admixed African and smaller levels of European ancestry AsianPacific Islanders constitute particularly diverse group California origins multiple countries California Latinos particularly youth population are largely Mexico and harbor higher risk of certain cancers particularly pediatric leukemias most common cancer children  however this higher risk is partially accounted by higher frequency of common risk alleles which do not address strong familial predisposition loci  and obviously cannot account their higher familial risk of solid tumors Clearly this higher risk identified relation family units US minorities has not been systematically studied and our results here beg analysis of comparative sources of genetic and environmental risk that contribute higher risk and familial clustering of certain cancers Latinos Blacks and AsianPacific Islanders',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   18): 'Therapy of first primary cancer is major factor induction of secondary independent malignancies    Multiple primary cancer diagnoses are considered key feature of hereditary cancer predisposition syndromes  As such secondary cancers are rare genetics are still likely play strong role  and our overall SPM results here emphasize similar patterning as cancer clustering FPMs Of note our analysis was not designed distinguish risk influences therapies primary cancers on secondary cancers',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   19): 'For some tumor types germline predisposition was readily noted this cohort example  of affected relatives who had proband retinoblastoma were diagnosed same cancer unsurprising finding given that germline mutations account significant proportion of retinoblastoma are highly penetrant and those tumors tend be diagnosed young We also observed increased relative risks sarcomas given proband leukemias suggesting presence of families Li–Fraumeni syndrome which is characterized spectrum of childhood and adult onset cancers including adrenocortical carcinoma breast cancer CNS tumors sarcomas and leukemia ',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   20): 'Populationlevel selection pressures are thought influence relative frequencies of alleles instance genetic adaptations that shaped Native American genome cold and warm environments  and immune response following colonization Europeans  Our result suggests that some adaptive selection pressures or simply genetic drift specific ethnic groups may differentially influence familial cancer clustering as it does immune and metabolic phenotypes several ethnic groups   If replicated other study settings this contrast genetic risk of child and adult onset cancers ethnicity should be studied further fuller understanding of familial risks',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   21): 'Our analyses capitalized on highly diverse population California allowing us quantify relative risks different ethnic groups Moreover utilization of linked populationbased registries California enabled us minimize selection and information biases introduced case–control study design or other strategies that only sample portions of population There are also some limitations of our study Despite large number of total cancer cases number of affected siblings and second primaries is very small some cancer types thus limiting power detect significant relative risks Also we are unable track cancer incidence affected siblings maternal cancers and SPMs that may have been diagnosed outside of California addition followup time of  years is not enough comprehensive detection of SPMs probands nor cancers arising proband mothers older ages These insufficient followup time and lossto followup issues have limited our ability quantify relative risks mothers cancer onset older ages  years Furthermore it is likely that low number of mothers cancer is result of bias some very strong cancer predispositions so patients could not survive long enough or be healthy enough reproduce Lastly lack of records on fathers reduces our ability quantify relative risks other firstdegree relatives and may reduce appreciation of potential contribution of highrisk cancer predisposition syndromes which can be inherited either parent',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   22): 'Accepting those limitations current dataset our study has several important implications that may open windows future research First genetic predispositions driving excessive earlyonset cancer risks Latino nonLatino Black and Asian populations whether higher frequencies of known cancer predisposition syndromes or mutations novel genes or higher burden of common or rare genetic risk alleles warrant further investigation Second comparative attributable fraction of familial risk based on environmental risk factors interacting genetic predispositions warrants further investigation Lastly descriptive studies on familial and secondary cancer risks raceethnic groups other NLW may provide additional insights cancer incidence variation leading incidence disparities raceethnicity and provide critical information tailoring appropriate messages familial genetic counseling'},\n",
       " {('Introduction',\n",
       "   'H1-1-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   0): 'During last decades several large randomized trials have demonstrated that neoadjuvant radiotherapy plays wellestablished role improvement of locoregional control of rectal cancer but is not associated increased longterm survival Therefore benefits and adverse events of radiotherapy should be carefully balanced when considering all potential effects of radiotherapy Radiotherapyassociated second primary cancer SPC is rare but notable late complication of cancer therapy',\n",
       "  ('Introduction',\n",
       "   'H1-1-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   1): 'Studies assessing risk of SPC are inconsistent regarding role of radiotherapy rectal cancer treatment Although some studies have demonstrated increased risk of overall SPCs radiotherapy rectal cancer treatment others have reported no obvious increased risk Because of likelihood of pelvic organs receiving greater radiotherapy dose organs nonpelvic areas it is necessary understand risk of SPCs organs irradiated volume Assessments of potential risk of radiotherapyassociated SPC pelvic cancers including malignant neoplasms of prostate and bladder have verified idea of increased risk of SPCs patients undergoing pelvic radiotherapy However whether risk of second gynecological malignant neoplasms SGMNs is increased radiotherapy rectal cancer has not been well addressed',\n",
       "  ('Introduction',\n",
       "   'H1-1-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   2): 'Although previous studies have investigated risk of SGMNs patients rectal cancer treated radiotherapy current research on this topic is limited and contradictory Most studies oversimplified risk estimation grouping various types of gynecological malignant neoplasms GMNs broad category consideration of great tumor heterogeneity and differences pathogenesis SGMN entities understanding of radiotherapyassociated SGMN has prognostic and therapeutic implications but has been rarely studied Therefore we performed this study aims of investigating radiotherapy and risk of individual types of SGMN and assessing patient survival outcomes',\n",
       "  ('Database and Participants',\n",
       "   'H2-1-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   3): 'Female patients diagnosed rectal cancer as first primary cancer were identified registries of Surveillance Epidemiology and End Results SEER database January   and December   All primary cancer sites were coded according The patients included were pathologically diagnosed rectal cancer C or rectosigmoid cancer C tumor stage was restricted localized and regional stage and details of tumor stage are shown eTable The exclusion criteria included patients whom rectal cancer were not their first primary cancer patients who were aged younger years patients distant stage patients who survived less years rectal cancer diagnosis patients who did not undergo surgery and patients missing data on radiotherapy surgery age tumor stage race survival status or followup information This study has been approved Ethics Committee of Cancer Hospital Chinese Academy of Medical Sciences access and use of SEER data did not require informed patient consent This study followed Strengthening Reporting of Observational Studies Epidemiology  reporting guideline cohort studies',\n",
       "  ('Treatment Interventions for Rectal Cancer',\n",
       "   'H2-2-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   4): 'Patients rectal cancer were classified groups according initial treatment modality radiotherapy group was composed of patients rectal cancer who received surgery and neoadjuvant externalbeam radiotherapy and noradiotherapy group was composed of patients who received surgery alone We excluded patients who received other types of radiotherapy ie brachytherapy combination therapy SEER database collected data only on initial course of cancer treatment and radiotherapy doses were not registered SEER database',\n",
       "  ('Definition and Follow-up of SGMNs',\n",
       "   'H2-3-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   5): 'The primary outcome of this study was development of SGMN which was defined as any type of GMN occurring more years treatment of rectal cancer because of least year latency period radiotherapy exposure solid tumor occurrence SEER program adheres guidelines distinguish SPCs recurrent disease obtain comprehensive estimations risk of SGMNs we first estimated risk all types of combined SGMNs and then separately estimated risk different types of female genital organs including cervix uteri CC corpus and uterus CC C ovary C and other female genital organs as  group CC C CC C followup SGMNs began  years rectal cancer diagnosis and ended date of diagnosis of any SGMN allcause death or years of followup whichever occurred first cutoff point followup was defined as January   April  SEER data release',\n",
       "  ('Statistical Analysis',\n",
       "   'H2-4-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   6): 'FineGray competing risk regression analysis was used assess cumulative incidence of SGMN development Experiencing nonSGMN and dying of all causes were considered competing events calculating hazard ratios HRs and  CIs SGMN occurrence multivariable risk model was built using backward selection procedure variables sided univariable analyses which was considered statistically significant and included multivariable analyses χ tests were used compare categorical data or Fisher exact test when frequencies were MannWhitney test were used analysis of continuous variables normal and nonnormal distribution respectively This procedure was performed R software version  R Project Statistical Computing',\n",
       "  ('Statistical Analysis',\n",
       "   'H2-4-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   7): 'The radiotherapyassociated risk RR was estimated using Poisson regression analysis relative risk and  CIs of SGMN development patients rectal cancer who received radiotherapy compared those who did not receive radiotherapy and RRs were calculated R software version  Then Poisson regression analysis was used calculate standardized incidence ratio SIR and  CIs SIR was defined as ratio of observed incidence SGMNs rectal cancer survivors incidence of GMNs US general population SIRs were calculated SEERStat  Both RRs and SIRs were adjusted age rectal cancer diagnosis and calendar year of rectal cancer diagnosis our analysis details of statistical methods are shown eFigure To further evaluate dynamic risks and incidence SGMNs associated radiotherapy we calculated RRs and SIRs stratified latency time rectal cancer diagnosis age rectal cancer diagnosis and year of rectal cancer diagnosis',\n",
       "  ('Statistical Analysis',\n",
       "   'H2-4-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   8): 'To evaluate prognosis of SGMNs KaplanMeier method was used calculate year overall survival SGMNs and only primary GMN and values were calculated logrank test Overall survival was defined as time SGMN diagnosis death any cause only primary GMN was defined as patients diagnosed only GMN and any other cancers throughout their lifetime Propensity score matching was used reduce possible bias survival comparison These analyses were performed using R software version ',\n",
       "  ('Patient Characteristics',\n",
       "   'H2-5-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   9): 'A total of   patients rectal cancer were identified eFigure After excluding patients nonmatching data   patients remained final cohort   patients  were White and median age was  years interquartile range  years median followup time was  months interquartile range  months total of   patients  were noradiotherapy group and  patients  were radiotherapy group baseline characteristics of patients rectal cancer treatment modality are shown After latency of  years  patients noradiotherapy group and  patients radiotherapy group developed SGMN baseline characteristics of patients who developed SGMN are shown eTable ',\n",
       "  ('Cumulative Incidences of SGMNs',\n",
       "   'H2-6-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   10): 'The cumulative incidence of combined SGMNs was rectal cancer diagnosis incidences were patients no radiotherapy and patients receiving radiotherapy organspecific analyses cumulative incidences of cancer of uterine corpus ovarian cancer and other SGMNs were significantly higher radiotherapy group noradiotherapy group including cancer of uterine corpus  vs    ovarian cancer  vs  =  and other SGMNs  vs  =  but no difference was observed cervical cancer BE',\n",
       "  ('Risk of SGMNs Attributable to Radiotherapy',\n",
       "   'H2-7-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   11): 'All variables listed were selected univariable competing risk regression analysis eTables In multivariable analysis radiotherapy was associated higher risk of developing combined SGMNs adjusted HR   CI analyses of each type of SGMN increased risks were observed cancer of uterine corpus adjusted HR   CI    and ovarian cancer adjusted HR   CI  =  but not cervical cancer or other SGMNs subgroup analyses increased risk of developing cancer of uterine corpus and ovarian cancer was associated radiotherapy most subgroups HRs greater eTables  and eFigures  and ',\n",
       "  ('Risk of SGMNs Attributable to Radiotherapy',\n",
       "   'H2-7-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   12): 'The RRs were calculated confirm risk of SGMNs attributable radiotherapy We found that adjusted RR of additional risk combined SGMNs was   CI    and increased risk was also observed cancer of uterine corpus adjusted RR   CI    ovarian cancer adjusted RR   CI  =  and other SGMNs adjusted RR   CI  =   We then found that SIR combined SGMNs was   CI patients who received radiotherapy and SIRs patients who underwent radiotherapy were significantly higher cancer of uterine corpus SIR   CI    and other SGMNs SIR   CI    ',\n",
       "  ('Dynamic Risk and Incidence Evaluation for SGMNs',\n",
       "   'H2-8-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   13): 'To assess risks of SGMNs attributable radiotherapy we established  dynamic RR plots based on latency period time of rectal cancer diagnosis and age rectal cancer diagnosis  eTables In dynamic latencyRR plot increased risk of cancer of uterine corpus was observed early latency but this risk presented downward trend late latency  months adjusted RR   CI     months adjusted RR   CI     months adjusted RR   CI  = eTable In dynamic ageRR plot no increased risk of cancer of uterine corpus was observed patients aged years rectal cancer but risk gradually increased and peaked age of older years  years adjusted RR   CI  =   years adjusted RR   CI    ≥ years adjusted RR   CI    B eTable In dynamic diagnosis timeRR plot slightly increased risk of cancer of uterine corpus was observed radiotherapy years to  and this risk remained elevated up years to   adjusted RR   CI  =   adjusted RR   CI     adjusted RR   CI    ≥ adjusted RR   CI  =  C eTable However we observed  opposite risk trends RR plots of ovarian cancer compared trends cancer of uterine corpus such as latencyRR plot  months adjusted RR   CI  =   months adjusted RR   CI  =   months adjusted RR   CI  =  Figure D Supplement Table  ageRR plot  years adjusted RR   CI  =   years adjusted RR   CI  =  ≥ years adjusted RR   CI  =  Figure E Supplement Table  and diagnosis timeRR plot  adjusted RR   CI  =   adjusted RR   CI  =   adjusted RR   CI  =  ≥ adjusted RR   CI  =  DF eTable  and eTable ',\n",
       "  ('Dynamic Risk and Incidence Evaluation for SGMNs',\n",
       "   'H2-8-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   14): 'In addition we evaluated dynamic SIRs patients treated radiotherapy and patients not treated radiotherapy patients not treated radiotherapy no increased incidences of cancer of uterine corpus eFigure AC were observed compared incidence US general population plots patients who underwent radiotherapy SIRs cancer of uterine corpus presented similar findings as RR plots eFigure AC In analyses of SIRs ovarian cancer we found that SIRs ovarian cancer patients who did not receive radiotherapy were significantly lower those US general population plots eFigure DF but no significant increased incidence of ovarian cancer was observed patients treated radiotherapy compared US general population eFigure DF The details of RRs and SIRs were shown eTables ',\n",
       "  ('Survival Outcome of SGMNs',\n",
       "   'H2-9-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   15): 'We compared survival patients cancer of uterine corpus radiotherapy and no radiotherapy and year overall survival of patients who developed cancer of uterine corpus radiotherapy was significantly lower that of patients no radiotherapy both propensity score matching and propensity score matching B We then used matched only primary cancer of uterine corpus patients as control group using propensity score matching We observed that year overall survival patients who developed cancer of uterine corpus radiotherapy was significantly lower that matched patients only primary cancer of uterine corpus year overall survival  vs  =  C and no difference was observed patients radiotherapy and matched patients only primary cancer of uterine corpus D Information on only primary GMNs and survival analyses combined SGMNs ovarian cancer cervical cancer and other SGMNs were shown eTables  and eFigures ',\n",
       "  ('Strengths and Limitations',\n",
       "   'H2-10-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   16): 'The strengths of present study include long followup period discover potential SGMNs as well as large observation population relatively homogenous treatment exposure identified SEER database This study has limitations First lack of randomization of initial treatment rectal cancer may be associated potential biases However occurrence of SGMNs may not only be associated radiotherapy exposure but may also be affected other crucial risk factors such as lifestyle genetic background environmental factors and other cancerrelated treatments Therefore it is impossible balance all factors treatment types Instead we adjusted all confounding risk factors using multivariable risk competing model reduce potential bias associated lack of randomization Second we could not determine associations modality of radiotherapy radiotherapy dose and number of administrations and risk of SGMNs Third SEER database records only initial treatment information of rectal cancer and whether patients rectal cancer received delayed radiotherapy subsequent treatment is unknown which may potentially misclassify patients radiotherapy group noradiotherapy group However this limitation is unlikely affect our main conclusion but reflects only underestimation of increased risk attributable radiotherapy',\n",
       "  ('Conclusions',\n",
       "   'H1-5-ZOI200984',\n",
       "   'no_sub_id',\n",
       "   17): 'In this cohort study several methodologies were used together assess increased risk of developing cancer of uterine corpus and ovarian cancer female patients rectal cancer who received radiotherapy and risk of SGMN was evaluated several dimensions which together could provide meaningful reference treatment and followup of SGMNs patients rectal cancer radiotherapy'},\n",
       " {('Introduction',\n",
       "   'Sec1',\n",
       "   'Par2',\n",
       "   0): 'Hematological malignancies are fourth most frequently diagnosed group of cancers worldwide annual incidence rate of  per  inhabitants Europe – They encompass heterogeneous group of diseases diverse etiology presentation and outcomes Our understanding of these neoplasms has evolved rapidly recent decades resulting multiple classification updates Currently World Health Organization WHO classification of hematologic malignancies first published and later updated and  is gold standard study of these neoplasms Such continuous definition refinements however have posed significant problems populationbased cancer registries present complete and accurate data full spectrum of hematological neoplasms and particularly myeloid neoplasms MNs',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par3',\n",
       "   1): 'MNs are group of clonal disorders characterized excessive proliferation impaired selfrenewal andor altered differentiation of hematopoietic stem cells and myeloid progenitor cells Broadly MNs are classified four large categories acute myeloid leukemia AML myeloproliferative neoplasms MPN myelodysplastic syndromes MDS and MDSMPN overlap syndromes However MDS and several MPN subtypes were first recognized as malignant disordersand thus reportable cancer registriesin publication of third revision of International Classification of Disease Oncology ICDO Regarding AML past epidemiological studies were prone group all leukemias together best differencing age range ie pediatricadult and chronicity ie acutechronic but ignoring cell lineage differences ie lymphoidmyeloid This situation changed correspondence was established WHO classifications and ICDO codes then several studies using largest European and North American datasets as well as hematologyspecialized cancer registries have reported detailed epidemiological data of MNs Still and given that most entities are too rare make power robust estimates regional studies populationbased data of several clinically meaningful histological subtypes are limited Particularly Spain there are no available comprehensive nationwide estimates only one previous study providing regional data',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par4',\n",
       "   2): 'The aim of this study was assess incidence of MNs subtypes Spain over period – and estimate number of MNs expected using harmonized data Spanish Network of Cancer Registries REDECAN',\n",
       "  ('Ethics approval',\n",
       "   'Sec3',\n",
       "   'Par8',\n",
       "   3): 'This study is based on data cancer registries gathered Spanish network of cancer registries REDECAN public health administration of each autonomous communityprovince authorized collection and use of this data its analysis requirement of informed consent and ethical approval covered Spanish general and public health laws  and ',\n",
       "  ('Ethics approval',\n",
       "   'Sec3',\n",
       "   'Par9',\n",
       "   4): 'The authorizing bodies each autonomous communityprovince are listed Asturias Sección de Información Sanitaria Servicio de Evaluación de la Salud Calidad y Programas de la Dirección General de Salud Pública Consejería de Sanidad Canary Islands Servicio de Epidemiología y Prevención Dirección General de Salud Pública Servicio Canario de la Salud Castellón Conselleria de Sanitat Dirección General de Salud Pública Ciudad Real Consejería de Sanidad y Asuntos Sociales de la Junta de Comunidades de CastillaLa Mancha Cuenca Consejería de Sanidad y Asuntos Sociales Junta de Comunidades de Castilla la Mancha Euskadi Dirección de Planificación Ordenación y Evaluación Sanitarias Departamento de Salud Gobierno Vasco Girona Plan Director de OncologíaInstituto Catalán de Oncología Granada Consejería de Salud de la Junta de Andalucía adscrito para su desarrollo la Escuela Andaluza de Salud Pública EASP La Rioja Servicio de Epidemiología y Prevención Sanitaria de la Consejería de Salud y Servicios Sociales del Gobierno de La Rioja Mallorca Dirección General de Salud Pública y Participación Murcia Consejería de Salud de Murcia Navarra Departamento de Salud del Gobierno de Navarra Instituto de Salud Pública y Laboral de Navarra Tarragona Hospital Universitario Sant Joan de Reus',\n",
       "  ('Myeloproliferative neoplasms',\n",
       "   'Sec5',\n",
       "   'Par12',\n",
       "   5): 'The CR and ASR MPN were   CI   and   CI   respectively most frequent subtype was essential thrombocythemia  of cases ASR =   CI   followed chronic myeloid leukemia  of cases ASR =   CI   and polycythemia vera  ASR =   CI   Table  Median age IQR diagnosis was  – years being slightly lower cases mastocytosis  – years Higher rates men in women were reported almost all subtypes being particularly higher primary myelofibrosis sex ratio =  while no difference sex was seen essential thrombocythemia sex ratio = incidence of MPN increased period – APC of   CI   Table  Moreover results specific subtype indicate that this increment incidence was namely due contribution of essential thrombocythemia   CI   primary myelofibrosis   CI   and polycythemia vera   CI   Conversely we evidenced decrease incidence of chronic myeloid leukemia −   CI −  −  and MPN NOS −   CI −  − ',\n",
       "  ('Myelodysplastic/myeloproliferative neoplasms',\n",
       "   'Sec6',\n",
       "   'Par13',\n",
       "   6): 'The CR and ASR MDSMPN were   CI   and   CI   respectively far most common subtype was chronic myelomonocytic leukemia  of cases ASR of   CI   and marked male predominance sex ratio =  Table median IQR age diagnosis was  – years incidence of MDSMPN rose markedly throughout – APC of   CI   Table ',\n",
       "  ('Myelodysplastic syndromes',\n",
       "   'Sec7',\n",
       "   'Par14',\n",
       "   7): 'The CR and ASR MDS were   CI   and   CI   respectively Table most frequent subtype was MDS excess of blasts  ASR =   CI   closely followed MDS multilineage dysplasia  ASR =   CI   and MDS single lineage dysplasia  ASR =   CI   while  of cases were MDS unclassifiable Median age IQR diagnosis was  – years and incidence rates were higher men except MDS associated isolated delq which we noted reverse sex ratio  There was positive incidence trend of overall MDS throughout period APC =   CI   mostly due MDS multilineage dysplasia APC =   CI   and MDS associated isolated delq APC =   CI   Conversely cases of MDS single lineage dysplasia decreased period of study APC = −  −  −  Table ',\n",
       "  ('Acute myeloid leukemia',\n",
       "   'Sec8',\n",
       "   'Par15',\n",
       "   8): 'The CR and ASR AML were   CI   and   CI   respectively Table AML cases  were AML NOC  were AML recurrent cytogenetic abnormalities  were AML multilineage dysplasia  were therapyrelated and  were NOS AML recurrent cytogenetic abnormalities  = most frequent subtype was AML t followed AML t male predominance was shared all subgroups overall sex ratio = exception of AML and MDS therapy related sex ratio = median IQR age of AML patients was  – years being lower AML cytogenetic abnormalities  – years incidence of overall AML was relatively stable over time yet there was increase incidence of specified cases detriment of AML NOS cases APC = −   CI −  −  Table ',\n",
       "  ('Acute myeloid leukemia with ambiguous lineage and NOS cases',\n",
       "   'Sec9',\n",
       "   'Par16',\n",
       "   9): 'There were  cases of acute myeloid leukemia ambiguous lineage  of them being biphenotypic acute leukemia overall CR and ASR were   CI   and   CI   respectively Finally there were  NOS cases  of overall dataset higher median age that of MNs as whole  – years We evidenced marked negative incidence trend period of study both acute leukemia of ambiguous lineage APC = −   CI −  −  and NOS cases APC = −   −  −  Table ',\n",
       "  ('Projections for 2021',\n",
       "   'Sec10',\n",
       "   'Par17',\n",
       "   10): 'Predicted incidence of MNs overall and sex are detailed Table  According our projections  new incident cases of MNs will be diagnosed Spain of which  will be MPN  MSDMPN  MDS  AML and  acute leukemia of ambiguous lineage and  NOS cases',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par18',\n",
       "   11): 'Limited epidemiological data are available on whole spectrum of hematologic disorders of myeloid lineage Europe most relevant data comes two large European datasets RARECARE – =  and HAEMACARE – =  collaborative projects and two hematospecialized registries Coté dOr France – =  and UK Haematological Malignancy Research Network HMRN – =  Our largepopulationbased study which includes  cases diagnosed introduction of WHO classification breakthrough further complements these data providing complete estimates of MNs burden Spain – predictions ',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par19',\n",
       "   12): 'In line previous studies incidence of MNs was markedly higher men in women most subtypes Notable exceptions included MDS associated isolated delq AML and MDS therapy related and essential thrombocythemia already reported literature Likewise incidence of all MNs increased advancing age being particularly marked NOS cases which incidence rose sharply age  years This might suggest decline quality of diagnostic workup elderly who are less likely receive aggressive diagnostic tests due comorbidity andor frailty and may therefore receive suboptimal treatment their conditions',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par20',\n",
       "   13): 'Regarding specific MNs subtypes lower incidence rates most entities were reported our study comparison most recent data provided HMRN This could be partly explained specialized nature of HMRN all diagnoses made and coded clinical specialists working single integrated hematopathology laboratory and lack of concordance recording of progressionstransformations contrast incidence rates of overall MPN MDS and MDSMPN our region were markedly higher comparison European and US datasets most of them covering years beforeclose implementation of ICDO and WHO classification As far as MPN are regarded disparities were mainly attributed polycythemia vera and essential thrombocythemia while rates of chronic myeloid leukemia consistently documented s identification of its causal chromosome transition primary myelofibrosis and mastocytosis were similar studies Such differences may be linked identification of JAK mutation and derived  WHO guidelines MPN whose impact is not documented series covering only previous years',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par21',\n",
       "   14): 'On other hand incidence of AML which is longestablished entity was more homogeneous different regions Indeed overall rates were consistent European and US findings as well as smaller European series while slightly lower rates were reported Canada and Switzerland Karyotypic information was not available many of our cases and thus proportion of AML cytogenetic abnormalities  was slightly lower comparison more specific studies However rates of AML tqq were still higher compared European average further supporting hypothesis that such entity might be more prevalent individuals Spanish ancestry Finally most of these studies included AML of ambiguous lineage AMLNOS subgroups although it is placed as distinct category AML introduction of WHO classification Further studies are warranted clarify epidemiology of these entities owing their clinical relevance',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par22',\n",
       "   15): 'We evidenced increasing incidence trends of MDSMPN MDS and several MPN previously reported literature and mostly linked refinements diagnostic classification and registration practices latter this was particularly seen three most frequent Philladelphia chromosome negative subtypes and thus may be linked implementation of screening JAK mutation same vein Girodon et al documented almost twofold increase incidence of essential thrombocythemia but not remaining MPN subtypes agreement few European studies examining AML incidence trends we found stable incidence of overall AML period of study contrast increasing trend was found Dutch pediatric study – and Canada – and US to general population latter mainly attributed changes registration of transformations Surveillance Epidemiology and End Results SEER program Finally NOS cases decreased remarkably period of study which could be attributed both more specific clinical diagnosis andor improved codification Spanish cancer registries',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par23',\n",
       "   16): 'The etiology of MNs line most hematological malignancies is still uncertain Several subtypes have been consistently associated treatments ie radiation alkylating agents or topoisomerase II inhibitors while environmental epidemiological studies suggest potential role of obesity tobacco exposure autoimmune disorders and infections myelodisplastic or myeloproliferative diseases However neither these factors nor genetic alterations currently described can explain large variability incidence of these neoplasms addition drawing etiological hypothesis based on geographic heterogeneity incidence rates is hampered heterogeneity accuracy and completeness registration of several subtypes Several medicalclaimsbased studies have shown underreporting of MNs namely MDS and MPN which are often diagnosed and managed outpatient setting and might be missed surveillance systems relying on hospital registration and elderly which diagnostic evaluation might not be as aggressively sought as younger individuals Indeed we evidenced marked differences incidence rates Spanish provinces highest incidence rates of MDS MPN and MDSMPN reported Girona cancer registry which has started several initiatives cope these challenges Following example of French Network of Cancer Registries FRANCIM training programs improve codification and registration of hematological neoplasm have been boosted REDECAN last few years which are expected start bear fruits future studies',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par24',\n",
       "   17): 'Since  there have been numerous advances identification of genetic biomarkers associated specific MNs which led release of updated WHO classification impact of these changes will be noticeable next years when they become routinely distinguished clinical practice and consistently coded cancer registries incorporation of these updates cancer registry level will be eased release of ICDO second revision which is recommended use Further studies contemporary data including these classification changes are warranted',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par25',\n",
       "   18): 'The number of expected MNs depicts present cancer burden of these malignancies Spain However these data should be interpreted caution due several factors First some subtypes are extremely rare making estimates less robust Furthermore estimates provided herein do not reflect impact of new  WHO classification nor that of coronavirus disease  COVID as they are based on extrapolations of cancer data collected previous years Regarding latter although full extent of impact of COVID pandemic remains unknown delays cancer diagnosis are expected cause shortterm decline cases followed increasing incidence of advancedstage diagnosis addition if over period – there had been increase completeness registration of MN cases corresponding positive effect on APC this would cause overestimation number of cases predicted year  Nonetheless these results are still interesting clinicians and public health specialists evaluating cost of management and new treatments these pathologies and account gap expected and observed cases COVID pandemic',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par26',\n",
       "   19): 'Among strengths of this populationbased study is large number of MNs that allowed us assess and compare incidence rates not only common but also relatively rare entities However several limitations must be considered when interpreting our results First changing classification and diagnostic criteria and consequent heterogeneity disease definitions countries clinical centers and cancer registries hamper interpretation of our incidence rates and trends as well as comparisons previous studies addition we cannot exclude aforementioned underreporting of cases particularly documented MDS and MPN and elderly addition we lacked centralized pathology and clinical review which could have decreased proportion of NOS cases and improved quality of our data This is particularly relevant MDS due poor interobserved concordance diagnosis and numerous nonneoplastic conditions that can mimic such neoplasms Nevertheless spite of unavoidable biases due variability and variation registration quality and coding practices over  of cases had adequate morphology specification',\n",
       "  ('Discussion',\n",
       "   'Sec11',\n",
       "   'Par27',\n",
       "   20): 'In conclusion this study presents first comprehensive populationbased analysis of MNs incidence Spain It highlights some useful points public health authorities such as increasing incidence of several subtypes remarkable variability incidence rates especially of MDS MPN and MDSMPN provinces and number of cases expected based on these data negative trend incidence of NOS cases suggests more specific diagnosis andor improvements registration of these cases study period however additional efforts should be made improve quality of MNs data future studies'},\n",
       " {('Introduction',\n",
       "   'Sec1',\n",
       "   'Par2',\n",
       "   0): 'Cancer is leading cause of death worldwide It is group of diseases that can initiate any tissue or organ when abnormal cells grow uncontrollably and migrate their original sites invade other parts of body Metastasis is process which cancer cells spread their origins secondary sites of body often bloodstream or lymphatic system most cases metastatic cancer cannot be cured treatment Because of this metastasis is major cause of cancer mortality and is responsible over  of cancer deaths  Forkhead box FOX proteins are vast group of transcription factors united evolutionarily conserved wingedhelix DNA binding domain FOXOs forkhead box proteins of class O subgroup are considered be tumour suppressors virtue of their established functions cell cycle arrest apoptosis senescence differentiation DNA damage repair and scavenging of reactive oxygen species  Besides these cellular processes essential cancer initiation tumorigenesis FOXOs have also emerged as key modulators of metastasis and angiogenesis two key factors critical cancer progression and establishment secondary sites',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par3',\n",
       "   1): 'The FOX wingedhelix structure reminiscent of butterfly consists of three Nterminal αhelices three βstrands and two loops this unique structural feature FOX proteins recognise regulatory sequences their target genes direct gene expression date  A–S subfamilies and  mammalian FOX proteins have been identified and are classified according their sequence homology wingedhelix and other functional domains Despite FOX proteins possessing highly analogous DNA binding domains their distinct tissuespecific expression patterns and regulatory mechanisms provide them their dedicated functions  However addition their specific roles evidence suggests that FOX proteins also possess certain degree of functional redundancy safeguard organisms broad spectrum of developmental and metabolic diseases due loss of function of singlecore FOX protein or gene haploid insufficiency consequence misregulation misexpression andor mutation of FOX genes can lead human genetic and metabolic diseases deregulated ageing and cancer',\n",
       "  ('Normal FOXO function',\n",
       "   'Sec2',\n",
       "   'Par4',\n",
       "   2): 'In mammals FOXO subfamily consists of four members FOXO FOXO FOXO and FOXO These four FOXO transcription factors bind their target genes as monomers or heterodimers control cell fate distinct conditions  They also interact coactivator corepressors and other protein partners modulate and finetune their activity All FOXO proteins have  different core functional domains namely wingedhelix DNA binding domain nuclear localisation sequence nuclear export sequence and transactivation domain FOXODNA binding domain recognises and binds consensus sequences ′GTAAACTA′ genome  Furthermore consensus flanking sequences also play critical part determining interaction specificity target gene and FOX protein  Each of FOXO proteins is differentially expressed distinct tissues instance FOXO and FOXO are highly expressed adipose tissue and skeletal muscle respectively  FOXO is ubiquitously expressed multiple tissues including brain kidney and heart whilst FOXO is predominantly expressed development and nervous tissue   Despite their distinct tissuespecific expression patterns regulatory overlap and functional redundancy FOXO proteins have been observed  This may impact role and regulation of FOXOs multiple FOXO protein–expressing cells ',\n",
       "  ('Normal FOXO function',\n",
       "   'Sec2',\n",
       "   'Par5',\n",
       "   3): 'FOXO genes are conserved throughout evolution lower organisms mammals but exist only as single gene invertebrates FOXO is known as dFOXO fruit fly  Daf nematode and FoxO In fact first forkhead FOX gene was initially identified fruit flies as genetic mutation homeotic gene leading development of abnormal forked head structure later study showed that dFOXO controls lifespan and mediates insulin signalling flies Daf is characterised as downstream target of insulininsulinlike growth factor  IGF pathway and expression of Daf is associated ageing and longevity FoxO is critical regulator unlimited lifespan  Whilst direct experimental evidence role FOXO longevity has not been demonstrated mammals studies these evolutionarily conserved model organisms suggest that FOXO proteins are important regulation of development and senescenceageing Collectively these FOXO transcription factors are involved regulation of cell cycle apoptosis and metabolism experimental model organisms FOXOs have also been found control stem cell maintenance and lifespan as well as agerelated diseases such as cancer ageing and diabetes Multiple upstream pathways regulate FOXO activity posttranslational modifications and cofactor interactions diversity of this upstream regulation and downstream effects of FOXOs suggest that they function as regulators of tissue homeostasis over time and coordinators of responses environmental changes including growth factor deprivation metabolic stress eg metabolite starvation and oxidative stress ',\n",
       "  ('Normal FOXO function',\n",
       "   'Sec2',\n",
       "   'Par6',\n",
       "   4): 'As transcription factors predominant mode of action of FOXO proteins is binding FHRE elements located proximal gene promoter regions and recruiting other components of transcription apparatus including other transcription factors transcriptional cofactors and chromatin regulators modulate target gene transcription  Compacted chromatin constitutes barrier transcription activators accessing promoters and studies using recombinant FOXO protein have shown that FOXO proteins can operate as pioneer factors recognising their cognate sites promoter on nucleosome opening up chromatin and conferring active chromatin state transcription proceed   This role of FOXO proteins as pioneer factors is further confirmed later studies showing that FOXO other forkhead proteins can open and remodel chromatin and recruit additional regulatory factors promote transcription its wingedhelix motif   Moreover recent epigenetic studies have shown that FOXO is also recruited more distal gene regulatory elements called enhancers these cases FOXO and probably other FOXOs function binding already active enhancers further promote their ability drive cell type–specific gene expression ',\n",
       "  ('FOXOs and tumorigenesis',\n",
       "   'Sec4',\n",
       "   'Par7',\n",
       "   5): 'FOXOs are considered be tumour suppressors virtue of their established functions cell cycle arrest senescence apoptosis differentiation DNA damage repair and scavenging of reactive oxygen species  Studies using FOXO gene knockout mice have helped confirm FOXO proteins as genuine tumour suppressors  FOXO  tripleknockout mice develop thymic lymphomas and haemangiomas These triple FOXOdeficient animals have been shown be predisposed lymphomagenesis loss of restriction on cellular proliferation and survival same time these tripleFOXOdeficient animal studies also reveal that FOXO isoforms have overlapping functions distinct biological functions specific tissues and that FOXO proteins are associated cancer progression metastasis and angiogenesis FOXO proteins have been proposed as tumour suppressors primarily because of their established functions promoting cell cycle arrest and apoptosis as well as preventing accumulation of damages induced genotoxic agents and oxidative stress   ',\n",
       "  ('FOXOs and senescence',\n",
       "   'Sec5',\n",
       "   'Par8',\n",
       "   6): 'Senescence is irreversible state of cell cycle arrest and critical tumoursuppressive barrier obstruct neoplastic transformation of stem cells It limits renewal capacity of stem cells and cancer cells role FOXO protein cellular senescence is confirmed study showing that oncogeneinduced senescence also involves repression of phosphoinositide kinase PIKAkt oncogenic signalling pathway and consequent induction of FOXO activity support of this FOXO overexpression or inhibition of PIKAkt signalling axis can induce cells enter senescence promoting expression of p addition FOXO promotes expression of retinoblastoma family protein p RB induce senescence proliferating cells   FOXO can also repress expression of potent oncogene FOXM limit stem cell renewal trigger senescence – FOXM can counteract oxidative stress–induced senescence enhancing transcription of cell selfrenewal Bmi gene  Moreover inhibition of FOXM cancer cells such as those of breast gastric gallbladder and liver cancer leads cellular senescence – agreement overexpression of cyclindependent kinase CDKtargeting microRNA miR can induce senescence ovarian cancer cells repressing FOXM  Likewise CDK inhibitor LEE can also induce senescence neuroblastoma cells restricting induction of FOXM  Collectively these findings propose key tumoursuppressive role FOXO proteins and downstream targets cellular senescence both normal and cancer cells',\n",
       "  ('FOXOs and autophagy',\n",
       "   'Sec6',\n",
       "   'Par9',\n",
       "   7): 'As tumour suppressors FOXOs play multiple roles restricting cancer development and progression FOXO proteins are involved regulation of autophagy which functions destroy and recycle cytoplasmic organelles and macromolecules Autophagy is tumoursuppressive mechanism that it can prevent cellular transformation preventing accumulation of carcinogenic defective lipids proteins and organelles Moreover it is also mediator of anticancer chemotherapy–induced cell death  Conversely autophagy also enables cancer cells survive stress conditions such as nutrient starvation oxidative stress and chemotherapy example haploinsufficiency of autophagy genes such as LC BECN and Bif has been shown drive chromosome instability increase migration and promote early tumorigenesis – One of first reports of FOXO having role autophagy comes mouse muscle atrophy study showing that FOXO activates protein degradation inducing autophagy skeletal muscle cells  FOXO proteins are also involved regulation of autophagy order recycle essential amino acids nutrient starvation  FOXO has been shown induce autophagy FOXOdependent fashion activating PIKCA enhance PIKAkt activity  Specifically FOXO depletion has been found attenuate FOXOinduced autophagy number of cell lines  Autophagic cell death is enhanced when acetylated FOXO binds Elike autophagyrelated protein  Atg essential initiator of autophagy  Despite these findings showing that FOXOs have tumoursuppressive role context of autophagy other reports indicate they have oncogenic role example studies neuronal cells reveal that cJun Nterminal kinase JNK deficiency causes increased autophagy promoting cell survival FOXOBNIPBeclin pathway these JNKdeficient neurons FOXO is activated promote expression of BNIP which displaces autophagic effector Beclin inactive BclXL complexes induce autophagy and cell survival  However energy stress conditions p mitogenactivated protein kinase MAPK has also been shown induce this FOXOBNIP axis repress mTORC and cell survival  Similarly deacetylase SIRT has been shown repress ability of acetylated FOXO induce BNIP expression promote apoptosis and attenuate autophagy  On evidence of these findings role of FOXO proteins autophagy is likely be contextdependent and can be doubleedged sword terms of tumour suppression and malignant transformation',\n",
       "  ('FOXOs and metastasis',\n",
       "   'Sec7',\n",
       "   'Par10',\n",
       "   8): 'Numerous histopathological studies have demonstrated connection low FOXO expression and increased cancer metastasis – critical event that plays multiple roles metastasis is epithelialmesenchymal transition EMT which is biological process which epithelial cells undergo changes that allow development of more aggressive mesenchymal cellular phenotype properties of stem cells  EMT has fact been suggested be engaged multiple steps of metastasis process recent study shows that FOXO silencing using small interfering ribonucleic acid siRNA hepatocellular carcinoma enhances mesenchymal and reduces epithelial marker expression as EMT study also reveals that EMT induced zinc finger Eboxbinding homeobox  ZEB can be suppressed FOXO overexpression metastasis suppressor gene nmH is involved restricting progression of number of human cancers including nonsmall cell lung cancer NSCLC and has also been shown be positively regulated FOXO lung cancer addition FOXO FOXO is also strongly associated metastasis of multiple malignancies including breast pancreatic and kidney cancers – Although overwhelming evidence has pinpointed FOXOs as suppressors of cell migration and metastasis some literature suggests that FOXOs have otherwise oncogenic role Some correlation studies have linked high FOXO expression poor cancer patient prognosis and enhanced metastasis – Specifically high FOXO and FOXO expression has been correlated matrix metalloproteinase MMP upregulation and enhanced cancer metastasis   Overexpression of FOXO can also promote podocyte EMT induced high glucose conditions  Equally FOXO has been demonstrated many studies promote cell invasion and migration inducing expression of MMPs including MMP MMP MMP and MMP  – However it is also notable that these studies have been centred normal endothelial cells Although FOXO has been shown activate expression of MMP essential vascular smooth muscle cell migration it also inhibits gastric cancer cell proliferation and migration fact that FOXOs are involved regulating cell migration is further supported observation that FOXO regulates Plxnamediated neuronal migration development  However when overexpressed FOXO has also been shown inhibit breast cancer cell migration and invasion  These conflicting findings may reflect cell type–specific roles of FOXOs cell migration and metastasis It is possible that FOXOs have prometastatic function normal endothelial cells but switch tumoursuppressive antimetastatic role cancer cells On whole these findings support hypothesis that FOXO proteins are genuine tumour suppressors but underlying mechanisms involved this switch normal cancer cells need further elucidation',\n",
       "  ('FOXOs and angiogenesis',\n",
       "   'Sec8',\n",
       "   'Par11',\n",
       "   9): 'Angiogenesis is process whereby new blood vessels are formed This process facilitates delivery of oxygen and nutrients target tissues and cells These functions also make angiogenesis essential spreading and establishment of tumour metastases Essentially angiogenesis facilitates escape of tumour cells bloodstream and establishment of metastatic colonies secondary sites manner similar angiogenesis lymphangiogenesis also helps disseminate lymphatic metastases Insights human endothelial cell studies and gene knockout mouse models have revealed clear role FOXO proteins regulating angiogenic activity of endothelial cells and blood vessel formation   Indeed overexpression of constitutively active FOXO or FOXO but surprisingly not FOXO significantly inhibits endothelial tube formation and migration Appropriately FOXO and FOXO are fact most abundant FOXO proteins mature endothelial cells Consistent this silencing of either FOXO or FOXO also leads significant increase migratory and sproutforming capacity of endothelial cells concordance key role FOXOs angiogenesis further gene expression profiling analysis also reveals that endogenous FOXO and FOXO negatively regulate set of angiogenesisrelated and vascular remodelling genes including angiopoietin  Ang and eNOS repress blood vessel formation and maturation role of FOXOs angiogenesis is further supported studies FOXO tripleknockout mice showing that FOXO depletion potentiates angiogenesis mouse liver response simulation proangiogenic growth factors such as vascular endothelial growth factor VEGF and basic fibroblast growth factor bFGF  Further work using FOXO knockout mouse system confirms that FOXOs directly regulate expression of endothelial cell morphogenic and vascular homeostatic mediators including Sprouty and PBX which control process of angiogenesis  FOXO has also been reported repress expression of potent angiogenic growth factor VEGF promoter level breast cancer  Similarly FOXO has also been found regulate VEGFA expression and promote angiogenesis ',\n",
       "  ('FOXO mutation in cancer',\n",
       "   'Sec10',\n",
       "   'Par12',\n",
       "   10): 'The human FOXO also known as FKHR forkhead rhabdomyosarcoma was first identified as fusion partner of paired box protein PAX alveolar rhabdomyosarcoma paediatric tumour of skeletal muscle majority of highly metastatic and aggressive alveolar rhabdomyosarcomas harbour FOXOPAX protein resulting tqq and tpq chromosomal translocation respectively   Both PAX and PAX are important regulators of myogenesis  and their fusion proteins FOXO carry FOXO transactivation domain which confers gainoffunction oncogenic PAX phenotype These genetic changes are somatic and not inherited family G protein–coupled receptor GPCR Cnr has previously been shown induce PAXFOXO expression augment cell invasive capacity alveolar rhabdomyosarcoma study use of Cnr antagonist or genetic deletion attenuates migration of alveolar rhabdomyosarcoma lungs similar manner FOXO chromosomal translocation alveolar rhabdomyosarcoma FOXO also known as FKHRL and FOXO also known as AFX are translocated MLL gene mixed lineage leukaemia MLL aggressive paediatric blood cancer  MLL is characterised presence of MLLFOXO fusion protein resulting tqq and tXqq chromosomal translocation respectively   Importantly these genetic rearrangements alveolar rhabdomyosarcoma and MLLs not only create new oncogenic fusion proteins but also cause loss of FOXO allele original chromosome resulting FOXO locus haploinsufficiency  Unlike other FOXOs FOXO has not been shown be involved chromosomal translocation It has also been reported that FOXO is tumour suppressor gene commonly deleted earlystage lung adenocarcinoma carcinogenesis   Characterisation of common chromosomal q deletion mature B cell lymphomas and childhood acute lymphoblastic leukaemia has also uncovered FOXO as being one of three tumour suppressor genes frequently deleted these rare blood cancers loss of FOXO chromosomal deletion q is associated tumorigenesis of benign mammary and vaginal myofibroblastomas  Similarly deletion of FOXO q is shown be linked rare highly aggressive lymphoid malignancy natural killer cell neoplasms  However despite these examples of translocation and deletion of FOXO genes alveolar rhabdomyosarcoma mixed lineage leukaemia lung adenocarcinoma and natural killer cell neoplasms FOXO genes are generally rarely mutated human cancers suggesting deregulated FOXO expression and function as predominant mechanism cancer development and progression reason lack of FOXO mutations cancer is unclear However it has been shown that monoallelic q deletion mammalian cells can result reduction FOXO expression levels and cellular proliferation stress which can turn cause oxidative stress activate p MAPK induce cellular senescence oestrogen receptor ER stressactivating transcription factor  ATF axis  This might represent tumour suppressor loss–induced senescence mechanism prevent loss of FOXO genes ',\n",
       "  ('Regulation of FOXOs by post-translational modifications',\n",
       "   'Sec11',\n",
       "   'Par13',\n",
       "   11): 'As mentioned FOXOs are predominantly deregulated posttranslational level most cancers response external stimuli FOXO proteins are rapidly reversibleregulated multiple layers of posttranslational and posttranscriptional modifications including phosphorylation acetylation ubiquitination glycosylation and methylation Fig  These modifications control FOXO functions adjusting their turnover stability altering their subcellular localisation changing their DNA binding affinity controlling their transcriptional activity and regulating their interaction cofactors example these posttranslational modifications can induce FOXO conformational changes and introduce new binding motifs FOXObinding proteins which turn regulate expression subcellular localisation DNA binding and transcriptional activity of FOXOs  FOXO proteins are best studied their regulation phosphorylation different conserved serine and threonine amino acid residues predominantly insulin and cellular stress pathways ',\n",
       "  ('FOXOs and Akt-mediated phosphorylation',\n",
       "   'Sec12',\n",
       "   'Par14',\n",
       "   12): 'The growth factor–regulated PIKAkt also known as PKB signalling cascade is one of most frequently dysregulated pathways cancer resulting commonly upregulation of Akt and thereby attenuation of FOXO activity  Consumption of glucosecontaining diets increases glucose levels blood serum which supplies different organs as primary source of energy response high serum glucose levels pancreatic βcells synthesise and secrete insulin lower elevated blood glucose level promoting cellular glucose uptake using insulinregulated glucose transporter GLUT PIKAkt signalling pathway   Indeed cancer cells utilise glucose proliferation and metastasis induction of insulin receptors activated Akt suppresses function and alter subcellular localisation of FOXO proteins Specifically high nutrient availability triggers insulin signalling pathway promote Aktmediated FOXO Thr Ser and Ser FOXO Thr Ser and Ser FOXO Thr Ser and Ser and FOXO Thr and Ser phosphorylations  Notably FOXO is only phosphorylated two sites and it is not regulated nucleocytoplasmic shuttling  FOXO Thr and Ser and FOXO Thr and Ser phosphorylations serve as docking sites chaperone protein  on Nterminus and DNA binding domain of FOXO protein binding of protein is believed expose FOXO nuclear export sequence promote nuclear exclusion Similarly binding of FOXO proteins reduces access of nuclear importing machinery nuclear localisation sequence NLS suggesting that interaction prevents FOXO nuclear translocation  Another study has shown that simultaneous binding of  on these phosphorylated sites also disrupts and affects FOXO DNA binding capability FOXO cytoplasmic sequestration is shown be promoted phosphorylation Ser which introduces negative charge basic nuclear localisation signal sequence response growth factor phosphorylation of FOXO Akt Ser also primes casein kinase  CK phosphorylate FOXO further Ser and Ser  These CK phosphorylation sites directly promote interaction FOXO and nuclear export machinery RanCRM complex  Conversely Aktmediated phosphorylated FOXO and FOXO nuclear exclusion can be rescued dephosphorylation mediated protein phosphatase PPA Fig   ',\n",
       "  ('FOXOs and Akt-mediated phosphorylation',\n",
       "   'Sec12',\n",
       "   'Par15',\n",
       "   13): 'High levels of Aktphosphorylated FOXO proteins are correlated poor patient overall diseasefree survival rate many cancers molecular level study shows that Akt signalling pathway suppresses cell migration and invasion FOXO inhibit runtrelated transcription factor  RUNX transcriptional activity prostate cancer  FOXO has also been identified genomewide RNAi screen be suppressor of metastasis antagonising PIKAKT signal pathway and RUNXdependent transcription prostate cancer  Besides RUNX its closed relatives RUNX and RUNX are also linked FOXO proteins restricting cancer survival   However these cases RUNX and RUNX bind and cooperate FOXO proteins promote cell death breast and gastric cancers Moreover Aktregulated FOXO has been shown promote antimetastatic protein ANXA bile duct cancer cholangiocarcinoma  FOXO can also modulate cell invasion regulating expression of MMP glioblastoma FOXO EGFR signalling controls SRYrelated HMGbox  SOX expression lung cancer  Recently SOX knockdown experiment shows that basal cell carcinoma migration is regulated Akt signalling pathway agreement another recent study shows that hypoxiainduced breast cancer cell migration is regulated SOX transcription factor ',\n",
       "  ('Stress signals in FOXO regulation',\n",
       "   'Sec13',\n",
       "   'Par16',\n",
       "   14): 'Unlike nutrient and growth factor–mediated PIKAkt signalling cascade FOXO activity can be enhanced stressactivated signalling pathway cancer cells stress can promote or restrict cancer growth and progression Reactive oxygen species ROS levels are often elevated cancers various factors including enhanced oncogenic activity and increased metabolic function mitochondria ROS is byproduct of oxidative phosphorylation where large amount of energy is generated process electron transport chain complex–produced superoxide is reduced hydrogen peroxide Sirtuinstimulated manganesedependent superoxide dismutase MnSOD also called SOD  This FOXOregulated SOD modulates cellular antioxidant capacity loss of FOXO function increases intracellular ROS pushing cancer cells rely on Warburg effect prevent further cellular damages   However lower SOD expression allows cancer cells acquire beneficial DNA damages enhanced proliferation and obtain drug resistance mutations  Similarly chemically induced stresses multiple chemotherapeutic treatments have also been shown integrate FOXO activity   Cancer cells control these stresses inducing JNK activate FOXOmediated oxidative stress resistance  Notably responses of FOXOs stress are dependent on stress intensity different conditions and contexts',\n",
       "  ('Stress signals in FOXO regulation',\n",
       "   'Sec13',\n",
       "   'Par17',\n",
       "   15): 'Oxidative stress–activated JNK can also phosphorylate protein Ser enhance FOXO activity phosphorylation releases FOXO proteins exposing nuclear localisation signals promote nuclear translocation parallel JNK also antagonises Akt activity phosphorylating FOXO Ser activation oxidative stress JNK phosphorylates FOXO directly Thr and Thr promote FOXO nuclear localisation  Similarly oxidative stress induces mammalian Stelike kinase  Mst kinase activation Hippo signalling pathway promote FOXOmediated apoptosis oxidative stress Mst phosphorylates FOXO Ser and FOXO Ser directly disrupt binding of  protein promote FOXO activity   Recently FOXO protein activity has been inversely linked epidermal growth factor receptor  EGFR also known as HER overexpression study shows that HER negatively regulates FOXO transcriptional level insulin signalling pathway this HER regulation of FOXO activity is mediated PIKAkt signalling pathway ',\n",
       "  ('Stress signals in FOXO regulation',\n",
       "   'Sec13',\n",
       "   'Par18',\n",
       "   16): 'Consistently treatment of cancer cells EGFRHERtyrosine kinase inhibitors EGFRHERTKI eg gefitinib and lapatinib or antiErbB monoclonal antibodies eg trastuzumab induces cell proliferative arrest andor cell death and this has been shown be mediated PIKAktFOXO signalling axis  – Appropriately HER upregulation induces both Akt and JNK promote gastric cancer growth and metastasis  These findings suggest that multiple stress signals converge and integrate regulate FOXO activity and that FOXO proteins are important factors pivot balance determine cell fates Fig  It is also plausible that intermediate degree of stress promotes cell metastasis evade source of stress whilst high level of stress induces cell death',\n",
       "  ('Stress signals in FOXO regulation',\n",
       "   'Sec13',\n",
       "   'Par19',\n",
       "   17): 'Beside stressinduced JNK FOXO is also regulated two other major MAPKs extracellular signal–regulated kinases ERKs and p family of stressactivated MAPKs  These signalling pathways JNK ERK and p modulate FOXOregulated intracellular ROS cooperatively fact outcome of FOXO activity regulation is predominantly controlled duration and magnitude of multiple MAPK signal integration  Each of MAPKs JNK ERK and p is regulated mitogenactivated protein kinase phosphatases MKPs control its activity and subcellular localisation increasing complexity of FOXO regulation  Indeed increased MKP expression elevates cancer progression and drug resistance linking MKPs FOXO function  Although there is no evidence of direct link MKP and FOXO activities human cancer study has demonstrated that insulininduced MKP also known as dualspecificity phosphatase  DUSP interacts and dephosphorylates FOXO on Ser mouse model promote its nuclear import gluconeogenic gene transcription  Noteworthy gluconeogenetic enzymes play crucial part regulation of cancer EMT study also shows that ERK directly phosphorylates FOXO Ser Ser Ser Ser Ser Ser Ser Ser and Ser alter transcriptional activity of Ets regulator of angiogenesisrelated genes  However functional consequence of ERKFOXOregulated Ets on induction of angiogenesis and metastasis has yet be confirmed cancer cells',\n",
       "  ('Stress signals in FOXO regulation',\n",
       "   'Sec13',\n",
       "   'Par20',\n",
       "   18): 'In cancer ERK and p MAPK pathways cooperate control anoikis form of cell death triggered loss of extracellular matrix ECM attachment  Anoikis resistance insensitivity anoikisinduced cell death is prerequisite EMT and cancer metastasis  Indeed anoikis has been shown be regulated FOXO activity breast cancer metastasis  It has also been shown that both ERK and p MAPK can activate FOXO phosphorylation  Nine serine residues FOXO are phosphorylated ERK whilst five of them ie Ser Ser Ser Ser and Ser are also phosphorylated p MAPK  Whilst physiological consequence of ERK and p MAPKdependent FOXO phosphorylation is unclear p MAPK induction promotes fibroblast cell invasion and anchorageindependent cell growth agreement inhibition of p MAPK reduces glioma invasiveness  MKK also mediates suppression of metastasis ovarian cancer activation of p MAPK  Moreover upstream regulator of ERK MEK can directly induce Akt FOXO phosphorylation promote cell migration  Another study shows that inhibition of both Akt and ERK signalling pathways synergistically induces FOXO transcriptional activity inhibit angiogenesis  Moreover UV irradiation induces stressmediated JNK suppress both ERK and Akt activities and promotes FOXO nuclear translocation probably DNA damage repair  Conversely ERK can also promote cell migration and invasion RacCdc guanine nucleotide exchange factor GEF DOCK which induces JNK activate FOXO and promote EMT  Paradoxically loss of FOXO which is followed upregulation of p initiates compensatory mechanism promote other FOXO protein activities p MAPK has been shown phosphorylate FOXO on Ser mediate nuclear localisation and senescence response doxorubicininduced DNA damages breast cancer similar manner p MAPK is also activated cetuximab induce cell death and inhibit cell proliferation FOXO colorectal cancer ER stress unfolded protein response UPR activates inositolrequiring enzyme  IRE protein kinase R PKRlike ER kinase PERK and ATF promote ER folding capacity and maintain cellular proteostasis cell survival   Furthermore PERK has previously been shown promote FOXO activity direct phosphorylation Ser Ser and Ser representing another layer of FOXO regulation cancer  Nevertheless recent study has shown that PERK instead of promoting FOXO activity can inhibit FOXO activity enhancing Akt activity  Together these findings suggest that cancer cell metastasis is regulated FOXO proteins whose activity is turn modulated stressactivated signals including JNK ERK and p MAPKs',\n",
       "  ('FOXO ubiquitination',\n",
       "   'Sec14',\n",
       "   'Par21',\n",
       "   19): 'The Aktphosphorylated FOXOs eg FOXO Ser are recognised activated Fbox protein Sphase kinaseassociated protein  SKP SCF E ligase complex which targets FOXO proteins polyubiquitination and degradation  Interestingly FOXO has also been shown be negative regulator of SKP expression and this could represent positive feedforward loop regulation of FOXO expression and activity  Collectively Aktphosphorylated FOXOs are sequestered cytoplasm transcriptionally inactive and targeted ubiquitinproteasome system degradation molecular level ERK phosphorylates FOXO and FOXO Ser Ser and Ser recruit MDM E ubiquitin ligase FOXO polyubiquitination and proteasomal degradation   Besides polyubiquitination study suggests that FOXO can be monoubiquitinated Lys and Lys MDM response oxidative stress nuclear translocation monoubiquitinated FOXO can be reversed ubiquitinspecific protease  USP also known as HAUSP–mediated deubiquitination   However monoubiquitination on other FOXO proteins has not been demonstrated and exact mechanism of this modification is still unclear Fig  As glucose is source of energy Aktmediated FOXO ubiquitination is also interconnected energy homeostasis regulator ′ adenosine monophosphate–activated protein kinase AMPK AMPK is intracellular energy sensor which senses ADPATP ratio and regulates cell growth autophagy and metabolism study shows that AMPKmediated FOXO phosphorylation Ser and Thr promotes FOXO protein stability nuclear translocation and transcriptional activity recent study also demonstrates that AMPK can phosphorylate FOXO Ser activate FOXO blocking Aktmediated FOXO sequestration protein cytoplasm  Indeed hypoxiainduced AMPK has been shown promote FOXO activity  Likewise FOXO is also phosphorylated AMPK Thr Ser Ser Ser Ser and Ser transcriptional activation but this AMPKmediated phosphorylation enhances activity of FOXO altering its subcellular localisation and DNA binding affinity  Indeed AMPKinduced FOXO phosphorylation has been shown suppress pancreatic cancer growth and metastasis  Of note response growth factor stimulation IκB kinase IKK also exclusively phosphorylates FOXO Ser ubiquitination and degradation as other FOXO proteins do not have similar amino acid residues ',\n",
       "  ('FOXO regulation by other kinases and factors',\n",
       "   'Sec15',\n",
       "   'Par22',\n",
       "   20): 'Besides PIKAkt and stressactivated MAPK signalling pathways many other kinases and dependent cascades also contribute FOXO regulation instance pactivated kinase PAK downstream target of PIK can bind and phosphorylate FOXO directly prevent its nuclear translocation breast cancer  Similarly transforming growth factor β–activated kinase TAKNemolike kinase NLK pathway also mediates FOXO phosphorylation transactivation domain drive its nuclear exclusion dualspecificity tyrosinephosphorylated and regulated kinase  DYRK phosphorylates FOXO Ser promote its activity unstimulated quiescent mammalian cells   Recently study shows that glucagonactivated PKA also phosphorylates FOXO Ser promote its nuclear relocalisation and stability liver cancer and limit insulininduced FOXO nuclear export and their ubiquitinationdegradation ',\n",
       "  ('FOXO regulation by other kinases and factors',\n",
       "   'Sec15',\n",
       "   'Par23',\n",
       "   21): 'During normal cell divisions CDKcyclin complexes are main regulators of cell cycle checkpoints which can influence cell fates However cancer these CDKcyclin complexes are commonly deregulated resulting deregulated and highly proliferative cells  Indeed CDK also called CDC and CDK have shown phosphorylate FOXO Ser alter its subcellular localisation Paradoxically FOXO has also been found be activated CDK induce apoptosis gene activation postmitotic neurons but FOXO phosphorylation CDK promotes its inhibition human prostate adenocarcinoma cells   These contrasting findings may reflect deregulation of normal FOXO control and function cancer cells On other hand CDK has been confirmed inhibit FOXO promoting its nuclear exclusion suppress FOXO transcriptional activity respect cell migration activator of CDK and CDK CdcA phosphatase can enhance FOXO stability promote MMPmediated metastasis breast cancer  Consistent this finding FOXOderived small peptide FOnl inhibits CDKmediated FOXO phosphorylation and prevents prostate cancer proliferation addition FOXO circular RNA circFOXO has been reported form inhibitory complex CDK and p restrict cell cycle progression cell division genotoxic stress induced cytotoxic chemotherapeutic agents can revert FOXO phosphorylation state and induce senescent andor apoptotic response cancer cells        – On other hand FOXO can also upregulate expression of DNA damage–inducible  GADD of DNA repair mechanism and has role ATMmediated DNA damage response prevent cancer acquiring further mutations   These findings further emphasise importance of FOXO prevention of cancer propagation and progression',\n",
       "  ('FOXO acetylation',\n",
       "   'Sec16',\n",
       "   'Par24',\n",
       "   22): 'Although mammalian cells have protein kinases place regulate FOXO activity another posttranslational modification PTM acetylation applies extra layers of control finetune their cellular functions general depending on sites of modification acetylation of nuclear proteins usually alters their DNA binding affinity and hence their activity FOXO proteins acetylation occurs predominantly Wing region of forkhead DNA binding domain where FOXO proteins were used recognising their DNA consensus sequences on target genes  however functional consequence of FOXO acetylation is not clearcut earlier report suggests that acetylation of sites Lys Lys and Lys located DNA binding domain of FOXO attenuates its transcriptional activity support of this it has been demonstrated that oxidative stress–induced CREBbinding protein CBPp acetylates FOXO Lys Lys and Lys restrict its DNA binding cancer  However another subsequent crystallographic structural analysis suggests that acetylation equivalent sites Lys and Lys FOXO enhances its DNA binding and therefore its transcriptional activity FOXO there is also controversial link phosphorylation and acetylation One study shows that FOXO acetylation requires insulininduced Akt phosphorylation prime modification  Yet another suggests that pmediated acetylation can increase sensitivity inhibitory FOXO phosphorylation Ser  Despite controversy over exact order which these modifications occur these data suggest that acetylation and Aktmediated phosphorylation cooperate inhibit FOXO activity acetylation FOXO has also been shown have reduced affinity genomic compacting protein nucleosomes affecting multiple gene accessibility other transcription factors ',\n",
       "  ('FOXO acetylation',\n",
       "   'Sec16',\n",
       "   'Par25',\n",
       "   23): 'FOXO acetylation is primarily mediated CBPp and reversed Sirtuins SIRTs which are group of highly conserved NADdependent deacetylases which have many roles epigenetics and human diseases including cancer earlier study suggests that SIRTmediated deacetylation promotes FOXO transactivation activity reduce cellular ROS and induce cell death cancer cells  However later study same research group has shown that SIRT and SIRT mediate deacetylation of FOXO promote FOXO ubiquitination and degradation Skpdependent manner implying that acetylation increases FOXO stability and enhances its tumoursuppressive function discrepancy two studies is likely due overlapping and compensatory roles played SIRT and SIRT cancer whilst inhibition of one leads induction of other support of tumoursuppressive role FOXO acetylation report shows that acetylation recruits FOXO promyelocytic leukaemia PML protein nucleus protect FOXO ubiquitination and promote its activity pancreatic beta cells agreement interaction FOXO and PML has also been observed breast cancer addition another study shows that fourandahalf LIM  FHL interacts FOXO facilitate SIRTmediated deacetylation reduce FOXO activity prostate cancer  SIRT also represses FOXO acetylation promote clonal renewal and survival breast cancer  Similarly FOXO acetylation induces apoptosis of podocytes diabetes activating proapoptotic gene Bim Bcll  Studies on mitochondrial reprogramming have produced further evidence that SIRTs repress FOXO acetylation promote cancer progression and metastasis Elevated ROS cancer has been shown lead mitochondrial reprogramming evolutionarily conserved SIRTFOXOSOD axis neutralise oxidative stress and promote cancer survival and metastasis   Besides SIRTs histone deacetylase HDAC has been shown be specifically recruited geminin FOXO facilitate FOXO deacetylation and breast cancer metastasis spite of this tumoursuppressive protective role geminin is also frequently overexpressed human cancers Collectively evidence accumulated date suggests that FOXO acetylation is mediated EPCBP and is reversed SIRTs general promoting tumoursuppressive function of FOXOs increasing transcription of genes important cell proliferative arrest senescence and cell death',\n",
       "  ('FOXO acetylation',\n",
       "   'Sec16',\n",
       "   'Par26',\n",
       "   24): 'Besides its tumoursuppressive function recent evidence also reveals that FOXO acetylation is also targeted anticancer chemotherapeutics mediate their cytotoxic and cytostatic function example it has been reported that capsaicin treatment induces CBP and represses SIRT expression resulting increase FOXO acetylation limit pancreatic tumour growth  Moreover SIRT can promote paclitaxel and epirubicin resistance breast cancer  EP and SIRT also coregulate cytotoxic function of EGFRHER inhibitor lapatinib modulating FOXO acetylation and activity breast cancer  Similarly SIRTmediated FOXO deacetylation has also been implicated lapatinib response and sensitivity and that SIRT can specifically antagonise cytotoxicity of lapatinib mediating FOXO deacetylation both sensitive and resistant nasopharyngeal carcinoma NPC cells synthetic glucocorticoid dexamethasone also targets FOXO phosphorylation on Ser and acetylation on LysLys mediate its cytotoxic function B acute lymphoblastic leukaemia BALL  These findings also propose that SIRTs can be important biomarkers metastatic and drugresistant clones and that targeting SIRTFOXO axis may provide novel strategies treating cancer and overcoming chemoresistance Indeed specific as well as panSIRT inhibitors have proved be effective tackling cancer and overcoming cancer drug resistance    ',\n",
       "  ('Other FOXO PTMs',\n",
       "   'Sec17',\n",
       "   'Par27',\n",
       "   25): 'Methylation is posttranslational modification which introduces methyl group proteins Protein methylation is predominantly associated histone methylation which modulates gene expression  However FOXO proteins are also direct targets of methylation instance ubiquitously expressed and tissuespecific protein arginine methyltransferase  PRMT has been reported methylate FOXO Arg and Arg block Aktmediated Ser phosphorylation and inhibition lysine methyltransferase Set has also been demonstrated methylate FOXO This Setmediated FOXO methylation Lys leads attenuation of its DNA binding activity and downregulation of transactivation affecting Aktmediated phosphorylation its protein stability and subcellular localisation  On evidence of these studies FOXO methylation appears promote activity of FOXO proteins fact protein methylation has been shown have role proteinprotein interaction DNA binding affinity protein stability and subcellular localisation ',\n",
       "  ('Other FOXO PTMs',\n",
       "   'Sec17',\n",
       "   'Par28',\n",
       "   26): 'It is also unclear whether methylation other less common posttranslational modifications ie glutathionylation glycosylation SUMOylation hydroxylation neddylation citrullination prenylation palmitoylation myristoylation and nitrosylation also directly modify FOXO proteins and if they are involved modulating FOXO activity cancer example neddylation inactivation specific inhibitor MLN can prevent FOXO nuclear export decrease its binding ESR oestrogen receptor gene promoter and improve fulvestrant sensitivity breast cancer Nevertheless this case it is still unknown whether FOXO is directly modified neddylation and if FOXO neddylation has role modulating its activity ',\n",
       "  ('Protein-protein interactions in FOXO regulation',\n",
       "   'Sec18',\n",
       "   'Par29',\n",
       "   27): 'Apart posttranslational modifications proteinprotein interactions also modulate FOXO function and activity Peroxisome proliferator–activated receptors PPARs are family of ligandactivated nuclear receptor transcription factors that function downstream of ERK regulate cell metabolism and adipocyte differentiation this respect FOXO and PPAR can compete ERK signals and thereby antagonise transcriptional activity of one another liver carcinoma cells PPAR can also interfere binding of apolipoprotein C III ApoCIII FOXO affecting lipid metabolism and serum triglyceride levels   ApoCIII plays key role regulation of triglyceride metabolism and has been suggested be predictive marker NSCLC  Nonetheless lipid metabolism and lipidmediated signalling are key cancer metastasis  and dysregulated lipid metabolic enzymes are known be associated cancer cell invasion and metastasis ',\n",
       "  ('Protein-protein interactions in FOXO regulation',\n",
       "   'Sec18',\n",
       "   'Par30',\n",
       "   28): 'In nucleus androgen receptor AR has been reported interact FOXO nuclear receptor AR which is expressed vast range of tissue responds male sex hormone androgen activation  Indeed development of prostate cancer is intimately associated androgen prostate cancer elevated AR expression promotes EMT  Likewise AR promotes haematogenous metastasis and angiogenesis of clear cell renal cell carcinoma CCRCC prostate cancer activated nuclear AR binds and reduces DNA binding capacity of FOXO Aktindependent manner affecting expression of proapoptotic genes such as Fas  Thus AR binding generally reduces tumoursuppressive function of FOXO proteins ER is another hormoneregulated receptor that has strong link cancer metastasis ER is overexpressed multiple cancers including breast and ovarian cancers breast cancer ER encoded oestrogen receptor alpha gene ESR is commonly deregulated gene amplification point mutations and genetic fusion leading enhanced cancer invasion and metastasis oestrogenactivated ER has been shown interact FOXO repress its activity and it is speculated that this interaction may play part regulation of cancer metastasis ',\n",
       "  ('Protein-protein interactions in FOXO regulation',\n",
       "   'Sec18',\n",
       "   'Par31',\n",
       "   29): 'PolyADPribose polymerase  PARP is nuclear protein important regulation of DNA damage repair chromatin remodelling cell death and gene transcription   PARP has been shown promote cell metastasis melanoma and prostate and lung cancers – FOXO interacts PARPand gets polyADPribosylated Aktindependent manner resulting suppression of FOXO transcriptional activity and cell proliferation cancer cells PPARγ coactivator α PGCα interacts FOXO and acts as coactivator hepatocytes activation of gluconeogenic genes study shows that interaction is involved cellular oxidative stress protection and can be interrupted insulinmediated Akt phosphorylation   Moreover FOXO has been shown regulate PGCα transcript level suggesting feedback mechanism oxidative stress regulation PGCα FOXO also interacts CEBPα promote expression of gluconeogenic genes including phosphoenolpyruvate carboxykinase PEPCK gluconeogenic enzymes are known affect cancer growth   Recently gluconeogenesis has also been shown be upregulated brain metastatic breast cancer cells suggesting that increase energy production can promote cancer metastasis FOXOs ',\n",
       "  ('Protein-protein interactions in FOXO regulation',\n",
       "   'Sec18',\n",
       "   'Par32',\n",
       "   30): 'Fanconi anaemia complementation group D FANCD is important DNA damage response protein which is activated DNA replication as well as DNA damage repair rare genetic disease Fanconi anaemia FA loss of FANCD activity has been shown contribute accumulation of genetic mutations and therefore promote leukaemogenesis or tumorigenesis cancer cells FANCD also interacts FOXO regulate antioxidant gene expression response oxidative stress  Whilst interaction FANCD and FOXO has not been directly linked cancer metastasis FANCD overexpression on its own has been shown be correlated lymph node metastasis of colon cancer  Elevated FANCD expression also increases cancer therapy tolerance and is associated increased risk of metastasis  Indeed induction of antioxidant gene expression FANCD and FOXO can also impact on cancer therapy resistance as radiotherapy and chemotherapeutic drugs can influence cancer treatment outcome their modulation of ROS   Notably parallel FOXO protein regulation MYC which controls least  of entire genome is also regulated PIKAkt pathway similar upstream regulation oncogenic MYC also competes FOXO binding of promoter regions of genes including p p is CDK inhibitor which regulates cell cycle progression and it is often downregulated cancer  FOXO proteins also cooperate other FOX proteins bind and drive transcription of target genes example FOXO and FOXAA have been shown facilitate one anothers binding and collaborate open chromatin insulinregulated genes   Furthermore FOXO also cooperates FOXA function as pioneer factors facilitate AR binding prostate cancer other words FOXOs also work together other FOX proteins facilitate recruitment of other transcriptional elements promote transcription of target genes',\n",
       "  ('FOXO post-transcriptional regulation by microRNAs',\n",
       "   'Sec19',\n",
       "   'Par33',\n",
       "   31): 'MicroRNAs miRs are small noncoding RNAs nucleotides that participate RNA silencing and these small RNAs also participate regulation of FOXO expression posttranscriptionally inducing FOXO messenger RNA mRNA degradation translation inhibition and gene silencing Fig    MicroRNAs such as miR miR miR and miR have been shown negatively regulate FOXO expression promote cell proliferation number of cancer cells – Likewise miR promotes proliferation of pancreatic ductal adenocarcinoma PDAC repressing FOXO expression   Notably miR has also been shown regulate cancer metastasis  Interestingly miR can also promote growth metastasis and drug resistance cancer cells targeting phosphatase and tensin PTEN homologue upstream repressor of AktPIK activity and therefore indirect activator of FOXOs  Thus miRs miR regulate not only FOXO expression but also their activity same time  Wntbetacatenin activates miRmiRmiR expression hepatocellular carcinoma promote cancer cell invasion Meanwhile similar group of microRNAs miR miR and miR also suppress FOXO expression hepatocellular carcinoma resulting enhanced cell invasion and metastasis similar outcome is also observed FOXO when targeted miRa and miR endometrial cancer miR miRa miR miR miR miR and miR also function cooperatively suppress FOXOregulated cell cycle arrest and cell death concerted effort of this group of miRNAs suppress FOXO renders depletion of one miR species having no effects on FOXO expression or endometrial cancer cell proliferation and survival microRNA miRc also represses FOXO expression facilitate breast cancer cell growth migration and invasion  whilst miRb inhibits FOXO expression promote cell proliferation and invasion osteosarcoma contrast miR and miR can enhance FOXO activity promote cell cycle arrest and delay cell proliferation respectively  ',\n",
       "  ('FOXO post-transcriptional regulation by microRNAs',\n",
       "   'Sec19',\n",
       "   'Par34',\n",
       "   32): 'Interestingly miR is found promote colorectal cancer proliferation targeting both FOXO and FOXO suggesting that there are common complementary sequences FOXOs miR binding  Similarly miR suppresses both FOXO and FOXO expression levels prostate and skin cancer respectively promote cancer cell migration and invasion agreement study antimiR mimetics xenograft mouse model has shown that miR inhibition can restrict ovarian cancer cell invasion and metastasis  Furthermore miR miR and miRa can induce proliferative arrest and cancer cell death FOXO and FOXO Alzheimer disease miR and miR also control FOXOmediated neuronal apoptosis  FOXO is also targeted miR and miR promote colorectal cancer metastasis and prostate cancer proliferation respectively   FOXO is targeted miRp and miRa enhanced cell metastasis colon and gastric cancers respectively   Similarly miR restricts expression of FOXO promote cervical cancer proliferation and lung cancer cell metastasis   Not only FOXO expression and activity are regulated miRs evidence also exists that miRs are also regulated FOXO proteins fact crosstalks miRp and FOXO have been shown modulate cell growth lung cancer miR has also been associated circular RNA FOXO circFOXO and FOXO lung cancer migration and invasion circFOXO shares identical sequences FOXO mRNA and can buffer several miRs interacting FOXO mRNA Thus circFOXO can upregulate FOXO expression preventing binding of miR FOXO mRNA  Furthermore FOXO upregulates miR suppress hypoxiainducible factor  alpha HIFα induce cell invasion and migration lung cancer  FOXO has also been shown bind and activate miR βcatenin inhibition which subsequently suppresses cell migration prostate cancer  Whilst many reports have documented direct relationships miR and FOXO expression levels another microRNA miR has been shown antagonise Akt signalling lung cancer providing indirect route activate FOXO activity  Although miRs have been established play key part regulating FOXO expression and cancer metastasis how these miRs are regulated themselves remains be explored Nonetheless these findings suggest that posttranscriptional regulation of FOXO expression is important regulation of FOXO activity modulation tumorigenesis and metastasis',\n",
       "  ('Cross-communication between FOXOs and other FOX proteins',\n",
       "   'Sec20',\n",
       "   'Par35',\n",
       "   33): 'In mammals there are  known FOX proteins Together they regulate wide range of biological processes encompassing cell proliferation survival differentiation migration and stress response These FOX proteins share highly homologous DNA binding domains and recognise overlapping gene targets consequence tissuespecific misregulation or misexpression of these FOX genes can lead gain of function and result cancer initiation and progression Recent evidence also suggests these FOX proteins share several attributes and intriguingly one of them common majority of FOX proteins is their regulation of cancer metastasis Apart having overlapping functions expression and activity of FOXOs are also influenced directly and indirectly their close cousins such as FOXM FOXC FOXC FOXF FOXS FOXG and FOXK Fig   FOXM also known as HFHB Trident Win and MPP is oncogenic transcription factor which is known be overexpressed early cancer development  It is also potent regulator of metastasis date many studies have documented that FOXM is key regulator of cancer cell proliferation DNA damage repair cancer drug resistance metastasis and invasion tumour suppressor FOXO can antagonise oncogenic activity of FOXM number of ways Apart FOXO and FOXM having opposite effects on chromatin remodelling of common target genes FOXO also competes FOXM DNA binding target genes and directly represses FOXM expression promoter level  These multiple levels of control of FOXM FOXO emphasise significance of FOXO as tumour suppressor FOXO and FOXM are also intimately associated chemotherapeutic drug resistance and cancer stem cell properties  – Furthermore FOXOFOXM axis has been shown regulate VEGF important factor angiogenesis and metastasis  Indeed targeting FOXM has been shown significantly inhibit cancer growth and metastasis  Interestingly FOXM and Aurora kinase AURKA promote activity and expression of each other positive feedback loop  AURKA has also been shown negatively regulate FOXO transcriptional level indicating that FOXM can indirectly regulate FOXO expression AURKA sustain its expression and activity cancer cells  Likewise Akt and FOXM both upstream inhibitors of FOXO also positively regulate cell migration positive feedback loop manner promote tongue squamous cell carcinoma cell migration  FOXC also known as FKHL is another forkhead protein closely related metastasis and FOXO function High FOXC expression has been found be associated highly metastatic colon breast and liver cancers – FOXC has also been shown induce MMP expression promote breast cancer metastasis  Furthermore overexpression of FOXC promotes tumour metastasis and predicts poor prognosis liver cancer  Conversely knockdown of FOXC reduces expression of mesenchymal genes such as vimentin fibronectin and Ncadherin  Furthermore FOXC knockdown displays lower expression levels of MMP MMP MMP and MMP reduced mesenchymal characteristics and metastatic capability melanoma FOXC has been shown promote tumorigenesis activating MSTRPIKAkt pathway and is associated poor prognosis  Thus FOXC can repress FOXO activity enhancing PIKAkt signalling Similarly FOXC also known as MGH and FKHL has been linked metastasis breast cancer colorectal cancer CRC and osteosarcoma – FOXC has been demonstrated also upregulate ERK and Akt activities mediate FOXO inhibition  Anoikis can also induce FOXC expression facilitate cancer migration osteosarcoma  This anoikisinduced osteosarcoma cell invasiveness and metastasis lung are dependent on ability of FOXC induce CXCR chemokine receptor responsible tumour growth invasion angiogenesis metastasis relapse and therapeutic resistance  High FOXC expression is strongly correlated invasion and metastasis of CRC  whereas downregulation of FOXC reduces colon cancer invasiveness and their metastatic potential concordance FOXC has been found be required EMT and display of mesenchymallike properties breast cancer   FOXF also known as FKHL is essential mesenchymal cell migration  Previously FOXF has been shown induce p MAPK activity one of upstream activators of FOXO and FOXO  Similarly FOXF suppresses osteosarcoma cell invasion and migration decreasing MMP and MMP expression levels agreement FOXF can be promoted tumour suppressor p induce expression of Ecadherin epithelial cadherin epithelial cell marker  Although FOXF has not been directly associated FOXOs it is plausible that FOXF can induce p MAPK activate FOXO activity On contrary FOXF has also been found induce EMT and angiogenesis activating SNAI and VEGFA respectively promote cancer metastasis and angiogenesis colon cancer tumour microenvironment FOXF also stimulates cancerassociated fibroblasts facilitate lung cancer tumorigenesis and migration  Based on this evidence it is likely that FOXF has different metastatic and angiogenic roles epithelial and mesenchymal cells FOXS also known as FKHL has been shown suppress transcriptional activity of FOXO and FOXO  Although FOXS is predominately expressed nervous system overexpression of FOXS can inhibit gastric cancer proliferation and metastasis  Microarray analysis of metastasisassociated mRNA also shows that FOXS is downregulated high metastatic lung cancer forkhead protein FOXG previously known as BF forms complex FOXO and SMAD proteins promote neuronal differentiation  Notably SMAD and SMAD also interact FOXO promote transcription of pCip important negative cell cycle regulator  Whilst FOXGFOXO complex has not been proved be directly linked cell metastasis suppression of FOXG miRb can promote cell proliferation and metastasis cervical cancer  Furthermore miRa also negatively regulates FOXG expression modulate liver cancer metastasis  FOXK has also been found regulate FOXO expression transcriptional level mediate cytotoxic effects of epirubicin and paclitaxel breast cancer  Interestingly FOXO FOXK has been shown be able repress breast cancer carcinogenesis ',\n",
       "  ('Cross-communication between FOXOs and other FOX proteins',\n",
       "   'Sec20',\n",
       "   'Par36',\n",
       "   34): 'Although direct relationship FOXOs and some of other FOX proteins has yet be established these FOX proteins have already been shown have key role cancer cell metastasis instance FOXQ has been shown modulate EMT breast gastric bladder and cervical cancers – FOXQ also promotes metastasis transactivating ZEB and VersicanV expression liver cancer  Likewise FOXQ also negatively regulates CDH which encodes epithelial cadherin or Ecadherin promote oesophageal squamous cell carcinoma metastasis colon cancer FOXQ transactivates Twist suppress Ecadherin expression  Notably loss of FOXF expression promotes EMT breast and liver cancers agreement FOXF has shown negatively regulate FOXCmediated cancer and EMT phenotypes  This occurrence of closely linked downstream genes FOXOs and other forkheads also highlights involvement of tissuespecific misregulation or misexpression of FOX proteins including FOXOs tumorigenesis particular cancer metastasis',\n",
       "  ('Targeting FOXO in cancer therapy',\n",
       "   'Sec21',\n",
       "   'Par37',\n",
       "   35): 'To date many naturally derived and chemically synthesised compounds have been appraised their potentials cancer treatment Remarkably many compounds studied demonstrated therapeutic capacities have been found modulate FOXO expression andor activity This is due involvement of FOXO proteins regulation of genes linked crucial drug action–related cellular processes including stem cell renewal DNA repair cell death metabolism cell migration angiogenesis cell cycle control and cell division as mentioned earlier Therefore not surprising mechanisms of resistance conventional cytotoxic chemotherapeutics and molecularly targeted therapies are also linked directly deregulated signalling mediated FOXO transcription factors Many currently used and proven cancer therapeutics including paclitaxel doxorubicin epirubicin lapatinib gefitinib imatinib and cisplatin have been confirmed mediate their cytotoxic and cytostatic functions FOXO example antiEGFRHER small molecule inhibitors lapatinib and gefitinib have been shown mediate their cytostatic and cytotoxic functions though activating FOXO modulating PIKAkt and pJNKERK pathways       Similarly therapeutic monoclonal antibody trastuzumab Herceptin directed extracellular domain of mutated HER also mediates its antiproliferative effects FOXO and its downstream target survivin BRC  Genotoxic agents including doxorubicin epirubicin cisplatin and fluorouracil FU can also cause DNA damage and oxidative stress FOXO anthracycline doxorubicin induces FOXO activation and nuclear translocation phosphorylating FOXO on Ser residue p MAPK  FOXO also induces doxorubicininduced apoptosis its transcriptional repression of miR which turn modulates expression of proapoptotic factors FasL Bim and survivin   Another study shows that FOXO activation increases expression of TRAIL and cell death response doxorubicin hepatocellular carcinoma HCC suggesting that FOXO is required doxorubicin sensitivity Conversely FOXO inactivation and sequestration cytoplasm are closely associated doxorubicin resistance  Furthermore SIRT has been shown deacetylate p and FOXO which contributes doxorubicin resistance similar manner another anthracycline epirubicin which is epimer of doxorubicin also mediates its anticancer activity FOXO  Other studies have verified FOXO as key mediator of cisplatin action   Accordingly it has been shown that cisplatin treatment causes decrease Aktmediated FOXO phosphorylation colon cancer cells resulting its nuclear translocation and activation  Conversely impaired FOXO nuclear accumulation and consequent failure induce apoptosis have been associated development of cisplatin resistance Interestingly increased FOXO activation cisplatinresistant colon cancer cells small molecule Akt inhibitor tricirbineAPI can override cisplatin resistance blocking Aktmediated FOXO phosphorylation  Paclitaxel functions inducing microtubule dysfunction and eventually cell death mitotic catastrophe     Paclitaxel has been shown induce JNKMAPK phosphorylate and activate FOXO directly as well as derepressing inhibition of Akt on FOXO induce apoptosis Bim and other proapoptotic molecules    Indeed FOXO phosphorylation pJNK MAPK on Ser can promote its nuclear localisation and activation as well as its acetylation CBPp on Lys  Compounds such as βlapachone and fluorouracil have been shown induce cancer apoptosis activation of FOXOs and its target FOXM  ',\n",
       "  ('Targeting FOXO in cancer therapy',\n",
       "   'Sec21',\n",
       "   'Par38',\n",
       "   36): 'Some naturally derived compounds including benzyl isothiocyanate resveratrol quercetin arsenic trioxide and caffeic acid phenethyl ester CAPE have been shown restrain cancer growth FOXO activation  Naturally derived compounds which can be found daily diets also have great potential preventing cancer progression Recently studies extracted compounds are intensified promote concern healthier diets instance resveratrol grapes promotes transcriptional activity of FOXOs AMPK reduce ROS number of cancers  Benzyl isothiocyanate BITC promotes expression of FOXOregulated Bim p and p reducing Aktmediated FOXO phosphorylation pancreatic tumour  Similarly pterostilbene blueberries activates FOXO suppression of Akt and ERK activity and increases FU chemosensitivity colon cancer glutamate receptor antagonist dizocilpine also known as MK has been shown enhance FOXO nuclear localisation and promote its tumour suppressor function chilli pepper extract capsaicin activates JNK induce FOXO acetylation Biminduced apoptosis pancreatic cancer  Polydatin natural precursor of resveratrol also upregulates FOXO inhibition of Akt and STAT signalling pathway suppress hepatocellular carcinoma cell migration and invasion  Isorhapontigenin another analogue of resveratrol also inhibits STAT enhance FOXO activity and limits bladder cancer cell invasion  Polyphenol epigallocatechingallate green tea can upregulate FOXO and suppress breast cancer metastasis  Ergosterol mushroom also increases FOXO expression inhibit cell migration and invasion  Although some studies have exposed underlying mechanisms of action of some of these compounds exact mechanisms rest of these naturally derived compounds are not fully understood Thus far none of these naturally derived compounds is officially used clinic cancer treatment consequence Nevertheless these findings further support hypothesis that FOXOs serve as sensor as well as mediator of anticancer agents',\n",
       "  ('Targeting FOXO in cancer therapy',\n",
       "   'Sec21',\n",
       "   'Par39',\n",
       "   37): 'As FOXO expression and activity are often adaptively downregulated malignancies and are further attenuated drugresistant cancer expression of some of their important downstream transcriptional targets is also diminished as result Thus it is rational propose that interventions aimed downstream targets of FOXO proteins could induce cancer and drugresistant cellspecific elimination and form basis novel anticancer therapies  Indeed recent research has shown that PERK PKRlike endoplasmic reticulum kinase also called eukaryotic translation initiation factor alpha kinase  EIFAK is regulated FOXO and thus exposed transformed cell and chemotherapeutic drug–resistant cancer cell vulnerability PERK this case small molecule PERK inhibitors which have been generated and tested neurodegenerative diseases can be repositioned target cancer cells',\n",
       "  ('Conclusion',\n",
       "   'Sec22',\n",
       "   'Par40',\n",
       "   38): 'Collectively research studies date have pointed key tumoursuppressive role FOXO transcription factors This is mediated ability of FOXOs regulate genes essential cell proliferative arrest cell death autophagy senescence angiogenesis cell migration and metastasis FOXO proteins also integrate diverse proliferative nutrient and stress signals distinct gene networks control cell fate metabolism and cancer development Notably evidence also exists that FOXO proteins can sometimes support cancer progression angiogenesis metastasis and drug resistance cell type and context–dependent manner Intriguingly mechanisms of action of conventional cytotoxic chemotherapeutics and novel molecularly targeted therapies are also invariably linked FOXO transcription factors Fig  Thus FOXO proteins have been firmly established as not only important markers cancer diagnosis and prognosis but also targets cancer intervention Whilst mechanisms underlying their roles and regulations are still being uncovered accumulated research has also shown that FOXO expression and activity are predominantly regulated posttranscriptional and posttranslational levels and are adaptively downregulated cancer cells Thus targeting upstream regulators of FOXOs may provide novel strategies of cancer treatment and overcoming drug resistance Equally FOXO downstream targets which are adaptively downregulated FOXOs cancer may represent vulnerabilities cancer intervention strategies'},\n",
       " {('INTRODUCTION',\n",
       "   'jcmm17228-sec-0001',\n",
       "   'no_sub_id',\n",
       "   0): 'Transcription factors are gatekeepers of cellular processes They control expression of genes encoding critical proteins of entire proteome proteins involved metabolism and cell communication those that regulate immune response and cell cycle Signal transducer and activator of transcription STAT refers family of seven transcription factors that regulate expression of genes controlling critical cellular processes mechanism distinct secondary messengers Activation of STATs is typically initiated ligand binding cell surface receptors followed kinase‐dependent phosphorylation of conserved tyrosine pY residue This leads Src  homology SH domain mediated STAT‐STAT parallel dimerization rapid translocation nucleus DNA binding and subsequent transcription of gene targets  Figure ',\n",
       "  ('INTRODUCTION',\n",
       "   'jcmm17228-sec-0001',\n",
       "   'no_sub_id',\n",
       "   1): 'All STAT members Figure  display similar biochemical features controlling their subcellular localization and mode of action Recent studies revealed that not only do they transduce signals control transcription they also regulate anabolism and catabolism mitochondria and are involved nuclear compartmentalisation and genome integrity Cytokine or growth factor signalling and their activation however is largely cell type dependent Although cytokine or growth factor interactions cellular components such as STATs are broadly deemed as protein–protein interactions their effective mechanism is incompletely understood Here we investigate STAT interactome gene product and cancer type‐specific manner Depending on biological processes involved presence of cytokines and underlying conditions and pathologies they have unique STAT interactome that illuminates pleiotropic action of STAT family members Numerous reports have shown that gain‐of‐function GOF mutations ie somatic or acquired variations STAT proteins are basis oncogenesis neoplastic cells   ',\n",
       "  ('INTRODUCTION',\n",
       "   'jcmm17228-sec-0001',\n",
       "   'no_sub_id',\n",
       "   2): 'Our investigation focussed on five major cancers ranked based on death rate namely lung breast prostate colorectal and liver cancers Due high number of driver mutations STAT pathway we further included blood cancers our interactome analysis We initially compiled all literature‐based STAT interactions reported analysed their member‐specific role and generated pathway‐based figure depicting common STAT activation pathways We then filtered STAT protein–protein interactions PPIs those exclusively reported association specific cancer type either lung breast prostate colorectal or liver cancer and compared them global STAT interactome We conducted thorough analysis of STAT interactome blood cancers following these solid cancers Overall our analyses confirmed central targets multiple cancers such as growth factor receptors eg EGFR while also revealing new viable targets such as nuclear hormone receptor eg ESR pathways lung cancers and supported application of new single and combinatorial targeted approaches treatment of specific cancers',\n",
       "  ('MATERIALS AND METHODS',\n",
       "   'jcmm17228-sec-0002',\n",
       "   'no_sub_id',\n",
       "   3): 'The level of activity and protein interactions of each STAT member varies significantly context of disease and specific cell type some STAT members have wider influence as demonstrated larger number of PPIs order capture and visualize this influence and their differential activities we summarized STAT interactions network map and segregated their PPIs disease and tissue contexts PPI data most human proteins can be effectively used identify pathogenic genes drug targets and drug efficacy     These data were collected using integrated interactions database IID  version IID gathers PPIs nine curated databases and segregates these interactions disease and tissue contexts IID assigns context based on gene expression if mas normalized expression gene expression levels derived NCBI GEO gene expression datasets   Given that PPIs are usually monitored cells or vitro two proteins are considered interact specific context if they have been shown interact two independent publicationsdatabasesassays and if both of those genes meet gene expression requirements specific context eg breast cancer interactions presented here are curated ensure minimum inclusion of false positive and negatives minimise false positive rate we only report interactions which are present at least two publications or confirmed at least two bioassays minimise false negative rate IID uses high confidence predictions look additional interactions generate interactome figures used here we input proteins we were interested STATs Enter IDs field and retrieved all PPIs of STATs humans We included experimental predicted and protein orthology interactions thresholds or more studies or two or more bioassays We exported these data source info disease and subcellular localization context labelled data were then imported NAViGaTOR network analysis software developed protein–protein interactions  which was used generate interactome maps',\n",
       "  ('MATERIALS AND METHODS',\n",
       "   'jcmm17228-sec-0002',\n",
       "   'no_sub_id',\n",
       "   4): 'Finally it should be noted that while we can interpret these PPIs achieve deeper understanding of STAT communication care should be taken when interpreting interactions that are not observed example interaction global interactome Figure  can be absent context of certain disease Figure  Figure  and Figure  due rarity of disease lack of study analysis interest lack of sufficient literature support or due complexity of given cancer subtypes as illustrated our breast cancer insights',\n",
       "  ('MATERIALS AND METHODS',\n",
       "   'jcmm17228-sec-0002',\n",
       "   'no_sub_id',\n",
       "   5): 'To analyse these PPI networks we examine several factors including degree and centrality of each protein its interaction partners Degree correlates how many interactions protein makes and degree also reports on how influential protein is its immediate environment centralitymeasured undirected all pairs shortest paths APSP analysisis indicative of how important protein is communication throughout network higher number of shortest paths pass that pass protein more central it is and thus more important it is communication proteins network Together these parameters offer strong indication of how important node is network and this can be extrapolated determine how influential protein is signalling pathways as well as identifying promising therapeutic targets   IID has been used recently as part of CoVex integrate protein–protein interactions system which helps identify already approved drugs treat COVID‐ summary table of all interactions interactor UniProt codes and Pubmed IDs referencing each interaction can be found Table ',\n",
       "  ('Global STAT interactions',\n",
       "   'jcmm17228-sec-0004',\n",
       "   'no_sub_id',\n",
       "   6): 'Although all STATs share role cell signalling and biogenesis member‐specific protein interactions reveal divergent activity of STAT members various biological processes Figure  Figure  Compilation of literature‐based data on STAT PPIs shows that STAT interacts largest numberdiversity of proteins  distinct proteins followed closely STAT  distinct proteins Figure number of publications on given STAT directly influences its appearance interactomes example while STAT as search term results publications STAT results ~ hits current PubMed database entry as of  July search term STAT STATAB results only hits STAT possesses exclusive and extensive interaction evidence towards oncogenic partners such as c‐Myc Histone deacetylase  HDAC and Mitogen‐activated protein kinase  MAPK Other key STAT‐exclusive binding partners include Androgen receptor AR Spleen tyrosine kinase SYK and PαβγδP regulatory subunits of Phosphatidylinositol ‐kinase PIK constant P subunit of PIK is bound GAB scaffold proteins that also bridge STATAB interaction cytoplasm and STAT can transcribe AKT isoform These interactions however were filtered by our interactome stringency rules Mutations that lead increased kinase activity of were found up of solid cancers including breast colorectal lung carcinomas head and neck cancers many others As such involvement of STAT family members PIK‐AKT‐mTOR‐S pathway is key these cancers All of these proteins also interact other non‐STAT proteins STAT interactome suggesting that while they are directly interacting STAT they are indirectly communicating other STATs fact that some of these interaction partners such as MAPK and c‐Myc are important oncogenes indicates that STAT could be vulnerable connector these oncogenes which also validates STAT as promising cancer cell target',\n",
       "  ('Global STAT interactions',\n",
       "   'jcmm17228-sec-0004',\n",
       "   'no_sub_id',\n",
       "   7): 'Although STAT has largest impact interactome every other STAT also has exclusive interacting partners STAT is largely antagonist of oncogenic STAT also reflected its function as heterodimerization partner of STAT balancing role of STAT as tumour suppressor protein over oncogenic STAT is well studied various cancer types including colorectal cancer STAT is most prominent STAT protein interacting tumour suppressor TP network analysis although STAT and STATAB have also been reported interact TP as well',\n",
       "  ('Global STAT interactions',\n",
       "   'jcmm17228-sec-0004',\n",
       "   'no_sub_id',\n",
       "   8): 'Exclusive interaction of STATA and STAT Brutons tyrosine kinase BTK and Interleukin‐ receptor IL‐R proteins respectively highlights another point of member‐specific STAT activity IL‐Rα chain is also direct target gene of STAT and both IL‐ and IL‐ can activate STAT and STAT Surprisingly STATA is only STAT that has been shown interact Estrogen receptor ESR Figure  and this is thought occur via N‐terminal domain of STAT fashion similar many other nuclear hormone receptors that drive sex‐specific cancers ESR has large number of interactions global STAT interactome Figure  and it has important role female reproductive tract cancers These representative key interactions predominantly differentiate roles of STAT members and increase diversity of STAT influence on biological processes',\n",
       "  ('Global STAT interactions',\n",
       "   'jcmm17228-sec-0004',\n",
       "   'no_sub_id',\n",
       "   9): 'Based on shared proteins core of interactome  proteins largest biological processes which STATs converge are signal transduction or reprogramming of nucleus largely kinase interactome shared interactions most of these proteins are tyrosine kinases such as JAK SRC MAPK EGFR human Epidermal growth factor receptor HER Figure  and phosphatases such as PTPN which is also part of MAPK pathway and is involved signal transduction cytoplasm nucleus These signalling proteins are important as phosphorylation of STATs is major contributor their activation subsequent dimerization nuclear shuttling or transcriptional elongation second largest family of proteins core of interactome are controllers of cellular processes including coactivators or corepressors of gene expression cell cycle regulators such as cell cycle inhibitors cell cycle kinases or cyclins and physiological responses circadian rhythm that is also controlled largely GR stress hormone action Of all shared interacting partners mentioned EGFR and JAK are most central STAT proteins Figure  and both modulate STAT signalling cascade recruitment and phosphorylation of STATs This is consistent their reliance on phosphorylation signalling Another aspect of cellular processes which STATs are involved appears be histone acetylation‐deacetylation Histone acetylation is epigenetic marker which determines DNA transcription kinetics CBP CREB‐binding protein p and NCoA‐ Nuclear receptor coactivator  display histone acetyl transferase activity while HDAC and HDAC deacetylate histones as well as some non‐histone substrates Contrastingly PML promyelocytic leukaemia protein is positive regulator of histone deacetylation and has been shown interact STATs AML This evidence of multiple positive and negative effectors of histone acetylation suggests that STATs have large and unobserved role play epigenetic regulation',\n",
       "  ('Global STAT interactions',\n",
       "   'jcmm17228-sec-0004',\n",
       "   'no_sub_id',\n",
       "   10): 'The shared interactions STATs further diversify based on their sequence and structure similarities example STATA paired STATB and STAT paired STAT have more PPIs common any other pair of STATs Figure  and this is supported their similarities both sequence alignment and structural alignment data Some of shared key interaction partners of STAT and STAT include mammalian Target of rapamycin mTOR HDAC and SRC kinase which phosphorylates both STAT and STAT Importantly STATA and STATB are direct phosphorylation targets of mTOR conserved S residue Interestingly STAT and STAT have more PPIs common more structural homologous STATA and STATB though this may again be biased more literature content available STAT STATAB It should be noted that partial correlation of STATs having common PPIs does not mean that two proteins are redundant function example despite over  structural identity STATA has  exclusive interactions absent STATB and STATB has  exclusive interacting partners insufficient evidence STATA binding Figure  This indicates that minor changes STAT protein could modulate its binding interface and interaction partners',\n",
       "  ('\\n<italic toggle=\"yes\">Lung</italic>\\n<italic toggle=\"yes\">cancer</italic>\\n',\n",
       "   'jcmm17228-sec-0006',\n",
       "   'no_sub_id',\n",
       "   11): 'Lung cancer is divided two main histopathological types small‐cell lung cancer and non‐small‐cell lung cancer Small‐cell lung cancer arises neuroendocrine cells and accounts up of lung cancers Most lung cancers are non‐small‐cell lung cancers NSCLC which are further divided adenocarcinoma squamous cell carcinoma and large‐cell carcinoma Adenocarcinoma is stratified different driver mutations such as activating mutations ‐ and and arises alveoli‐lining epithelial cells of airways STAT lung cancer interactome Figure  focuses predominantly on adenocarcinomas which accounts up of lung cancers lung cancer interactome we observe larger number of central proteins aside EGFR and STAT All these key proteins are actively involved lung cancer STAT and EGFR share similar level of centrality lung cancers much more so in global interactome Figure  This suggests role EGFR that is more important disease phenotype in healthy lung tissue and is critical lung cancer pathology Furthermore NSCLC pathway Figure  appears be centralized STAT and its direct interaction partners alongside EGFR majority of lung cancer studies described STAT as oncogene particularly hyperactive EGFR signalling of autocrine IL‐ stimulation however context of KRAS mutations STAT possesses tumour suppressive activity Such complications make targeting of STAT NSCLC difficult decision While there are many proteins which act as partial communication hubs due their centrality such as STAT ESR or TP concentration of lung cancer pathway STAT and EGFR suggests that their inhibition would have largest detrimental effect on disease preventing activation of drug resistance pathways combinatorial treatments Targeting of oncogenic RAS or tumour suppressiveoncogenic TP mutations is challenging and will require innovative therapy concepts however as suggested interactome nuclear hormone receptor eg ESR pathways lung cancer also appear be central represented yellow hollows Figure  and can serve as new viable target these cancers Future studies could evaluate anti‐estrogen drugs such as tamoxifen as part of combinatorial treatment approaches',\n",
       "  ('\\n<italic toggle=\"yes\">Breast</italic>\\n<italic toggle=\"yes\">cancer</italic>\\n',\n",
       "   'jcmm17228-sec-0007',\n",
       "   'no_sub_id',\n",
       "   12): 'There are many subtypes of breast cancers initiating different regions of breast such as ductal areas lobules or more rare cases connecting cell types Triple‐negative breast cancer TNBC is most aggressive and difficult treat subtype accounting – of breast cancers and is de novo resistant estrogen therapy Breast cancer biomarkers TNBC include Estrogen receptor ER Progesterone receptor PR and human epidermal growth factor receptor  HER all three being absent TNBC World Health Organization WHO distinguished least  different histological breast cancer types Luminal breast cancers are largest group and they display estrogen receptor ER as biomarker of good prognosis if highly expressed ER‐positive carcinomas account ~ of all cases of breast cancers Western societies Whereas  of ER positive breast cancers displays PR expression as second biomarker HER is third biomarker breast cancer accounting – of cases HER amplification is associated metastasis and its persistent activation promotes STAT oncoprotein activation however their role as being oncogene or tumour suppressor protein breast cancer is controversial due complexity of different breast cancer subtypes or driver mutation context Thus biomarkers are highly relevant different breast cancer subtypes Due their heterogeneous driver mutation landscapes treatment protocols involving personalized precision medicine have been described be useful and effective Because of tumour heterogeneity different breast cancer subtypes are not accounted and subtype overlaps cannot be avoided our network analysis of breast cancer Nonetheless analysis of simplified or more homogenous breast cancers mainly luminal as opposed most aggressive TNBC revealed that member‐exclusive STAT activity becomes more apparent when STAT PPIs are filtered relation STAT‐linked cancers',\n",
       "  ('\\n<italic toggle=\"yes\">Breast</italic>\\n<italic toggle=\"yes\">cancer</italic>\\n',\n",
       "   'jcmm17228-sec-0007',\n",
       "   'no_sub_id',\n",
       "   13): 'In breast cancer STAT has large number of interactions and many of these interactions involve moderately central proteins STAT‐breast cancer interactome Figure  STAT is most central protein followed closely EGFR revealing surprising similarity lung cancer This may part explain why breast cancer might favour lung cancer metastasis insight that could obtain attention different breast cancer subtypes or lung metastasis of all STATs STAT and STAT possess largest number of interactions and large centrality governing communication other proteins being most important STATs breast cancer network Although non‐STAT proteins such as TP ESR SRC and JAK are often linked breast cancer their dominance network is overshadowed exclusion of non‐STAT interacting proteins general comparison of PPIs diseased and healthy mammalian tissue shows that these proteins become more central communication disease context highlighting upregulated protein–protein communication breast cancer Although inhibition of STAT is considered severely hinder viability of breast cancer cells this high degree of centrality and signalling redundancy multiple central oncogenes again suggests that combination therapies targeting STAT and other key proteins including TP ESR EGFR or STAT may present higher degree of success clinic',\n",
       "  ('\\n<italic toggle=\"yes\">Breast</italic>\\n<italic toggle=\"yes\">cancer</italic>\\n',\n",
       "   'jcmm17228-sec-0007',\n",
       "   'no_sub_id',\n",
       "   14): 'Signal transducer and activator of transcription interactome analysis of TNBC was performed investigating tumour‐relevant pathways this most aggressive highly metastasising subtype and isolating specific proteins Compared overall breast cancer interactome mainly comprising of luminal subtype STAT influence on TNBC interactome is predominantly shifted towards STAT and STAT Figure  However all of central non‐STAT proteins TP EGFR and ESR breast cancer network are still interacting and they are central TNBC interactome SRC and JAK kinases also display more distinct influence TNBC centrality of ESR TNBC is again interesting as its epigenetic silencing has been observed TNBC patients India These findings suggest that while several STATs collectively govern breast cancer STAT and STAT become more influential proteins TNBC progression',\n",
       "  ('\\n<italic toggle=\"yes\">Prostate</italic>\\n<italic toggle=\"yes\">cancer</italic>\\n',\n",
       "   'jcmm17228-sec-0008',\n",
       "   'no_sub_id',\n",
       "   15): 'Prostate cancers are androgen‐driven tumours and they are classified as luminal adenocarcinomas majority of cases Luminal adenocarcinomas are castration‐sensitive androgen‐responsive anti‐androgen treatment other types of prostate cancers are neuroendocrine prostate cancer or small‐cell carcinoma which account less and these are not covered our analysis prostate luminal adenocarcinomas we observe that STATAB are all interacting substantial number of proteins moderate centrality Figure  STAT is also present although it has significantly fewer interactions low centrality suggesting it is not critical protein STAT interacts largest number of proteins diverse array of gene ontologies and many of shared interaction partners centre of network STAT is known be constitutively activated prostate tumours and related cell lines Again similar our observations lung cancer or breast cancer key STAT interaction partner is ERBB family member namely EGFR second most central protein network Figure STAT interactome prostate cancer supports that EGFR is key signal transducer Indeed EGFR is already known promoting motility and growth of prostate cancer cells interactions passing network are centralized on STAT and EGFR STATAB TP and ESR playing supporting role Interestingly both STAT and STATA interact STAT and STATB but not each other EGFR however interacts all STATs except STAT This appears be cause of substantial centrality of EGFR as it interacts all major STATs present prostate cancer This also illuminates divergence STAT and STATA and this is bridged other STATs and EGFR interaction',\n",
       "  ('\\n<italic toggle=\"yes\">Colorectal</italic>\\n<italic toggle=\"yes\">cancer</italic>\\n',\n",
       "   'jcmm17228-sec-0009',\n",
       "   'no_sub_id',\n",
       "   16): 'In contrast prostate cancer however non‐STAT proteins appear be more important communication STATs colorectal cancer Figure  Although STATA  interactions and STAT  interactions are interconnected STAT  interactions and STAT  interactions have more interactions and show higher centrality Figure  Collectively these findings suggest that STATs STAT and STAT are far most important colorectal cancer progression while other STATs such as STATA STATB and STAT are vastly understudied EGFR TP and ESR also have high centrality and degree colorectal cancers TP and ESR are both more central interactome STAT and STATA their respective exclusive interaction partners both of which have been shown be linked colorectal cancer This situation arose because larger number of TP and ESR interactions have been reported association colorectal cancer while many of physiological interactions of STAT and STATA healthy cells were not identified colorectal cancer Notably STAT is well known interact TP and both have been shown collaborate mediating apoptosis response colorectal cancer',\n",
       "  ('\\n<italic toggle=\"yes\">Liver</italic>\\n<italic toggle=\"yes\">cancer</italic>\\n',\n",
       "   'jcmm17228-sec-0010',\n",
       "   'no_sub_id',\n",
       "   17): 'Liver cancer shows one of most surprising interactomes where non‐STAT proteins have larger role even STAT Figure  TP has far largest centrality of any protein shown here followed closely EGFR Connecting these two central liver cancer proteins are STAT and ESR These four proteins have largest influence STAT interactome liver cancer STAT following closely STAT EGFR ESR and TP have all been shown be important progression of liver cancer with STAT signalling pathway      Notably two clinical trials phase III trial on tamoxifen ESR antagonist and phase II trial of tamoxifen combination cisplatin and doxorubicin hydrochloride have already been performed treatment of liver cancers postulated central role of estrogen receptor should be further investigated address whether both classes of estrogen receptors ERα and ERβ are involved and relevant hepatocellular carcinoma progression',\n",
       "  ('\\n<italic toggle=\"yes\">Liver</italic>\\n<italic toggle=\"yes\">cancer</italic>\\n',\n",
       "   'jcmm17228-sec-0010',\n",
       "   'no_sub_id',\n",
       "   18): 'There is dominant role IL‐‐JAK‐STAT component reported many liver cancer studies which clearly implicates JAKJAK‐STAT axis as oncoproteins but expression of JAK kinases general is much lower expression of STAT proteins causing bias systems biology analysis However JAK kinases are frequently mutated and if gain or loss of function mutation would be found then this analysis would strongly influence systems biology insight This can be best illustrated most abundant and frequent JAK mutation which is found JAKVF driving myeloproliferative neoplasms MPN However we did not include MPN our blood cancer analysis we wanted only include acute leukaemia or lymphoma insights dominant role of JAK MPN is described elsewhere and we have not included these our analysis of blood cancers that are discussed next due large diversity of hematopoietic cancers',\n",
       "  ('\\n<italic toggle=\"yes\">Blood</italic>\\n<italic toggle=\"yes\">cancers</italic>\\n',\n",
       "   'jcmm17228-sec-0011',\n",
       "   'no_sub_id',\n",
       "   19): 'Hematopoietic cancers are heterogeneous diseases of mesenchymal origin central role of perturbed JAKSTAT signalling initiation and progression of blood cancers is not surprising given its essential node normal haematopoiesisthe development and function of blood cells of myeloid and lymphoid lineages There it is involved transmission of complex signalling pathways that are mediated numerous cytokines and their receptors',\n",
       "  ('\\n<italic toggle=\"yes\">Blood</italic>\\n<italic toggle=\"yes\">cancers</italic>\\n',\n",
       "   'jcmm17228-sec-0011',\n",
       "   'no_sub_id',\n",
       "   20): 'Myeloid STAT signalling is distinct lymphoid STAT networks myeloid branch binding of cytokines their receptors initiates JAK activation which turn ignites particular STAT proteins MAPK and PIK‐AKT‐mTOR pathway receptor‐specific fashion our analysis EGFR and TP are only central non‐STATs two networks of hematopoietic cancers Figure  while ESR is central only myeloid leukaemia EGFR displays comparable level of centrality STATs and as such combination therapies targeting EGFR have been proven effective AML cells centrality of TP well‐known interactor of STAT proteins is most important tumour suppressor transcription factor human cancer half cases carrying genetic mutation or loss Quite interestingly TP represses STAT transcription but mutated TP is shown boost STAT transcription AML cells On contrary lymphoid JAK‐STAT signalling cytokines that bind common‐γ‐chain containing receptors such as IL‐ are central physiological T‐ NK‐ and B‐cell development and function Hyperactivation of JAKJAK results high oncogenic STAT and STAT activity',\n",
       "  ('\\n<italic toggle=\"yes\">Blood</italic>\\n<italic toggle=\"yes\">cancers</italic>\\n',\n",
       "   'jcmm17228-sec-0011',\n",
       "   'no_sub_id',\n",
       "   21): 'Overall STATAB are distinctly activated andor overexpressed hematologic neoplasms STAT acts as leukaemogenic oncogene B‐lymphoid leukaemia and mutations SH domain affecting dimerization and activation have been detected numerous leukaemia samples patients LGL  Whereas mutations are associated poor survival AML patients ESR methylation is reported correlate hypermethylation of several oncogenes linked AML and more work is needed understand centrality of EGFR TP and ESR blood cancers conclusion STAT and STAT are only STATs interacting majority of proteins hematopoietic cancer interactome network showing high degree of centrality Figure  Figure  Comparably other STATs STAT STAT and STAT display smaller number of interactions This is unsurprising due specific expression pattern of STAT and STAT or more restricted role of STAT viralbacterial defence',\n",
       "  ('Subcellular localization of STAT proteins',\n",
       "   'jcmm17228-sec-0012',\n",
       "   'no_sub_id',\n",
       "   22): 'Due their common function of transferring signals cytoplasm nucleus all STAT members appear both cytoplasm and nucleus and they interact many of same proteins Figure cytoplasm and nucleus is where majority of STAT pathway‐associated proteins reside see Figure  interactomes filtering these two subcellular compartments are very similar compared full STAT interactome cytoplasmic STAT interactome given their high centrality STAT EGFR and STAT are responsible bulk of communication proteins nucleus however TP STATA and ESR appear be central communication hubs  STAT and STAT play regulatory role nucleus Taken together these findings and associations suggest that transmission of information is more delocalized nucleus in cytoplasm Thus therapeutic strategies targeting central cytoplasmic proteins would provide less room oncogenic signalling be offloaded another protein',\n",
       "  ('Subcellular localization of STAT proteins',\n",
       "   'jcmm17228-sec-0012',\n",
       "   'no_sub_id',\n",
       "   23): 'STAT delocalizes all four subcellular compartments nucleus cytoplasm mitochondrion and plasma membrane and it interacts SRC Receptor of activated protein C kinase  RACK MAPK tyrosine‐protein kinase Lyn LYN mitochondrial GRIM and Sorcin SRI these compartments Mitochondrial STAT action is required RAS‐RAF transformation and is triggered via actions such as stress kinase‐mediated serine phosphorylation of STAT Apart STAT both STAT and STAT are also found translocate mitochondria  Unlike nucleus and cytoplasm one of direct interaction partners of STAT mitochondria was described be proteins of complex I and complex III of respiratory chain and ‐Oxoglutarate dehydrogenase OGDHL which is observed our interactomes and has high degree of centrality There are two other highly central proteins mitochondria TP and Dihydrolipoyl dehydrogenase DLD DLD and OGDHL both function as oxidoreductases and OGDHL is associated cervical cancer relatively large numbers of central proteins this network suggests that STAT is not as important mitochondrial signalling as cytosolic or nuclear localisation of STAT Recently STAT has been shown be located portion of ER associated mitochondria instead of mitochondria itself putting its crucial role mitochondria question Furthermore presence of multiple proteins above similar functions ie oxidoreductases mitochondrion indicates existence of redundant molecular pathway plasma membrane STAT with EGFR dominates network similar number of interactions and degree of centrality  Due high number of shared interactions plasma membrane interactome both STAT and EGFR appear critical signalling plasma membrane followed consecutively JAK and SRC Due its servitude as reliable interaction partner and communication hub STATs plasma membrane nucleus EGFR disruption can clearly be foreseen and is shown be beneficial arresting or eradicating cancer cell growth Notably STAT is only other STAT delocalized plasma membrane although it does not appear play key role communication there Overall while interactomes of nucleus and cytoplasm appear remarkably similar whole STAT interactome STAT appears be only influential STAT plasma membrane and displays minimal importance mitochondria',\n",
       "  ('FUTURE DIRECTIONS AND CONCLUSIONS',\n",
       "   'jcmm17228-sec-0013',\n",
       "   'no_sub_id',\n",
       "   24): 'In all carcinoma and hematopoietic cancer networks STAT and STAT interact similar panel of proteins including MTOR SRC and EGFR Figure  Figure  Figure and Figure observed crosstalk these STATs as well as STATA and STATB suggests that formation of heterodimer is important diseased states Interestingly although STAT‐STATA interaction is reported breast and lung cancers or leukaemia there is no evidence STAT‐STATB or STAT‐STATA interaction observed any of interactomes investigated While all STATs interact larger number of oncogenes tumour suppressors ratio of oncogenes tumour suppressors is highest STATA and STATB Figure each disease investigated this paper STAT‐STAT interaction has been consistently reported Figure  Figure  Figure and Figure  These interactions clearly indicate importance of STAT crosstalk diseased states and hence their ongoing exploration drug discovery efforts will be important Targeting of STATs is long‐standing strategy and variety of small‐molecule drugs and degraders such as fludarabine pimozide sulforaphane pyrimethamine and SD‐ have been developed Our analysis indicates that although inhibition of STATs is said severely hinder viability of certain cancers combinatorial therapy of STATs alongside other key proteins including TP ESR and EGFR may result higher degree of success especially solid cancers Furthermore based on our interactome ESR appears be central and it can serve as new viable combinatorial target lung cancers blood cancers however STAT STAT and STAT play dominant role and single STAT‐targeting therapies may suffice also reflecting their less complex genetic driver mutation landscape most cases of STAT‐linked diseases such as solid carcinomas combination therapy of STAT dual inhibitors or combination therapy upstream TKI such as ERBB family member blockers or JAKinibs will likely be more successful',\n",
       "  ('CONFLICT OF INTEREST',\n",
       "   'jcmm17228-sec-0015',\n",
       "   'no_sub_id',\n",
       "   25): 'The authors declare no competing interests',\n",
       "  ('AUTHOR CONTRIBUTIONS',\n",
       "   'jcmm17228-sec-0016',\n",
       "   'no_sub_id',\n",
       "   26): 'Data curation equal Formal analysis equal Investigation equal Methodology equal Writing – original draft lead Writing – review  editing lead Data curation lead Formal analysis equal Methodology supporting Software lead Visualization lead Writing – original draft supporting Visualization supporting Writing – review  editing supporting Visualization supporting Writing – review  editing supporting Project administration supporting Resources supporting Writing – review  editing supporting Investigation supporting Writing – review  editing supporting Writing – review  editing supporting Writing – original draft supporting Writing – review  editing supporting Supervision equal Writing – review  editing supporting Supervision equal'},\n",
       " {('Introduction',\n",
       "   'Sec1',\n",
       "   'Par2',\n",
       "   0): 'The World Health Organization WHO classification of tumours is evidencebased classification of cancers occurring various organ systems It is standard diagnosis research cancer registries and public health monitoring worldwide first time inception of classification over  years ago current series th edition has been developed unified relational database framework that encompasses entirety of human cancers Tumours of each organ system and volumes blue books are classified hierarchically this novel framework taxonomy principles and set of nonnegotiables that include process transparency bibliographic rigor and avoidance of bias development of th edition is overseen editorial board that includes representatives major medical and scientific organizations worldwho oversee entire series addition appointed their leadership and contemporaneous expertise relevant particular volume editorial board turn identifies authors informed bibliometry process emphasis on broad geographic representation and multidisciplinary expertise design multidisciplinary authoreditor groups total of  contributors shared overlapping coverage of disease categories ensure conceptual continuity and content harmonization This approach reflects ways which classification is meant be implemented multidisciplinary input that emphasizes holistic approach patient management diagnosis disease monitoring',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par3',\n",
       "   1): 'The aim of this paper is provide overview of new edition of WHO classification myeloid and histiocyticdendritic tumours last edition of haematolymphoid classification dates back and was revised overview of lymphoid tumours is provided companion manuscript ',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par4',\n",
       "   2): 'The classification structure follows lineagebased framework flowing broadly benign malignant and branching down category family type diseasetumour and subtype Where possible triad of attributes was systematically applied and included lineage  dominant clinical attribute  dominant biologic attribute Lineage attribution rests on immunophenotyping flow cytometry andor immunohistochemistry Dominant clinical attributes are general features of untreated disease and include descriptors such as acute chronic cytopenias myelodysplasia and cytosises myeloproliferation Most biologic attributes include gene   and  Fusions are part of nomenclature of typessubtypes when identities of both implicated genes are required or often desirable criteria diagnosis eg  Rearrangements broad term that encompasses range of structural genomic alterations leading gene fusions are part of nomenclature of typessubtypes when there are multiple possible fusion partner genes of biologically dominant gene eg  Of note use of term rearrangements is maintained classification due its wide usage prior editions although it is recognized that it is more appropriate genomic modifications genes consisting of various segments eg immunoglobulin genes and Tcell receptor genes deliberate attempt is made prioritize classifying tumour types based on where possible',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par5',\n",
       "   3): 'Emerging entities are listed as disease subtypes novel rubric of  This is envisioned as landing spot classification incorporate newrare entities whose recognition is increasing as highthroughput molecular diagnostic tools become more available This approach replaces assignment of provisional status such entities It is recognized that diagnosis of such subtypes might not be feasible all practice settings set of decision support guidelines was adopted aid determining what subtypes would qualify this context they include  having distinct molecular or cytogenetic features driven established oncogenic mechanisms  not meeting subtype criteria other tumour types defining genetic abnormalities  having distinct pathologic and clinical features including  but not limited response therapeutic interventions and least two quality peerreview publications distinct investigator groups',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par6',\n",
       "   4): 'The application of this classification is predicated on integrating morphologic cytology and histology immunophenotypic molecular and cytogenetic data This is line previous editions expanded numbers of disease types and subtypes that are molecularly defined It is hoped that genetic underpinnings of classification will prompt provision of health resources ensure that necessary genetic testing platforms are available peruse full potential of classification Notwithstanding full published classification will include listing of essential diagnostic criteria that have broadest possible applicability particularly limited resource settings further aid broader applicability is improved hierarchical structure of classification which permits reverting family classlevel definitions when detailed molecular genetic analyses may not be feasible this approach is further elaborated on introduction of blue book',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par7',\n",
       "   5): 'In line rest of WHO th edition series classification of myeloid and histiocyticdendritic neoplasms follows Human Genome Organization Gene Nomenclature Committee recommendations including new designation of gene fusions using double colon marks  ',\n",
       "  ('Summary Box:', 'FPar1', 'Par11', 6): '',\n",
       "  ('Chronic myeloid leukaemia risk factors are refined, and accelerated phase is no longer required',\n",
       "   'Sec4',\n",
       "   'Par15',\n",
       "   7): 'Chronic myeloid leukaemia CML is defined fusion resulting tqq natural history of untreated CML introduction of targeted tyrosine kinase inhibitors TKI was biphasic or triphasic initial indolent CP followed blast phase BP or intervening accelerated phase AP TKI therapy and careful disease monitoring incidence of progression advanced phase disease has decreased and year overall survival rate CML is – designation of AP has thus become less relevant where resistance stemming kinase mutations andor additional cytogenetic abnormalities and development of BP represent key disease attributes   Accordingly AP is omitted current classification favour of emphasis on high risk features associated CP progression and resistance TKI Criteria BP include  ≥ myeloid blasts blood or bone marrow or presence of extramedullary proliferation of blasts or presence of increased lymphoblasts peripheral blood or bone marrow optimal cutoff lymphoblasts and significance of lowlevel Blymphoblasts remain unclear and require additional studies',\n",
       "  ('Minor changes in diagnostic criteria for <italic toggle=\"yes\">BCR::ABL1</italic>-negative myeloproliferative neoplasms',\n",
       "   'Sec5',\n",
       "   'Par16',\n",
       "   8): 'The classification retains emphasis on distinguishing polycythaemia vera PV essential thrombocythaemia ET and primary myelofibrosis PMF using diagnostic criteria established previous editions minor refinements Distinction these types is based on integrating peripheral blood findings molecular data and bone marrow morphologic evaluation findings as none of these parameters alone provide sufficient diagnostic specificity',\n",
       "  ('Minor changes in diagnostic criteria for <italic toggle=\"yes\">BCR::ABL1</italic>-negative myeloproliferative neoplasms',\n",
       "   'Sec5',\n",
       "   'Par17',\n",
       "   9): 'Major diagnostic criteria diagnosis of PV include elevated haemoglobin concentration andor haematocrit accompanied trilineage hyperplasia panmyelosis pleomorphic mature megakaryocytes bone marrow and NMJAK pVF or exon  mutations As determination of increased red cell mass Crlabeled red cells has become uncommon routine clinical practice it has been removed as diagnostic criterion diagnostic criteria of ET are wellestablished and have not changed',\n",
       "  ('Minor changes in diagnostic criteria for <italic toggle=\"yes\">BCR::ABL1</italic>-negative myeloproliferative neoplasms',\n",
       "   'Sec5',\n",
       "   'Par18',\n",
       "   10): 'Primary myelofibrosis PMF is characterized proliferation of abnormal megakaryocytes and granulocytes bone marrow which is associated fibrotic stages polyclonal increase fibroblasts that drive secondary reticulin andor collagen marrow fibrosis osteosclerosis and extramedullary haematopoiesis Recognizing prefibrotic PMF remains necessary separate it not only ET and PV but also fibrotic PMF importance of serial monitoring of bone marrow fibrosis and spleen size using reproducible and standardized criteria remain pertinent especially patients receiving JAK inhibitors PV and ET progress AP  blasts and BP ≥ blasts minority of cases but leukaemic transformation is more frequent PMF and leukaemiafree survival is shorter fibrotic prefibrotic PMF  ',\n",
       "  ('Minor changes in diagnostic criteria for <italic toggle=\"yes\">BCR::ABL1</italic>-negative myeloproliferative neoplasms',\n",
       "   'Sec5',\n",
       "   'Par19',\n",
       "   11): 'While   and mutations are considered driver events mutations other genes – particularly   and are found over half of patients MPN Mutations affecting splicing regulators  and other regulators of chromatin structure epigenetic functions and cellular signaling eg  are less common These additional mutations are more frequent PMF and advanced disease compared PV and ET and some are known correlate poorer prognostic risk eg  and mutations PMF',\n",
       "  ('Minor changes in diagnostic criteria for <italic toggle=\"yes\">BCR::ABL1</italic>-negative myeloproliferative neoplasms',\n",
       "   'Sec5',\n",
       "   'Par20',\n",
       "   12): 'Chronic neutrophilic leukaemia CNL is negative MPN characterized sustained peripheral blood neutrophilia white blood cell count WBC ≥  ×  L ≥ segmented neutrophils and bands bone marrow hypercellularity due neutrophilic granulocyte proliferation and hepatosplenomegaly mutations are common this disease and detected of cases  ',\n",
       "  ('Minor changes in diagnostic criteria for <italic toggle=\"yes\">BCR::ABL1</italic>-negative myeloproliferative neoplasms',\n",
       "   'Sec5',\n",
       "   'Par21',\n",
       "   13): 'Chronic eosinophilic leukaemia CEL is multisystem disorder characterized sustained proliferation of morphologically abnormal eosinophils and eosinophil precursors resulting persistent hypereosinophilia blood and bone marrow – Several changes diagnostic criteria of CEL are introduced time interval required define sustained hypereosinophilia is reduced months weeks  addition of requirement both clonality and abnormal bone marrow morphology eg megakaryocytic or erythroid dysplasia and  elimination of increased blasts ≥ peripheral blood or bone marrow as alternative clonality These criteria improve distinction CEL and entities such as idiopathic hypereosinophilic syndrome and hypereosinophilia of unknown significance  As criteria of CEL and its place relative other disorders eosinophilia have become well characterized qualifier not otherwise specified is no longer needed and has been omitted name',\n",
       "  ('Minor changes in diagnostic criteria for <italic toggle=\"yes\">BCR::ABL1</italic>-negative myeloproliferative neoplasms',\n",
       "   'Sec5',\n",
       "   'Par22',\n",
       "   14): 'As prior editions MPN not otherwise specified MPNNOS is designation that should be reserved cases clinical laboratory morphologic and molecular features of MPN but lacking diagnostic criteria of any specific MPN type or features that overlap distinct MPN types',\n",
       "  ('Summary Box:', 'FPar2', 'Par24', 15): '',\n",
       "  ('Summary Box:', 'FPar3', 'Par32', 16): '',\n",
       "  ('New terminology and grouping framework',\n",
       "   'Sec9',\n",
       "   'Par36',\n",
       "   17): 'The classification introduces term abbreviated MDS replace myelodysplastic syndromes underscoring their neoplastic nature and harmonizing terminology MPN These clonal haematopoietic neoplasms are defined cytopenias and morphologic dysplasia As indicated cytopenia definitions are adopted consistency CCUS MDS and MDSMPN Additionally recommended threshold dysplasia is set for all lineages MDS entities are now grouped as those having and those that are  Table  It is posited that such reorganization enhances classification rigor emphasizing geneticallydefined disease types and ceding prior emphasis on riskbased grouping classification based on blast percentage ring sideroblasts and number of lineages dysplasia favour of more comprehensive riskstratification schemes such as Revised International Prognostic Scoring System MDS IPSSR additional modification is clarified terminology distinguish MDS blasts MDSLB and MDS blasts MDSIB while retaining longstanding cutoffs',\n",
       "  ('MDS with defining genetic abnormalities',\n",
       "   'Sec10',\n",
       "   'Par37',\n",
       "   18): 'Myelodysplastic neoplasms defining genetic abnormalities are grouped together and include MDSq MDS and MDSbi latter supersedes MDSq and MDS',\n",
       "  ('MDS with defining genetic abnormalities',\n",
       "   'Sec10',\n",
       "   'Par38',\n",
       "   19): 'The diagnostic criteria of MDSq have not changed While recognized as factors that may potentially alter biology andor prognosis of disease presence of or mutation not multihit does not per se override diagnosis of MDSq',\n",
       "  ('MDS with defining genetic abnormalities',\n",
       "   'Sec10',\n",
       "   'Par39',\n",
       "   20): 'Recent studies have identified MDS as distinct disease type that includes over  of MDS ≥ ring sideroblasts term is retained as acceptable alternative be used cases wildtype and ≥ ring sideroblasts This permits inclusion of rare MDS cases harbouring driver mutations other RNA splicing components',\n",
       "  ('MDS with defining genetic abnormalities',\n",
       "   'Sec10',\n",
       "   'Par40',\n",
       "   21): 'Pathogenic alterations of any type sequence variations segmental deletions and copy neutral loss of heterozygosity are detected of MDS – these twothirds of patients have multiple hits multihit consistent biallelic alterations  Biallelic bi alterations may consist of multiple mutations or mutation concurrent deletion of other allele This multihit mutational status results neoplastic clone that lacks any residual wildtype p protein Clinical detection of biallelic alterations is based on sequencing analysis covering least exons often coupled technique detect copy number status usually fluorescence situ hybridization probe set specific locus on p andor array techniques eg comparative genomic hybridization or single nucleotide polymorphism arrays  Loss of genetic material locus may also be inferred nextgeneration sequencing VAF ≥  may be regarded as presumptive not definitive evidence of copy loss on trans allele or copy neutral loss of heterozygosity when constitutional variant can be ruled When two or more mutations are detected they usually affect both alleles  and can be considered multihit status Over  of patients MDSbi have complex mostly very complex  karyotype   and thus are regarded as very high risk IPSSR  Additional studies are needed determine whether bi status is per se AMLdefining point consideration future editions Notwithstanding published data suggests that MDSbi may be regarded as AMLequivalent therapeutic considerations  ',\n",
       "  ('MDS, morphologically defined',\n",
       "   'Sec11',\n",
       "   'Par41',\n",
       "   22): 'Hypoplastic MDS MDSh is listed as distinct MDS type this edition Long recognized as having distinctive features MDSh is associated Tcell mediated immune attack on haematopoietic stem and progenitor cells with oligoclonal expansion of CD  cytotoxic Tcells overproducing IFNγ andor TNFα Several features overlap triad of MDSh paroxysmal nocturnal haemoglobinuria PNH and aplastic anaemia AA including association CH – Many patients MDSh have sustainable responses agents used patients AA ie antithymocyte globulin ATG As such emphasis is placed on careful morphologic evaluation typically requiring trephine biopsy evaluation addition evaluation of bone marrow smears and touch preparations and detection of mutations andor clonal cytogenetic abnormalities Individuals germline pathogenic variants Fanconi anaemia FA or telomerase complex genes can have hypoplastic bone marrow and evolve MDS andor AML and do not respond immunosuppressive treatment',\n",
       "  ('MDS, morphologically defined',\n",
       "   'Sec11',\n",
       "   'Par42',\n",
       "   23): 'As number of dysplastic lineages is usually dynamic and often represents clinical and phenotypic manifestation of clonal evolution – rather per se defining specific MDS type distinction single lineage and multilineage dysplasia is now considered optional updated MDS classification scheme and incorporation of CCUS classification obviates need NOS or unclassifiable attributes Specifically MDS unclassifiable which was present prior edition is removed',\n",
       "  ('The boundary between MDS and AML is softened, but the 20% blast cutoff to define AML is retained',\n",
       "   'Sec12',\n",
       "   'Par43',\n",
       "   24): 'Reassessment of bone marrow blast percentage defining boundary of MDSIB and AML has been advocated several cogent reasons and view of novel therapeutic approaches that show efficacy patients currently classified as MDS or AML myeloid blasts – Salient practical challenges underpinning arguments such reassessment include  any blastbased cutoff is arbitrary and cannot reflect biologic continuity naturally inherent myeloid pathogenic mechanisms  blast enumeration is subject sampling variationserror and subjective evaluation and  no gold standard blast enumeration exists and orthogonal testing platforms can and often do produce discordant results pros and cons of merging MDSIB AML and adopting cutoff what would be called MDSAML were explored multidisciplinary expert discussions and editorial board meetings course of producing this classification Lowering blast cutoff define AML was felt suffer same challenges listed and would merely replace one cutoff another Further arbitrary cutoff of  blasts define AML even if qualified as MDSAML or AMLMDS carries risk of overtreatment Accordingly balanced approach was adopted eliminating blast cutoffs most AML types defining genetic alterations but retaining blast cutoff delineate MDS AML Notwithstanding there was broad agreement that MDSIB may be regarded as AMLequivalent therapeutic considerations and clinical trial design perspective when appropriate',\n",
       "  ('Summary Box:', 'FPar4', 'Par47', 25): '',\n",
       "  ('Chronic myelomonocytic leukaemia diagnostic criteria, subtypes, and blast-based subgrouping criteria reflect diagnostic refinement and emphasize unifying characteristics',\n",
       "   'Sec15',\n",
       "   'Par55',\n",
       "   26): 'The prototype and most common MDSMPN is chronic myelomonocytic leukaemia CMML which is characterized sustained peripheral blood monocytosis and various combinations of somatic mutations involving epigenetic regulation spliceosome and signal transduction genes Diagnostic criteria are revised include prerequisite and supporting criteria Table first prerequisite criterion is persistent absolute ≥ ×  L and relative ≥ peripheral blood monocytosis Namely cutoff absolute monocytosis is lowered ×L ×L incorporate cases formerly referred as oligomonocytic CMML – enhance diagnostic accuracy when absolute monocytosis is ≥ ×L but  ×L detection of one of more clonal cytogenetic or molecular abnormality and documentation of dysplasia at least one lineage are required Abnormal partitioning of peripheral blood monocyte subsets is introduced as new supporting criterion   Additional studies are needed determine optimal approach classifying individuals unexplained clonal monocytosis  who do not fit new diagnostic criteria of CMML',\n",
       "  ('Chronic myelomonocytic leukaemia diagnostic criteria, subtypes, and blast-based subgrouping criteria reflect diagnostic refinement and emphasize unifying characteristics',\n",
       "   'Sec15',\n",
       "   'Par56',\n",
       "   27): 'Two disease subtypes salient clinical and genetic features are now formally recognized based on WBC CMML MDCMML WBC   × L and CMML MPCMML WBC ≥  × L MPCMML is commonly associated activating RAS pathway mutations and adverse clinical outcomes blastbased subgroup of CMML  blasts blood and  blasts bone marrow introduced previous edition has been eliminated view of evidence that its addition provides no or limited prognostic significance  ',\n",
       "  ('Summary Box:', 'FPar5', 'Par58', 28): '',\n",
       "  ('Enhanced grouping framework permitting scalable genetic classification and deemphasizing blast enumeration where relevant',\n",
       "   'Sec18',\n",
       "   'Par62',\n",
       "   29): 'The classification of AML is reenvisioned emphasize major breakthroughs over past few years how this disease is understood and managed Foremost is separation of AML defining genetic abnormalities AML defined differentiation Table latter eliminates previously confusing use of term AML NOS which types based on differentiation were listed Another key change as indicated is elimination of blast requirement AML types defining genetic abnormalities exception of AML fusion and AML mutation Removal of blast cutoff requires correlation morphologic findings and molecular genetic studies ensure that defining abnormality is driving disease pathology This approach was deemed more appropriate assigning another arbitrary lower bone marrow blast cutoff third component of new structure is introduction of section on AML landing spot new andor uncommon AML subtypes that may or may not become defined types future editions of classification As such overall AML classification structure continues emphasize integration of clinical moleculargenetic and pathologic parameters and emphasis on clinicopathologic judgement',\n",
       "  ('AML with defining genetic abnormalities',\n",
       "   'Sec19',\n",
       "   'Par63',\n",
       "   30): 'While classification retains much of established diagnostic criteria AML AML and AML increased recognition of importance of highly sensitive measurable residual disease MRD evaluation techniques and impact of concurrent molecular alterations reflect factors that impact patient management and therapeutic decisions current practice Namely prognostic factors have expanded mutations which are still relevant include additional cytogenetic features and MRD status post induction diagnostic criteria of AML and AML formerly  have also remained largely unchanged',\n",
       "  ('AML with defining genetic abnormalities',\n",
       "   'Sec19',\n",
       "   'Par64',\n",
       "   31): 'AML and AML mutation are only disease types defined genetic abnormality that require least  blasts diagnosis blast cutoff requirement is needed former avoid overlap CML Distinguishing AML from initial myeloid blast phase of CML can be challenging and additional evidence continues be needed better characterize this AML type There is insufficient data support any change blast cutoff criterion AML mutation  ',\n",
       "  ('AML with defining genetic abnormalities',\n",
       "   'Sec19',\n",
       "   'Par65',\n",
       "   32): 'Three AML types characteristic rearrangements involving  and are recognized blast count is acceptable based on studies demonstrating that patients blasts MDS and any of these rearrangements have clinical features that resemble those higher blast counts It is important note that rearrangements involving these three genes particularly  may be cryptic on conventional karyotyping is new term that replaces AML tpq  More fusion partners have been described and being most common While not required identification of fusion partner is desirable it could provide prognostic information and may impact disease monitoring Adult patients often present high blast counts usually monocytic differentiation children particularly AML and  show megakaryoblastic differentiation andor low blast counts bone marrow aspirate smears',\n",
       "  ('AML with defining genetic abnormalities',\n",
       "   'Sec19',\n",
       "   'Par66',\n",
       "   33): 'AML defined mutations include AML and AML mutation AML mutation can be diagnosed irrespective of blast count albeit again emphasis on judicious clinicopathologic correlation This approach aligns data showing that cases previously classified as MDS or MDSMPN progress AML short period of time Similar data have emerged patients CH who acquire mutation definition of AML mutation has changed include biallelic biCEBPA as well as single mutations located basic leucine zipper bZIP region of gene smbZIP favourable prognosis associated smbZIP has been demonstrated cohorts of children and adults up years old mutations AML overlap such broad range of defining molecular features that it was determined lack enough specificity define standalone AML type',\n",
       "  ('AML with defining genetic abnormalities',\n",
       "   'Sec19',\n",
       "   'Par67',\n",
       "   34): 'Several changes were introduced entity formerly designated AML myelodysplasiarelated changes now called AMLMR This AML type is defined as neoplasm ≥ blasts expressing myeloid immunophenotype and harboring specific cytogenetic and molecular abnormalities associated MDS arising or following known history of MDS or MDSMPN Key changes include  removal of morphology alone as diagnostic premise make diagnosis of AMLMR  update of defining cytogenetic criteria and  introduction of mutationbased definition based on set of  genes –    of which are present specifically AML arising post MDS or MDSMPN presence of one or more cytogenetic or molecular abnormalities listed Table andor history of MDS or MDSMPN are required diagnosing AMLMR',\n",
       "  ('AML with defining genetic abnormalities',\n",
       "   'Sec19',\n",
       "   'Par68',\n",
       "   35): 'AML represents landing spot new often rare emerging entities whose recognition is desirable determine whether they might constitute distinct types future editions present subtypes this heading include AML rare genetic fusions',\n",
       "  ('AML defined by differentiation',\n",
       "   'Sec20',\n",
       "   'Par69',\n",
       "   36): 'This AML family includes cases that lack defining genetic abnormalities Table  It is anticipated that number of such cases will diminish as discoveries provide novel genetic contexts their classification Notwithstanding categorizing AML cases lacking defining genetic abnormalities based on differentiation offers longstanding classification paradigm practical prognostic and perhaps therapeutic implications',\n",
       "  ('AML defined by differentiation',\n",
       "   'Sec20',\n",
       "   'Par70',\n",
       "   37): 'The classification includes updated comprehensive framework of differentiation markers and criteria harmonized those of mixedphenotype acute leukaemia MPAL and early Tprecursor lymphoblastic leukaemialymphoma ETPALL see section on acute leukaemia of ambiguous lineage Indeed recent identification of rearrangements MPAL TMyeloid ETPALL acute leukaemia of ambiguous lineage ALAL and subset of AML minimal differentiation suggests biologic continuum these entities finding likely implications on future editions of classification –',\n",
       "  ('AML defined by differentiation',\n",
       "   'Sec20',\n",
       "   'Par71',\n",
       "   38): 'Acute erythroid leukaemia AEL previously pure erythroid leukaemia acceptable related term this edition is distinct AML type characterized neoplastic proliferation of erythroid cells features of maturation arrest and high prevalence of biallelic alterations Diagnostic criteria include erythroid predominance usually ≥ of bone marrow elements of which ≥ are proerythroblasts or pronormoblasts occurrence of AEL cases which nucleated erythroid cells constitute less of bone marrow cellularity is recognized such cases share same clinicopathologic features of other AEL central role that biallelic mutations play this aggressive AML type is underscored diagnosis of AEL supersedes AMLMR AEL and cases that arise following MDS or MDSMPN share distinctive morphologic features prominent proerythroblast proliferation Proerythroblast have been shown play important role treatment resistance and poor prognosis AML patients  ',\n",
       "  ('AML defined by differentiation',\n",
       "   'Sec20',\n",
       "   'Par72',\n",
       "   39): 'Several molecular drivers can give rise acute megakaryoblastic leukaemia AMKL which arises three clinical groups children Down syndrome children Down syndrome and adults Immunophenotyping and detection of markers of megakaryocytic differentiation are required make diagnosis of AMKL and detect newly described RAM immunophenotype which correlates subtype of ',\n",
       "  ('Summary Box:', 'FPar6', 'Par74', 40): '',\n",
       "  ('A newly segregated category encompassing diseases that arise in the setting of certain\\xa0known predisposing factors',\n",
       "   'Sec23',\n",
       "   'Par80',\n",
       "   41): 'Myeloid neoplasms that arise secondary exposure cytotoxic therapy or germline predisposition are grouped this category AML transformation of MPN is retained MPN category while AML transformation of MDS and MDSMPN is kept AMLMR see framework of this disease category was redesigned eye towards two important areas  providing scalable structure incorporating novel discoveries area of germline predisposition myeloid neoplasia  recognizing dual importance of cataloguing myeloid neoplasms that arise following exposure cytotoxic therapies clinical purposes as well as population health purposes latter factor is gaining increased recognition as cancer survival is prolonged and incidence of late complications of therapy such as secondary myeloid neoplasia increases overarching principle this context is requirement consider post cytotoxic therapy and associated germline gene variant as disease attributes that should be added as qualifiers relevant myeloid disease types whose criteria are fulfilled as defined elsewhere classification eg or ',\n",
       "  ('Myeloid neoplasms post cytotoxic therapy: introduction of more precise terminology and novel associations with new cytotoxic drug classes',\n",
       "   'Sec24',\n",
       "   'Par81',\n",
       "   42): 'As previous editions this category includes AML MDS and MDSMPN arising patients exposed cytotoxic DNAdamaging therapy unrelated condition terminology and definitions of this disease category have been modified slightly reflect improved understanding of risk that CH plays as risk factor myeloid neoplasia related particularly expansion of preexisting clones secondary selection pressures of cytotoxic therapy agents altered marrow environment  Thus diagnosis of myeloid neoplasms post cytotoxic therapy MNpCT entails fulfilment of criteria myeloid neoplasm addition documented history of chemotherapy treatment or largefield radiation therapy unrelated neoplasm  This would exclude CCUS which definition lacks sufficient support morphologic dysplasia Cases molecular signature such as mutation and corebinding factor leukaemias should still be assigned this category designation is based on medical history and indication of most specific diagnosis pathology report is recommended when possible Exposure PARP inhibitors is added as qualifying criterion MNpCT and methotrexate has been excluded It is recommended that specification of type of myeloid neoplasm is made when possible appendix post cytotoxic therapy appended eg CMML post cytotoxic therapy',\n",
       "  ('Myeloid neoplasms post cytotoxic therapy: introduction of more precise terminology and novel associations with new cytotoxic drug classes',\n",
       "   'Sec24',\n",
       "   'Par82',\n",
       "   43): 'The majority of AMLpCT and MDSpCT are associated mutations outcomes of such patients are generally worse biallelic multihit alterations manifesting as ≥ mutations or concomitant p deletion or copy neutral LOH Less frequent mutations involve genes such as and DNAdamage response genes that may require additional workup germline predisposition',\n",
       "  ('Summary Box:', 'FPar7', 'Par84', 44): '',\n",
       "  ('Summary Box:', 'FPar8', 'Par92', 45): '',\n",
       "  ('Summary Box:', 'FPar9', 'Par100', 46): '',\n",
       "  ('Plasmacytoid dendritic cell neoplasms: recognition of clonal proliferations detected in association with myeloid neoplasms and refinement/update of the diagnostic criteria for blastic plasmacytoid dendritic cell neoplasm',\n",
       "   'Sec29',\n",
       "   'Par105',\n",
       "   47): 'Mature plasmacytoid dendritic cell proliferation MPDCP associated myeloid neoplasm reflects recent data showing that these represent clonal proliferation of pDCs low grade morphology identified context of defined myeloid neoplasm Clonal MPDCP cells accumulate bone marrow of patients myeloproliferative CMML harbouring activating RAS pathway mutations  Patients AML can have clonally expanded pDCs pDCAML which share same mutational landscape as CD blasts and frequently arise association mutations   It is unknown whether pathogenetic mechanisms leading MPDCP association MDS or MDSMPN and AML are same framework diagnosing blastic plasmacytoid dendritic cell neoplasm remains largely same emphasis on immunophenotypic diagnostic criteria Table ',\n",
       "  ('Summary Box:', 'FPar10', 'Par111', 48): '',\n",
       "  ('Genetic tumor syndromes with predisposition to myeloid neoplasia',\n",
       "   'Sec31',\n",
       "   'Par116',\n",
       "   49): 'Fanconi anaemia is heterogeneous disorder caused germline variants BRCAFanconi DNA repair pathway ≥ genes resulting chromosomal breakage and hypersensitivity crosslinking agents used diagnosis Clinical features include congenital anomalies bone marrow failure and cancer predisposition new classification distinguishes  haematologic categories depending on blast percentage cytopenia and chromosomal abnormalities  Dysgranulopoiesis and dysmegakaryopoiesis are histologic indicators of progression  Allogenic haematopoietic stem cell transplantation is efficacious',\n",
       "  ('Genetic tumor syndromes with predisposition to myeloid neoplasia',\n",
       "   'Sec31',\n",
       "   'Par117',\n",
       "   50): 'The term RASopathies encompasses diverse group of complex multisystem disorders associated variants genes involved RAS mitogenactivating protein kinase MAPK pathway Myeloid neoplasms RASopathies involve MAPK hyperactivation leading myeloid cell proliferation  Genomic analysis of     and myeloid neoplasms of patients suspected of having RASopathy is important and aids diagnosis of JMML majority of cases   Diagnostic criteria include pathogenic variants genes associated RAS pathway andor classic phenotype suggestive of RASopathy ',\n",
       "  ('Disclaimer',\n",
       "   'Sec32',\n",
       "   'Par118',\n",
       "   51): 'The content of this article represents personal views of authors and does not represent views of authors employers and associated institutions This work is intended provide preview and summary of content whose copyright belongs solely International Agency Research on CancerWorld Health Organization Any or all portions of material this work may appear future International Agency Research on CancerWorld Health Organization publications',\n",
       "  ('no_title', 'Sec33', 'no_sub_id', 52): ''},\n",
       " {('Genotyping of Transcriptomes (GoT) couples targeted cDNA genotyping with single-cell whole transcriptomes to reveal that <italic toggle=\"yes\">CALR</italic> mutant progenitor cells are comingled with wildtype cells throughout differentiation',\n",
       "   'S2',\n",
       "   'P8',\n",
       "   0): 'To link genotypes singlecell RNAseq scRNAseq highthroughput dropletbased platforms we modified x Genomics platform Pleasanton CA amplify targeted transcript and locus of interest    We then interrogated amplicon reads mutational status and linked genotype singlecell gene expression profiles via shared cell barcodes  We tested ability of GoT comap singlecell genotypes and transcriptomes speciesmixing experiment wherein mouse cells mutant transgene were mixed human cells wildtype transgene  Consistent precision genotyping vast majority of cells mouse transcripts showed mutant  whereas cells human transcripts showed wildtype  of cells matching expected species  –',\n",
       "  ('Genotyping of Transcriptomes (GoT) couples targeted cDNA genotyping with single-cell whole transcriptomes to reveal that <italic toggle=\"yes\">CALR</italic> mutant progenitor cells are comingled with wildtype cells throughout differentiation',\n",
       "   'S2',\n",
       "   'P9',\n",
       "   1): 'While mutations have been demonstrated activate MPL resulting megakaryocytic proliferation how mutations perturb early hematopoietic stem progenitor cell HSPC differentiation is largely unknown We therefore applied GoT CD bone marrow cells five patients mutated essential thrombocythemia ET not treated diseasemodifying therapy time of biopsy  genotyping data were available of  cells  compared only interrogation of conventional x Genomics data  –',\n",
       "  ('Genotyping of Transcriptomes (GoT) couples targeted cDNA genotyping with single-cell whole transcriptomes to reveal that <italic toggle=\"yes\">CALR</italic> mutant progenitor cells are comingled with wildtype cells throughout differentiation',\n",
       "   'S2',\n",
       "   'P10',\n",
       "   2): 'To interrogate cellular identities of these progenitors we performed clustering agnostic genotyping information based on transcriptome information alone  – Genotype projection onto progenitor maps demonstrated that mutated cells involved all CD stem and progenitor clusters consistent previous bulk PCR analysis of FACSsorted CD subsets  see validation alternative clustering framework Notably mutated cells did not form novel independent clusters confirming that scRNAseq alone cannot distinguish mutant wildtype cells and demonstrating that mutations ET impact entire hematopoietic differentiation hierarchy',\n",
       "  ('The fitness impact of <italic toggle=\"yes\">CALR</italic> mutations increases with myeloid differentiation, associated with increased proliferation in mutant progenitors',\n",
       "   'S3',\n",
       "   'P11',\n",
       "   3): 'While mutant cells were observed all progenitor clusters their frequencies varied clusters mutated cell frequency was higher committed myeloid progenitors  especially MkPs which are closely associated disease phenotype of elevated platelets compared uncommitted HSPC clusters samples value  linear mixed model   Consistently pseudotemporal ordering pseudotime analysis showed that mutated cells were enriched cells later pseudotime points compared wildtype cells  value  linear mixed model  We orthogonally validated this finding via bulk gDNA droplet digital PCR showing lower variant allele frequency VAF CDCD HSPCs compared CDCD progenitors value =  Wilcoxon ranksum test  Thus while mutations arise uncommitted HSCs and therefore propagate populate entire differentiation tree impact of mutations on fitness increases myeloid differentiation ',\n",
       "  ('The fitness impact of <italic toggle=\"yes\">CALR</italic> mutations increases with myeloid differentiation, associated with increased proliferation in mutant progenitors',\n",
       "   'S3',\n",
       "   'P12',\n",
       "   4): 'GoT uniquely enables direct transcriptional program comparison mutant and wildtype cells not only same sample but also same progenitor cluster example mutated progenitors displayed increased expression of genes upregulated progenitors mutated ET most significantly MkP clusters combined value  Fishers method  as and mutations partially converge activation of similar downstream pathways We therefore reasoned that progenitor subtypespecific comparison of cellcycle gene expression mutant vs wildtype cells may reveal whether lower fitness impact of mutations HSPCs compared MkPs stems differences cell proliferation Indeed while mutant HSPCs exhibited only modest increase cell cycle gene expression compared wildtype value =  Wilcoxon ranksum test mean fold change   confidence interval – mutant MkPs demonstrated robust increase cell cycle expression vs their wildtype counterparts value =  ×  Wilcoxon ranksum test fold change  –   Notably degree of cell cycle gene expression increase mutant MkPs correlated patients platelet counts  suggesting that interrogation of early progenitor cells may correlate clinical phenotypes and inform our understanding of patienttopatient variability despite shared mutated genotypes',\n",
       "  ('The fitness impact of <italic toggle=\"yes\">CALR</italic> mutations increases with myeloid differentiation, associated with increased proliferation in mutant progenitors',\n",
       "   'S3',\n",
       "   'P13',\n",
       "   5): 'Celltocell variation exists even progenitor clusters example MkPs represent heterogeneous population composed of less differentiated cells higher expression of HSC genes HSCMkP and more committed MkP cells displaying high expression of MkPrelated genes HSCMkP   Even MkP cluster HSCMkP cells showed increased cell cycle gene expression and higher mutant cell frequency compared HSCMkP cells value =  Fishers exact test Similarly mutant cells plateletprimed HSPCs MkPTGFβ had higher cell cycle gene expression wildtype MkPTGFβ HSPCs whereas mutant and wildtype HSPCs more quiescent state MkPTGFβ showed no cell cycle difference  These findings further emphasize that impact of mutation is dependent on cell state and imparts greater proliferative advantage more differentiated cells These data also reveal that mutations skew differentiation myeloid progenitors including megakaryocytic priming early hematopoiesis ',\n",
       "  ('De novo differential expression analysis reveals cell identity dependent upregulation of the unfolded protein response in <italic toggle=\"yes\">CALR</italic>-mutant cells',\n",
       "   'S4',\n",
       "   'P14',\n",
       "   6): 'GoT data further offer unique opportunity differential gene expression discovery examining wildtype vs mutant cells same progenitor subset Crucially wildtype cells serve as ideal comparison set as they share all potential environmental and patientspecific variables as mutated cells We identified  genes be differentially expressed mutant and wildtype MkPs FDR adjusted value     Mutated MkPs upregulated that encodes BiP key player protein quality control that modulates activities of three transmembrane transducers of unfolded protein response UPR PERK IRE and ATF Consistently mutant MkPs showed upregulation of UPR genes adjusted value  ×  and ATFmediated activation of chaperone genes adjusted value =    providing direct validation of studies that have shown increased UPR mutated cells UPR this context may signal ER stress response misfolded proteins as CALR chaperone activity may be compromised mutation Notably differentially expressed genes mutant HSPCs important regulator of UPR was upregulated mutant cells suggesting that UPR activation mutations extends uncommitted progenitors  further supported upregulation of ATFtarget genes mutant compared wildtype HSPCs   ',\n",
       "  ('De novo differential expression analysis reveals cell identity dependent upregulation of the unfolded protein response in <italic toggle=\"yes\">CALR</italic>-mutant cells',\n",
       "   'S4',\n",
       "   'P15',\n",
       "   7): 'UPR was previously demonstrated be preferentially mediated HSPCs PERK resulting enhanced apoptosis ER stress helping eliminate ER stressed cells HSC pool contrast committed progenitors have robust IREXBP activity promoting survival ER stress challenge We observed that specific context of mutationinduced ER stress PERKbranch of UPR was not enhanced contrast targets of XBP were upregulated mutant MkPs value =  ×  linear mixed model as well as mutant HSPCs value =  ×  linear mixed model    As IRE catalyzes unconventional splicing of unspliced mRNA active spliced form   we further validated that mutations induce activation of IREbranch of UPR repurposing GoT probe spliced region of single cells mutations robustly augmented amount of MkPs  Remarkably mutations also resulted enhanced  ratio HSPCs indicating IRE activity  These data thus suggest that mutationinduced UPR IRE is activated both HSPCs and MkPs skewing ER stresschallenged stem and progenitor cells survival',\n",
       "  ('De novo differential expression analysis reveals cell identity dependent upregulation of the unfolded protein response in <italic toggle=\"yes\">CALR</italic>-mutant cells',\n",
       "   'S4',\n",
       "   'P16',\n",
       "   8): 'Differential gene expression analysis HSPCs also revealed upregulation of NFκB pathway adjusted value =  including upregulation of and  and  Furthermore NFκB gene set upregulation mutant vs wildtype HSPCs was most notable early uncommitted HSPCs   Mutant cells this early HSPC subcluster also upregulated antiapoptotic related genes   As NFκB pathway activation has been previously associated antiapoptotic effects and HSC selfrenewal our data thus points another potential mechanism linking mutation and HSC outgrowth',\n",
       "  ('IRE1-mediated UPR by mutant <italic toggle=\"yes\">CALR</italic> is maintained through progression to myelofibrosis',\n",
       "   'S5',\n",
       "   'P17',\n",
       "   9): 'As proportion of patients mutated ET eventually progresses postET myelofibrosis MF or present initially MF we examined whether mutation imparted similar proliferative and survival advantage progenitor cells patients mutated MF examining  genotyped cells of total  cells  genotyping rate four MF samples contrast ET we did not observe enrichment of mutated cells differentiated progenitors compared HSPCs   consistent previous reports suggesting that context of MF mutations impart strong fitness advantage even HSPCs Indeed mutant cells were highly enriched cell cycle activity  ',\n",
       "  ('IRE1-mediated UPR by mutant <italic toggle=\"yes\">CALR</italic> is maintained through progression to myelofibrosis',\n",
       "   'S5',\n",
       "   'P18',\n",
       "   10): 'As megakaryocytes have been demonstrated play principle role development of marrow fibrosis we performed differential expression analysis mutant and wildtype MkPs showing  differentially expressed genes FDR adjusted value     We identified upregulation of  previously implicated fibroblast stimulation megakaryocytes thereby demonstrating that TGFβ production is dysregulated even early progenitors Indeed TGFβ signaling upregulation mutant MkPs correlated degree of fibrosis patients bone marrow  As mutated ET we observed robust upregulation of UPR genes mutated MkPs adjusted value =  ×  and specifically IRE activation adjusted value =    Notably comparison of cycling noncycling wildtype cells did not show UPR upregulation affirming that UPR activation is not simply byproduct of increased proliferation  and  These findings suggest that enhanced survival of mutant progenitors upregulation of IREmediated UPR is maintained disease progression myelofibrosis',\n",
       "  ('Multiplexed GoT reveals subclonal transcriptomic identities',\n",
       "   'S6',\n",
       "   'P19',\n",
       "   11): 'Ongoing clonal evolution results multiclonal malignant populations requiring genotyping of multiple mutations parallel test ability of GoT target multiple mutations we targeted three mutations affecting VAF bulk exon sequencing VAF  and VAF CD cells patient MF relative VAFs of these mutations suggest that this malignancy follows nested linear evolution clonal structure clonal mutation progeny subclone harboring mutation which has additional mutated progeny singlecell cloning validation GoT provided genotyping and and  of cells respectively and showed mutant frequencies  and  respectively comparable those of single cell cloning  and  respectively performed unsorted peripheral blood cells',\n",
       "  ('Multiplexed GoT reveals subclonal transcriptomic identities',\n",
       "   'S6',\n",
       "   'P20',\n",
       "   12): 'In this context GoT allows compare transcriptional outputs of different mutations alone or combination example mutations have been shown block erythroid maturation we examined whether addition of mutation would still confer increased proliferative status megakaryocyticerythroid progenitors We found that double mutants exhibited increased proliferative advantage over single mutants  while addition of mutation triplemutant did not further increase cell cycle activation Thus multiplexed GoT demonstrated ability interrogate complex clonal structures as well as need assess combinatorial transcriptional output of mutations context of highresolution cell identity mapping',\n",
       "  ('Circularization GoT enables genotyping of mutations distant from transcript ends',\n",
       "   'S7',\n",
       "   'P21',\n",
       "   13): 'GoT amplicon recovery is not only dependent on expression level of gene but also on distance of mutation locus transcript ends  Capture efficiency of mutation distant end  kb eg genotyping of  of cells  was lower for targets closer end While driver mutations are often found kb of either transcript ends  loci of interest may reside larger distances and thus dependency on relative proximity transcript end is limiting We reasoned that lower genotyping efficiency resulted least partially inability of larger amplicon fragments cluster efficiently on Illumina flow cells sequencing We further integrated our protocol longread sequencing nanopore GridION X Oxford Nanopore Technology which demonstrated that transcripts were captured accurately our procedure  and further confirmed low intra and intertranscript PCR recombination rate even these relatively large fragments ',\n",
       "  ('Circularization GoT enables genotyping of mutations distant from transcript ends',\n",
       "   'S7',\n",
       "   'P22',\n",
       "   14): 'To overcome this limitation we applied sequential rounds of circularization and inverse PCR remove intervening sequence region of interest and cell barcode  Circularization GoT showed high concordance uncircularized linear GoT genotyping  When applied mutation capture circularization GoT significantly increased yield of genotyped cells to  cells of cells  These results demonstrate ability of circularization GoT extend our reach even targets distant gene ends',\n",
       "  ('Circularization GoT enables genotyping of mutations distant from transcript ends',\n",
       "   'S7',\n",
       "   'P23',\n",
       "   15): 'To further demonstrate ability of circularization GoT genotype despite significant distance transcript end we targeted ~ kb We first validated circularization GoT via mixing experiment barcoded cDNA TF cell line wildtype  and HEL cells homozygous  showing accurate genotype assignment  Next we genotyped primary CD cells individual ET obtaining genotyping information of cells  even this very lowly expressed gene Mutant cell frequency was higher MkPs compared HSPCs whereas mutant cell frequency remained low erythroid progenitors  concordant clinical phenotype of ET rather polycythemia vera disease associated same mutation but erythrocytosis as leading abnormality Consistent this observation we observed albeit small number of genotyped HSPCs trend towards increased MkPpriming mutant HSPCs value =  Wilcoxon ranksum   These data suggest skewing of differentiation megakaryopoiesis HSPCs and may provide insights isolated megakaryocytic proliferation mutated ET',\n",
       "  ('Discussion',\n",
       "   'S8',\n",
       "   'P24',\n",
       "   16): 'Here we present GoT which cocaptures somatic genotypes and transcriptomic identities thousands of single cells primary cancer specimens Building on previous experience targeted amplification dropletbased scRNAseq GoT overcomes unique set of challenges presented somatic mutation genotyping including lower expression levels and large distances end of sequenced transcripts',\n",
       "  ('Discussion',\n",
       "   'S8',\n",
       "   'P25',\n",
       "   17): 'Collectively GoT allowed us directly interrogate transcriptional impact of mutation primary MPN samples where wildtype cells sample provide ideal comparison set controlling patientspecific and technical confounders We observed that mutant provided greater fitness advantage differentiation ET associated higher proliferation committed myeloid progenitors compared uncommitted HSPCs GoTs ability finemap mutant vs wildtype transcriptional differences HSPCs revealed upregulation of NFκB pathway genes most undifferentiated mutant HSPCs supporting cellintrinsic role mutation NFκB activation We further applied GoT target unconventional splice site of demonstrate that IRE activity was increased mutant cells including HSPCs Our data thus nominates IREXBP pathway as potential therapeutic target eradication of mutant clone uncommitted HSPCs patients mutated MPNs',\n",
       "  ('Discussion',\n",
       "   'S8',\n",
       "   'P26',\n",
       "   18): 'In conclusion highthroughput linking of singlecell genotypic and transcriptomic data underscored cell identitydependency of somatic mutations human hematopoiesis allowing us superimpose native differentiation tree tree corrupted somatic mutations GoT further provides means gain insight integration of clonal diversification lineage plasticity or differentiation topologies cancer Thus GoT may pave way resolve central questions related link genetic mutations and cellular identities and unravel underlying programs that enable clonal expansions and evolution human neoplasms',\n",
       "  ('Species mixing experiment',\n",
       "   'S10',\n",
       "   'P27',\n",
       "   19): 'Previously published UT and BaF cell lines expressing human and either human wildtype or mutant type   bp deletion kindly provided Dr Mullallys lab were used species mixing study Briefly human expressing BaF and UT cell lines were generated retroviral transduction which they were subjected infection variant lentiviral supernatants Wildtype UT cells and mutant BaF cells were mixed equal proportions which underwent GoT targeting ~ cells While UT has been listed as commonly misidentified cell line it was used sole purpose of validating mutation status of cells All cell lines used study were tested mycoplasma contamination',\n",
       "  ('Patient samples',\n",
       "   'S11',\n",
       "   'P28',\n",
       "   20): 'The study was approved local ethics committee and Institutional Review Board IRB of Memorial SloanKettering Cancer Center and Weill Cornell Medicine and conducted accordance Declaration of Helsinki protocol All patients provided informed consent Cryopreserved bone marrow mononuclear BMMCs or peripheral blood mononuclear cells PBMCs patients documented mutations were retrieved database search See clinical information Cryopreserved BMMCs or PBMCs were thawed and stained using standard procedures  min °C surface antibody CDPEVio clone AC lot  dilution  Miltenyi Biotec and DAPI SigmaAldrich Cells were then sorted DAPInegative CD and CDnegative cells using BD Influx Weill Cornell Medicine flow cytometry core',\n",
       "  ('Targeted myeloid panel',\n",
       "   'S12',\n",
       "   'P29',\n",
       "   21): 'To determine presence and location of recurrent somatic mutations and their VAF targeted nextgeneration sequencing was performed on DNA samples extracted unfractionated PBMCs patients ET MF MF MF MF CDnegative sorted BMMCs patients ET ET ET ET CD sorted BMMC patient ET and CD sorted PBMC patient MF as previously described Briefly targeted enrichment of  genes  recurrently mutated myeloid malignancies was performed using Thunderstorm system Raindance Technologies Billerica MA custom primer panel followed sequencing using Illumina MiSeq v chemistry',\n",
       "  ('Genotyping of Transcriptomes (GoT)',\n",
       "   'S13',\n",
       "   'P30',\n",
       "   22): 'Extending recent experience targeted amplicon sequencing scRNAseq we developed GoT order simultaneously capture genotyping data and whole transcriptomic data single cells adapting x Genomics platform Pleasanton CA standard x Genomics Chromium  v or v chemistry and  libraries were carried according manufacturers recommendations after emulsion breakage and recovery of first strand cDNA  step libraries if targeted gene of interest eg  was not robustly detected standard x procedure ie if  of expected cells showed expression based on knowledge similar dataset genespecific primer was spiked x primer mix of concentration of cDNA amplification primers initial cDNA PCR step  see list of primers and primer positions libraries presence of X cell barcodes CB and UMI on  side of transcript enabled genespecific primer spikein RT step Guide RT primer  μM final concentration increase capture and detection of transcript of interest eg cDNA amplification step another spikein primer Additive primer is added increase yield of same transcript amplification step libraries v chemistry only x cDNA library underwent extra cycle of PCR beyond manufacturers recommended number of cycles  v chemistry and  libraries do not require extra cycles of PCR amplification step cDNA amplification and cleanup SPRIselect small portion of cDNA library  μL v and  μl v chemistry and  libraries were aliquoted targeted genotyping and remaining cDNA underwent standard x protocol case of  v chemistry cDNA set aside GoT was amplified to  additional cycles using KAPA HiFi HotStart ReadyMix KAPABiosystems and x primer mix provide sufficient material enrichment step cleanup locusspecific reverse primers and generic forward SIPCR were used amplify site of interest of cDNA template   Number of PCR cycles was determined experimentally and was dependent on level of expression of targeted gene instance  cycles were used locusspecific reverse primers contain partial Illumina read  handle stagger increase complexity of library optimal sequencing and gene specific region allow specific priming SIPCR oligo x Genomics anneals partial Illumina read  sequence either  or  end of molecule when using  or  libraries respectively preserving CB and UMI initial amplification and SPRI purification remove unincorporated primers second PCR was performed generic forward PCR primer Pgeneric retain CB and UMI together RPIx primer Illumina complete P end of library and add sample index targeted amplicon library was subsequently spiked remainder of x library be sequenced together on HiSeq  or sequenced separately on MiSeq Illumina cycle settings were as follows  cycles read   or  cycles read  and  cycles sample index v chemistry and  libraries or  cycles read   or  cycles read  and  cycles sample index v chemistry',\n",
       "  ('Circularization GoT',\n",
       "   'S14',\n",
       "   'P31',\n",
       "   23): 'For patient samples we used same starting material as GoT ie nonfragmented x cDNA fraction cDNA mixing study we mixed barcoded cDNA two cells lines TF wildtype ATCC CRL HEL Homozygote VF ATCC TIB these cDNA libraries we first performed PCR enrich amplicon amplifying ~ bp upstream our region of interest end of x library fragment therefore retaining cell barcode CB and unique molecule identifier UMI using KAPA HiFi Uracil master mix Kapa Biosystems and following PCR conditions °C to  cycles of °C °C °C °C Complementary Uoverhang are added forward Fw and reverse Rv primers allow circularization Fwprimer AGGUCAGTCUbpupstreamlocusspecific Rvprimer AGACUGACCUCTACACGACGCTCTTCCGATCT genes lowly represented cDNA library such as  we specifically preenriched gene of interest doing PCR targeting ~bp upstream our region of interest end of x library fragment using KAPA HiFi Ready mix Kapa Biosystems and following PCR conditions °C cycles of °C °C °C °C PCR product resulting first single or double PCR was then cleanedup and concentrated using X SPRI beads Next amplicon cohesive ends were created using UmL USERII enzyme MNEB digestion hour °C X CutSmart buffer Reaction was stopped incubating at °C Relying on complementary overhang both end of amplicon circularization was performed large volume  mL favor intramolecule ligation following reaction was setup and incubated overnight °C USERIIdigested amplicon  UmL T ligase NEB X CutSmart Buffer NEB  mM ATP Roche Next T DNA ligase was inactivated incubating at °C Then unwanted unligated products were removed adding U of lambda exonuclease NEB MS ligation mix and incubating at °C Exonuclease was inactivated at °C Ligated product was cleanedup and concentrated using X SPRI beads second PCR was setup retain locus of interest and barcodes on same molecule while removing unwanted  downstream region of targeted region PCR reaction was setup and performed as previously described using following primers Fwprimer AGGUCAGTCUendlocusspecific Rvprimer AGACUGACCUbpdownstreamlocusspecific',\n",
       "  ('Circularization GoT',\n",
       "   'S14',\n",
       "   'P32',\n",
       "   24): 'After PCR SPRI cleanup USERII digestion overnight T ligation lambda exonuclease digestion were performed as previously described second ligation ligated product was again cleanedup and concentrated using X SPRI beads increase ligation efficiency circularization step and also reduce protocol duration  days vs  day we further improve ligation using Gibson assembly molecular cloning approach Instead of Uoverhang handles complementary Gibson handles are added forward Fw and reverse Rv primers allow circularization post PCR and PCR   PCR and PCR are performed as previously described Uoverhang version of this protocol but using KAPA HiFi Ready mix Ligation is now perform hour °C large volume  mL X CutSmart Buffer and using  μl of Gibson master mix NEB E Finally linearize product of ligation we performed third PCR Fwprimer CCTTGGCACCCGAGAATTCCAbpupstreamspecificlocus Rvprimer SIPCR x Genomics We used KAPA HiFi master mix Kapa Biosystems and following PCR conditions °C cycles of °C °C °C °C After SPRI purification last PCR was performed generic forward PCR primer Pgeneric and RPIx primer Illumina complete P end of library and add sample index °C cycles of °C °C °C °C Thus this method generates amplicons that retain contiguity of original molecules but are short enough cluster effectively be sequenced standard parameters targeted amplicon library was subsequently sequenced using PE on MiSeq Illumina',\n",
       "  ('Single-cell RNA-seq data processing, alignment, cell type classification and clustering',\n",
       "   'S15',\n",
       "   'P33',\n",
       "   25): 'x data was processed using Cell Ranger default parameters Reads were aligned human reference sequence GRCh or hg or mouse reference mm species mixing experiment genomic region of interest genotyping was examined determine how many UMIs targeted sequence were present conventional x data  ',\n",
       "  ('Single-cell RNA-seq data processing, alignment, cell type classification and clustering',\n",
       "   'S15',\n",
       "   'P34',\n",
       "   26): 'The Seurat package v  was used perform unbiased clustering of CD sorted cells patient samples Briefly individual datasets cells UMI  or UMI  standard deviation mean UMI and mitochondrial gene percentage  were filtered data was log normalized using scale factor of  Prior clustering ET and MF datasets were integrated and underwent batchcorrection which implements canonical correlation analysis CCA and principles of mutual nearest neighbor Recommended settings were used integration ie  canonical correlation vectors CCA FindIntegrationAnchors function and  principle components anchor weighting procedure IntegrateData function datasets potential confounders eg number of UMI per cell and proportion of mitochondrial genes were regressed of data principle component analysis PCA was performed using variable genes JackStraw method was used determine statistically significant PCs be used graphbased clustering tSNE was used visualize clusters Clusters were manually assigned based on differentially expressed genes using FindAllMarkers function using default settings ie using all genes that are detected minimum of  of cells either of two comparison sets as input and logfold change of  as threshold Wilcoxon ranksum test is applied rank genes top ten differentially expressed genes per cluster presented We identified  distinct clusters integrated data ETET which were annotated according marker genes identified Velten  tdistributed stochastic neighbor embedding tSNE and clustering heatmap and tSNE representative marker genes Pseudotime analysis was performed using Monocle R package v individual datasets and URD package v integrated datasets Linear mixed effects analysis was performed using lme package v – mutant frequency analysis HSPCs and MkPs  genotype status was defined as fixed effect and as random effects we had intercepts individual patients ie subjects and iterative downsampling integrated analysis of pseudotime comparison  and gene module expression eg  genotype status was entered as fixed effect and subjects as random effects values were obtained likelihood ratio tests of full model fixed effect model fixed effect',\n",
       "  ('Deep Generative Model for Single Cell Analysis',\n",
       "   'S16',\n",
       "   'P35',\n",
       "   27): 'We applied deep generative modeling approach of Lopez single cell analysis of ETET  Using scVI package we trained variational autoencoder VAE that takes as input feature vector each cell consisting of transcript counts genes highest standard deviation all samples as well as indicator batch ID Using  of cells training and holding for validation these features are provided VAE unit hidden layers both encoder and decoder modules and fourdimensional internal latent vector of gaussiandistributed values that provide more concise representation of biological variability cells tSNE is applied these vectors visualization',\n",
       "  ('IronThrone GoT: Targeted genotype amplicon sequence processing and mutation calling',\n",
       "   'S17',\n",
       "   'P36',\n",
       "   28): 'To ensure correct priming targeted amplicon reads read  were screened presence of primer sequence and expected intervening sequence primer and start of mutation site shared sequence circularization GoT PCR Fw and PCR Rv primer sequences   of reads mixing study showed expected primer and shared sequences Subsequently reads that passed priming step corresponding read  was screened presence of bp or  bp long CB that matched CB whitelist provided x Genomics CB reads that were Hammingdistance from whitelisted CB probability that observed barcode originated whitelisted CB was calculated taking account base quality BQ score differing base whitelisted CB highest probability was used replace observed CB only if probability exceeded duplicate reads same CB and UMI genotype wildtype vs mutant of UMI was assigned based on majority rule supporting reads or according read highest BQ score rare case when only two supporting but discordant reads were available',\n",
       "  ('IronThrone GoT: Targeted genotype amplicon sequence processing and mutation calling',\n",
       "   'S17',\n",
       "   'P37',\n",
       "   29): 'The speciesmixing study type  mutation was used further optimize optimize analytical assignment of genotypes cells overcome technical sources of noise such as PCR errors ambient mRNA and PCR recombination which may accompany targeted amplification scRNAseq mean ± standard deviation of  ±  UMIs were detected per cell amplicon data ±  reads per UMI We integrated targeted amplicon measures including BQ number of base pair mismatches and number of duplicate reads per UMI and determined optimized parameters that maximize number of genotyped cells while minimizing genotype misassignment – Setting thresholds minimum number of duplicate reads and maximum frequency of mismatches contributed significantly filtering misassigned reads likely due technical errors eg PCR recombinations combination of threshold of two or more duplicate reads given UMI and threshold of allowing less or equal mismatch ratio significantly improved correct assignment of cells while maximizing number of included cells analysis and was adopted analysis here  Results of precision and recall analyses also affirmed this combination of thresholds minimum duplicate reads and maximum mismatch ratio  Moreover given high number of transcripts cell lines and thus higher potential impact of PCR recombination cells were assigned as wildtype or mutant if  of amplicon UMIs were wildtype or mutant respectively',\n",
       "  ('IronThrone GoT: Targeted genotype amplicon sequence processing and mutation calling',\n",
       "   'S17',\n",
       "   'P38',\n",
       "   30): 'To further assess impact of various parameters of amplicon reads on precision of mutation calling we tested these parameters random forest classification using mixing study as implemented R randomForest package v \\u200e– – Mean decrease accuracy was determined as measure of importance of each variable used calculation of splits trees each combination of mismatch ratio and duplicate thresholds random forest was run  times find optimal number of random variables used each tree and minimum outofbag error was selected  This random forest analysis also showed minimum duplicate read threshold of  and maximum mismatch ratio threshold of be optimal minimizing misassignments and relatively low contribution of additional quality metrics',\n",
       "  ('IronThrone GoT: Targeted genotype amplicon sequence processing and mutation calling',\n",
       "   'S17',\n",
       "   'P39',\n",
       "   31): 'Moreover genotyping information is derived transcribed molecules and may be affected capture of transcripts wildtype vs mutant alleles of heterozygous mutations primary patient samples which median targeted amplicon UMI per cell was  ±  median absolute deviation This may be due incomplete sampling of transcript pool or due transcriptional bursts which leads skewed transcript pools Consequently as number of UMIs per cell increases likelihood of capturing mutant transcript increases resulting apparently higher frequency of mutated cells Thus number of mutant reads may be underestimated cells lower amplicon UMI counts Nonetheless frequency of mutant cells eg patient sample ET as determined GoT using all cells that harbor least one UMI yielded values that were similar that determined bulk DNA exon sequencing of CD cells mutant cell fraction of  based on VAF of diploid heterozygous mutation While bulk of downstream analyses mutant and wildtype cells used threshold of two or greater genotyping amplicon UMIs we systematically applied three approaches exclude impact of this confounder ie expression level of target gene on conclusions First exclude possibility that higher expression committed progenitors can result greater ability detect mutant alleles and thereby result higher mutated cell frequency we downsampled all cells single amplicon UMI prior mutation calling and found that increase mutation frequencies MkP compared HSPC remained unchanged  Second we explored sensitivity of difference mutant and wildtype cells eg pseudotime mutant cell frequency increasing minimal amplicon UMI threshold allowed mutation calling and demonstrated that this did not impact central findings of this study  Third we explicitly modeled impact of amplicon UMI multivariable models generalized linear model using R Stats package v eg pseudotime analysis which number of amplicon UMI was included model alongside mutation status  We further note that GoT procedure did not result significant loss of genes or UMIs per cell comparison published data of CD selected cells standard x library splicing analyses we required cell have least one unspliced inclusion analyses',\n",
       "  ('Mutant cell frequency analysis',\n",
       "   'S18',\n",
       "   'P40',\n",
       "   32): 'For integrated analysis of ETET or MFMF equal number of cells each sample n = ET and n = MF were subsampled randomly Genotyping amplicon UMIs were downsampled x iterations one per cell and mutant cell frequency was determined each cluster either integrated dataset or individual samples This frequency was then divided total mutant cell frequency all progenitor subsets each of iterations    ',\n",
       "  ('Differential expression and gene set enrichment analysis',\n",
       "   'S19',\n",
       "   'P41',\n",
       "   33): 'For gene module analysis aggregate gene expression levels of modules of genes involved biological processes of interest see complete list of genes each module were calculated as log of ratio of UMI gene module per  UMIs per cell gene modules have been previously published see references main text and Differential gene expression analysis mutant and wildtype cells each of progenitor cluster each patient was performed via FindMarkers function Seurat Package using logistic regression differential gene expression variable genes as input and requiring expression at least  of cells either group UMI was included as latent variable differentially expressed genes were examined individually each patient they were also examined combination each cluster patients combining values differentially expressed genes via Fishers method and performing weighted average of logfold change  Genes that were differentially expressed FDR   and logfold change =  were included gene set enrichment analysis Hypergeometric test gene set enrichment analysis was performed using gProfileR package v  Multiple hypothesis testing correction was performed using gSCS algorithm developed authors of gProfileR package KEGG Reactome GOMF and GOBP data sources were included analyses ',\n",
       "  ('Comparison of mutant allelic fraction in whole exome sequencing (WES) and RNA-seq',\n",
       "   'S20',\n",
       "   'P42',\n",
       "   34): 'We compared mutant allelic fractions gDNA and RNA estimated WES and RNAseq data respectively five cancer cohorts BRCA breast invasive carcinoma HNSC head and neck squamous cell carcinoma KIRC kidney renal clear cell carcinoma LUAD lung adenocarcinoma STAD stomach adenocarcinoma this analysis we thank Dr TaeMin Kim Cancer Research Institute College of Medicine Catholic University of Korea sharing curated datasets based on his previous study brief datasets of each cancer cohorts were initially prepared somatic mutation sets that are reported Cancer Genome Atlas TCGA portal  Then reference and alternative alleles these mutations were counted bam files of WES and RNAseq using SAMtools mpileup and filtered coverage of reads We then converted genomic coordinates of datasets hg hg assembly identify frequencies of somatic mutations cancers we used CNT values CosmicCodingMutsvcf v Catalogue of Somatic Mutations Cancer COSMIC database Then we further annotated variants as oncogene or tumor suppressor gene TSG Vogelstein   and as driver or passenger mutations Bailey  ',\n",
       "  ('Determination of targeted loci distance from 3’ or 5’ ends of transcripts',\n",
       "   'S21',\n",
       "   'P43',\n",
       "   35): 'To identify Ensembl transcript ID ENST corresponding each mutation datasets of five cancer cohorts described we matched them COSMIC ID and annotated file of CosmicMutantExporttsv v We used biomaRt R package GRCh version annotate transcript including length of transcript and position of cDNA start codon transcript positions of untranslated region UTR ends were determined calculate distance end target site',\n",
       "  ('Oxford Nanpore Technology (ONT)',\n",
       "   'S22',\n",
       "   'P44',\n",
       "   36): 'The cDNA amplicon samples were barcoded ONT D native barcoding kit EXPNBD barcoded samples were fed ONT SQKLSK library preparation and sequencing workflow FLOMIN RevD flowcells and GridION X sequencer were used sequencing Data were basecalled ONT Guppy analysis adaptor sequences were trimmed Porechop  Then reads were assessed correct priming as shown correctly primed reads were aligned reference genome Grch minimap v variant calling cell barcodes underwent same processing described for IronThrone GoT  ',\n",
       "  ('Droplet digital PCR',\n",
       "   'S23',\n",
       "   'P45',\n",
       "   37): 'Peripheral blood three ET patients mutations underwent Ficoll density gradient separation immunomagnetic selection CD cells Miltenyi Biotech and fluorescenceactivated cell sorting FACS Influx BectonDickinson using PeCylabeled CD clone  lot B BioLegend APClabeled CD clone HIT lot B BioLegend and FITClabeled CD clone HIa lot B BioLegend antibodies were used isolate CDCD CDCD and CDCD cell compartments DNA was extracted sorted cells Qiagen and VAF of mutations was measured droplet digital PCR QX Droplet Digital PCR System BioRad primers that specifically detect type  mutations bp deletion pLfs type  mutations bp TTGTC insertion pKfs or wildtype alleles',\n",
       "  ('Single cell colony genotyping assay',\n",
       "   'S24',\n",
       "   'P46',\n",
       "   38): 'Viably frozen mononuclear cells were thawed and plated H Methocultä media StemCell Technologies Cambridge MA containing recombinant human SCF GMCSF IL and EPO according manufacturers specifications Individual colonies n =  were picked methylcellulose media days of culture °C and sequenced Sanger sequencing and mutations using primers listed '},\n",
       " {('Introduction',\n",
       "   's1',\n",
       "   'no_sub_id',\n",
       "   0): 'Pancreatic cystic neoplasms PCN are estimated be present – of general population PCN comprise clinically challenging entity as their biological behaviour ranges benign malignant disease Consequently correct management of PCN may prevent progression pancreatic cancer while minimising need lifelong screening and related costs Unfortunately it is often difficult differentiate various types of PCN European Study Group on Cystic Tumours of Pancreas association United European Gastroenterology UEG and European Pancreatic Club EPC published European expert consensus statement on PCN',\n",
       "  ('Introduction',\n",
       "   's1',\n",
       "   'no_sub_id',\n",
       "   1): 'In  as group these stakeholders felt that sufficient data were available mandate update of these guidelines contrast previous European and international guidelines evidencebased approach was chosen Similar previous European but contrast other international guidelines present guideline deals all common PCN European evidencebased guidelines on PCN aim improve diagnosis and management of all PCN and identify areas that require further research',\n",
       "  ('Definitions',\n",
       "   's2a',\n",
       "   'no_sub_id',\n",
       "   2): 'PCN are defined and classified according WHO criteria  Diseasefree survival was defined as length of time patient lives primary treatment any signs or symptoms of recurrence',\n",
       "  ('Blood', 's3a1a', 'no_sub_id', 3): '',\n",
       "  ('Cyst fluid', 's3a1b', 'no_sub_id', 4): '',\n",
       "  ('Cyst fluid', 's3a1b', 'no_sub_id', 5): '',\n",
       "  ('Cyst fluid',\n",
       "   's3a1b',\n",
       "   'no_sub_id',\n",
       "   6): 'The role of CEA cyst fluid is discussed recommendation ',\n",
       "  ('Cyst fluid',\n",
       "   's3a1b',\n",
       "   'no_sub_id',\n",
       "   7): 'Additional biomarkers differential diagnosis of PCN are amylaselipase levels Amylase may exclude pancreatic pseudocysts amylase  UL sensitivity  specificity  but does not differentiate other nonmucinous and mucinous cysts',\n",
       "  ('2.1\\xa0What is the accuracy of MRI/cholangiopancreatography (MRI/MRCP) and CT for identifying the specific type of PCN?',\n",
       "   's3b1',\n",
       "   'no_sub_id',\n",
       "   8): '',\n",
       "  ('2.1\\xa0What is the accuracy of MRI/cholangiopancreatography (MRI/MRCP) and CT for identifying the specific type of PCN?',\n",
       "   's3b1',\n",
       "   'no_sub_id',\n",
       "   9): 'PCN are increasingly being detected reported prevalence of – CT and of – MRIMRCP difference CT and MRI most probably due higher contrast resolution of MRI compared CT and thus increased sensitivity but not specificity However accuracy remains relatively low using either single or combining imaging modalities identifying specific type of PCN differentiating small PCN nonneoplastic or nonepithelial cysts or connection ductal system',\n",
       "  ('2.2\\xa0Which radiological (cross-sectional) imaging method is preferred for the surveillance of patients with PCN taking into consideration accuracy, cost, and modality-related risk factors?',\n",
       "   's3b2',\n",
       "   'no_sub_id',\n",
       "   10): '',\n",
       "  ('2.2\\xa0Which radiological (cross-sectional) imaging method is preferred for the surveillance of patients with PCN taking into consideration accuracy, cost, and modality-related risk factors?',\n",
       "   's3b2',\n",
       "   'no_sub_id',\n",
       "   11): 'Dedicated pancreatic protocol CT and pancreatic MRIMRCP are reported have similar accuracy characterisation of PCN MRIMRCP is more sensitive CT identifying communication PCN and pancreatic duct system and presence of mural nodule or internal septations addition MRIMRCP is very sensitive identifying whether patient has single or multiple PCN latter favouring diagnosis of multifocal sidebranch IPMN Patients PCN may require lifelong imaging followup This is important as studies have shown that repeated exposure ionising radiation following CT increases risk of malignancy',\n",
       "  ('2.3\\xa0Are there specific clinical scenarios where use of one cross-sectional imaging modality (CT/MRI) instead of another, or combined use is preferable?',\n",
       "   's3b3',\n",
       "   'no_sub_id',\n",
       "   12): '',\n",
       "  ('2.3\\xa0Are there specific clinical scenarios where use of one cross-sectional imaging modality (CT/MRI) instead of another, or combined use is preferable?',\n",
       "   's3b3',\n",
       "   'no_sub_id',\n",
       "   13): 'The use of CT should be considered following clinical situations',\n",
       "  ('2.4\\xa0What are the minimum technical requirements for MRI or CT for the diagnosis and surveillance of patients with PCN?',\n",
       "   's3b4',\n",
       "   'no_sub_id',\n",
       "   14): '',\n",
       "  ('2.4\\xa0What are the minimum technical requirements for MRI or CT for the diagnosis and surveillance of patients with PCN?',\n",
       "   's3b4',\n",
       "   'no_sub_id',\n",
       "   15): 'In short protocol surveillance of PCN that included Tweighted ultrafast spin echo technique THASTE and Tweighted precontrast imaging was found one retrospective study provide equivalent information longer protocol which included diffusionweighted imaging DWI and contrast enhanced Tweighted sequences DWI may be added this short protocol order minimise risk of missing concomitant pancreatic cancer combination of THASTE and DWI has been shown have similar accuracy comprehensive contrastenhanced MRI protocol detection of pancreatic cancer recent study suggested that MRI MRCP has better diagnostic performance endoscopic ultrasound EUS differentiating malignant benign pancreatic IPMN and MCN but conclusive evidence is lacking',\n",
       "  ('3.1\\xa0What are the indications for performing EUS in PCN?',\n",
       "   's3c1',\n",
       "   'no_sub_id',\n",
       "   16): '',\n",
       "  ('3.1\\xa0What are the indications for performing EUS in PCN?',\n",
       "   's3c1',\n",
       "   'no_sub_id',\n",
       "   17): '',\n",
       "  ('3.1\\xa0What are the indications for performing EUS in PCN?',\n",
       "   's3c1',\n",
       "   'no_sub_id',\n",
       "   18): '',\n",
       "  ('3.1\\xa0What are the indications for performing EUS in PCN?',\n",
       "   's3c1',\n",
       "   'no_sub_id',\n",
       "   19): 'Data EUSbased differentiation benign and malignant PCN are conflicting addition there is considerable interobserver variation EUSbased diagnoses',\n",
       "  ('3.2\\xa0When should contrast harmonic enhanced EUS (CH-EUS) be performed for PCN and does it alter management?',\n",
       "   's3c2',\n",
       "   'no_sub_id',\n",
       "   20): '',\n",
       "  ('3.2\\xa0When should contrast harmonic enhanced EUS (CH-EUS) be performed for PCN and does it alter management?',\n",
       "   's3c2',\n",
       "   'no_sub_id',\n",
       "   21): '',\n",
       "  ('3.2\\xa0When should contrast harmonic enhanced EUS (CH-EUS) be performed for PCN and does it alter management?',\n",
       "   's3c2',\n",
       "   'no_sub_id',\n",
       "   22): 'CHEUS seems superior standard EUS and CT identification of mural nodules Interobserver agreement is excellent Sonazoid and moderate Sonovue',\n",
       "  ('3.3\\xa0What are the indications and contraindications for EUS-FNA for PCN?',\n",
       "   's3c3',\n",
       "   'no_sub_id',\n",
       "   23): '',\n",
       "  ('3.3\\xa0What are the indications and contraindications for EUS-FNA for PCN?',\n",
       "   's3c3',\n",
       "   'no_sub_id',\n",
       "   24): '',\n",
       "  ('3.3\\xa0What are the indications and contraindications for EUS-FNA for PCN?',\n",
       "   's3c3',\n",
       "   'no_sub_id',\n",
       "   25): '',\n",
       "  ('3.3\\xa0What are the indications and contraindications for EUS-FNA for PCN?',\n",
       "   's3c3',\n",
       "   'no_sub_id',\n",
       "   26): '',\n",
       "  ('3.3\\xa0What are the indications and contraindications for EUS-FNA for PCN?',\n",
       "   's3c3',\n",
       "   'no_sub_id',\n",
       "   27): '',\n",
       "  ('3.3\\xa0What are the indications and contraindications for EUS-FNA for PCN?',\n",
       "   's3c3',\n",
       "   'no_sub_id',\n",
       "   28): 'The role of EUSFNA diagnosis of PCN is still matter of debate and consensus literature is lacking',\n",
       "  ('3.4\\xa0When EUS-FNA is performed, which tests should be performed and what is their yield?',\n",
       "   's3c4',\n",
       "   'no_sub_id',\n",
       "   29): '',\n",
       "  ('3.4\\xa0When EUS-FNA is performed, which tests should be performed and what is their yield?',\n",
       "   's3c4',\n",
       "   'no_sub_id',\n",
       "   30): '',\n",
       "  ('3.4\\xa0When EUS-FNA is performed, which tests should be performed and what is their yield?',\n",
       "   's3c4',\n",
       "   'no_sub_id',\n",
       "   31): '',\n",
       "  ('3.4\\xa0When EUS-FNA is performed, which tests should be performed and what is their yield?',\n",
       "   's3c4',\n",
       "   'no_sub_id',\n",
       "   32): 'In recent metaanalysis cytological analysis of cyst fluid had  sensitivity and  specificity differentiating mucinous nonmucinous PCN cyst fluid CEA level of ≥ ngmL can distinguish mucinous nonmucinous cysts sensitivity of – and specificity of – Differentiating MCN and IPMN based on CEA andor cytology is not possible and CEA seems inaccurate differentiate benign mucinous cysts and cysts highgrade dysplasia or associated invasive carcinoma',\n",
       "  ('3.5\\xa0What is the diagnostic performance of EUS\\xa0+/−FNA?',\n",
       "   's3c5',\n",
       "   'no_sub_id',\n",
       "   33): '',\n",
       "  ('3.5\\xa0What is the diagnostic performance of EUS\\xa0+/−FNA?',\n",
       "   's3c5',\n",
       "   'no_sub_id',\n",
       "   34): '',\n",
       "  ('3.5\\xa0What is the diagnostic performance of EUS\\xa0+/−FNA?',\n",
       "   's3c5',\n",
       "   'no_sub_id',\n",
       "   35): 'The reported accuracy of EUS morphology alone differentiating mucinous nonmucinous PCN is relatively low – sensitivity of – and specificity of – Although cytology is highly specific – it is relatively insensitive – resulting low diagnostic accuracy –',\n",
       "  ('3.5\\xa0What is the diagnostic performance of EUS\\xa0+/−FNA?',\n",
       "   's3c5',\n",
       "   'no_sub_id',\n",
       "   36): 'Combination tests such as EUS morphology cytology and cyst fluid CEA provide greater accuracy detecting mucinous PCN either EUS morphology or cytology alone',\n",
       "  ('3.6\\xa0What are the potential adverse events associated with EUS-FNA of PCN? Are there any measures that can be taken to prevent complications?',\n",
       "   's3c6',\n",
       "   'no_sub_id',\n",
       "   37): '',\n",
       "  ('3.6\\xa0What are the potential adverse events associated with EUS-FNA of PCN? Are there any measures that can be taken to prevent complications?',\n",
       "   's3c6',\n",
       "   'no_sub_id',\n",
       "   38): '',\n",
       "  ('3.6\\xa0What are the potential adverse events associated with EUS-FNA of PCN? Are there any measures that can be taken to prevent complications?',\n",
       "   's3c6',\n",
       "   'no_sub_id',\n",
       "   39): 'Following EUSFNA   patients developed adverse event These complications were mild moderate nine and severe one patients One retrospective study of  patients found that antibiotic prophylaxis had no effect on risk of infection  vs  although conclusive evidence is lacking Current practice is often single shot antibiotic treatment EUSFNA of cystic lesion',\n",
       "  ('3.7\\xa0Is there any role for endoscopic retrograde cholangiopancreatography (ERCP) and/or pancreatoscopy and/or confocal laser endomicroscopy (nCLE) in the diagnosis of PCN?',\n",
       "   's3c7',\n",
       "   'no_sub_id',\n",
       "   40): '',\n",
       "  ('3.7\\xa0Is there any role for endoscopic retrograde cholangiopancreatography (ERCP) and/or pancreatoscopy and/or confocal laser endomicroscopy (nCLE) in the diagnosis of PCN?',\n",
       "   's3c7',\n",
       "   'no_sub_id',\n",
       "   41): '',\n",
       "  ('3.7\\xa0Is there any role for endoscopic retrograde cholangiopancreatography (ERCP) and/or pancreatoscopy and/or confocal laser endomicroscopy (nCLE) in the diagnosis of PCN?',\n",
       "   's3c7',\n",
       "   'no_sub_id',\n",
       "   42): '',\n",
       "  ('3.7\\xa0Is there any role for endoscopic retrograde cholangiopancreatography (ERCP) and/or pancreatoscopy and/or confocal laser endomicroscopy (nCLE) in the diagnosis of PCN?',\n",
       "   's3c7',\n",
       "   'no_sub_id',\n",
       "   43): 'ERCP has higher risk of adverse events and lower sensitivity and specificity identifying type of PCN conventional radiology and EUS and should not be used this indication',\n",
       "  ('3.7\\xa0Is there any role for endoscopic retrograde cholangiopancreatography (ERCP) and/or pancreatoscopy and/or confocal laser endomicroscopy (nCLE) in the diagnosis of PCN?',\n",
       "   's3c7',\n",
       "   'no_sub_id',\n",
       "   44): 'The accuracy rate of pancreatoscopy is higher MDIPMN in branch duct BDIPMN  Intraoperative main pancreatic duct MPD pancreatoscopy combined frozen section of intraductal biopsies may be helpful establishing extent of IPMN involvement of MPD and assist surgical decisionmaking extent of resection required Although promising further studies are required and it should not be used routine clinical care major concern nCLE is rate of adverse events – Some suggest that nCLE could be useful correctly diagnosing serous cystadenomas and thereby might prevent unnecessary surgery these patients',\n",
       "  ('4.1\\xa0What is the risk of malignant progression of an IPMN lesion and what risk factors are predictive of cancer progression?',\n",
       "   's3d1',\n",
       "   'no_sub_id',\n",
       "   45): '',\n",
       "  ('4.1\\xa0What is the risk of malignant progression of an IPMN lesion and what risk factors are predictive of cancer progression?',\n",
       "   's3d1',\n",
       "   'no_sub_id',\n",
       "   46): '',\n",
       "  ('4.1\\xa0What is the risk of malignant progression of an IPMN lesion and what risk factors are predictive of cancer progression?',\n",
       "   's3d1',\n",
       "   'no_sub_id',\n",
       "   47): 'Nine studies including  surgically resected IPMN have concluded that presence of jaundice contrastenhancing mural nodule or solid component or MPD dilatation of ≥ mm has positive predictive value malignancy of – Several series including surgically resected IPMN have reported high risk of harbouring least highgrade dysplasia or cancer of – even MPD size of – mm Several studies have recently identified serum CA  as independent predictor of malignancy IPMN Analyses of surgical series of patients BDIPMNs who have undergone surgical resection have found that mural nodule measuring  mm on EUS has sensitivity of – and specificity of – presence of highgrade dysplasia or cancer presence of cyst size ≥ mm any other radiological or clinical risk factors has positive predictive value malignancy of and  Patients IPMN measuring ≥ mm have risk of developing malignancy which they will die years whereas years diseasefree survival resection of IPMN is  Even BDIPMN  mm year risk developing malignancy is reported be  if cyst increases size mmyear One study imaging surveillance months detected fold higher risk of malignant progression IPMN whose size increased  mmyear or had total growth of  mm predominantly surgical series presence of newonset diabetes pancreatitis and abdominal pain have been associated malignancy varying rates indicating that level of evidence these risk factors is low shows risk of highgrade dysplasia or malignancy according dilatation of main pancreatic duct IPMN',\n",
       "  ('4.1\\xa0What is the risk of malignant progression of an IPMN lesion and what risk factors are predictive of cancer progression?',\n",
       "   's3d1',\n",
       "   'no_sub_id',\n",
       "   48): 'Followup of BDIPMN is required as progression of disease is expected about – of patients – years of followup Surveillance should also include entire pancreatic gland because of increased risk of newonset cancer patients MDIPMN and those mixedtype MTIPMN several factors may predict progression surveillance eg diffuse MPD dilatation serum CA  serum alkaline phosphatase and absence of extrapancreatic cysts',\n",
       "  ('4.2\\xa0What are the clinical implications of the presence of potential risk factors, including morphological features, with regard to determining follow-up investigations, and the decision to proceed with surgical resection',\n",
       "   's3d2',\n",
       "   'no_sub_id',\n",
       "   49): 'For patients IPMN indication operative intervention routine followup is recommended month followup first year and yearly followup thereafter is adequate when no risk factors are present that establish indication surgery Changes clinical symptoms should trigger investigations GRADE B strong agreement',\n",
       "  ('4.2\\xa0What are the clinical implications of the presence of potential risk factors, including morphological features, with regard to determining follow-up investigations, and the decision to proceed with surgical resection',\n",
       "   's3d2',\n",
       "   'no_sub_id',\n",
       "   50): 'For patients relative indication surgery see statement elderly and those affected severe comorbidity month followup is recommended GRADE B strong agreement',\n",
       "  ('4.2\\xa0What are the clinical implications of the presence of potential risk factors, including morphological features, with regard to determining follow-up investigations, and the decision to proceed with surgical resection',\n",
       "   's3d2',\n",
       "   'no_sub_id',\n",
       "   51): 'In young individuals risk of malignancy and surgery has be balanced burden of lifelong followup However partial pancreatectomy IPMN lifelong followup is still indicated Resection therefore does not eliminate need regular followup screening',\n",
       "  ('4.3\\xa0Is there a certain size cut-off point\\xa0for resecting an IPMN regardless of the absence of clinical symptoms or (other) risk factors? Is age of the patient a co-factor that should be analysed to define better management strategy?',\n",
       "   's3d3',\n",
       "   'no_sub_id',\n",
       "   52): '',\n",
       "  ('4.3\\xa0Is there a certain size cut-off point\\xa0for resecting an IPMN regardless of the absence of clinical symptoms or (other) risk factors? Is age of the patient a co-factor that should be analysed to define better management strategy?',\n",
       "   's3d3',\n",
       "   'no_sub_id',\n",
       "   53): 'Several studies including both surgically resected or observed IPMN have reported increased risk of malignancy ranging to cases of cyst  mm some of these series risk of malignancy produced cyst size was stratified presence of other features malignancy indicating that cyst size alone is not appropriate indication surgery risk of malignancy is actual but low If multiple risk factors are present sensitivity detect malignancy increases',\n",
       "  ('4.4\\xa0What is the best imaging modality for the follow-up of IPMN?',\n",
       "   's3d4',\n",
       "   'no_sub_id',\n",
       "   54): '',\n",
       "  ('4.4\\xa0What is the best imaging modality for the follow-up of IPMN?',\n",
       "   's3d4',\n",
       "   'no_sub_id',\n",
       "   55): 'See section details',\n",
       "  ('4.5\\xa0Should the progress of IPMN be followed for as long as the patient is fit for surgery?',\n",
       "   's3d5',\n",
       "   'no_sub_id',\n",
       "   56): '',\n",
       "  ('4.5\\xa0Should the progress of IPMN be followed for as long as the patient is fit for surgery?',\n",
       "   's3d5',\n",
       "   'no_sub_id',\n",
       "   57): 'The risk of progression of IPMN increases over time as does risk of developing indications surgical resection Interruption of surveillance is not recommended if patient is fit potential surgical resection single study on IPMN concluded that patients Charlsonage comorbidity index ≥ have fold risk of comorbidityrelated death years and only  of patients will die of malignant IPMN',\n",
       "  ('4.6\\xa0Should patients with IPMNs be screened for other tumours (including pancreatic cancer)?',\n",
       "   's3d6',\n",
       "   'no_sub_id',\n",
       "   58): '',\n",
       "  ('4.6\\xa0Should patients with IPMNs be screened for other tumours (including pancreatic cancer)?',\n",
       "   's3d6',\n",
       "   'no_sub_id',\n",
       "   59): 'A systematic review concluded that available data remain inconclusive Two large studies including both surgically resected or followed IPMN did not find any difference terms of incidence of extrapancreatic neoplasms patients IPMN if compared general population',\n",
       "  ('4.7\\xa0Should MD-IPMN always be resected?', 's3d7', 'no_sub_id', 60): '',\n",
       "  ('4.7\\xa0Should MD-IPMN always be resected?',\n",
       "   's3d7',\n",
       "   'no_sub_id',\n",
       "   61): 'Surgery MDIPMN is universally accepted considering highrate of malignancy due MDIPMN even though no randomised trials comparing surgery observation are available As discussed statement MDIPMN measuring and  mm is relative indication surgical resection while MDIPMN measuring  mm see statement details is absolute indication surgical resection',\n",
       "  ('4.8\\xa0Should mixed-type (MT)-IPMN be managed in a similar manner to MD-IPMN?',\n",
       "   's3d8',\n",
       "   'no_sub_id',\n",
       "   62): '',\n",
       "  ('4.8\\xa0Should mixed-type (MT)-IPMN be managed in a similar manner to MD-IPMN?',\n",
       "   's3d8',\n",
       "   'no_sub_id',\n",
       "   63): 'Few studies have investigated MTIPMN as single entity Malignancy rates appear similar MTIPMN and MDIPMN Recently pathological classification distinguishing minimal microscopic and extensive macroscopic involvement of MPD showed significant difference risk of highgrade dysplasia or cancer  and  respectively However this classification can be used only resection and is thus irrelevant clinical assessment surgery',\n",
       "  ('4.9\\xa0What type of resection is indicated when the entire MPD is dilated on imaging?',\n",
       "   's3d9',\n",
       "   'no_sub_id',\n",
       "   64): '',\n",
       "  ('4.9\\xa0What type of resection is indicated when the entire MPD is dilated on imaging?',\n",
       "   's3d9',\n",
       "   'no_sub_id',\n",
       "   65): '',\n",
       "  ('4.9\\xa0What type of resection is indicated when the entire MPD is dilated on imaging?',\n",
       "   's3d9',\n",
       "   'no_sub_id',\n",
       "   66): 'It is important assess MPD mural nodule surgical exploration see sections  and details There are conflicting data and opinions extent of surgery MDIPMN Some authors advocate total pancreatectomy every patient affected MDIPMN radiological involvement of entire MPD because of relatively highrisk of highgrade dysplasia and cancer Others suggest total pancreatectomy only when there is positive family history of pancreatic cancer or partial pancreatectomy followed close surveillance completion pancreatectomy where progression or recurrence is suspected this situation pancreatoscopy may be useful determine extent of MPD involvement see statement details Where there is either radiological suspicion or histological proof of IPMNassociated invasive carcinoma head of pancreas total pancreatectomy is not recommended as cancer will determine prognosis',\n",
       "  ('4.10\\xa0At what MPD diameter should surgery be considered?',\n",
       "   's3d10',\n",
       "   'no_sub_id',\n",
       "   67): '',\n",
       "  ('4.10\\xa0At what MPD diameter should surgery be considered?',\n",
       "   's3d10',\n",
       "   'no_sub_id',\n",
       "   68): 'The main goal of surgery is resect IPMNs when highgrade dysplasia is present and patients develop pancreatic cancer Given recent studies and goal of surgery cutoff point of  mm is reasonable see ',\n",
       "  ('4.11\\xa0What are the absolute criteria for resection of BD-IPMN?',\n",
       "   's3d11',\n",
       "   'no_sub_id',\n",
       "   69): '',\n",
       "  ('4.11\\xa0What are the absolute criteria for resection of BD-IPMN?',\n",
       "   's3d11',\n",
       "   'no_sub_id',\n",
       "   70): 'See statements – detailed description of rationale this',\n",
       "  ('4.12\\xa0Which are the relative criteria for resection of BD-IPMN?',\n",
       "   's3d12',\n",
       "   'no_sub_id',\n",
       "   71): '',\n",
       "  ('4.12\\xa0Which are the relative criteria for resection of BD-IPMN?',\n",
       "   's3d12',\n",
       "   'no_sub_id',\n",
       "   72): 'shows absolute and relative indications surgery',\n",
       "  ('4.12\\xa0Which are the relative criteria for resection of BD-IPMN?',\n",
       "   's3d12',\n",
       "   'no_sub_id',\n",
       "   73): 'CA  values serum  UmL have been associated positive predictive value of  and accuracy of identify patients invasive IPMN Highly elevated levels of CA  may thus be helpful as additional but not sole indicator invasive IPMN',\n",
       "  ('4.12\\xa0Which are the relative criteria for resection of BD-IPMN?',\n",
       "   's3d12',\n",
       "   'no_sub_id',\n",
       "   74): 'A recent large cohort of patients who underwent surveillance IPMN accordance previous European expert statement validates safety of observation of BDIPMN measuring  mm absence of other risk factors However other data show that even small IPMN may develop highgrade dysplasia or cancer This highlights importance of evaluating presence of multiple risk factors greater number of risk factors higher probability of malignancy shows risk of highgrade dysplasia or malignancy according cyst size BDIPMN',\n",
       "  ('4.13\\xa0Which kind of surgery should be performed for patients with BD-IPMN?',\n",
       "   's3d13',\n",
       "   'no_sub_id',\n",
       "   75): '',\n",
       "  ('4.13\\xa0Which kind of surgery should be performed for patients with BD-IPMN?',\n",
       "   's3d13',\n",
       "   'no_sub_id',\n",
       "   76): 'Considering that surgery is indicated only lesions potential risk of cancer or highgrade dysplasia indications PSP are very limited Diagnostic use of these procedures is reported occasionally patients increased risk of malignancy ie familial pancreatic cancer morbidity of PSP is same as that of conventional pancreatectomies advantage of performing PSP over conventional pancreatectomy is unclear',\n",
       "  ('4.14\\xa0When is full lymph node dissection required?',\n",
       "   's3d14',\n",
       "   'no_sub_id',\n",
       "   77): '',\n",
       "  ('4.15\\xa0How should multifocal BD-IPMN be evaluated for surgery? Is it safe to leave in place BD-IPMN without clinical or radiological signs of high-grade dysplasia or cancer when resecting another part of the pancreas?',\n",
       "   's3d15',\n",
       "   'no_sub_id',\n",
       "   78): '',\n",
       "  ('4.15\\xa0How should multifocal BD-IPMN be evaluated for surgery? Is it safe to leave in place BD-IPMN without clinical or radiological signs of high-grade dysplasia or cancer when resecting another part of the pancreas?',\n",
       "   's3d15',\n",
       "   'no_sub_id',\n",
       "   79): 'In cases of multifocal IPMN each lesion should be evaluated surgical resection as single entity according criteria reported statements – Once this appraisal is performed tailored surgical approach can be planned intraoperative analysis of surgical margins may help determine need expanded resection',\n",
       "  ('4.16\\xa0Should frozen section analysis be performed routinely in IPMN undergoing surgical resection?',\n",
       "   's3d16',\n",
       "   'no_sub_id',\n",
       "   80): '',\n",
       "  ('4.16\\xa0Should frozen section analysis be performed routinely in IPMN undergoing surgical resection?',\n",
       "   's3d16',\n",
       "   'no_sub_id',\n",
       "   81): 'Although frozen section analysis is recommended data on its clinical impact on resection margin of IPMN undergoing surgical resection are contradictory',\n",
       "  ('4.17\\xa0How will the frozen section result alter the surgical procedure?',\n",
       "   's3d17',\n",
       "   'no_sub_id',\n",
       "   82): '',\n",
       "  ('4.17\\xa0How will the frozen section result alter the surgical procedure?',\n",
       "   's3d17',\n",
       "   'no_sub_id',\n",
       "   83): 'Extending resection may be considered young fit patients especially those increased risk cancer ie familial pancreatic cancer lowgrade dysplasia resection margin Frozen section analysis is useful detecting microscopic spread of cancerous lesions but is unable detect presence of discontinuous skip lesions which occur − of cases Moreover detailed observation of remnant MPD using intraoperative pancreatoscopy may provide identification of preoperatively undetected lesions Patients should always be counselled potential need total pancreatectomy',\n",
       "  ('4.18\\xa0What is the value of the\\xa0frozen section in resected IPMN with cancer?',\n",
       "   's3d18',\n",
       "   'no_sub_id',\n",
       "   84): '',\n",
       "  ('4.18\\xa0What is the value of the\\xa0frozen section in resected IPMN with cancer?',\n",
       "   's3d18',\n",
       "   'no_sub_id',\n",
       "   85): 'Data vary on value of positive frozen section predict IPMN cancer recurrence surgery IPMN associated invasive carcinoma no lymph node metastases appears be associated better longterm outcome pancreatic cancer this reason extension of resection margin cases of cancer or highgrade dysplasia appears reasonable these patients',\n",
       "  ('4.19\\xa0How are surgical outcomes affected by cyst location, comorbidity, patient age, and how should these features be weighted?',\n",
       "   's3d19',\n",
       "   'no_sub_id',\n",
       "   86): '',\n",
       "  ('4.19\\xa0How are surgical outcomes affected by cyst location, comorbidity, patient age, and how should these features be weighted?',\n",
       "   's3d19',\n",
       "   'no_sub_id',\n",
       "   87): 'A more conservative approach may be considered IPMN located head of pancreas elderly patients or patients multiple comorbidities However this conservative approach should be weighted potential risk of progression or development of highgrade dysplasia or cancer',\n",
       "  ('4.20\\xa0How should patients be followed up\\xa0who underwent surgical resection for an IPMN?',\n",
       "   's3d20',\n",
       "   'no_sub_id',\n",
       "   88): '',\n",
       "  ('4.20\\xa0How should patients be followed up\\xa0who underwent surgical resection for an IPMN?',\n",
       "   's3d20',\n",
       "   'no_sub_id',\n",
       "   89): 'Several studies have reported that IPMN recurrence is possible years resection risk of BDIPMN and MDIPMN recurrence is similar – Resected IPMN lowgrade dysplasia have low risk of recurrence − diseasefree survival of approximately  months while IPMN highgrade dysplasia or IPMNassociated invasive carcinoma have higher risk diseasefree survival of  months',\n",
       "  ('4.21\\xa0What preoperative investigation\\xa0should be performed for a patient with an IPMN-associated invasive carcinoma? Should the same criteria be used as for pancreatic cancer?',\n",
       "   's3d21',\n",
       "   'no_sub_id',\n",
       "   90): '',\n",
       "  ('4.21\\xa0What preoperative investigation\\xa0should be performed for a patient with an IPMN-associated invasive carcinoma? Should the same criteria be used as for pancreatic cancer?',\n",
       "   's3d21',\n",
       "   'no_sub_id',\n",
       "   91): 'No studies have examined differences IPMNassociated invasive carcinoma and spontaneous pancreatic cancer respect local tumour extension or staging distant metastases',\n",
       "  ('4.22\\xa0Should patients with an IPMN and a family history of pancreatic cancer be managed in a similar manner to patients with an IPMN but no family history?',\n",
       "   's3d22',\n",
       "   'no_sub_id',\n",
       "   92): '',\n",
       "  ('4.22\\xa0Should patients with an IPMN and a family history of pancreatic cancer be managed in a similar manner to patients with an IPMN but no family history?',\n",
       "   's3d22',\n",
       "   'no_sub_id',\n",
       "   93): 'There is no reported evidence that IPMN occurring patients family history of pancreatic cancer have more rapid progression highgrade dysplasia or cancer sporadic cases',\n",
       "  ('4.23\\xa0Should patients who have undergone an organ transplant, and have an IPMN be managed in\\xa0the same way as non-transplanted patients with IPMN?',\n",
       "   's3d23',\n",
       "   'no_sub_id',\n",
       "   94): '',\n",
       "  ('4.24\\xa0Should patients who have an IPMN which fulfils criteria for surgical resection but who\\xa0are not surgical candidates be treated with ablative techniques?',\n",
       "   's3d24',\n",
       "   'no_sub_id',\n",
       "   95): 'Further studies are required clarify indications and safety of EUSguided ablative injection techniques ethanol paclitaxel radiofrequency ablation or cryoablation treatment of IPMNs These should not be performed outside of clinical trials approved institutional review board GRADE C strong agreement',\n",
       "  ('4.24\\xa0Should patients who have an IPMN which fulfils criteria for surgical resection but who\\xa0are not surgical candidates be treated with ablative techniques?',\n",
       "   's3d24',\n",
       "   'no_sub_id',\n",
       "   96): 'EUS ablative procedures treatment of IPMN are not standardised and their efficacy is unclear Furthermore there is lack of reliable markers indicate successful and complete ablation',\n",
       "  ('5.1\\xa0Should patients with MCN always undergo surgical resection?',\n",
       "   's3e1',\n",
       "   'no_sub_id',\n",
       "   97): '',\n",
       "  ('5.1\\xa0Should patients with MCN always undergo surgical resection?',\n",
       "   's3e1',\n",
       "   'no_sub_id',\n",
       "   98): 'The rate which size of MCN increases should be considered Some case reports have suggested considerably faster growth of MCN pregnancy potentially leading tumour rupture Therefore patients MCN should be observed closely pregnancy',\n",
       "  ('5.2\\xa0Is it safe to follow up\\xa0presumed MCN, which measures\\xa0<40\\u2009mm?',\n",
       "   's3e2',\n",
       "   'no_sub_id',\n",
       "   99): '',\n",
       "  ('5.2\\xa0Is it safe to follow up\\xa0presumed MCN, which measures\\xa0<40\\u2009mm?',\n",
       "   's3e2',\n",
       "   'no_sub_id',\n",
       "   100): 'For patients MCN measuring and  mm clinicians can incorporate other factors such as age comorbidities patients surgical risk and patient preference cysts measuring  mm it may be difficult make definitive diagnosis of MCN and smaller MCN may sometimes be difficult distinguish other cystic lesions We therefore recommend similar surveillance MCN and IPMN measuring  cm',\n",
       "  ('5.3\\xa0How should MCN, which is not resected, be followed\\xa0up?',\n",
       "   's3e3',\n",
       "   'no_sub_id',\n",
       "   101): '',\n",
       "  ('5.3\\xa0How should MCN, which is not resected, be followed\\xa0up?',\n",
       "   's3e3',\n",
       "   'no_sub_id',\n",
       "   102): 'Earlier studies have evaluated features associated malignant transformation all mucinous lesions combined However IPMNs and MCN may have different rates of growth and malignant transformation and different features predictive of malignancy',\n",
       "  ('5.4\\xa0Is cyst fluid analysis recommended for MCN?',\n",
       "   's3e4',\n",
       "   'no_sub_id',\n",
       "   103): 'See statement ',\n",
       "  ('5.5\\xa0Which surgical procedure(s) should be performed for an MCN?',\n",
       "   's3e5',\n",
       "   'no_sub_id',\n",
       "   104): '',\n",
       "  ('5.5\\xa0Which surgical procedure(s) should be performed for an MCN?',\n",
       "   's3e5',\n",
       "   'no_sub_id',\n",
       "   105): '',\n",
       "  ('5.5\\xa0Which surgical procedure(s) should be performed for an MCN?',\n",
       "   's3e5',\n",
       "   'no_sub_id',\n",
       "   106): '',\n",
       "  ('5.5\\xa0Which surgical procedure(s) should be performed for an MCN?',\n",
       "   's3e5',\n",
       "   'no_sub_id',\n",
       "   107): 'PSP are associated higher early morbidity and longer hospitalisation laparoscopic approach is feasible MCN Its benefit over open approach is comparable other indications',\n",
       "  ('6.1\\xa0Does malignant SCN exist? is there a risk of malignant transformation?',\n",
       "   's3f1',\n",
       "   'no_sub_id',\n",
       "   108): '',\n",
       "  ('6.1\\xa0Does malignant SCN exist? is there a risk of malignant transformation?',\n",
       "   's3f1',\n",
       "   'no_sub_id',\n",
       "   109): 'Cases reported as malignant do not fulfil WHO criteria SCN',\n",
       "  ('6.2\\xa0If\\xa0there is a clear diagnosis of an SCN, can follow-up be discontinued?',\n",
       "   's3f2',\n",
       "   'no_sub_id',\n",
       "   110): '',\n",
       "  ('6.3\\xa0When does a possible SCN require follow-up?',\n",
       "   's3f3',\n",
       "   'no_sub_id',\n",
       "   111): '',\n",
       "  ('6.4\\xa0When does a SCN require surgery and which procedure should be performed?',\n",
       "   's3f4',\n",
       "   'no_sub_id',\n",
       "   112): 'When diagnosis of SCN is clear surgery is recommended only patients symptoms related compression of adjacent organs ie bile duct stomach duodenum portal vein GRADE C strong agreement',\n",
       "  ('6.4\\xa0When does a SCN require surgery and which procedure should be performed?',\n",
       "   's3f4',\n",
       "   'no_sub_id',\n",
       "   113): 'The size of of SCN remains stable increase cyst size is seen but rate of growth is slow and new onset of symptoms is very rare',\n",
       "  ('7.1\\xa0When the diagnosis of a cyst is unclear based on a specific imaging modality, should other investigations always be undertaken?',\n",
       "   's3g1',\n",
       "   'no_sub_id',\n",
       "   114): '',\n",
       "  ('7.1\\xa0When the diagnosis of a cyst is unclear based on a specific imaging modality, should other investigations always be undertaken?',\n",
       "   's3g1',\n",
       "   'no_sub_id',\n",
       "   115): 'For cysts ≥ mm or if diagnosis is unclear both crosssectional imaging and EUS should be performed including EUSFNA if warranted',\n",
       "  ('7.2\\xa0How should a small, undefined cyst be followed\\xa0up?',\n",
       "   's3g2',\n",
       "   'no_sub_id',\n",
       "   116): '',\n",
       "  ('7.2\\xa0How should a small, undefined cyst be followed\\xa0up?',\n",
       "   's3g2',\n",
       "   'no_sub_id',\n",
       "   117): 'As undefined cyst may be mucinous nature surveillance is recommended Most studies report that risk of malignant transformation of PCN increases size This probably also applies cysts of unclear aetiology',\n",
       "  ('7.2\\xa0How should a small, undefined cyst be followed\\xa0up?',\n",
       "   's3g2',\n",
       "   'no_sub_id',\n",
       "   118): 'A prospective populationbased study found that unidentified cysts are very common  when including diameters of ≥ mm increase number and size age of population  of subjects but have no effect on pancreatic diseaseassociated mortality over  years',\n",
       "  ('7.2\\xa0How should a small, undefined cyst be followed\\xa0up?',\n",
       "   's3g2',\n",
       "   'no_sub_id',\n",
       "   119): 'Recommendations that include month surveillance intervals may therefore constitute overtreatment cases where IPMN and MCN have been ruled out',\n",
       "  ('7.3\\xa0Duration of follow-up of undefined cysts',\n",
       "   's3g3',\n",
       "   'no_sub_id',\n",
       "   120): '',\n",
       "  ('7.3\\xa0Duration of follow-up of undefined cysts',\n",
       "   's3g3',\n",
       "   'no_sub_id',\n",
       "   121): 'The longterm evolution of PCN is still largely unknown which also applies undefined pancreatic cysts Therefore no rational term termination of surveillance can be given However recent data suggest that risk of progression increases over time',\n",
       "  ('7.4\\xa0Should all solid-pseudopapillary neoplasms (SPN) be resected?',\n",
       "   's3g4',\n",
       "   'no_sub_id',\n",
       "   122): '',\n",
       "  ('7.4\\xa0Should all solid-pseudopapillary neoplasms (SPN) be resected?',\n",
       "   's3g4',\n",
       "   'no_sub_id',\n",
       "   123): 'Even absence of large series surgical resection of SPN is internationally recommended and associated positive longterm outcome',\n",
       "  ('7.5\\xa0Can locally advanced SPN be resected? Should synchronous or metachronous metastases be resected?',\n",
       "   's3g5',\n",
       "   'no_sub_id',\n",
       "   124): '',\n",
       "  ('7.5\\xa0Can locally advanced SPN be resected? Should synchronous or metachronous metastases be resected?',\n",
       "   's3g5',\n",
       "   'no_sub_id',\n",
       "   125): 'SPNs are rare and there is lack of highquality studies guide care Most studies are small retrospective case series making comparison studies difficult',\n",
       "  ('7.6\\xa0How is the diagnosis of a cystic pancreatic neuroendocrine tumour (PNEN) established?',\n",
       "   's3g6',\n",
       "   'no_sub_id',\n",
       "   126): 'A definitive diagnosis of cystic PNEN can be established only histological examination preoperative diagnosis is often suspected based on particular features of crosssectional imaging and can be confirmed EUSguided cytology GRADE C strong agreement',\n",
       "  ('7.6\\xa0How is the diagnosis of a cystic pancreatic neuroendocrine tumour (PNEN) established?',\n",
       "   's3g6',\n",
       "   'no_sub_id',\n",
       "   127): 'Cystic PNEN often have peripheral hypervascular rim visible on arterial phase CT scan However SCN may have similar appearance hampering differentiation Data on functional imaging Octreoscan or Gallium Octreotate positron emission tomography cystic PNEN are limited',\n",
       "  ('7.7\\xa0What are the indications to resect cystic PNEN and which procedures are recommended?',\n",
       "   's3g7',\n",
       "   'no_sub_id',\n",
       "   128): 'For cystic PNEN  mm surgery is recommended pancreatoduodenectomy distal pancreatectomy or enucleation including lymphadenectomy according tumour localisation',\n",
       "  ('7.7\\xa0What are the indications to resect cystic PNEN and which procedures are recommended?',\n",
       "   's3g7',\n",
       "   'no_sub_id',\n",
       "   129): '',\n",
       "  ('7.7\\xa0What are the indications to resect cystic PNEN and which procedures are recommended?',\n",
       "   's3g7',\n",
       "   'no_sub_id',\n",
       "   130): 'A recent metaanalysis concluded that cystic PNENs tend be biologically less aggressive their solid counterparts Despite this cystic PNENs have approximately  risk of malignancy year overall survival of – small tumour diameter is favourable prognostic factor PNENs Therefore small cystic PNENs ≤ mm may be considered as indolent tumours small risk of malignant transformation and observational strategy has been suggested absence of symptoms',\n",
       "  ('7.8\\xa0Which are the rare cystic pancreatic lesions? When should they be considered and how is the diagnosis established?',\n",
       "   's3g8',\n",
       "   'no_sub_id',\n",
       "   131): 'Rare cystic pancreatic lesions include hydatid cysts haemangioma lymphoepithelial cysts acinar cell cystadenomas desmoid cysts and haemolymphangiomas Such cysts require multidisciplinary approach expert pancreatic centre determine optimum management strategy Surgery may be necessary if diagnosis remains unclear GRADE C strong agreement',\n",
       "  ('8.1\\xa0Is adjuvant treatment recommended for resected IPMN or MCN with associated invasive carcinoma? if yes, what is the optimal regimen?',\n",
       "   's3h1',\n",
       "   'no_sub_id',\n",
       "   132): '',\n",
       "  ('8.1\\xa0Is adjuvant treatment recommended for resected IPMN or MCN with associated invasive carcinoma? if yes, what is the optimal regimen?',\n",
       "   's3h1',\n",
       "   'no_sub_id',\n",
       "   133): 'As patients pancreatic cancer adjuvant treatment can also be recommended patients lymph node involvement but there is no scientific evidence support this',\n",
       "  ('8.1\\xa0Is adjuvant treatment recommended for resected IPMN or MCN with associated invasive carcinoma? if yes, what is the optimal regimen?',\n",
       "   's3h1',\n",
       "   'no_sub_id',\n",
       "   134): '',\n",
       "  ('8.1\\xa0Is adjuvant treatment recommended for resected IPMN or MCN with associated invasive carcinoma? if yes, what is the optimal regimen?',\n",
       "   's3h1',\n",
       "   'no_sub_id',\n",
       "   135): '',\n",
       "  ('8.2\\xa0Is neoadjuvant treatment recommended for locally advanced carcinoma associated with an IPMN or MCN?',\n",
       "   's3h2',\n",
       "   'no_sub_id',\n",
       "   136): '',\n",
       "  ('8.2\\xa0Is neoadjuvant treatment recommended for locally advanced carcinoma associated with an IPMN or MCN?',\n",
       "   's3h2',\n",
       "   'no_sub_id',\n",
       "   137): 'Two case reports have been published supporting use of preoperative chemotherapy IPMN and MCN approach similar that used patients pancreatic cancer can be considered given similarities two diseases',\n",
       "  ('8.3\\xa0Is adjuvant or neoadjuvant treatment indicated for SPN? If yes, what is the optimum regimen?',\n",
       "   's3h3',\n",
       "   'no_sub_id',\n",
       "   138): '',\n",
       "  ('8.3\\xa0Is adjuvant or neoadjuvant treatment indicated for SPN? If yes, what is the optimum regimen?',\n",
       "   's3h3',\n",
       "   'no_sub_id',\n",
       "   139): 'The only data neoadjuvant or adjuvant therapy SPN are case reports majority of which report different chemotherapy regimens and many of which were used palliative setting postsurgical recurrence',\n",
       "  ('8.4\\xa0Is palliative chemotherapy recommended for non-resectable or recurrent malignant cystic tumours of the pancreas?',\n",
       "   's3h4',\n",
       "   'no_sub_id',\n",
       "   140): '',\n",
       "  ('8.4\\xa0Is palliative chemotherapy recommended for non-resectable or recurrent malignant cystic tumours of the pancreas?',\n",
       "   's3h4',\n",
       "   'no_sub_id',\n",
       "   141): 'Given similarity pancreatic cancer palliative chemotherapy may be considered patients nonresectable recurrent or metastatic disease occurring setting of malignant IPMN or MCN analogous pancreatic cancer',\n",
       "  ('8.5\\xa0Is surgical resection of metastases, or recurrence of an IPMN or MCN cancer justified?',\n",
       "   's3h5',\n",
       "   'no_sub_id',\n",
       "   142): '',\n",
       "  ('Specimen dissection', 's3i1a', 'no_sub_id', 143): '',\n",
       "  ('Specimen dissection',\n",
       "   's3i1a',\n",
       "   'no_sub_id',\n",
       "   144): 'No studies have been published on optimal grossing of pancreatic resection specimens cystic lesions',\n",
       "  ('Macroscopic examination', 's3i1b', 'no_sub_id', 145): '',\n",
       "  ('Tissue sampling', 's3i1c', 'no_sub_id', 146): '',\n",
       "  ('Tissue sampling',\n",
       "   's3i1c',\n",
       "   'no_sub_id',\n",
       "   147): 'The minimum number of tissue samples that should be taken ensure accurate diagnosis has not been established PCN',\n",
       "  ('Gross examination', 's3i2a', 'no_sub_id', 148): 'See statement ',\n",
       "  ('Histopathological examination', 's3i2b', 'no_sub_id', 149): '',\n",
       "  ('Histopathological examination', 's3i2b', 'no_sub_id', 150): '',\n",
       "  ('Histopathological examination',\n",
       "   's3i2b',\n",
       "   'no_sub_id',\n",
       "   151): 'The term should not be used Instead it should be simply stated whether invasion is present or not It is important assess histological subtype of IPMN it is associated prediction of postoperative patient prognosis pancreatobiliary subtype example is considered be strongly associated malignancy',\n",
       "  ('Gross examination', 's3i3a', 'no_sub_id', 152): 'See statement ',\n",
       "  ('Histopathological examination', 's3i3b', 'no_sub_id', 153): '',\n",
       "  ('9.4\\xa0Use of potential molecular markers',\n",
       "   's3i4',\n",
       "   'no_sub_id',\n",
       "   154): 'See statement ',\n",
       "  ('9.5\\xa0Methodology for evaluation of cytology in PCN',\n",
       "   's3i5',\n",
       "   'no_sub_id',\n",
       "   155): '',\n",
       "  ('9.5\\xa0Methodology for evaluation of cytology in PCN',\n",
       "   's3i5',\n",
       "   'no_sub_id',\n",
       "   156): 'Cytology PCN has low sensitivity but high specificity see statement  Low sensitivity and frequent nondiagnostic yield are mainly due low cellularity of aspirated fluid',\n",
       "  ('9.6\\xa0How to interpret and report PCN cytology',\n",
       "   's3i6',\n",
       "   'no_sub_id',\n",
       "   157): '',\n",
       "  ('9.6\\xa0How to interpret and report PCN cytology',\n",
       "   's3i6',\n",
       "   'no_sub_id',\n",
       "   158): 'International consensus on standardised terminology pancreas cytology is lacking',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   159): 'The European evidencebased guidelines on PCN aim improve diagnosis and management of PCN Eventually European Study Group on Cystic Tumours of Pancreas strives develop global evidencebased guideline PCN joint venture various national and international guideline groups order harmonise care and avoid confusion caused conflicting statements Future studies should deal optimal diagnosis aetiology and neoplastic grade appropriate selection criteria surgery surgical strategy ie partial or total pancreatectomy and followup strategy Especially identification of patients who do not require followup and may be discharged deserves further attention as patient burden and societal costs of lifelong followup crosssectional imaging are substantial',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   160): 'Compared recently updated Fukuoka guidelines this evidencebased guideline shows similar relative and absolute indications surgery based on radiological findings This guideline is however more conservative management of sidebranch IPMN Furthermore newonset diabetes mellitus is relative indication surgery whereas this is not mentioned Fukuoka guidelines',\n",
       "  ('Discussion',\n",
       "   's4',\n",
       "   'no_sub_id',\n",
       "   161): 'Also recent international survey revealed that consensus is lacking international experts management of MTMDIPMN These dilemmas clearly demonstrate that future prospective multicentre studies are required provide necessary evidence guide management see European study group supports international multicentre PACYFIC study accessible cyst registry which aims obtain longterm followup of over  people asymptomatic pancreatic cyst'},\n",
       " {('INTRODUCTION',\n",
       "   'vco12827-sec-0001',\n",
       "   'no_sub_id',\n",
       "   0): 'In  Smedley et al published Prognostic Markers Canine Melanocytic Neoplasms Comparative Review of Literature and Goals Future Investigation critical review of canine melanocytic neoplasm studies published prior February  as initiative of American College of Veterinary Pathologists ACVP Oncology Committee authors based that review on criteria described consensus Webster et al Recommended Guidelines Conduct and Evaluation of Prognostic Studies Veterinary Oncology main goal of review was report which published parameters had most statistically supported validity prognostic use canine melanocytic neoplasia Similarly as update of review this current manuscript provides critical consensus review of canine melanocytic neoplasm diagnostic and prognostic pathology studies that have been published to  based on same guidelines published Webster et al This consensus is based on work of canine melanoma subgroup as part of Oncology Pathology Working Group OPWG joint initiative of Veterinary Cancer Society and ACVP that was formed ACVP Oncology Committee We provide recommendations diagnosis and histopathologic prognostication of canine cutaneous and orallip melanocytic neoplasms diagnostic setting suggest guidelines reporting provide recommendations clinical interpretation and discuss future directions This document represents opinions of working group and authors and does not constitute formal endorsement ACVP or Veterinary Cancer Society',\n",
       "  ('Development of the consensus report',\n",
       "   'vco12827-sec-0003',\n",
       "   'no_sub_id',\n",
       "   1): 'The canine melanoma subgroup of OPWG which includes all coauthors of this article reviewed recent canine melanocytic literature canine melanoma subgroup includes  board‐certified veterinary oncologists PJB CS CT CAC NC PW and  board‐certified veterinary pathologists RCS LB CB JG PR JD AP chairs PJB and RCS initially selected articles review which included review paper Smedley et al and subsequent diagnostic or prognostic articles February December                 Articles were searched using phrase canine melanoma abstracts were then evaluated determine whether or not paper addressed any diagnostic or prognostic markers If it was uncertain chairs PJB and RCS scanned articles determine if any previous or new diagnostic or prognostic parameters were evaluated as minor portion of study Articles related treatment or prognostic clinical criteria of canine cutaneous and orallip melanocytic tumours were not included this review but were saved subsequent consensus report focus of this consensus statement is on histological features of and molecular markers cutaneous and orallip melanocytic neoplasms Three subgroup members were assigned each article critical review avoiding assignment of articles they authored Each member used Excel table template that was same as one used Smedley et al and was based on standards outlined Webster et al This table provided summary of objectivehypothesis study design materials and methods statistical soundness conclusions articles authors and conclusions of reviewing subgroup member addition other criteria co‐chair RCS then combined reviews each author one review per article same Excel table format expedite review of additional  articles including one published and  published July March co‐chair RCS completed review of these articles and distributed reviews subgroup comments and discussion Next co‐chair RCS summarized and condensed reviews and drafted initial consensus report Additional articles were referenced report as needed but were not critically reviewed reviews and consensus report were distributed all subgroup members edits discussion and comments and then submitted OPWG Executive Committee review consensus was made available OPWG membership large which approved report popular vote and then it was made available online on OPWG webpage August  While preparing current manuscript  additional articles             were identified that were published November August  Again expedite review of these  additional articles co‐chair RCS completed reviews and distributed them subgroup comments and discussion All authors agreed on inclusion of these references here but they were not present OPWG consensus statement and therefore were not voted on OPWG membership',\n",
       "  ('Review of the literature',\n",
       "   'vco12827-sec-0004',\n",
       "   'no_sub_id',\n",
       "   2): 'Since  there have been few published studies that have identified novel diagnostic or prognostic markers canine melanocytic neoplasms that have enough statistical soundness and that can easily be used diagnostic setting conclusions most of these studies still require further validation via additional corollary studies Unfortunately there have only been rare published prospective prognostic studies canine melanocytic neoplasms and those particular studies have not yielded established prognostic markers this point While not major goal some of new studies do provide further support use of parameters recommended review studies that provide most potentially useful data support previous recommendations and have future utility are discussed below',\n",
       "  ('Diagnostic markers for melanocytic neoplasms',\n",
       "   'vco12827-sec-0006',\n",
       "   'no_sub_id',\n",
       "   3): 'The first step prognostication and decide correct therapeutic approach is obtain accurate diagnosis This should also be first step when performing and reviewing prognostic studies If melanocytic origin has not been definitively confirmed every neoplasm study population results of that study cannot be interpreted accurately Diagnosis is based on specific histologic features of cutaneous and mucosal melanocytic tumours However when histologic features alone are not confirmatory of melanocytic origin demonstration of immunohistochemical IHC labelling specific melanocytic markers is needed Table ',\n",
       "  ('Diagnostic markers for melanocytic neoplasms',\n",
       "   'vco12827-sec-0006',\n",
       "   'no_sub_id',\n",
       "   4): 'Melanocytic neoplasms veterinary species have been shown label several different IHC markers but each marker has different sensitivities and specificities species including humans thereby limiting use of single antibody diagnosing amelanotic melanocytic neoplasms most sensitive and specific markers detect melanocytic neoplasms veterinary species are still Melan‐A and PNL which are antigens that are found on melanocytes dogs antibodies tyrosinase‐related proteins  and  TRP‐ and TRP‐ have also been shown be highly sensitive and specific diagnostic melanoma cocktail that contains antibodies Melan‐A PNL TRP‐ and TRP‐ has been shown have  specificity and  sensitivity detecting canine oral melanocytic neoplasms compared soft tissue sarcomas one study and is commercially available This cocktail has been shown have sensitivity that is greater individual sensitivities of each individual antibody and result greater labelling intensity Thus this cocktail makes it easier identify labelling small samples and tumours that only exhibit small amount of labelling individual markers and it is considered be current gold standard diagnosing canine amelanotic malignant melanomas MM most common cells label melanocytic markers are intraepithelial neoplastic cells which are most differentiated of neoplastic cells as growth of neoplasm begins epithelium Thus it is extremely important clinicians submit non‐ulcerated portions of mass as well as wide lateral margins that include intact lateral flanking epithelium order increase likelihood of identifying intraepithelial nests of neoplastic melanocytes and improve likelihood of complete excision Small nests can sometimes be difficult discern routine histology but they are easily identified IHC labelling',\n",
       "  ('Diagnostic markers for melanocytic neoplasms',\n",
       "   'vco12827-sec-0006',\n",
       "   'no_sub_id',\n",
       "   5): 'IHC S‐ and microphthalmia‐associated transcription factor MITF have also been explored These markers showed  and  sensitivity respectively but only showed  and  specificity respectively differentiating melanocytic tumours soft tissue sarcomas Campagne et al used immunofluorescent labelling MITF identify neoplastic and non‐neoplastic melanocytes that study immunofluorescent method showed  sensitivity and  specificity contrast authors stated that IHC labelling MITF did not identify tumuoral cells all of samples',\n",
       "  ('Diagnostic markers for melanocytic neoplasms',\n",
       "   'vco12827-sec-0006',\n",
       "   'no_sub_id',\n",
       "   6): 'SOX‐ is marker that has been used diagnose melanocytic neoplasms humans but recently there had been no published studies of its use dogs humans it is not specific melanocytes and has been shown be consistently expressed benign Schwann cell tumours of soft tissue and gastrointestinal tract and be variably present malignant peripheral nerve sheath tumours It has also been shown label myoepithelial cell origin tumours granular cell tumours histiocytes occasional alveolar rhabdomyosarcomas and some epithelial tumours including rare squamous cell carcinomas of head and neck and pulmonary small cell carcinomas addition SOX‐ can be expressed entrapped non‐neoplastic Schwann cells or melanocytes various neoplasms and this has be considered when diagnosing SOX‐‐positive tumours humans soft tissue sarcomas are uncommon and often are not differential melanoma contrast soft tissue sarcomas including peripheral nerve sheath tumours dogs are very common and are primary differential spindloid melanoma',\n",
       "  ('Diagnostic markers for melanocytic neoplasms',\n",
       "   'vco12827-sec-0006',\n",
       "   'no_sub_id',\n",
       "   7): 'The diagnostic melanoma cocktail has lowest sensitivity spindloid variants of amelanotic MM Thus recent study examined additional IHC markers and gene expression patterns these tumours improve ability differentiate oral amelanotic spindloid MMs and oral soft tissue sarcomas IHC labelling SOX‐ was also examined that study Tsoi et al examined  oral MMs and  soft tissue sarcomas SOX‐ immunoexpression and found that all  oral MMs and of  soft tissue sarcomas labelled SOX‐ resulting sensitivity but only  specificity that antibody addition authors examined various gene expression patterns and determined that mRNA levels of TYR CD and CALD can be used differentiate canine oral spindloid amelanotic MMs and soft tissue sarcomas that are negative specific melanocytic markers Melan‐A PNL TRP‐ and TRP‐ specificity and   and  sensitivity respectively Availability of gene expression analysis canine melanomas diagnostic setting would greatly improve pathologists ability more confidently distinguish these two tumour types',\n",
       "  ('Diagnostic markers for melanocytic neoplasms',\n",
       "   'vco12827-sec-0006',\n",
       "   'no_sub_id',\n",
       "   8): 'Cytologic − immunocytochemical ICC examination of potential melanocytic neoplasms should not be forgotten as potential useful preoperative diagnostic tool one study authors found that ICC using anti‐Melan‐A anti‐Vimentin and anti‐cytokeratin improved ability diagnose canine amelanotic oral melanomas cytology diagnosis reached ICC matched histologic diagnosis study also showed that ICC Melan‐A can correctly identify metastatic amelanotic melanoma regional lymph nodes especially when they are low numbers or have round cell morphology It still may be difficult differentiate metastatic neoplastic melanocytes and draining melanocytes however',\n",
       "  ('\\nTumour location of cutaneous, oral and lip melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0008',\n",
       "   'no_sub_id',\n",
       "   9): 'Historically canine oral melanocytic tumours have been regarded as malignant and cutaneous melanocytic tumours have been regarded as benign While general digitalsubungual and lip tumours have been shown have increased recurrence and metastasis compared tumours other cutaneous sites Other studies have shown that this is not always case and that location alone cannot predict prognosis one study  of oral and  of feet  lip melanocytic neoplasms were originally classified as malignant but only  of oral and  of feet  lip neoplasms showed malignant behaviour and subset of cutaneous melanocytic neoplasms showed malignant behaviour that would have been predicted be benign based on location and current microscopic criteria prognostication Recently significant correlation histologic diagnosis of cutaneous melanocytic neoplasms and location was found when diagnostic criteria described Smedley et al were used Similar Spangler and Kass these authors found that cutaneous MMs were more likely be on digit compared melanocytomas They also found that there were fewer MMs melanocytomas on abdomen',\n",
       "  ('\\nTumour location of cutaneous, oral and lip melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0008',\n",
       "   'no_sub_id',\n",
       "   10): 'Overall challenge is identify benign orallip melanocytic neoplasms and malignant cutaneous ones this time histologic criteria and Ki labelling use of commercially available antibodies are evaluated this purpose',\n",
       "  ('\\nHistological criteria\\n',\n",
       "   'vco12827-sec-0009',\n",
       "   'no_sub_id',\n",
       "   11): 'In terms of histologic criteria nuclear atypia mitotic count MC degree of pigmentation level of infiltrationinvasion and vascular invasion have been shown be statistically relevant predicting prognosis of cutaneous and oral melanocytic neoplasms dogs studies prior and Histologically evaluated ulceration  and macroscopically assessed tumour thickness are only predictive of prognosis cutaneous tumours',\n",
       "  ('\\nHistological criteria\\n',\n",
       "   'vco12827-sec-0009',\n",
       "   'no_sub_id',\n",
       "   12): 'While assessment of nuclear atypia can result significant interobserver variation this parameter continues show statistical relevance when correctly applied Only one paper reported lack of association nuclear atypia and survival dogs oral MMs Nuclear atypia should be assessed according strict criteria outlined Spangler and Kass Using those criteria threshold value of  atypical nuclei cutaneous melanocytic neoplasms and threshold of  atypical nuclei canine orallip melanocytic neoplasms have shown statistical significance predicting survival times most accurate way determine percentage of atypical nuclei is count number of atypical nuclei cells',\n",
       "  ('\\nHistological criteria\\n',\n",
       "   'vco12827-sec-0009',\n",
       "   'no_sub_id',\n",
       "   13): 'Despite inter‐ and intraobserver variation of MC it has still shown statistical relevance several studies of melanocytic neoplasms various locations including cutaneous studies published and is more objective nuclear atypia        It should be noted that most veterinary studies incorrectly refer MC as mitotic index Mitotic index is number of mitotic figurestotal number of cells defined area or volume of tumour and this has never been done veterinary pathology MC is number of mitotic figures defined square mm area area  mm was proposed animal tumours because this is area fields of view × objective and × ocular that has field number FN of  engraved eyepiece ocular FN  is most common ocular manufactured commercial sources pathologists this consensus statement we have defined MC as number of mitoses fields × magnification× objective which we will refer as hpf throughout this text because that is how earlier studies performed MC Therefore these terms and definition will be used throughout this report regardless of how it is stated cited reference',\n",
       "  ('\\nHistological criteria\\n',\n",
       "   'vco12827-sec-0009',\n",
       "   'no_sub_id',\n",
       "   14): 'The MC threshold cutaneous melanocytic tumours was established counting mitoses random high power fields However order decrease rate of underestimation of malignant neoplasms MC should be determined area of highest mitotic activity similar how threshold orallip melanocytic neoplasms was determined Therefore first scan neoplasm × magnification× objective locate areas of potentially high mitotic activity Locate field containing one or more mitotic figures if possible and begin counting mitoses that area × magnification× objective Count mitotic figures consecutive hpf Avoid areas of ulceration necrosis and inflammation when counting mitoses heavily pigmented neoplasms bleaching may be needed better assess MC Ideally MCs should now be reported per  mm cutaneous neoplasms MC of  or greater hpf has been associated more aggressive behaviour and shorter survival times Neoplasms less mitoses hpf generally exhibit benign behaviour One study showed that  of dogs neoplasms MC of ≥ random hpf were alive months while  of dogs neoplasms MC random hpf were still alive years orallip melanocytic neoplasms cut‐off of  mitoses per  hpf is statistically determined threshold value MC dogs having tumours ≥ mitoses showing shorter survival times marked difference survival year two groups created this cut‐off value has been demonstrated sensitivity of  and specificity of one orallip study',\n",
       "  ('\\nHistological criteria\\n',\n",
       "   'vco12827-sec-0009',\n",
       "   'no_sub_id',\n",
       "   15): 'For pigmentation it is difficult measure objectively validated cutoff points but high degree of pigmentation does suggest favourable clinical outcome cutaneous and orallip melanocytic neoplasms    Orallip neoplasms ≥ of pigmented cells have been shown have longer survival times However outcome is not predictable orallip or cutaneous neoplasms moderate low or no pigmentation  Pigmentation should be evaluated but should not be used as sole predicting factor',\n",
       "  ('\\nHistological criteria\\n',\n",
       "   'vco12827-sec-0009',\n",
       "   'no_sub_id',\n",
       "   16): 'In addition ulceration is another prognostic marker that can be used cutaneous melanocytic neoplasms Ulceration of cutaneous melanocytic neoplasms has been associated significantly shorter survival times and was shown be independent prognostic factor two studies',\n",
       "  ('\\nMolecular markers\\n',\n",
       "   'vco12827-sec-0010',\n",
       "   'no_sub_id',\n",
       "   17): 'Several molecular markers have been investigated their potential as prognostic markers canine melanocytic neoplasms Table  Currently immunohistochemical evaluation of Ki as Ki index or Ki count is only established prognostic molecular marker and it has been shown be highly predictive of behaviour both oral and cutaneous melanocytic tumours dogs multiple studies including four that were published Whereas MC only accounts cells M phase of cell cycle Ki is nuclear protein that is expressed all phases of cell cycle except resting phase therefore it is measure of growth fraction level of Ki expression is much more objective and has been shown have similar or higher predictive value as traditional histologic criteria both cutaneous and orallip melanocytic neoplasms Some neoplasms histological criteria of malignancy but low level of Ki expression have longer survival times expected histology It is also much easier identify areas most proliferation looking red nuclear labelling it is identify area of high mitotic activity when scanning tumour Thus this marker is more objective MC Nuclei weak strong diffuse labelling and nuclei only nucleolar labelling are counted while avoiding areas of ulceration and inflammation heavily pigmented neoplasms bleaching sections immunohistochemical labelling may be needed better assess Ki labelling If sections are bleached immunohistochemistry Ki labelling does not work cutaneous melanocytic neoplasms Ki index is determined as percentage of positive nuclei cells Thus number of cells evaluated is standardized Assistance of cm optical grid reticle is very helpful grid reticle simply helps pathologist keep track of which cells have been counted already orallip melanocytic neoplasms Ki count is determined as average number of positively labelled neoplastic cell nuclei per area of cm optical grid reticle x magnificationx objective  grid areas counted highest labelling area This grid method standardizes area assessed so that it is same no matter what microscope is used It should be noted that previous references refer this method orallip melanocytic tumours as Ki index However similar incorrect use of term mitotic index it may be more accurate refer this method of evaluating Ki labelling orallip melanocytic tumours as Ki count as it is not reported as percentage of cells threshold value of  was statistically determined using receiver operator characteristic ROC curve Kaplan–Meier survival analysis showed that survival curves dogs Ki count  and dogs Ki count ≥ are significantly different based on one‐year survival period cutaneous melanocytic neoplasms threshold value of  had been previously empirically determined and has been evaluated regard survival Kaplan–Meier survival curves Statistically significant lower survival rates were reported dogs neoplasms Ki index ≥ that study as well as more recent study one study none of behaviourally benign cutaneous melanocytic neoplasms had Ki index greater or equal percentage of correctly classified neoplasms using Ki index  was higher that of MC  and histological criteria one study Thus threshold of  should be used predict prognosis of cutaneous melanocytic neoplasms  Assessment of Ki value is especially helpful melanocytic neoplasms that exhibit both prognostically favourable and poor histological parameters or so called grey zone cases but it is never wrong perform Ki immunolabelling added confidence',\n",
       "  ('\\nNewly examined prognostic parameters for canine cutaneous melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0011',\n",
       "   'no_sub_id',\n",
       "   18): 'Recently tumour thickness has been shown be useful prognostic marker cutaneous melanocytic neoplasms two studies although authors of those studies state that additional studies larger case numbers are needed further support its use as independent prognostic marker Nonetheless study Silvestri et al  provides convincing statistical evidence that greater tumour thickness is associated shorter overall survival and disease‐free time and provides easy method measure tumour thickness established cut‐off values that can be used diagnostic setting ROC curve analysis and Youden Index identified cutoffs of  and  cm which were associated higher hazard unfavourable outcome and develop recurrencemetastasis respectively Kaplan–Meier survival curves and log‐rank tests were used compare overall survival according diagnosis Via univariate analysis dogs greater tumour thickness had approximately  times higher hazard of death and greater times higher hazard develop recurrencemetastasis dogs thinner tumours cutoff of  cm discriminated favourable and unfavourable tumour‐related death clinical outcomes sensitivity =  specificity =  ROC curve analysis AUC =  CI – shorter overall survival time was seen dogs tumours that were  cm thick compared those tumour thickness ≤ cm this study none of dogs tumour thickness ≤ cm died thus ‐year estimated survival probability was  ±  while it was only  ± dogs tumour thickness  cm predict which tumours would be more likely develop recurrencemetastasis thickness cutoff of  cm was determined sensitivity =  specificity =  ROC curve analysis AUC =   CI –  Those that were  cm were associated shorter disease‐free time those that were ≤   Dogs tumours that were  cm thick had ‐year estimated probability of not developing recurrencemetastasis that was  ±  whereas it was  ± dogs tumours that were ≤ cm One must remember that false positives and false negatives can still occur these thresholds individual cases and prognostic significance of tumour thickness was not able be confirmed multivariable analysis this study nor was it compared Ki index addition tumour thickness cutoff of  cm was determined ROC curve analysis distinguish cutaneous MMs melanocytomas as defined histopathology sensitivity of  and specificity of  However authors stated that these values are not optimal due possibility of false‐positive results authors used both ocular micrometre as well as standard ruler measure tumour thickness and found that these two methods had excellent agreement Thus it is recommended routine diagnostics measure tumour thickness simply applying ruler surface of glass slide perpendicularly epidermis and measuring largest thickness of tumour This study also examined usefulness of modified Clark level measurement predicting prognosis however this measurement was not associated clinical outcome or presence of recurrencemetastasis and did not show prognostic significance Studies that compare tumour thickness other established parameters such as Ki index are still needed further evaluate this parameter and determine if this parameter adds value other parameters conjunction other described prognostic parameters pathologists should begin report tumour thickness cutaneous melanocytic neoplasms and use cut‐offs of  and  cm as one means of predicting survival times and risk of recurrencemetastasis respectively This will allow greater data collection regarding this parameter Tumour symmetry and growth pattern expansive vs infiltrative are two additional parameters that have shown prognostic significance one study but still require further evaluation larger case numbers',\n",
       "  ('\\nNewly examined prognostic parameters for canine cutaneous melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0011',\n",
       "   'no_sub_id',\n",
       "   19): 'A few studies have evaluated various molecular markers as potential prognostic markers cutaneous melanocytic neoplasms and some may hold future promise However most have low sample sizes limited or no follow‐up or other limitations that prevent them being used diagnostic setting this time One such marker that requires further investigation is survivin one study nuclear survivin expression was significantly greater malignant cutaneous melanomas compared melanocytomas and increased expression ≥ of neoplastic cells was related presence of metastasis and death of animal due melanoma recent study survivin gene expression formalin fixed‐paraffin embedded FFPE tumour tissue was assessed both cutaneous and oral melanocytic tumours and confirmed correlation of this marker tumour related death and Ki index same study gene expression FFPE tissue of another marker HAFZ showed promising results as new prognostic marker being correlated MC Ki index presence of metastasis and death due melanoma',\n",
       "  ('\\nNewly examined prognostic parameters for canine cutaneous melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0011',\n",
       "   'no_sub_id',\n",
       "   20): 'RACK is another marker that has been investigated as potential diagnostic as well as potential prognostic marker one study RACK distribution differed benign and malignant canine melanocytic neoplasms and RACK homogeneous labelling pattern was highly correlated other criteria such as classic histologic features of malignancy Ki‐ index and MC However sample size was very small and included both cutaneous and mucosal neoplasms and there was lack of follow‐up data this study thus additional testing is needed this marker can be used diagnostic setting Even then evaluation of this marker diagnostic setting may prove be too complicated and it has not been shown add additional value over Ki index and MC addition other neoplasms can also label RACK  so this marker cannot be used as standalone marker diagnosis of melanocytic origin',\n",
       "  ('\\nNewly examined prognostic parameters for canine cutaneous melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0011',\n",
       "   'no_sub_id',\n",
       "   21): 'Several papers have been published recent years on prognostic significance of tumour infiltrating lymphocytes TILs canine melanocytic neoplasms Several markers used identify different TIL subtypes such as regulatory T cells T or B cells have been investigated FoxP IDO and CTLA‐ expression markers of T have been shown hold promise as prognostic markers canine cutaneous and oral melanocytic neoplasms but also require further evaluation larger sample sizes comparisons other established prognostic markers besides MC and separating cutaneous oral melanomas Ideally this should be done prospective study',\n",
       "  ('\\nNewly examined prognostic parameters for canine cutaneous melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0011',\n",
       "   'no_sub_id',\n",
       "   22): 'A high number of CD TILs B cells has been shown be associated tumour‐related death presence of metastasisrecurrence shorter overall and disease‐free survival increased hazard of death and of developing recurrencemetastasis No associations were found related infiltrating CD TILs T cells This study compared degree of CD TILs other histologic parameters including MC tumour thickness and modified Clark level cutaneous tumours nuclear atypia pigmentation ulceration necrosis and cellular pleomorphism There was statistically significant association quantity of CD TILs and MC Tumour size was significantly lower tumours that lacked CD TILs compared those mild moderate or severe infiltrates terms of quantity association was also seen quantity of CD TILs and percent pigmentation or cellular pleomorphism Based on these results high quantity of CD TILs appears be new potential negative prognostic factor both oral and cutaneous melanocytic tumours However authors state that they need be confirmed using larger case numbers and studying cutaneous and oral melanocytic tumours separately',\n",
       "  ('\\nNewly examined prognostic parameters for canine cutaneous melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0011',\n",
       "   'no_sub_id',\n",
       "   23): 'A few studies have evaluated role of canine cutaneous as well as oral melanocytic neoplasms but no significant association KIT labelling and survival time has been demonstrated    Gomes et al demonstrated decreased expression of KIT protein cutaneous MMs compared cutaneous melanocytomas decreased number of cells labelled malignant versus benign tumours may give some insight role of melanocytic tumour progression but lack of correlation of either labelling extension or intensity other morphologic grading factors does not suggest this will be important prognostic marker or diagnostic tool Gramer et al study only included three melanomas and two of three showed KIT expression One of these tumours had missense or non‐synonymous mutation but this was not prognostic study and sample size was too small draw any significant conclusions',\n",
       "  ('\\nNewly examined prognostic parameters for canine cutaneous melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0011',\n",
       "   'no_sub_id',\n",
       "   24): 'Other studies that included canine cutaneous melanocytic neoplasms could not demonstrate prognostic utility markers they evaluated may have found promising statistical significance but were too preliminary make any significant conclusions were not designed as prognostic studies or only used melanoma cell lines       These included expression of SA E‐cadherinβ‐catenin COX‐ and COX‐ P‐glycoprotein  and MCAMCD      ',\n",
       "  ('\\nNewly examined prognostic parameters for canine oral/lip mucosal melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0012',\n",
       "   'no_sub_id',\n",
       "   25): 'There are few new prognostic markers that have been investigated canine oral melanocytic neoplasms and few of them show potential usefulness example Iussich et al provides good statistical support considering platelet‐derived growth factor receptors PDGFR‐α and ‐β as prognostic markers oral MM of dogs purpose of this study was evaluate expression of PDGFR‐α and ‐β stage II and III canine oral MMs and correlate it prognosis neoplasms this study were confirmed as melanocytic origin via IHC labelling PNL‐ and pathologists recorded nuclear atypia MC pigmentation and Ki values each tumour This study suggests that PDGFRs may play role pathogenesis of oral canine MM and co‐expression of both PDGFRs‐α and ‐β should be considered as negative prognostic marker addition despite unclear methodology determining Ki value that is not consistent published method Bergin et al  statistical analysis showed that co‐expression of PDGFRs and Ki values were both associated worse prognosis further supporting prognostic importance of Ki assessment PDGFRs were detected not only tumour tissue but also stroma suggesting potential role matrix remodelling and tumour invasion authors stated that further prospective studies on greater number of cases are warranted confirm these findings they are used diagnostic setting',\n",
       "  ('\\nNewly examined prognostic parameters for canine oral/lip mucosal melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0012',\n",
       "   'no_sub_id',\n",
       "   26): 'Higher protein expressions of Kynurenine ‐monooxygenase KMO signal transducer and activator of transcription  STAT and STATphosphorylated pSTAT have recently been shown be associated reduced survival times canine melanoma patients one study Liu et al authors used IHC evaluate expression of these proteins cases of canine melanoma that included mostly oral tumours  oral  lip  skin  digit and  other sites KMO expression was more common oral tumours tumours other sites authors also found correlation high MC ≥ mitoses per hpf and oral location metastatic cases those that were  cm and higher stage KMO STAT and pSTAT expressions were all significantly higher tumours MC ≥ mitoses per  hpf combination of MC and KMO had sensitivity of specificity of  and diagnostic accuracy of combination of MC and STAT had sensitivity of specificity of  and diagnostic accuracy of ',\n",
       "  ('\\nNewly examined prognostic parameters for canine oral/lip mucosal melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0012',\n",
       "   'no_sub_id',\n",
       "   27): 'Another group demonstrated that somatic focal amplification of chromosome  CFA  but not CFA was significantly associated amelanotic phenotype high MC and shorter survival times set of  canine oral MM',\n",
       "  ('\\nNewly examined prognostic parameters for canine oral/lip mucosal melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0012',\n",
       "   'no_sub_id',\n",
       "   28): 'Thus KMO STAT and pSTAT these parameters may prove be useful prognostic parameters future but they first should be compared other established prognostic parameters such as Ki and nuclear atypia see if they add value',\n",
       "  ('\\nNewly examined prognostic parameters for canine oral/lip mucosal melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0012',\n",
       "   'no_sub_id',\n",
       "   29): 'The presence of TILs and levels of expression of their markers tumour tissue has been suggested have prognostic significance oral melanomas as well expression of markers RACK FoxP and IDO and quantity of CD TILs have been examined both cutaneous and oral melanocytic neoplasms and discussed under cutaneous melanocytic neoplasms Furthermore presence and distribution of TILs including frequency of CD T cells CD T cells and T cells histopathology and flow cytometry have been investigated retrospective study of  canine oral MMs confirming their potential utility as prognostic markers Higher survival rates were seen dogs that had higher TIL scores specific TIL patterns termed brisk and nonbrisk compared those no TILs and increased frequency of CD T lymphocytes infiltrating tumour Evaluation of TILs is emerging as potential prognostication method canine melanocytic tumours and further evaluation is warranted',\n",
       "  ('\\nNewly examined prognostic parameters for canine oral/lip mucosal melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0012',\n",
       "   'no_sub_id',\n",
       "   30): 'Also discussed under cutaneous melanocytic neoplasms was role of  Murakami et al evaluated KIT labelling canine oral MMs and found no association overall survival or WHO stage addition no significant mutations were identified exon  of  While this study did have some limitations such as relatively low sample size lack of complete detail regarding diagnosis and follow‐up times and inclusion of only MMs this study concluded that KIT expression does not appear be prognostic factor canine melanoma Brocca et al similarly did not find correlation KIT protein expression and mutation status as they did not find any mutations canine oral melanocytic neoplasms Another recent study Smedley et al completely sequenced gene canine oral melanocytic neoplasms authors identified nine nonsynonymous mutations that resulted amino acid changes predicted affect protein function These mutations were more common MMs in those of low malignant potential but authors did not find any correlation mutation status KIT labelling or histologic features Both of studies concluded that there are no current documented indications regards mutation status or KIT labelling suggest tyrosine kinase inhibitors TKIs would be beneficial these tumours However recent single case report described dog gingival MM that had novel deletion mutation cdel KIT which was considered be oncogenic driver mutation',\n",
       "  ('\\nNewly examined prognostic parameters for canine oral/lip mucosal melanocytic neoplasms\\n',\n",
       "   'vco12827-sec-0012',\n",
       "   'no_sub_id',\n",
       "   31): 'Other oral melanocytic neoplasm studies that were reviewed could not demonstrate prognostic utility markers that they evaluated may have found promising statistical significance but were too preliminary make any significant conclusions were not designed as prognostic studies or only used melanoma cell lines             These markers included metabolite profile that included citric acid lactic acid oleic acid linoleic acid palmitoleic acid octadecenoic acid and glycerol E‐cadherinβ‐catenin expression COX‐ and COX‐ expression P‐glycoprotein  expression expression of MCAMCD activation of MAPK and PIKAKT pathways expression pattern of Cx and Cx nBAP protein expression E‐cadherin expression Cyclin D index expression of Galectin‐ expression of B‐cell lymphoma BCL  and caspase CASP  and expression of MAGE‐A            ',\n",
       "  ('Recommendations for prognostication',\n",
       "   'vco12827-sec-0013',\n",
       "   'no_sub_id',\n",
       "   32): 'Tables and can be used as guides prognostication each of evaluated parameters favourable prognosis relates expected survival times longer year and poor prognosis relates expected death due melanocytic neoplasia less ‐year post‐diagnosis all melanocytic neoplasms These predictions are based solely on publications that met our strict criteria inclusion each single parameter These predictions do not take account stage of disease or treatment strategies',\n",
       "  ('Recommendations for prognostication',\n",
       "   'vco12827-sec-0013',\n",
       "   'no_sub_id',\n",
       "   33): 'Ideally using criteria Table cutaneous melanocytic neoplasm should be categorized as cutaneous melanocytoma benign melanocytic tumour or cutaneous MM Typically cutaneous melanocytoma is non‐ulcerated often raised generally small  cm diameter and ≤ cm thickness limited dermis heavily pigmented has very bland appearing nuclei and has low MC and very low Ki index some cases cutaneous MM may have several of same features as melanocytoma but may have only one or two parameters that suggest malignant behaviour such as high nuclear atypia MC threshold value tumour thickness  cm extension beyond dermis or Ki index threshold value Clear‐cut cutaneous MMs are often ulcerated poorly pigmented exhibit marked nuclear atypia have high MC and high Ki index are  cm thick extend beyond dermis and may exhibit vascular invasion ',\n",
       "  ('Recommendations for prognostication',\n",
       "   'vco12827-sec-0013',\n",
       "   'no_sub_id',\n",
       "   34): 'Ideally using criteria Table mucosal lip or oral neoplasm should be able be categorized as oral MM or histologically well‐differentiated melanocytic neoplasm HWDM also known as melanocytic neoplasm of low malignant potential term melanocytoma should be avoided oral and lip mucosal melanocytic neoplasms as long term  years behaviour of these neoplasms if not excised is still uncertain Thus they should be treated as neoplasms of low malignant potential HWDMs are usually raised non‐ulcerated  cm diameter heavily pigmented lack cellular atypia do not invade bone and have rare mitoses very low Ki index and abundant collagenous stroma They also often lack junctional activity and lateral surface epithelial spread which improves chance of complete excision and likely plays role longer survival time of these tumours mean survival time of  months has been reported HWDMs one study These features are strict contrast oral MMs which often show junctional activity lateral epithelial spread poor pigmentation bone invasion and marked nuclear atypia and often have very high MC and Ki index',\n",
       "  ('Recommendations for prognostication',\n",
       "   'vco12827-sec-0013',\n",
       "   'no_sub_id',\n",
       "   35): 'When there are mixed results results each parameter should be reported but Ki index should be used final interpretation most cases cases that are still ambiguous due all parameters being or very near threshold values diagnosis of melanocytic neoplasm should be made and each parameter should be discussed',\n",
       "  ('Future directions',\n",
       "   'vco12827-sec-0015',\n",
       "   'no_sub_id',\n",
       "   36): 'None of published prognostic studies meet all of standards defined Webster et al white paper but recommendations this consensus are based on results of studies that adhere most of those standards first step any prognostic study is ensure accurate diagnosis of melanocytic origin each case study population This involves use of specific histologic criteria and IHC labelling highly sensitive and specific markers if those specific histologic criteria are lacking  Gene expression may also be used differentiate amelanotic spindloid MMs and soft tissue sarcomas near future Once melanocytic origin is established neoplasms should be classified based on location as well as established histomorphologic and molecular prognostic parameters',\n",
       "  ('Future directions',\n",
       "   'vco12827-sec-0015',\n",
       "   'no_sub_id',\n",
       "   37): 'Another major requirement sound prognostic study is follow‐up data that includes disease free survival times progression free survival times overall survival cause of death and post‐mortem results Collection of follow‐up data is one of most challenging tasks veterinary medical research studies and post‐mortem examination of significant number of cases is often not possible However researchers should always have initial study design ideally prospective that will allow as much follow‐up data as possible',\n",
       "  ('Future directions',\n",
       "   'vco12827-sec-0015',\n",
       "   'no_sub_id',\n",
       "   38): 'There are very few published studies that are true prognostic studies of canine melanocytic neoplasms and only one of these evaluated prognostic studies is prospective While prospective studies are very challenging studies conduct veterinary medicine ideally effort should be made conduct such studies order verify recommendations made referenced retrospective studies Additionally new potential prognostic markers should be evaluated conjunction and compared current statistically proven prognostic parameters such as nuclear atypia MC and Ki index',\n",
       "  ('Future directions',\n",
       "   'vco12827-sec-0015',\n",
       "   'no_sub_id',\n",
       "   39): 'Much of recent literature has focused on genetic features of canine melanocytic neoplasms and this field holds promise better diagnosis prognostication and prediction of metastasis of these tumours as well as identification of potential targets therapy future genetic analysis may prove be gold standard diagnosis and prognostication but this point most accurate diagnostic methods are immunohistochemical markers Melan‐A PNL TRP‐ and TRP‐ and most accurate predictors of prognosis include histologic features described and Ki index',\n",
       "  ('Future directions',\n",
       "   'vco12827-sec-0015',\n",
       "   'no_sub_id',\n",
       "   40): 'Clinical parameters prognostication other location cutaneous versus orallip are not addressed here but are slated future evaluation and consensus It is hoped that combination of histologic molecular and clinical parameters will further improve our ability prognosticate these neoplasms order better determine appropriate therapy each case',\n",
       "  ('CONFLICT OF INTEREST',\n",
       "   'vco12827-sec-0017',\n",
       "   'no_sub_id',\n",
       "   41): 'Philip J Bergman is paid consultant and speaker Boerhinger Ingelheim Animal Health and also receives minority royalty stream payment Oncept melanoma vaccine'},\n",
       " {('Introduction',\n",
       "   'caac21552-sec-0001',\n",
       "   'no_sub_id',\n",
       "   0): 'Cancer as self‐sustaining and adaptive process that interacts dynamically its microenvironment continues thwart patients researchers and clinicians despite significant progress understanding its biological underpinnings Given this complexity dilemmas arise every stage of cancer management including reliable early detection accurate distinction of preneoplastic and neoplastic lesions determination of infiltrative tumor margins surgical treatment tracking of tumor evolution and potential acquired resistance treatments over time and prediction of tumor aggressiveness metastasis pattern and recurrence Technological advances medical imaging and minimally invasive biomarkers hold promise addressing such challenges spectrum of cancer detection treatment and monitoring However interpretation of large volume of data that is generated these advancements presents barrage of new potential challenges',\n",
       "  ('Introduction',\n",
       "   'caac21552-sec-0001',\n",
       "   'no_sub_id',\n",
       "   1): 'As we learn more disease itself we are learning more power of tools that are already available us which may be used unprecedented ways When neoplastic lesion is initially detected it needs be distinguished nonneoplastic mimickers and classified based on its predicted clinical course and biological aggressiveness optimize type and intensity of treatment widespread availability of computed tomography CT and magnetic resonance imaging MRI have fueled incidental detection of lesions body unclear clinical significance which then initiates cascade of observation further testing or empiric intervention treatment which includes cytoreduction surgery elicitation of direct and indirect mechanisms of tumor kill radiation and pharmacotherapies cancers may adapt stressors imposed evolve and recur radiographic appearance of lesion that increases size treatment distinction has be made neoplasm or tissue response injury On recurrence neoplastic lesions have been shown harbor new molecular aberrations distinct primary tumor which may confer resistance medical or radiation therapies This is compounded innate intratumoral heterogeneity of cancers time of initial diagnosis which is increasingly demonstrated research but difficult capture routine clinical pathological sampling and profiling demand noninvasive imaging as most common method track response treatment and suggest critical information tumors themselves has never been greater',\n",
       "  ('Introduction',\n",
       "   'caac21552-sec-0001',\n",
       "   'no_sub_id',\n",
       "   2): 'Traditional radiographic imaging evaluation of tumor relies largely qualitative features such as tumor density pattern of enhancement intratumoral cellular and acellular composition including presence of blood necrosis and mineralization regularity of tumor margins anatomic relationship surrounding tissues and impact on these structures Size‐based and shape‐based measures of tumor can be quantified ‐ ‐ ‐dimensional analyses These qualitative phenotypic descriptions are collectively termed semantic features comparison rapidly evolving field called radiomics is enabling digital decoding of radiographic images quantitative features including descriptors of shape size and textural patterns Recent advances artificial intelligence AI methodologies have made great strides automatically quantifying radiographic patterns medical imaging data Deep learning subset of AI is especially promising method that automatically learns feature representations sample images and has been shown match and even surpass human performance task‐specific applications Despite requiring large data sets training deep learning has demonstrated relative robustness noise ground truth labels others automated capabilities of AI offer potential enhance qualitative expertise of clinicians including precise volumetric delineation of tumor size over time parallel tracking of multiple lesions translation of intratumoral phenotypic nuances genotype implications and outcome prediction cross‐referencing individual tumors databases of potentially limitless comparable cases Furthermore deep learning approaches promise greater generalizability diseases and imaging modalities robustness noise and reduction of errorseventually leading earlier interventions and significant improvements diagnosis and clinical care Although these studies remain largely preclinical research domain continued development of such automatic radiographic radiomic biomarkers may highlight clinically actionable changes tumors and drive paradigm shift discrimination of cancer over time',\n",
       "  ('Introduction',\n",
       "   'caac21552-sec-0001',\n",
       "   'no_sub_id',\n",
       "   3): 'At dawn of this exciting technological transformation we review current evidence and future directions AI approaches as applied medical imaging common cancer types lung brain breast and prostate cancer We describe clinical problems and limitations cancer detection and treatment how current methods are attempting address these and how AI can affect future directions',\n",
       "  ('AI Applications in Cancer Imaging',\n",
       "   'caac21552-sec-0002',\n",
       "   'no_sub_id',\n",
       "   4): 'The desire improve efficacy and efficiency of clinical care continues drive multiple innovations practice including AI ever increasing demand health care services and large volumes of data generated daily parallel streams optimization and streamlining of clinical workflows have become increasingly critical AI excels recognizing complex patterns images and thus offers opportunity transform image interpretation purely qualitative and subjective task one that is quantifiable and effortlessly reproducible addition AI may quantify information images that is not detectable humans and thereby complement clinical decision making AI also can enable aggregation of multiple data streams powerful integrated diagnostic systems spanning radiographic images genomics pathology electronic health records and social networks',\n",
       "  ('AI Applications in Cancer Imaging',\n",
       "   'caac21552-sec-0002',\n",
       "   'no_sub_id',\n",
       "   5): 'Within cancer imaging AI finds great utility performing  main clinical tasks detection characterization and monitoring of tumors Fig  Detection refers localization of objects of interest radiographs collectively known as computer‐aided detection CADe AI‐based detection tools can be used reduce observational oversights and serve as initial screen errors of omission Formulated pattern‐recognition context regions suspicious imaging characteristics are highlighted and presented reader CADe has been used as auxiliary aide identify missed cancers low‐dose CT screening detect brain metastases MRIs improve radiology interpretation time while maintaining high detection sensitivity locate microcalcification clusters screening mammography as indicator of early breast carcinoma and more generally has improved radiologist sensitivity detecting abnormalities',\n",
       "  ('AI Applications in Cancer Imaging',\n",
       "   'caac21552-sec-0002',\n",
       "   'no_sub_id',\n",
       "   6): 'Characterization broadly captures segmentation diagnosis and staging of tumors It also can extend include prognostication based on given ailment as well as outcome prediction based on specific treatment modalities Segmentation defines extent of abnormality This can range basic ‐dimensional D measurements of maximal in‐plane tumor diameter more involved volumetric segmentations which entire tumor and possible surrounding tissues are assessed Such information can be used subsequent diagnostic tasks as well as dosage administration calculations radiation planning current clinical practice tumors are typically manually defined associated limitations including interrater bias inconsistent reproducibility even experts and consumption of time and labor Although manually traced segmentation frequently is used as basis judging accuracy of automated segmentation algorithms it has potential neglect subclinical disease and restrict region of analysis human bias AI has potential increase efficiency reproducibility and quality of tumor measurements dramatically automated segmentation Finally rapid expansion of computing speed and increased efficiency of AI algorithms it is likely that future analysis of cancer lesions will not require separate segmentation step and whole‐body imaging data could be evaluated directly AI algorithm whole‐body approach also can allow analysis of organ structures that may be pathological but are not apparent human vision',\n",
       "  ('AI Applications in Cancer Imaging',\n",
       "   'caac21552-sec-0002',\n",
       "   'no_sub_id',\n",
       "   7): 'On radiologic data subsequent diagnosis of suspicious lesions as either benign or malignant ultimately results visual interpretation radiologists Clinically human experience and expertise are applied solving such problems using subjective qualitative features comparison computer‐aided diagnosis CADx systems use systematic processing of quantitative tumor features allowing more reproducible descriptors CADx systems have been used diagnose lung nodules thin‐section CT as well as prostate lesions multiparametric MRI which inconsistencies interpretation human readers have been observed Characterization also includes staging which tumors are classified predefined groups based on differences their cancers appearance and spread that are informative expected clinical course and treatment strategies most widely used cancer staging system is TNM classification other schemes applied specific organs such as central nervous system CNS Recent studies have extended systems perform staging assessing tumor extent and multifocality breast MRI whereas others have developed automated lesion volume measurement tools contrast‐enhanced magnetic resonance mammography MRM',\n",
       "  ('AI Applications in Cancer Imaging',\n",
       "   'caac21552-sec-0002',\n",
       "   'no_sub_id',\n",
       "   8): 'An additional level of characterization interrogates biological characterization of tumors emerging field of imaging genomics correlates radiographic imaging features biological data including somatic mutations gene expression chromosome copy number or other molecular signatures maturity of genomics analyses data standpoint provides synergistic opportunities AI‐based imaging efforts',\n",
       "  ('AI Applications in Cancer Imaging',\n",
       "   'caac21552-sec-0002',\n",
       "   'no_sub_id',\n",
       "   9): 'Finally AI can play increasing roles monitoring changes tumor over time either natural history or response treatment Traditional temporal monitoring of tumors often has been limited predefined metrics including tumor longest diameter measured established Response Evaluation Criteria Solid Tumors RECIST and World Health Organization WHO criteria estimating tumor burden and determining treatment response addition being criticized as oversimplifying complex tumor geometry captured sophisticated imaging instruments generalizability and efficacy of such criteria have been questioned as case of osseous lesions which chemotherapywhich has proven improve survivaldoes not result radiographic responses as measured RECIST AI‐based monitoring however is able capture large number of discriminative features images over time that go beyond those measured human readers Although seemingly disparate constituents of computer‐aided monitoring are active areas of research computer‐aided registration of temporal images segmentation and diagnosis field is still its infancy applications yet surface',\n",
       "  ('AI Applications in Cancer Imaging',\n",
       "   'caac21552-sec-0002',\n",
       "   'no_sub_id',\n",
       "   10): 'In addition imaging other minimally invasive biomarkers also are being developed cancer diagnosis and longitudinal tracking of disease Most notably liquid biopsies or analysis of circulating tumor DNA ctDNA released tumor cells provide window current and dynamic state of cancer and allows tracking of disease progression or regression and monitoring emergence of targetable or resistance‐associated cancer mutations near real‐time  Thus it is conceivable that liquid biopsies combined radiomics profiling may significantly improve cancer treatment noninvasive characterization of cancer biology more accurate assessment of prognosis and real‐time disease monitoring purposes of precision medicine',\n",
       "  ('AI Applications in Cancer Imaging',\n",
       "   'caac21552-sec-0002',\n",
       "   'no_sub_id',\n",
       "   11): 'Within clinic aforementioned AI interventions are expected augment their respective current standard‐of‐care counterparts Fig addition supporting clinicians assistive information multiple efforts also have demonstrated utility of AI clinical decision‐making phases of workflow AI‐based integrated diagnostics combining molecular and pathological information image‐based findings will add rich layers of intelligence findings eventually leading more informed decision making',\n",
       "  ('Clinical Applications of AI in Lung Cancer Screening',\n",
       "   'caac21552-sec-0004',\n",
       "   'no_sub_id',\n",
       "   12): 'Until recently method detect early‐stage lung cancer has been elusive even high‐risk populations National Lung Screening Trial NLST demonstrated that screening low‐dose CT LDCT was associated significant  reduction overall mortality high‐risk current and former smokers Lung cancers identified early stage whether LDCT screening or incidentally are more amenable surgical cure and improved survival outcomes compared lung cancers that are detected presentation clinical symptoms which are more frequently later stage of disease Although emergence of immune checkpoint inhibitors and targeted therapies have demonstrated durable long‐term survival subsets of patients not all patients benefit such treatment modalities thus early detection has benefit of improving patient survival and may limit need extensive treatment On basis of these NSLT findings annual LDCT is now recommended high‐risk individuals and is second only primary prevention smoking cessation mitigating lung cancer mortality especially those who have quit smoking but remain risk Although NLST demonstrated clear benefit reducing all‐cause mortality many limitations are associated early detection of lung cancer that could be enhanced advanced computational analyses sections we describe current problems and limitations lung cancer screening how conventional methods are attempting overcome these limitations and how AI can improve these areas',\n",
       "  ('Clinical Applications of AI in Lung Cancer Screening',\n",
       "   'caac21552-sec-0004',\n",
       "   'no_sub_id',\n",
       "   13): 'Lung cancer screening frequently identifies large numbers of indeterminate pulmonary nodules of which only fraction are diagnosed as cancer Fig NLST  of pulmonary nodules identified LDCT screens were not cancerous Currently there are no established approaches classify whether these nodules are cancerous or benign Another potential harm of lung cancer screening is overdiagnosis of slow‐growing indolent cancers which may pose no threat if left untreated As such it is imperative that overdiagnosis needs be recognized identified and significantly reduced Next if nodule is detected clinical guidelines provide evaluation and follow‐up of nodules but do not offer decision tools diagnostic discrimination and predict risk and probability of future cancer development Although conventional biostatistics and machine‐learning approaches have been used address many of limitations lung cancer screening AI has potential supplant such approaches identify biomarkers that reduce imaging false‐positive results and more accurately differentiate benign and cancerous nodules This can lead more quantitative prediction of lung cancer risk and incidence leading robust better defined clinical decision guidelines',\n",
       "  ('Clinical Applications of AI in Lung Cancer Screening',\n",
       "   'caac21552-sec-0004',\n",
       "   'no_sub_id',\n",
       "   14): 'The majority of indeterminate pulmonary nodules are incidentally detected ie they are not encountered screening but routine cross‐sectional imaging other diagnostic indications such as CT angiography and pose dilemma patients and their providers Annually more million Americans are diagnosed incidentally detected nodule whereas most of these nodules are benign granulomas up may be malignant Fleischner Society and American College of Radiology Lung CT Screening Reporting and Data System Lung‐RADS provide recommendations follow‐up and management of these incidentally detected nodules which usually require follow‐up imaging and  months confirm growth intervening more invasive diagnostics eg biopsy These systems are semantic that they describe features that are commonly used radiology lexicon describe regions of interest human experts Because they are scored manually there is high potential large inter‐reader variability recent study model incorporating  quantitatively scored semantic features short‐axis diameter contour concavity and texture conferred accuracy of distinguish malignant benign nodules lung cancer screening setting separate study was conducted identify semantic features small pulmonary nodules less mm predict lung cancer incidence lung cancer screening setting and revealed final model yielded area curve of receiver operating characteristic of  based on total emphysema score attachment vessel nodule location border definition and concavity Although there was imbalance malignant and benign nodules aforementioned analyses these studies provide compelling evidence utility of semantic features lung cancer screening As nodules detected lung cancer screening setting standard of care incidental pulmonary nodules lacks accurate decision tools predicting malignancy versus benign disease and indolent versus aggressive behavior Thus appropriate management of incidental pulmonary nodules is dictated probability of cancer and potential aggressiveness of its behavior Prediction of nature of nodule may justify diametrically opposing strategies such as biopsy versus observation Erroneous prediction carries significant consequences including risk of premature mortality delayed intervention on one hand and morbidity and mortality resulting invasive testing on other Lung cancer screening also detects cancers that exhibit wide spectrum of behaviors some are clinically indolent and others are aggressive mandating prompt treatment One study estimated that greater of all lung cancers detected LDCT NLST seem be indolent',\n",
       "  ('Clinical Applications of AI in Lung Cancer Screening',\n",
       "   'caac21552-sec-0004',\n",
       "   'no_sub_id',\n",
       "   15): 'In Arnold Foundation supported million prize automated lung cancer detection and diagnosis challenge this challenge thousands of annotated CT images Cancer Imaging Archive National Cancer Institute NCI were provided community train and validate their models All of top teams used convolutional neural networks CNNs automatically both detect and diagnose lesions and winners had make their network model publicly available winning team reported high performance log loss = which perfect model would have log loss of  Although this is encouraging it is notable that winning networks require more detailed evaluation of their performance clinical settings Furthermore there was significant bias cancer prevalence this challenge which was higher prevalence screening population indeterminate nodules Although this challenge identified promising methods it is likely that significant fine tuning will be required they can have any clinical use',\n",
       "  ('Clinical Applications of AI in Lung Cancer Screening',\n",
       "   'caac21552-sec-0004',\n",
       "   'no_sub_id',\n",
       "   16): 'Although incidence of lung cancer is declining United States and most Western nations lung cancer will remain major public health burden decades come Even smoking cessation former smokers remain increased risk especially compared lifetime never smokers of developing lung cancer Therefore improvements lung cancer screening will remain relevant and important improve patient outcomes of this disease As lung cancer imaging research has evolved conventional biostatics machine learning deep learning we contend that AI could emerge next develop clinically adoptable approaches precisely identify those risk improve risk prediction of future cancer incidence discriminate malignant nonmalignant nodules and distinguish indolent tumors versus biologically aggressive cancers',\n",
       "  ('Characterizing Lung Cancers Using Imaging',\n",
       "   'caac21552-sec-0005',\n",
       "   'no_sub_id',\n",
       "   17): 'Lung cancers exhibit wide spectrum of behaviors some that are clinically indolent and others that are aggressive mandating prompt treatment Although there are prognostic factors associated better survival such as female sex tumors harboring epidermal growth factor receptor  mutation early‐stage disease no regional lymph node involvement and good performance status as well as factors associated poor survival eg poor pulmonary function presence of cardiovascular disease male sex current smoking status advanced age and late‐stage tumor    these factors have limited clinical utility address heterogeneous dynamic nature of cancer as moving target Specifically tumor lesion is constantly evolving and diversifying modifying its phenotype and genomic composition and metastatic spread even its location This is even truer when subjected selection pressure of therapeutic intervention which cancer evolution rapidly explores and exploits resistance mechanisms potentially even aided mutagenic nature of systemic cytotoxic chemotherapy leaving treating oncologist chasing constantly changing disease ',\n",
       "  ('Characterizing Lung Cancers Using Imaging',\n",
       "   'caac21552-sec-0005',\n",
       "   'no_sub_id',\n",
       "   18): 'Image‐based biomarkers conversely can noninvasively and longitudinally capture radiographic phenotype and characterize underlying pathophysiology of tumor Because of ease of clinical implementation size‐based measures such as longest diameter of tumor eg RECIST and WHO are widely used staging and response assessment However sized‐based features and stage of disease have limitations as these metrics are associated marked variability outcomes and response As such research efforts identify semantic features and automatic radiomic features predict outcomes of patients lung cancer have been successful instance CANARY tool Computer Aided Nodule Assessment and Risk Yield offers semantic‐based risk stratification identify potentially vulnerable subset of lung adenocarcinomas that harbor more aggressive course Preliminary work has indicated that AI can quantify radiographic characteristics tumor phenotype automatically and that this information is significantly prognostic several cancer types including lung cancer    × addition it is associated distant metastasis lung adenocarcinoma  =  ×  tumor histologic subtypes  =  ×  and underlying biological patterns including somatic mutations and gene expression profiles',\n",
       "  ('Assessing Intratumor Heterogeneity Through Medical Imaging',\n",
       "   'caac21552-sec-0006',\n",
       "   'no_sub_id',\n",
       "   19): 'Medical imaging also can play important role quantifying intratumor characteristics of lung cancer Sequencing studies which multiple independent samples same tumor have been analyzed have demonstrated that intratumor heterogeneity ITH is common feature solid tumor cancers tumor consists of billions of independent cancer cells Low levels of DNA damage or changes epigenetic regulation are introduced each cell division causing slight changes cancer cell genome that increase over time When change induces selective advantage particular microenvironment clonal expansion can give rise cancer subclone all cancer cells sharing single recent common ancestor Genomic ITH defined as coexistence of independent cancer subclones same tumor is associated poor prognosis non–small cell lung cancer NSCLC and clear cell renal cancer    However tumor subclones may be spatially separated and can carry significantly different mutation loads ranging highly homogeneous greater heterogeneous mutations differing individual regions same tumor',\n",
       "  ('Assessing Intratumor Heterogeneity Through Medical Imaging',\n",
       "   'caac21552-sec-0006',\n",
       "   'no_sub_id',\n",
       "   20): 'ITH analysis has indicated that although targetable somatic alterations may appear be clonal single tumor biopsy they may be entirely absent additional biopsies different regions of same tumor  This evidence that phenotypic diversification exists tumors has ramifications application of precision medicine techniques based on molecular characterization of tissue single‐region biopsies Because targets identified single‐tumor biopsies may be subclonal therapies them would be effective only subset of cancer cells leaving cancer subclones target unharmed Fig  Different strategies have been proposed quantify ITH clinical setting including multiregion sequencing of primary tumor analysis of circulating tumor DNA and use of medical imaging data  Unfortunately although multiregion sequencing provides improved measures of extent of ITH compared single‐sample analysis it requires high‐quality tumor specimen of sufficient size and remains subject potential sampling bias potential miss important cancer subclones because of incomplete sampling of tumor its entirety',\n",
       "  ('Assessing Intratumor Heterogeneity Through Medical Imaging',\n",
       "   'caac21552-sec-0006',\n",
       "   'no_sub_id',\n",
       "   21): 'Medical imaging can play important role quantifying intratumor characteristics of lung cancer and improve ability capture and quantify ITH Furthermore because evolutionary fitness is contextual and depends on particular microenvironment it is likely that these environments can be identified imaging Similar most tumor‐based biomarkers there are many limitations that they can be subjective sampling bias because of heterogeneous nature of tumors and requirement of tumor specimens biomarker testing and assays often can be timely expensive and require large amounts of tissue or tissue analytes contrast image‐based features guided AI are available real time standard‐of‐care images do not require timely and often expensive laboratory assay testing are not subject sampling bias and artifact and of course are noninvasive And image‐based features represent phenotype of entire tumor dimensions D and not just portion that was subjected biomarker testing ie biopsy',\n",
       "  ('AI for Assessing Response to Targeted Therapies and Immunotherapies',\n",
       "   'caac21552-sec-0007',\n",
       "   'no_sub_id',\n",
       "   22): 'The success of quantitative imaging endpoints based on RECIST criteria paved way development of AI oncology because widespread adoption of these endpoints as early indicators of survival clinical trials generated large data sets of CT images clinical metadata Retrospective analysis of these clinical trial data sets has been invaluable meeting need of AI big data enable training and validating AI algorithms which otherwise might have been prohibited expense and effort necessary generate these data sets scratch part because of success of RECIST quantitative CT analysis is now workhorse of contemporary oncology creating immediate translational potential AI predictive models',\n",
       "  ('AI for Assessing Response to Targeted Therapies and Immunotherapies',\n",
       "   'caac21552-sec-0007',\n",
       "   'no_sub_id',\n",
       "   23): 'The strengths of AI are well suited overcome challenge posed current generation of targeted and immunotherapies which can produce clear clinical benefit that is poorly captured endpoints based on RECIST These endpoints rely on assumption that successful response therapy will be reflected tumor shrinkage and particular measurement of response based on tumor diameter assumes that tumors are spherical and undergo uniform spatial change treatment Targeted therapies and immunotherapies lead novel patterns of response that confound current RECIST‐based endpoints and may contribute high failure rate of clinical trials and cost of drug development Thus ability of AI quantify biological processes associated response other size answers urgent need field',\n",
       "  ('AI for Assessing Response to Targeted Therapies and Immunotherapies',\n",
       "   'caac21552-sec-0007',\n",
       "   'no_sub_id',\n",
       "   24): 'Currently response prediction targeted and immunotherapies is based on biomarkers immunogenic tumor microenvironment eg programmed cell death ligand  PD‐L expression and mutational status eg  These are acquired via biopsy which is invasive difficult perform longitudinally and limited single region of tumor predictive value of PD‐L expression also may be limited example KEYNOTE‐ clinical trial immunotherapy pembrolizumab combination standard chemotherapy produced survival benefit all patients regardless of PD‐L expression even those PD‐L tumor proportion score less which should indicate small chance of benefit',\n",
       "  ('AI for Assessing Response to Targeted Therapies and Immunotherapies',\n",
       "   'caac21552-sec-0007',\n",
       "   'no_sub_id',\n",
       "   25): 'A growing body of evidence suggests that AI could assess response immunotherapy recognition of radiomic biomarkers associated response Imaging phenotype was associated overall survival OS patients NSCLC second‐line treatment anti‐PD nivolumab this study OS was predicted significantly  = radiomics features baseline region dissimilarity hazard ratio HR   confidence interval  CI ‐  =  and entropy HR   CI ‐  =  which indicate more heterogeneous primary lung tumor irregular patterns of intensities on contrast‐enhanced CT Another lung cancer study demonstrated that prognosis of OS was improved adding genomic and radiomic information clinical model leading increase CI of  Noether = CI of   =  ×  and that inclusion of radiomic data resulted significant increase performance  =  These findings indicate that radiomic and genomic biomarkers are complementary creating potential role AI elucidate predictive associations their combined data Although machine learning has been deployed genetically classify lung cancer based on identification of patterns microarray gene expression its use detect radiomic‐genomic correlations predictive of outcome remains understudied',\n",
       "  ('AI for Assessing Response to Targeted Therapies and Immunotherapies',\n",
       "   'caac21552-sec-0007',\n",
       "   'no_sub_id',\n",
       "   26): 'AI analysis of quantitative imaging data also may improve assessment of response targeted therapy decrease fluorodeoxyglucose uptake NSCLC tumors treated bevacizumab monoclonal antibody vascular endothelial growth factor VEGF identified more patients who responded treatment conventional CT criteria  vs that study neither positron emission tomography PET nor CT was associated OS PET =  CT =  Currently predicting response targeted therapy is driven largely biopsy assay status of mutation being targeted AI predictive models could supplement this identifying imaging phenotypes that are associated mutational status This approach has advantage of being able characterize mutational status of all tumors repeatedly and noninvasively not merely site of biopsy which can avoid lack of predictive power associated intratumoral heterogeneity and emergence of distinct acquired resistance mechanisms separate metastases same patient Support this approach comes quantitative imaging study of patients NSCLC who were treated gefitinib Those results indicated that mutation status could be significantly predicted radiomic feature Laws‐Energy area curve AUC =  = ',\n",
       "  ('AI for Assessing Response to Targeted Therapies and Immunotherapies',\n",
       "   'caac21552-sec-0007',\n",
       "   'no_sub_id',\n",
       "   27): 'Biomarkers must be objectively and reproducibly measurable serve as criteria response assessment AI affords high objectivity its ability characterize complex patterns tumor images interobserver variability associated visual assessment human experts Understanding measurement error of radiomic features is important establish reproducibility of AI predictive models based on them Different tumor segmentation algorithms introduce variance known affect calculation of radiomic features and thus perhaps performance of AI techniques which require semiautomatic segmentation Imaging settings including CT scanners slice thickness and reconstruction kernels also affect calculation of radiomic features Variation these settings exists clinical practice and clinical trials and may affect power and reproducibility of biomarkers developed AI training and validation of CNNs may reduce this effect selecting predictive features that are reproducible and discarding those that vary image sets but this needs be proven There is also tension rapid pace of development AI field and need clinical trial endpoints maintain historical consistency and achieve validation large data warehouses criteria are updated eg RECIST Continued progress size and appropriateness of public domain cancer data sets is necessary meet latter requirement',\n",
       "  ('Diagnostic Dilemmas in CNS',\n",
       "   'caac21552-sec-0009',\n",
       "   'no_sub_id',\n",
       "   28): 'Imaging plays important role initial diagnosis of brain tumors and is routine part of both initial and subsequent evaluation complex imaging features of brain tumors as well as frequent genetic heterogeneity tumor types and invasive nature of procedures needed obtain tissue diagnosis give rise diagnostic dilemmas this field Table               ',\n",
       "  ('Diagnostic Dilemmas in CNS',\n",
       "   'caac21552-sec-0009',\n",
       "   'no_sub_id',\n",
       "   29): 'In setting of gliomas most common malignant primary brain tumors adults cross‐sectional imaging techniques such as CT and MRI provide high‐resolution spatial information as well as tissue contrast allowing radiologists characterize different glioma subtypes and grades AI can improve utility of current standard diagnostic imaging techniques refining preoperative classification of gliomas beyond what human experts can provide example AI has been applied research setting preoperative MRI distinguish low‐grade and high‐grade tumors as well as individual WHO grades training machine‐learning classifiers using image texture features obtained spatially coregistered multimodal MRIs Table                Furthermore clinically relevant molecular subtypes of gliomas such as presence of isocitrate dehydrogenase IDH mutation can be identified using machine‐learning methods including deep CNNs trained on conventional MR images ',\n",
       "  ('Diagnostic Dilemmas in CNS',\n",
       "   'caac21552-sec-0009',\n",
       "   'no_sub_id',\n",
       "   30): 'Subtype classification problems are not unique adult gliomas however Conceptually similar work has been done on other brain tumors which it has been demonstrated that classification algorithms trained on radiomics features extracted conventional MRI can generate predictive models pituitary adenoma subtypes and pediatric brain tumors Table               ',\n",
       "  ('Diagnostic Dilemmas in CNS',\n",
       "   'caac21552-sec-0009',\n",
       "   'no_sub_id',\n",
       "   31): 'Diagnostic ambiguity also can arise when distinguishing different tumor types One key clinical dilemma is when differentiating primary CNS lymphoma and glioblastoma which can have similar imaging phenotypes Radiomics models using image‐based texture features have been shown enhance differences glioblastoma and primary CNS lymphoma Interestingly similar diagnostic dilemma often arises when evaluating histopathology slides of these same  disease processes as CNNs are being applied increasingly histopathology image classifications research studies globe we expect robust predictive models emerge that address this problem as well',\n",
       "  ('Diagnostic Dilemmas in CNS',\n",
       "   'caac21552-sec-0009',\n",
       "   'no_sub_id',\n",
       "   32): 'To date most research applications of AI brain tumors have focused on addressing challenges distinguishing histopathologic and molecular subtypes of brain tumors accomplish this AI algorithms are trained using preselected patient populations specific tumor subtypes This approach makes it challenging integrate diagnostic models clinical workflow because models diagnostic accuracy can be consistent only when testing population resembles that of training data sufficient training data based on more general patient populations it is likely that diagnostic capability of AI will expand include accuracy differentiation multiple tumor types as well as nontumor mimickers',\n",
       "  ('Tumor Detection and Delineation',\n",
       "   'caac21552-sec-0010',\n",
       "   'no_sub_id',\n",
       "   33): 'Synergistic accurate diagnostic differentiation tumor subtypes is ability of computational algorithms automatically detect presence and extent of tumor itself On MRI which is most common modality of delineating CNS neoplasms tumors may manifest variable levels of contrast enhancement or none all may be associated peritumoral edema or hemorrhage and may blur margins adjacent bone blood vessels fat or surgical packing materials Furthermore neural response treatment also known as pseudoprogression contributes additional layer of complexity discerning tumor nontumor as detailed Although these features challenge automatic detection of CNS tumors need develop robust volumetric algorithms analysis of tumor and its adjacent microenvironment remains vital',\n",
       "  ('Tumor Detection and Delineation',\n",
       "   'caac21552-sec-0010',\n",
       "   'no_sub_id',\n",
       "   34): 'An escalating cascade of studies and methodologies semiautomatic and automatic detection of CNS tumors has been published recent years largely applied conventional MR imaging but also PET and ultrasound images       Although they are used most frequently exploratory and research setting semiautomatic algorithms have been applied treatment planning stereotactic radiosurgery quantitating volume of residual tumor surgery and tracking tumor growth over time One can envision benefits of robust automatic tumor‐detection algorithm assessment of patients who have numerous intracranial lesions such as setting of CNS metastases and their differential growth rate or response treatment over time Likewise skull‐base lesions which often are irregularly shaped and extend intracranial and extracranial compartments automatic volumetric reconstruction may detect sensitive changes growth that are missed casual observer',\n",
       "  ('Tumor Detection and Delineation',\n",
       "   'caac21552-sec-0010',\n",
       "   'no_sub_id',\n",
       "   35): 'The near universal accessibility of computational tools image analysis and sharing of open‐source code several researchers promises accelerate pace of advancement this field addition publicly available imaging databases offer powerful resources hypothesis testing and validation including Multimodal Brain Tumor Image Segmentation challenge BRaTS data Medical Image Computing  Computer Assisted Intervention MICCAI group Cancer Imaging Archive and Ivy Glioblastoma Atlas Project Ultimately fruit of such efforts hopefully will develop tools that minimize interobserver variability tracking tumors time and treatments and extract deeper layers of data beyond radiographic phenotype routine imaging CNS tumors',\n",
       "  ('Monitoring Response to Treatment',\n",
       "   'caac21552-sec-0011',\n",
       "   'no_sub_id',\n",
       "   36): 'In of patients glioblastoma who receive standard upfront radiation adjuvant temozolomide enlargement of contrast‐enhancing lesions that stabilize or resolve changes treatment are observed and termed pseudoprogression Similarly approximately  of CNS metastases develop necrosis irradiated field manifesting as enlarging enhancement that mimics recurrent tumor stereotactic radiosurgery of brain metastasis Although many conventional or advanced imaging techniques have been investigated distinguish true tumor treatment‐related changes it remains challenging spatially characterize heterogeneous tissues that often contain both viable tumor and treatment‐related changes Combining multiple imaging features using machine‐learning approaches can improve ability construct accurate tissue classifier that can account heterogeneity of treated tumors Texture features extracted conventional MRI have been identified distinguish radionecrosis recurrent brain tumors Perfusion‐weighted and susceptibility weighted MRI sequences also can be combined differentiate recurrence radionecrosis patients high‐grade glioma Texture analysis also has been applied amino acid PET imaging diagnose pseudoprogression provide more direct historical correlation of tumor and necrotic tissues voxel‐based evaluation of MRI coregistered sites of stereotactic biopsy has resulted parametric model that correlates cell counts of biopsied specimens Overall most of this research is phase of moving pilot data validation clinical trials Only more rigorous proof of clinical utility of such technology can regulatory approval and commercialization be achieved followed dissemination widespread clinical use',\n",
       "  ('Biologic Characterization of CNS Tumors: Prospects and Promise',\n",
       "   'caac21552-sec-0012',\n",
       "   'no_sub_id',\n",
       "   37): 'A molecular taxonomy is being defined most common CNS tumors wide availability and decreasing cost of next‐generation sequencing Furthermore it has been observed that molecular signatures confer prognostic implications beyond standard histopathologic classifications including adult and pediatric gliomas meningiomas pituitary tumors craniopharyngiomas medulloblastomas and ependymomas These molecular imprints increasingly guide frequency of surveillance imaging tumor patient consultation clinical outcome and recurrence risk and decisions on type of treatment administer eg radiation or observation  However such information is largely determined only tissue sampling of tumor intervention addition as systemic cancers brain tumors harbor incredible molecular heterogeneity individual tumor and on recurrence using multifocal sampling and single‐cell sequencing strategies Such heterogeneity likely contributes limited effectiveness of current pharmacotherapeutics brain tumors and perceived acquired resistance period of apparent disease control Therefore noninvasive method of tracking tumor genotype over time that can capture entire landscape of tumor heterogeneity offers appeal',\n",
       "  ('Biologic Characterization of CNS Tumors: Prospects and Promise',\n",
       "   'caac21552-sec-0012',\n",
       "   'no_sub_id',\n",
       "   38): 'Radiomic analysis of CNS tumor imaging has potential characterize phenotype of entire tumor rather core of tumor as is frequently sampled molecular analysis and provides noninvasive window internal growth pattern of tumor Previous works have reported significant connections imaging features molecular pathways and clinical outcomes brain tumors behavior of gliomas is significantly associated their molecular alterations especially alterations O‐methylguanine‐DNA methyltransferase  and chromosomes p and q WHO recognized significance of molecular stratification gliomas its  update on classification of gliomas Machine‐learning algorithms trained on preoperative MR images have been able distinguish each of these features to  sensitivity and specificity including prediction of glioblastoma subtypes and survival mutation status high‐grade and low‐grade gliomas presence of chromosome p and q loss low‐grade gliomas MGMT methylation status EGFR amplification status and presence of EGFR receptor variant III as well as extracellular domain mutations Fig  Moreover unsupervised deep learning methods are showing promise discerning molecular subgroups glioblastoma differential prognoses',\n",
       "  ('Biologic Characterization of CNS Tumors: Prospects and Promise',\n",
       "   'caac21552-sec-0012',\n",
       "   'no_sub_id',\n",
       "   39): 'In meningioma benign variants grade I most commonly carry mutation one of several putative oncogenic drivers whereas high‐grade variants grade II‐III tumors harbor variable number of chromosomal alterations Radiomic analysis of preoperative MRIs patients meningioma revealed ability of computer‐extracted imaging features strongly associate meningioma grade and also certain genomic features WLB and HJWLA et al unpublished data addition quantitative radiomic features could discern subtleties such as number of atypical features associated grade I meningiomas beyond capacity of qualitative radiologist‐rated imaging features',\n",
       "  ('Biologic Characterization of CNS Tumors: Prospects and Promise',\n",
       "   'caac21552-sec-0012',\n",
       "   'no_sub_id',\n",
       "   40): 'Similar radiomic analyses are developing pituitary tumors craniopharyngiomas chordomas and other CNS tumors Beyond single‐tumor subtype analysis future efforts need improve accuracy and sensitivity such that such methods can be applied clinical setting confidence derive more nuanced molecular signatures beyond that of single or dual marker and accommodate artifacts associated recurrent and post‐treatment disease states allow truly longitudinal application of radiomics throughout course of patients who have CNS tumors',\n",
       "  ('Clinical Trial Applications',\n",
       "   'caac21552-sec-0013',\n",
       "   'no_sub_id',\n",
       "   41): 'Predictive biomarkers can have important roles clinical trials because of their ability select patients who are more likely respond treatment and thereby improve chance of detecting clinical benefit and lowering risk of drug toxicity ineffective therapies best known predictive biomarkers treatment of glioblastoma is MGMT promoter status which methylated tumor subtypes have shown greater response alkylating agents Recently antiangiogenic treatment of newly diagnosed glioblastoma was evaluated phase  clinical trials which bevacizumab antibody targeting VEGF did not result improved OS when added standard treatment Currently there is no clinically useful molecular marker predictive of treatment response antiangiogenic therapy Imaging‐based biomarkers of treatment response prediction newly diagnosed recurrent glioblastoma have been investigated using both conventional and advanced modalities Radiomic imaging predictors of response based on conventional imaging features have been identified using retrospective single‐center data set of patients recurrent glioblastoma who received bevacizumab treatment retrospective evaluation of single‐institution and multi‐institutional single‐arm data sets radiomic models were constructed using conventional and diffusion MRI features differentiate long‐term short‐term survivors Unsupervised clusters of radiomic features based on nonparametric parameters of preoperative perfusion MRI were first extracted independently data sets of patients glioblastoma and feature clusters subsequently were combined and evaluated their association patient survival outcome radiomic cluster that was associated poor survival HR  was associated mutations angiogenesis and hypoxia pathways These preliminary investigations were based on patients receiving therapy availability of control treatment arm and thus only establish prognostic values of these imaging markers',\n",
       "  ('Clinical Trial Applications',\n",
       "   'caac21552-sec-0013',\n",
       "   'no_sub_id',\n",
       "   42): 'There are several advantages of using clinical trial data both retrospectively and prospectively screen and validate radiomic biomarkers Because these patient populations are relatively uniform including treatment regimen type dose and duration as well as imaging assessment timing and frequency pretreatment and on‐treatment periods predictive accuracy patient outcome will likely improve predictive models constructed this setting can be applied more readily future prospective trials that use similar protocols Recent efforts standardize imaging acquisition protocols brain tumor trials also should increase generalizability of radiomic models different clinical trials and actual clinical implementation',\n",
       "  ('Breast Cancer Screening: Breast Imaging Reporting and Data System Analog to Digital',\n",
       "   'caac21552-sec-0015',\n",
       "   'no_sub_id',\n",
       "   43): 'CADe and CADx breast cancer imaging have been development decades  CADe systems specifically screening mammography interpretation have been routine clinical use late s detection of cancer radiologists is limited presence of structure noise camouflaging normal anatomic background incomplete visual search patterns fatigue distractions assessment of subtle andor complex disease states vast amounts of image data and physical quality of breast image itself computer‐aided detection computer aims locate suspect lesions leaving classification radiologist',\n",
       "  ('Breast Cancer Screening: Breast Imaging Reporting and Data System Analog to Digital',\n",
       "   'caac21552-sec-0015',\n",
       "   'no_sub_id',\n",
       "   44): 'Although CADe continues be developed screening mammography investigators also have sought automate detection of breast lesions on D ultrasound breast MRI and breast tomosynthesis images incorporating predefined algorithms as well as novel deep learning methods motivation computerized detection on D breast images arose arrival of D ultrasound and MRI use as adjunct imaging screening women dense breast tissue',\n",
       "  ('Breast Cancer Screening: Breast Imaging Reporting and Data System Analog to Digital',\n",
       "   'caac21552-sec-0015',\n",
       "   'no_sub_id',\n",
       "   45): 'CNNs have been used medical image analysis early s detection of microcalcifications digitized mammograms as well as distinguishing biopsy‐proven masses and normal tissue on mammograms More recently deep learning methods have allowed computer‐aided detection of breast lesions breast MRI ultrasound and mammography  ',\n",
       "  ('Breast Cancer Risk Assessment: Density and Parenchyma',\n",
       "   'caac21552-sec-0016',\n",
       "   'no_sub_id',\n",
       "   46): 'Computer vision techniques have been developed extract density and characteristics of parenchyma patterns on breast images yield quantitative biomarkers use breast cancer risk prediction and ultimately personalized screening regimes',\n",
       "  ('Breast Cancer Risk Assessment: Density and Parenchyma',\n",
       "   'caac21552-sec-0016',\n",
       "   'no_sub_id',\n",
       "   47): 'Both area‐based and volumetric‐based assessments of density are used estimate mammographic density because increased density serves as breast cancer risk factor as well as provides masking effect that obscures lesions  Breast density refers amount of fibroglandular tissue breast relative amount of fatty tissue full‐field digital mammography FFDM these tissue types are distinguishable because fibroglandular tissue attenuates x‐rays much more fat tissue Because FFDMs are D projections of breast D percentage density values are estimated',\n",
       "  ('Breast Cancer Risk Assessment: Density and Parenchyma',\n",
       "   'caac21552-sec-0016',\n",
       "   'no_sub_id',\n",
       "   48): 'In addition breast density there is also evidence that variability parenchymal patterns eg characterizing spatial distribution of dense tissue also is related breast cancer risk using radiomic texture analysis investigators have characterized spatial distribution of gray‐scale levels regions on FFDM when skewness measure was incorporated analysis of mammograms describe density variation Others have used texture analysis and deep learning discriminate BRCABRCA gene mutation carriers or women breast cancer contralateral breast women low risk of breast cancer and using almost  cases found that women high risk of breast cancer have dense breasts parenchymal patterns that are coarse and low contrast AUC approximately   Further efforts have applied texture analysis breast tomosynthesis images characterize parenchyma pattern ultimate use breast cancer risk estimation preliminary results indicating that texture features correlated better breast density on breast tomosynthesis  = regression analysis on digital mammograms',\n",
       "  ('Breast Cancer Risk Assessment: Density and Parenchyma',\n",
       "   'caac21552-sec-0016',\n",
       "   'no_sub_id',\n",
       "   49): 'In addition characterization of breast parenchymal patterns has also been extended breast parenchymal enhancement BPE on dynamic contrast‐enhanced DCE‐MRI limited data set of  BRCABRCA carriers quantitative measures of BPE were associated presence of breast cancer and relative changes BPE percentages were predictive of breast cancer development risk‐reducing salpingo‐oophorectomy    Deep learning methods are increasingly being evaluated assess breast density as well as parenchymal characterization example of which includes performance assessment of transfer learning distinction women normal risk of breast cancer and those high risk based on their BRCABRCA status',\n",
       "  ('AI to Improve Breast Cancer Diagnosis',\n",
       "   'caac21552-sec-0017',\n",
       "   'no_sub_id',\n",
       "   50): 'Since s various investigators have been developing machine learning techniques CADx task of distinguishing malignant and benign breast lesions These AI methods CADx involve automatic characterization of tumor which is indicated initially either radiologist or computer computer characterizes suspicious region or lesion andor estimates its probability of disease leaving patient management physician',\n",
       "  ('AI to Improve Breast Cancer Diagnosis',\n",
       "   'caac21552-sec-0017',\n",
       "   'no_sub_id',\n",
       "   51): 'With application of AI methods breast image data characteristics of tumor size shape morphology texture and kinetics can be quantitatively obtained example use of dynamic assessment of contrast uptake on breast MRI allows investigators quantify cancers terms of heterogeneity yielding phenotypes of spatial features and dynamic characteristics example entropy is mathematical descriptor of randomness and provides information on how heterogeneous pattern is tumor thus describing heterogeneous pattern of vascular system uptake ie contrast uptake tumors imaged on contrast‐enhanced breast MRI Such analyses potentially could reflect heterogeneous nature of angiogenesis and treatment susceptibility as shown NCIs Cancer Genome Atlas TCGA Breast Cancer Phenotype Group',\n",
       "  ('AI to Improve Breast Cancer Diagnosis',\n",
       "   'caac21552-sec-0017',\n",
       "   'no_sub_id',\n",
       "   52): 'With CADx both predefined and deep‐learned algorithms have been evaluated It is interesting note that investigators have shown that use of either human‐engineered or deep learning features perform well classification of breast lesions task of distinguishing malignant and benign lesions and that fusion of methods can yield statistically significant improvement performance all  breast‐imaging modalities  DCE‐MRI cases  FFDM cases and  ultrasound cases fusion classifier performed best indicating potential complimentary use of both engineered and deep learning tumor features diagnostic breast cancer workup DCE‐MRI AUC =  standard error =  FFDM AUC =  standard error =  and ultrasound AUC =  standard error =  Other investigators have used transfer learning CNNs pretrained on  digitized screen‐films and FFDMs use characterizing tumors on  breast tomosynthesis volumes which demonstrated ability transfer knowledge of imaged patterns imaging modalities',\n",
       "  ('Predictive Image‐Based Biomarkers',\n",
       "   'caac21552-sec-0018',\n",
       "   'no_sub_id',\n",
       "   53): 'Beyond CADe and CADx other AI applications breast imaging include assessing molecular subtypes prognosis and therapeutic response yielding predictive image‐based phenotypes of breast cancer precision medicine major area of interest breast cancer research is attempt understand relationships macroscopic appearance of tumor and its environment These relationships can be extracted clinical breast images and biologic indicators of risk prognosis or treatment response Such effective development of biomarkers benefits integration of information multiple patient examinations ie clinical molecular imaging and genomic data ie other ‐omics that often are obtained diagnostic workup and subsequent biopsies',\n",
       "  ('Predictive Image‐Based Biomarkers',\n",
       "   'caac21552-sec-0018',\n",
       "   'no_sub_id',\n",
       "   54): 'In one collaborative effort NCIs TCGA Breast Phenotype Group multidisciplinary investigators phenotypically characterized  solid breast tumors gain image‐based information on underlying molecular characteristics and gene expression profiles Fig  Statistically significant associations were observed enhancement texture entropy and molecular subtypes normal‐like luminal luminal B HER‐enriched basal‐like even controlling tumor size  = lesions ≤ cm = lesions to ≤ cm MRI‐genomic associations also were unveiled furthering understanding of genetic mechanisms that regulate development of tumor phenotypes',\n",
       "  ('Predictive Image‐Based Biomarkers',\n",
       "   'caac21552-sec-0018',\n",
       "   'no_sub_id',\n",
       "   55): 'With regard predicting patients response particular therapeutic treatment example semimanual delineation of functional tumor volume breast MRI  women recurrence and was identified as predictor of recurrence‐free survival patients receiving neoadjuvant therapy American College of Radiology Imaging Network ACRIN study demonstrated potential automation',\n",
       "  ('Prostate Cancer Imaging',\n",
       "   'caac21552-sec-0019',\n",
       "   'no_sub_id',\n",
       "   56): 'Prostate cancer is most frequently diagnosed noncutaneous male malignancy and second leading cause of cancer‐related mortality men United States Statistics of prostate cancer frequency morbidity and mortality can be examined many different ways It is very common cancer as it is tumor of aging but it has very low disease‐specific mortality all of which reinforce its characterization as complex public health concern that impacts large population Although prostate cancer is serious disease most men diagnosed prostate cancer do not die of it ‐year survival rate patients prostate cancer ranges approximately patients metastatic disease in patients localized disease key clinical problems prostate cancer diagnosis today include  overdiagnosis and overtreatment resulting inability predict aggressiveness and risk of given cancer and  inadequate targeted biopsy sampling leading misdiagnosis and disease progression men seemingly low‐risk prostate cancer meta‐analysis reported rate of overdiagnosis of nonclinically significant prostate cancer was as high as  leading unnecessary treatment and associated morbidity Because of this range of clinical behavior it is necessary differentiate men who have clinically significant tumors those biopsy Gleason score  andor pathologic volume  mL as candidates therapy those who have clinically insignificant tumors and can safely undergo active surveillance It has been noted that potential survival benefits aggressively treating early‐stage prostate cancer are undermined harm unnecessary treatment of indolent disease',\n",
       "  ('Prostate Cancer Imaging',\n",
       "   'caac21552-sec-0019',\n",
       "   'no_sub_id',\n",
       "   57): 'The biological heterogeneity of prostate cancer leads different clinical outcomes ranging indolent highly aggressive tumors high morbidity and mortality and differences therapy planning therapy response and prognosis of patients This is reflected incorporation of genomic profiling National Comprehensive Cancer Network guidelines including Decipher GenomeDx Biosciences San Diego California Oncotype DX Prostate Genomic Health Inc Redwood City California Prolaris Myriad Genetics Inc Salt Lake City Utah and others parallel molecular characterization AI also has potential empower clinicians detection localization characterization staging and monitoring of prostate cancer There are no widespread multicenter trials as yet and therefore much of initial work is limited single‐center single‐algorithm analyses and on small data sets However some groups such as National Institutes of Health and MICCAI are developing infrastructure allow larger well annotated data sets become available AI development',\n",
       "  ('Prostate Cancer Imaging',\n",
       "   'caac21552-sec-0019',\n",
       "   'no_sub_id',\n",
       "   58): 'Computational methods mostly based on supervised machine learning have been successfully applied imaging modalities such as MRI and ultrasound detect suspicious lesions and differentiate clinically significant cancers rest recent application of deep learning prostate cancer screening and aggressive cancer diagnosis has produced promising results',\n",
       "  ('Prostate Cancer Imaging',\n",
       "   'caac21552-sec-0019',\n",
       "   'no_sub_id',\n",
       "   59): 'Multiparametric magnetic resonance imaging mpMRI provides required soft‐tissue contrast detection and localization of suspicious clinically significant prostate lesions and gives information regarding tissue anatomy function and characteristics Importantly it has superior capabilities detect so‐called clinically significant diseaseone Gleason pattern of  or higher Gleason score ≥ andor tumor volume  cm Recent years have seen growth volume of mpMRI examination of prostate cancer because of its ability detect these lesions and allow targeted biopsy sampling large population study United Kingdom suggested that use of mpMRI as triage primary biopsy can reduce number of unnecessary biopsies one‐quarter and can decrease overdiagnosis of clinically insignificant disease This was further validated data sets that were smaller would be considered optimal multinational PRECISION study of  patients men randomized undergo mpMRI biopsy experienced significant increase detection of clinically significant disease over current standard of care which uses ‐core ‐core transrectal ultrasound‐guided biopsy  vs ',\n",
       "  ('Prostate Cancer Imaging',\n",
       "   'caac21552-sec-0019',\n",
       "   'no_sub_id',\n",
       "   60): 'The growing trend mpMRI has introduced demand experienced radiologists interpret exploding volumes of oncological prostate MRIs Furthermore reading challenging cases and reducing high rate of interobserver disagreements on findings is remaining challenge prostate MRI European Society of Urogenital Radiology American College of Radiology and AdmeTech Foundation published second version of Prostate Imaging Reporting and Data System PI‐RADS This provides guidelines radiologists reading and interpreting prostate mpMRI which aim increase consistency of interpretation and communication of mpMRI findings Over past  years AI models have been developed as CADe and CADx systems detect localize and characterize prostate tumors conjunction PI‐RADS accurate CAD systems can increase interrater reliability and improve diagnostic accuracy of mpMRI reading and interpretation preliminary analyses it has been shown that addition of CADx system can improve performance of radiologists prostate cancer interpretation',\n",
       "  ('Prostate Cancer Imaging',\n",
       "   'caac21552-sec-0019',\n",
       "   'no_sub_id',\n",
       "   61): 'Preliminary work mpMRI CADx systems focused primarily on classic supervised machine learning methodologies including combinations of feature extractors and shallow classifiers this category of AI systems feature engineering plays central role overall performance of CAD system Combinations of CADe and CADx systems have been reported that use intensity anatomic pharmacokinetic pharmacokinetic modeling texture and blobness features Pharmacokinetics are detailed metrics that can be extracted time‐signal analysis of intravenous contrast passing given volume of tissue They include parameters such as wash‐in and wash‐out Texture features also are signal‐based and depend heavily on imaging technique Others have use intensity features calculated mpMRI sequences including T‐weighted MRI apparent diffusion coefficient high b‐values diffusion‐weighted MRI and T estimation proton density mapping or they have only used features extracted pharmacokinetic analysis and diffusion tensor imaging parameter maps Similar image‐based features were included CAD systems   and many of these systems use support vector machines classification   ',\n",
       "  ('Prostate Cancer Imaging',\n",
       "   'caac21552-sec-0019',\n",
       "   'no_sub_id',\n",
       "   62): 'In past years deep learning networks and particularly CNNs have been revolutionizing investigative research prostate cancer detection and diagnosis These methods use different modality types CNN architectures and learning procedures train deep networks prostate cancer classification and have achieved state‐of‐the‐art performance Some investigators use CNNs classify MRI findings auto‐windowing mechanism overcome high dynamic range of MR images and normalization whereas others use different combinations of mpMRI images stacking each modality as D channel of RGB images and use them as training examples Furthermore D CNNs can be designed that use specific MRI‐based parameters such as apparent diffusion coefficient high b‐value and volume transfer constant K modalities',\n",
       "  ('Prostate Cancer Imaging',\n",
       "   'caac21552-sec-0019',\n",
       "   'no_sub_id',\n",
       "   63): 'Deep learning systems have been applied localize and classify prostate lesions same time Both de novo training  and transfer learning of pretrained models have been successful training CNNs prostate cancer diagnosis MRI explicit addition of anatomically aware features last layers of CNNs has been used successfully boost their performance addition MRI AI techniques have achieved promising results incorporating ultrasound data specifically radiofrequency prostate cancer classification Here again both classic machine learning approaches and deep learning have been used train classifiers grade prostate cancer temporal ultrasound data',\n",
       "  ('Prostate Cancer Imaging',\n",
       "   'caac21552-sec-0019',\n",
       "   'no_sub_id',\n",
       "   64): 'The results of ongoing research use of AI detection and characterization of prostate cancer are promising and demonstrate ongoing improvement recent body of research prostate cancer image analysis reveals transition feature engineering and classic machine learning methods deep learning and use of large training sets Unlike lung and breast cancers clinical routines prostate cancer have not yet adopted regulated CAD systems However recently achieved results of deep learning techniques on midsize data sets such as PROSTATEx benchmark are promising It is now evident that there has been rapid growth prostate MR examination volumes worldwide and increasing demand accurate interpretations Accurate CAD systems will improve diagnostic accuracy of prostate MRI readings which will result better care individual patients because fewer patients benign and indolent tumors false‐positives will need undergo invasive biopsy andor radical prostatectomy procedures which can lower their quality of life Conversely early detection of prostate cancer improves prognosis of patients who have clinically significant prostate cancer Gleason pattern  Computer‐assisted detection and diagnosis systems prostate cancer help clinicians potentially reducing chances of either missing or overdiagnosing suspicious targets on diagnostic MRIs although this merits additional validation trials routine clinical incorporation',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   65): 'Despite reported successes of AI cancer imaging several limitations and hurdles must be overcome widespread clinical adoption increasing demand CT and MR imaging care providers are constantly generating large amounts of data Standards including Picture Archiving and Communication System PACS and Digital Imaging and Communications Medicine DICOM have ensured that these data are organized easy access and retrieval However such data are rarely curated terms of labeling annotations segmentations quality assurance or fitness problem hand curation of medical data represents major obstacle developing automated clinical solutions because it requires trained professionals making process expensive both time and cost These issues are exacerbated data‐hungry methods including deep neural networks Unsupervised and self‐supervised methods do not require explicit labeling and hence promise alleviate some of these issues whereas synthetic data can potentially enable faster route curation address inevitable class imbalance and mitigate patient privacy concerns Standardized benchmarking is of particular importance medical domain especially given multitude of imaging modalities and anatomic sites as well as acquisition standards and hardware research community has yet reach consensus on specific data sets that can be used comparing and contrasting efforts terms of performance generalizability and reproducibility although volume of medical data being made public is encouraging move forward Furthermore access available data sets should be improved promote intellectual collaboration Institutional professional and government groups should be encouraged share validated data support development of AI algorithms which requires overcoming certain fundamental technical legal and perhaps ethical concerns example National Institutes of Health recently shared chest x‐ray and CT repositories help AI scientists Such efforts bear expansion much wider audience disease states',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   66): 'Another limitation includes interpretability of AI and ability interrogate such methods reasons specific outcome as well as anticipation of failures Although current state of research has prioritized performance gains over explainability and transparency interpretability of AI is active area of research benefits of trust and transparency AI systems will differ based on their performance allowing identification of failures when AI is subhuman and consequently transforming superhuman AI learning resource legal standpoint policy makers have taken note discussions improving AI accountability explanations have recently been debated EU General Data Protection Regulation and continue surface sensitive applications which explanation is currently required law or is anticipated be required near future',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   67): 'From ethical perspective question poses itself What would Hippocratic Oath clinically deployed AI systems be and how would it be enforced Although data curation and modeling practices are biased nature because they take account specific patient cohorts conscious effort must be put understanding exactly who will be ultimate beneficiaries and stakeholders of such technology Algorithms can be unethical design and might exacerbate already existing tension providing care and turning profits addition safeguard learned helplessness must be used as means curb high reliance on automation and ultimate abandonment of common sense Finally automated systems also might challenge dynamics of responsibility doctor‐patient relationship as well as expectation of confidentiality',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   68): 'In terms of regulatory aspects US Food and Drug Administration has been regulating automated clinical decision‐making systems s advent of new prediction techniques including deep learning predictive models seeking approval must be further scrutinized terms of ground truth data used training them their intended use cases and their generalizability and robustness edge cases as well as their life‐long learning aspects as they are continuously updated more learning and more data It is likely that AI application software will need meet rigorous testing that is mandated new submissions regulatory approval including quality control and risk assessment Because cloud computing and virtualization are being used increasingly process medical data health care information technology is gradually becoming part of big data revolution This offers fertile environment incorporating state‐of‐the‐art AI systems that often are distributed Nevertheless it raises data security and privacy concerns because maintaining Health Insurance Portability and Accountability Act compliance is essential Current cyber security research starts offer solutions including cryptonets which homomorphic encryption allows neural networks run training and inference on encrypted data',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   69): 'Todays diagnostic paradigm medicine focuses on detection of visually recognizable findings that suggest discrete pathologies images However focus of such detection of singular disease processes may miss concurrent conditions individual as whole Imaging methods simple x‐rays advanced cross‐sectional imaging methods such as MRI or CT provide opportunity assess cancer context of its surrounding organ system',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   70): 'With integration of AI complex assessments of biological networks may have profound impact on assessment of response and prognosis and treatment planning addition finding of neoplasm imaging may detect changes adjacent or distant organs beyond tumor that alter patient susceptibility systemic morbidities which ultimately can contribute mortality This may occur as byproduct of disease progression itself or as byproduct of treatment such as radiation or chemotherapy example patients undergoing treatment thoracic or breast cancer chemotherapy may lead myocardial damage whereas radiation therapy promotes advanced coronary atherosclerosis patients who survive cancer also experience high rate of cardiovascular events Collectively these cardiotoxicities may confer signal on routine imaging monitoring of cancer and be detected earlier stages of development comprehensive analytical systems that capture diorama of disease processes Initial concepts apply AI this clinical scenario stemmed finding that thoracic cancers and cardiovascular pathology are adjacent each other and may be detected simultaneously ie coronary calcification or pericardial fat on chest CT development of automated AI‐based detection and quantification algorithms therefore would enable assessment of cardiometabolic markers need additional imaging this manner role of AI can be extended screening simultaneously evaluating additional risks same data source Because health care ultimately aims prevent disease generation of accurate risk models is essential guiding actionable risk‐modification strategies',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   71): 'Although AI can detect incidental findings that may be clinically beneficial these findings also may be clinically irreverent and if not carefully framed correct clinical context may increase patient stress health care costs and undesired side effects treatment It is likely that early phase of AI when human experts will continue play key roles gatekeeping AIs output majority of incidental findings detected AI will still be evaluated humans discern whether or not they are clinically significant same manner as when humans detected incidental findings Over time as AI systems mature these incidental findings may become part of standard data evaluation and reporting same way primary lesions are evaluated and reported patients clinical context',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   72): 'In addition imaging is not isolated measure of disease Increasingly it is appreciated that molecular signatures of cancers including noninvasive blood biomarkers of tumor socioeconomic status and even social networks have impact on outcome of patients cancer Sources of data also are rapidly expanding beyond direct medical testing and include input wearables mobile phones social media unstructured electronic health records and other components of digital age AI is well suited integrate parallel streams of informationbiological demographic and socialover time improve predictive models patient outcome',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   73): 'As power and potential of AI are increasingly proven multiple directions remain AI transition routine clinical practice imaging analysis accuracy and predictive power of AI methodologies need significant improvement and demonstration of comparable efficacy or better human experts controlled studies if they are be poised supplant clinician workflows This shows initial promise several disease conditions but requires additional proof of clinical utility prospective trials and education of physicians technologists and physicists incorporate widespread use Although there likely will always be black box human experts viewing AI‐generated results data visualization tools are increasingly available allow some degree of visual understanding of how algorithms make decisions',\n",
       "  ('Challenges and Future Directions',\n",
       "   'caac21552-sec-0020',\n",
       "   'no_sub_id',\n",
       "   74): 'The curation of comprehensive data sets and outcomes that incorporate both disease‐related and unrelated elements also will help train and expand AI systems account risks beyond cancer itself global settings limited access expert clinicians or exposure uncommon pathologies AI may offer repertoire of expert experiences disease interpretation Conversely strategies that predict outcomes ground truth provided human experts may disrupt traditional workflow familiar clinicians and patients today Furthermore increased incorporation of AI monitoring health resources and outcomes likely will improve efficiency and reduce cost As any new innovative technology possibilities development reside beyond current imagination'},\n",
       " {('Introduction',\n",
       "   'Sec1',\n",
       "   'Par2',\n",
       "   0): 'Neoplasms represent second cause of death following cardiovascular diseases million deaths and  million disabilityadjusted lifeyears DALYs worldwide Cancer cases has been increasing over last decades between  and  reaching  million new cancer cases largely due population ageing and growth While agestandardized incidence rates remained relatively stable agestandardized death rates have been decreasing globally over last decades due improvements cancer diagnosis and treatment as well as control of some risk factors such as tobacco and alcohol However large variability incidence and mortality cancer rates still exists particularly high and lowincome countries  due different sociodemographic level education prevention strategies and access effective treatments and specialized care',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par3',\n",
       "   1): 'In Italy according National Institute of Statistics and Global Cancer Observatory there are new cancer cases and  cancer deaths each year Overall cancer mortality has been declining both sexes over last decades favorable trends most common cancer sites Data on cancer incidence and other indicators of cancer burden Italy are scanty continuous monitoring of burden of cancer is of outmost importance order plan proper allocation of health resources cancer prevention diagnosis and management',\n",
       "  ('Introduction',\n",
       "   'Sec1',\n",
       "   'Par4',\n",
       "   2): 'In this regard using Global Burden of Disease GBD  study we provide specific focus on burden of cancer Italy including information on cancer incidence mortality years of life lost YLLs years lived disability YLDs and DALYs overview of mortality trends and  as well as comparison of incidence mortality and DALYs other countries of Western Europe is also provided',\n",
       "  ('Incidence',\n",
       "   'Sec3',\n",
       "   'Par5',\n",
       "   3): 'In Italy there were  new cancer cases  UI – men and  – women corresponding agestandardized incidence rate ASIR per  of   UI – and   UI – respectively Table  Cancer of nonmelanoma skin  prostate  trachea bronchus and lung TBL  and colorectum  were most frequent sites men accounting of all male cancers women most common incident cancers were breast  nonmelanoma skin  colorectal  and TBL  cancer these representing  of all female cancer cases',\n",
       "  ('Incidence',\n",
       "   'Sec3',\n",
       "   'Par6',\n",
       "   4): 'Between  and  incident cancer cases incidence rate and lesser extent ASIR significantly increased both sexes combined     and   Supplementary Table S Cancer cases and incidence rates significantly increased almost all cancer sites only exceptions being stomach and laryngeal cancer while ASIRs significantly increased several cancers but significantly declined TBL bladder stomach ovarian lip and oral laryngeal and esophageal cancer',\n",
       "  ('Mortality',\n",
       "   'Sec4',\n",
       "   'Par7',\n",
       "   5): 'In  there were   UI – cancer deaths men and   UI – women corresponding agestandardized death rate ASDR per  of   UI – men and of   UI  – women Table men most common causes of cancer deaths were TBL colorectum prostate and stomach cancer and  deaths respectively women major causes of cancer deaths were breast colorectal TBL and pancreatic cancer deaths respectively',\n",
       "  ('Mortality',\n",
       "   'Sec4',\n",
       "   'Par8',\n",
       "   6): 'While cancer deaths and death rate significantly increased and and  respectively ASDR significantly decreased Supplementary Table S Deaths and death rates both sexes combined significantly increased many cancer sites but significantly decreased stomach esophageal laryngeal Hodgkin lymphoma and testicular cancer ASDRs significantly decreased most neoplasms exceptions of cancer of pancreas multiple myeloma and uterus',\n",
       "  ('DALYs, YLLs and YLDs',\n",
       "   'Sec5',\n",
       "   'Par9',\n",
       "   7): 'In  cancer caused   UI – DALYs Italy of which  came YLLs  and YLDs  Supplementary Tables S–S proportion of DALYs due YLLs was highest ≥ cancer of TBL pancreas liver gallbladder and esophagus while was lowest cancer of prostate uterus and thyroid Supplementary Table S',\n",
       "  ('DALYs, YLLs and YLDs',\n",
       "   'Sec5',\n",
       "   'Par10',\n",
       "   8): 'The leading causes of cancer DALYs and YLLs both sexes combined were TBL  and  respectively colon and rectum  and  breast  and  and pancreatic  and  cancer Supplementary Tables S–S leading causes of cancer YLDs were breast  colon and rectum  prostate  and bladder  cancer Supplementary Table S',\n",
       "  ('DALYs, YLLs and YLDs',\n",
       "   'Sec5',\n",
       "   'Par11',\n",
       "   9): 'Between  and decline DALYs −  and DALY rates −  was observed Supplementary Table S DALYs and DALY rates significantly decreased several cancer sites including TBL stomach and leukemia although they significantly increased other cancer sites such as pancreatic prostate kidney multiple myeloma uterine cervical and nonmelanoma skin cancer Agestandardized DALY rates declined overall  and most cancer sites',\n",
       "  ('DALYs, YLLs and YLDs',\n",
       "   'Sec5',\n",
       "   'Par12',\n",
       "   10): 'The patterns YLLs YLL rates and agestandardized YLL rates were consistent those DALYs DALY rates and agestandardized DALY rates declines −  −  and − all cancers combined Supplementary Table S',\n",
       "  ('DALYs, YLLs and YLDs',\n",
       "   'Sec5',\n",
       "   'Par13',\n",
       "   11): 'Overall and all cancer sites YLDs and YLD rates significantly increased and and  respectively all cancers Supplementary Table S Similarly agestandardized YLD rates significantly increased overall   and many cancer sites including most frequent ones although they significantly decreased some other cancers such as bladder stomach and larynx',\n",
       "  ('Trends in mortality rates and ASDRs over time',\n",
       "   'Sec6',\n",
       "   'Par14',\n",
       "   12): 'Figure shows trends death rates and ASDRs all cancers over period  and men and women separately Cancer ASDRs declined over last decades both men and women while death rates levelledoff mid s men and early s women Fig ',\n",
       "  ('Trends in mortality rates and ASDRs over time',\n",
       "   'Sec6',\n",
       "   'Par15',\n",
       "   13): 'Figures and b give corresponding trends cancer categories Death rates increased over last decades several neoplasms including female TBL breast pancreas prostate bladder and kidney Death rates were stable least over more recent calendar years cancer of liver late s leukemia mid s nonHodgkin lymphoma female gallbladder cervix mid s and female upper aerodigestive tract cancers Declines death rates were observed male TBL male upper aerodigestive tract cancers colorectum late s stomach female thyroid Hodgkin lymphoma and testicular cancer',\n",
       "  ('Trends in mortality rates and ASDRs over time',\n",
       "   'Sec6',\n",
       "   'Par16',\n",
       "   14): 'ASDRs declined most cancers longterm reductions TBL male upper aerodigestive tract male bladder female gallbladder breast stomach prostate ovarian mesothelioma nonmelanoma skin thyroid and Hodgkin lymphoma and more recent declines colorectum late s liver late s leukemia early s nonHodgkin lymphoma late s and cervix cancer late s Figs and b ASDRs were stable over last decades female TBL other female upper aerodigestive tract cancers female bladder cancer kidney male gallbladder brain multiple myeloma melanoma female mesothelioma and uterus late ′s Only pancreatic cancer ASDRs non significantly increased up more recent calendar years even if levellingoff was observed ',\n",
       "  ('Comparisons with Western European countries',\n",
       "   'Sec7',\n",
       "   'Par17',\n",
       "   15): 'In  Italy had lower agestandardized incidence  death  and DALY  rates compared Western Europe overall   and  respectively Table particular these rates were lower those of other most populous Western European countries ie France Germany and United Kingdom only exception of Spain Moreover and  ASIR increased lower extent Italy in Western Europe   and other Western European countries while ASDRs and agestandardized DALY rates decreased more strongly Italy −  and − in Western Europe −  and −  and other Western European countries',\n",
       "  ('Limitations',\n",
       "   'Sec9',\n",
       "   'Par24',\n",
       "   16): 'As prior GBD studies estimates presented this study depend on quality and quantity of data sources available inform estimates Because of lag time data reporting estimates were mainly based on data and trends recent years Cancer mortality estimates are predominantly based on vital registration data cancer registry data and much lesser extent other data sources Italy vital registration data are available long time has coverage and cancer certification is reasonably reliable and valid particularly most common neoplasms Italian cancer registries cover approximatively  of Italian population Incidence estimates used this paper were predicted values models that used observed mortality data as inputs and use of MIRs Although MIRs can change example as consequence of COVID incidence mortality is estimated careful estimation of MIRs using selected data sources Moreover MIRs allow uniform method estimate incidence and have been used other cancer estimation frameworks which have detailed its benefits including greater representativeness especially absence of quality or complete populationbased cancer registry systems Although proportion of miscoded deaths Italy is low redistribution of unspecified codes socalled garbage codes may have somehow affected mortality as well as incidence estimates Misclassification of metastatic sites as primary cancer sites eg liver TBL and brain is another source of potential bias but again it should be limited Italy where sufficient diagnostic resources exist Further changes coding practices or coding systems may also have effect even though mapping GBD causes list includes adjustments account different coding systems GBD incidence and mortality estimates were somewhat higher those provided Global Cancer Observatory but differences were for many cancers except selected cancer sites such as corpus uteri brain and stomach incidence and nasopharynx cervix and prostate mortality Such differences may be due different estimation methods used and particular redistribution of garbage codes made GBD',\n",
       "  ('Conclusions',\n",
       "   'Sec10',\n",
       "   'Par25',\n",
       "   17): 'Agestandardized cancer rates Italy showed favorable patterns over last few decades particularly mortality thanks improvements lifestyles early diagnosis and treatment However absolute number of cancer cases and lower extent of cancer deaths increased likely due progressive ageing of population Such increase may threaten already progressively reducing country health resources Therefore health care professionals researchers and policy makers should made continuous effort health promotion and prevention maximize control of behavioral and environmental risk factors namely tobacco alcohol low physical activity high body mass index and air pollution cancer but also of other noncommunicable diseases as well as promote early diagnosis and further improve cancer treatment and management',\n",
       "  ('Estimation framework',\n",
       "   'Sec12',\n",
       "   'Par27',\n",
       "   18): 'Details of GBD estimation framework are provided eAppendix of GBD  Cancer Collaboration paper Briefly GBD cancer estimation process starts mortality Mortality estimates are based on vital registration data using ensemble model approach Singlecause mortality estimates are scaled separately estimated allcause estimate Cancer incidence estimates are derived mortality estimates dividing them mortality incidence ratio MIR MIR is separately estimated using spatiotemporal Gaussian process regression each cancer type sex year age group location and year correlation survival data and MIR is used estimate year cancer prevalence total prevalence is then partitioned four sequelae ie diagnosistreatment remission metastaticdisseminated and terminal phase and each sequela prevalence is multiplied disability weight estimate YLDs Lifetime prevalence of procedurerelated disability is estimated larynx breast colorectal bladder and prostate cancer YLLs are calculated as difference corresponding standard life expectancy persons age sex and year of actual age death DALYs are sum of YLDs and YLLs and represent loss years due premature death or morbidity one DALY can be regarded as one lost year of fully healthy life',\n",
       "  ('Estimation framework',\n",
       "   'Sec12',\n",
       "   'Par28',\n",
       "   19): 'The GBD world population standard is used calculation of agestandardized rates All rates are reported per  personyears We also provide  uncertainty intervals UI all estimates',\n",
       "  ('no_title', 'Sec213', 'no_sub_id', 20): ''},\n",
       " {('Introduction',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   0): 'Differences cancer survival less and more deprived patients have been well documented most types of cancer and different geographical settings There is evidence some explanations related patient tumour and healthcare characteristics but these can only explain part of differences depending on cancer type and healthcare system Cancer survival England has been improving steadily s but socioeconomic inequalities survival persist most cancers despite concerted efforts and investment National Health Service',\n",
       "  ('Introduction',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   1): 'After CalmanHine report first fully detailed strategy tackle cancer England was NHS Cancer Plan introduced It set governments plans investment and reform aiming improving prevention delivery of care including implementation of multidisciplinary teams and research It led inflation adjusted increase of annual expenditure on cancer services and main aims were improving cancer survival levels comparable rest of Europe and reducing socioeconomic inequalities Cancer Reform Strategy focused on consolidation of progress made publication of NHS Cancer Plan and set plans cancer services over ensuing five years Again tackling inequalities and promoting equality access cancer services England were central strategy which also led foundation of National Cancer Equality Initiative multidisciplinary initiative dedicated this purpose National Awareness and Early Diagnosis Initiative NAEDI was launched purpose of stimulating action diagnose cancer earlier and improve cancer outcomes Some of key target areas were tackling negative attitudes cancer and barriers seeing doctor supporting primary care and optimising access diagnostic tests and referral pathways These initiatives occurred concomitantly major reorganisation of NHS and funding pressure on NHS spending reduction of health spend as proportion of gross domestic product publication of white paper ',\n",
       "  ('Introduction',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   2): 'We investigated effectiveness of NHS Cancer Plan and subsequent strategies improving one year survival and reducing socioeconomic inequalities cancer survival up years introduction of plan context of major changes NHS We focused on one year survival because most inequalities cancer survival England arise shortly diagnosis We examined trends cancer survival and deprivation gap survival patients receiving diagnosis three predefined calendar periods cancer plan  initialisation period and  implementation period followup This allowed comparison of trends and introduction of NHS Cancer Plan including initialisation period reflect latency such extensive and wide ranging strategy might take effect We also analysed changes survival patterns fixing calendar periods priori examine survival trends successive cancer policy initiatives but imposing assumptions on calendar periods which those changes might occur',\n",
       "  ('Data',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   3): 'We extracted data population based National Cancer Registry database held Office National Statistics ONS primary source of cancer registration records is range of healthcare providers such as hospitals pathology laboratories and other services that provide all information on cancer diagnoses given year This information is collected and maintained National Cancer Registration and Analysis Service Public Health England which actively updates database up nine months registration year vital status of registered patients cancer alive emigrated dead not traced is updated ONS and HSCIC Health and Social Care Information Centre now known as NHS Digital estimated completeness of this dynamic database is registration calendar year but it can reach five years',\n",
       "  ('Data',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   4): 'We included all young people and adults age  years diagnosis of one of most common primary malignant ICDO international classification of diseases oncology behaviour code  invasive neoplasms and potential followup end of  These represent of all cancers diagnosed England Tumour site was coded according ICD international classification of diseases th revision whereas morphology and behaviour were coded according international classification of diseases oncology second edition ICDO data owners undertake various cleaning procedures ensure high quality of data but we also apply standard set of additional checks cancer survival analysis aiming flag or exclude incomplete ineligible or incoherent tumour records as well as second or higher order tumours arising same organ as previous primary cancer Overall these procedures led exclusion of less of patients analyses included over  million patients',\n",
       "  ('Deprivation',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   5): 'The index of multiple deprivation IMD  is ecological measure of deprivation seven distinct domains and combined measure assigned individuals living given Lowerlayer Super Output Area LSOA LSOAs are administrative geographical areas established improve reporting of small area statistics England and Wales Patients cancer were assigned one of   LSOAs England mean population  on basis of their postcode of residence diagnosis our study we used income domain score which measures proportion of population low income given LSOA five deprivation categories were based on fifths of national distribution of scores LSOAs England and patients cancer were assigned deprivation category of their LSOA indicating least deprived or affluent indicating most deprived',\n",
       "  ('Net survival estimation',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   6): 'We estimated one year net survival each cancer sex year of diagnosis and deprivation category Patients diagnosis and  had potential be followed up at least one year so we used classic cohort approach',\n",
       "  ('Net survival estimation',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   7): 'Net survival is probability of survival if cancer were only possible cause of death It is only survival measure enabling comparisons populations ie periods and socioeconomic levels which mortality hazard other causes may differ because this measure does not depend on these hazards Estimation of net survival requires comparison of overall mortality hazard experienced patients cancer their expected mortality hazardthat is hazard other causes of death This leads estimate of excess mortality hazard ie hazard of death due cancer of interest which mathematically is complement of net survival Because cause of death is not considered as reliable population based data expected mortality hazard of patients cancer is estimated general population that patients come We therefore built life tables England general population calendar year sex age and deprivation absence of data on recent deaths general population we used mortality rates and ',\n",
       "  ('Net survival estimation',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   8): 'We estimated net survival using consistent nonparametric estimator defined PoharPerme This estimator accounts informative censoring due patient factors such as agethat is when some groups of patients are more likely be censored because of death other causes estimator is implemented Stata command',\n",
       "  ('Age standardisation',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   9): 'Survival estimates all ages combined were age standardised International Cancer Survival Standard weights Age standardisation required estimate survival unique combinations of cancer men and women sex year of diagnosis  years deprivation five categories and age groups five groups of these combinations it was not possible estimate survival owing sparse data those cases we combined data adjacent age groups and assigned pooled survival estimate both age groups corresponding weights these age groups being also combined If survival estimates were missing more one age group we report only unstandardised survival estimate  combinations These issues arose mostly mesothelioma thyroid and testicular cancer Hodgkin lymphoma and myeloma which tend be rare either very young or very old patients',\n",
       "  ('Trends in survival, deprivation gap, and trends in deprivation gap',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   10): 'We used multivariable linear regression investigate survival patterns each cancer and sex outcome was one year age standardised net survival and predictors were year of diagnosis representing trend and deprivation model also included interaction year of diagnosis and deprivation which defined temporal trend deprivation gap significance level of this term was set This allowed us test statistical significance of interaction and decide if there was evidence change deprivation gap',\n",
       "  ('Trends in survival, deprivation gap, and trends in deprivation gap',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   11): 'A continuous linear effect was considered effect of deprivation We tested series of linear restricted regression splines constrained knot location effect of year and interaction term Knots were fixed calendar years  and align three periods we defined relation NHS Cancer Plan final number of knots was determined algorithm embedded program STATA Starting model of maximum complexity this closedtest algorithm uses backward elimination choose best fitting spline while overall type I error is kept predefined level here ',\n",
       "  ('Trends in survival, deprivation gap, and trends in deprivation gap',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   12): 'From regression models applied entire dataset each sexcancer combination we estimated both survival and deprivation gap survival each year Survival is predicted age standardised one year net survival patients diagnosis each calendar year deprivation gap is absolute difference predicted net survival estimates most affluent and most deprived groups convention negative value deprivation gap implies that survival was lower deprived in affluent patients We derived  confidence intervals linear combination of coefficients acquired flexible models',\n",
       "  ('Relaxed assumptions',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   13): 'Our main analysis incorporated assumption that  and  were starting points any change slope of trend survival or deprivation gap survival We then relaxed this assumption including internal knot each year initial model again allowing knots be selected algorithm embedded command deprivation gap was derived same final models as described previously We performed similar analyses using cubic splines allow possibility of nonlinear trends',\n",
       "  ('Patient involvement',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   14): 'This study is part of Cancer Survival Groups commitment describe and explain inequalities cancer survival affecting older patients patients of low socioeconomic status and all patients living England and UK where cancer survival still lags survival other comparably wealthy countries',\n",
       "  ('Patient involvement',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   15): 'We repeatedly receive feedback patients cancer and advocacy bodies national and international meetings effect that cancer survival statistics we produce are invaluable support their efforts lobby improved care of patients cancer We have longstanding collaboration National Cancer Research Institute Consumer Liaison Groupa group of patients representatives that is actively involved our research We organise regular meetings which we discuss our research exchange ideas and receive valuable feedback More members of this group participated our most recent meeting on  February which our research including this study was presented and discussed plenary session and small groups Two patients are also members of Advisory Panel Cancer Survival Programme of which this study is component part We recently received special recognition Cancer Research UK involvement and engagement of patients design and delivery of our research',\n",
       "  ('Patient involvement',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   16): 'Our international research programme on cancer survival is also officially endorsed many cancer patient bodies including Association of European Cancer Leagues Brussels Belgium European Institute Womens Health Dublin Ireland and European Cancer Patient Coalition These agencies have all used our cancer survival estimates press improvements cancer care locally but also improve cancer policy nationally',\n",
       "  ('Trends in one year net survival',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   17): 'One year survival improved of cancers examined women and  of cancers examined men ',\n",
       "  ('Trends in one year net survival',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   18): 'The largest improvements were observed cancers that were of poor or intermediate prognosis s those diagnosis such as cancers of oesophagus liver men lung women and kidney mesothelioma and myeloma these cancers average annual absolute increase one year age standardised net survival was often greater over whole study period  Survival men diagnosed as having cancer of larynx or testis or Hodgkin lymphoma was already high s and it improved little ',\n",
       "  ('Trends in one year net survival',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   19): 'For  of cancersex combinations survival improved steadily but no statistically significant acceleration ie predefined implementation period This was case eight of malignancies men six cancers of digestive tract melanoma and nonHodgkin lymphoma and of  malignancies women six cancers of digestive tract lung cancer mesothelioma melanoma four gynaecological cancers brain cancer thyroid cancer nonHodgkin lymphoma myeloma and leukaemia',\n",
       "  ('Trends in one year net survival',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   20): 'Changes survival trend were observed several cancers mesothelioma men one year survival changed little mean annual increase  but accelerated each year similar change occurred brain tumours men same time point each year',\n",
       "  ('Trends in one year net survival',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   21): 'For thyroid cancer men one year survival changed little year period  but then increased each year and similar pattern was seen Hodgkin lymphoma women which increased year and ',\n",
       "  ('Trends in one year net survival',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   22): 'The one year survival trends seen accelerated for lung cancer myeloma and leukaemia men and kidney cancer both sexes average annual increases were less year but increased up year and kidney cancer annual rate of increase one year survival doubled increasing to year men and to year women',\n",
       "  ('Trends in one year net survival',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   23): 'For prostate cancer mean annual increase one year survival was null and by  one year survival had reached ',\n",
       "  ('Trends in one year net survival',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   24): 'When we relaxed assumption that trend could only change or  fitting flexible splines that allow trend change year year results differed little data not shown',\n",
       "  ('Deprivation gap in one year net survival and trends',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   25): 'When survival increased it concerned all deprivation groups most sexcancer combinations Survival nevertheless remained consistently lower more deprived patients less deprived and deprivation gap one year net survival remained unchanged cancers men and  cancers women and survival gap narrowed only six of  cancers men and two of  cancers women and widened three cancers All these changes were linear deprivation gaps were more similar men and women than ',\n",
       "  ('Deprivation gap in one year net survival and trends',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   26): 'In  there was clear deprivation gradient one year survival which was lower more deprived less deprived patients all cancers and both sexes  Seventeen years later survival was still lower more deprived groups all cancers except Hodgkin lymphoma men narrowing deprivation gap was observed cancers survival near or higher among men and women',\n",
       "  ('Deprivation gap in one year net survival and trends',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   27): 'In largest deprivation gap men was observed rectal cancer − and nonHodgkin lymphoma − deprivation gap narrowed slightly during both colon and rectal cancer and for nonHodgkin lymphoma However largest reduction was seen Hodgkin lymphoma  and prostate cancer melanoma of skin deprivation gap decreased between  and deprivation gap these cancers ranged − − In largest deprivation gap was rectal cancer − and brain cancer −',\n",
       "  ('Deprivation gap in one year net survival and trends',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   28): 'In women largest deprivation gap as was bladder cancer − mesothelioma − and oesophageal cancer − reduction was only seen cervical cancer − to − and uterine cancer − − respectively',\n",
       "  ('Deprivation gap in one year net survival and trends',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   29): 'The deprivation gap survival widened brain tumours men and lung cancer women from − to and − to − respectively',\n",
       "  ('Deprivation gap in one year net survival and trends',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   30): 'The deprivation gap was narrow for few malignancies and remained narrowest Hodgkin lymphoma − and skin melanoma − women and thyroid − and testicular cancers − men',\n",
       "  ('Strengths and weaknesses of this study',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   31): 'A major strength of this study is that it is based on virtually all cancer cases registered England and quality and completeness of English cancer registry data are acknowledged be high study also updates seven years our previous evaluations total of  years of incidence data These extra years of data allowed us estimate trends more accurately',\n",
       "  ('Strengths and weaknesses of this study',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   32): 'Since our previous evaluations new more flexible methodologies were introduced assumption that trends survival and deprivation gap should be different three predefined periods was now relaxed and periods could vary substantially initial assumption was that changes would be expected or  or both but further analyses were conducted using more flexible models which enabled number and location of knots vary all years of diagnosis estimates were not all identical but they did not affect our main conclusions particular on common absence of inflexion points trends survival and deprivation gap',\n",
       "  ('Strengths and weaknesses of this study',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   33): 'Short term net survival mostly reflects speed of patient management including diagnosis staging and first definitive treatment as well as quality of surgical treatment and postoperative care persistent deficit short term cancer survival England and more generally UK compared most wealthy countries has been observed decades Meanwhile wide socioeconomic inequalities cancer survival also seen decades are mostly due higher short term mortality more deprived patients',\n",
       "  ('Strengths and weaknesses of this study',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   34): 'Although trends cancer survival have been regularly used inform governments on progress towards aims of their cancer policies our knowledge little has been specifically published on evaluation of how cancer policies impact survival and inequalities national level Most studies were subnational level or focused on very specific interventions such as screening contrast our study was designed evaluate such policies We acknowledge that changes survival trends are decided solely on acceleration survival and comparison countries of similar wealth would put any observed improvements perspective This limitation however does not apply our findings on persistent socioeconomic inequalities cancer survival Furthermore weak evidence acceleration cancer survival echoes constant gap cancer survival England and some other wealthy countries Our study also may be too early detect full impact of recently implemented cancer initiatives although it confirms findings of our earlier studies Such studies should be regularly updated',\n",
       "  ('Meaning of the study',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   35): 'Since introduction of NHS Cancer Plan  acceleration positive survival trends was witnessed only few cancers and mostly men who experienced lower initial increase compared women cancer of lung brain and thyroid mesothelioma myeloma and leukaemia No such acceleration was found women lung cancer and more specifically nonsmall cell carcinoma proportion of patients receiving surgical treatment was low England but this proportion increased around to This improvement may be partly result of higher number of specialised surgeons and higher proportion of patients managed specialised centres which could reduce variability postoperative mortality These changes may have impacted outcome mesothelioma too continuous expansion availability of diagnostic tools eg computed tomography magnetic resonance imaging ultrasound machines England is likely have increased proportion of brain and thyroid tumours diagnosed earlier stage Survival pattern bladder cancer is particular as one year survival decreased slightly and  then stabilised It reflects change coding under which papillomas were reclassified invasive uncertain whether benign or malignant therefore excluded survival analyses Omitting these tumours good prognosis resulted decrease cancer survival Despite these improvements survival there was no reduction inequalities survival lung brain or thyroid tumour or mesothelioma',\n",
       "  ('Meaning of the study',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   36): 'Particular efforts were dedicated England high incidence cancers intermediate prognosis one year survival and such as colon and rectal cancers and one could have expected faster improvement survival and reduction of deprivation gap policy initiatives Survival these cancers England remained internationally and inequalities survival these cancers hardly narrowed Short term survival increased dramatically for most other digestive cancers poor prognosis one year survival but more deprived patients still experienced lower survival',\n",
       "  ('Meaning of the study',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   37): 'It is likely that longstanding deficit survival and socioeconomic inequalities survival England share same causal factors which can be grouped patient tumour and healthcare system factors National Awareness and Early Diagnosis Initiative and Be Clear on Cancer Campaign aimed specifically tackle some of patient related cancer awareness barriers and tumour related tumour stage issues Although cancer awareness varies internationally and deprivation it seems explain none of international disparities cancer survival and little of socioeconomic inequalities lot of effort has also gone diagnosing cancers earlier stage Patients tend have diagnosis of more advanced tumours England compared wealthy countries and more deprived patients compared least deprived However as stage specific survival tends be lower England more advanced stage would explain only part of international and socioeconomic inequalities cancer survival higher proportion of patients are now receiving diagnosis Two Week Wait or GP referral while some cancers there is major decrease emergency presentation Although stage distribution might have slightly moved towards earlier stages picture remains patchy and there was no evidence suggest narrowing of these gaps survival',\n",
       "  ('Meaning of the study',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   38): 'These policy initiatives put greater emphasis on individual factors on observed suboptimal management of patients cancer variations cancer management eg differential route diagnosis staging investigation treatment are likely explain some of low survival observed England and more deprived patients whereas role of individual factors observed variations management seems minor example background consultation rate primary care of patients cancer does not differ routes cancer diagnosis emergency presentation or not contrast interventions on healthcare system factors might have large impact on cancer survival as shown recent changes management of patients lung cancer However such interventions have not influenced socioeconomic inequalities cancer survival yet possibly because they do not directly address differential interactions healthcare system and patients which could lead suboptimal management of subgroups of population',\n",
       "  ('Conclusion and policy implications',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   39): 'Little evidence has been found acceleration cancer survival successive national cancer policy initiatives Survival most deprived has been consistently lower and deprivation gap has shown little change over years patients diagnosis and England and Wales This study contributes more recent data and updates evidence that deprivation gap persisted England even introduction of successive national policies which other goals targeted social inequalities related cancer',\n",
       "  ('Conclusion and policy implications',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   40): 'These findings should be taken consideration cancer policy makers and inform future initiatives Shifting focus individual factors healthcare system factors might prove be beneficial improving cancer outcomes most disadvantaged Further research on these factors can help shed light and improve efficacy of future cancer policies'},\n",
       " {('INTRODUCTION',\n",
       "   'S1',\n",
       "   'no_sub_id',\n",
       "   0): 'The success human longevity achieved recent decades is impressive and could be even greater if major challenges of neurodegenerative diseases cardiovascular disease and cancer could be controlled',\n",
       "  ('INTRODUCTION',\n",
       "   'S1',\n",
       "   'no_sub_id',\n",
       "   1): 'Of three challenges cancer treatment is perhaps achieving more success other two not only because of better prevention and earlier diagnosis but also because of increasingly effective and bettertolerated treatment',\n",
       "  ('INTRODUCTION',\n",
       "   'S1',\n",
       "   'no_sub_id',\n",
       "   2): 'Viruses offer first approximation aetiological diagnosis case of cancer and role some of them play pathogenesis of certain tumours is today indisputable Their prevention such as case of HPV and cervical cancer has radically changed our expectations future and allows us envision eradication of this tumour Unfortunately viruscancer relationship is not so clearcut many other tumours and when we look global data on that relationship we find scattered and inaccurate irregular literature of very uneven nature and quality',\n",
       "  ('INTRODUCTION',\n",
       "   'S1',\n",
       "   'no_sub_id',\n",
       "   3): 'For this reason Health Sciences Foundation has proposed examining viruscancer relationship more generally multidisciplinary forum aiming obtain answers series of simple questions experts different aspects of problem This meeting has included oncologists gastroenterologists internists gynaecologists specialists infectious diseases and HIV microbiologists basic biologists representatives of patient associations and media and specialists preventive medicine and ethics',\n",
       "  ('INTRODUCTION',\n",
       "   'S1',\n",
       "   'no_sub_id',\n",
       "   4): 'A first block of questions was aimed putting dimension of VirusCancer relationship cancers most clearly caused viruses great historical milestones of this relationship and some aspects of oncogenesis perspective',\n",
       "  ('INTRODUCTION',\n",
       "   'S1',\n",
       "   'no_sub_id',\n",
       "   5): 'In second block some potential solutions ranging vaccines treatment of hepatitis C were addressed and possible role of bacteria and parasites as alternative oncogenic agents was also discussed We also wanted understand importance that cancer patient associations place on this relationship understanding that media has of problem and ethical aspects that all this raises',\n",
       "  ('MATERIAL AND METHODS',\n",
       "   'S2',\n",
       "   'no_sub_id',\n",
       "   6): 'The members of Board of Trustees of Health Sciences Foundation proposed series of questions on relationship viruses and cancer that would answer main uncertainties of problem present questions were accepted multidisciplinary panel of experts Each question was reported one of experts and subsequently text and its conclusions were discussed working group conclusions were reached that were accepted all',\n",
       "  ('MATERIAL AND METHODS',\n",
       "   'S2',\n",
       "   'no_sub_id',\n",
       "   7): 'We now turn questions and their development views expressed are not intended set any particular recommendation or therapeutic indication and represent only opinion of groups speakers and not necessarily that of institutions which they work',\n",
       "  ('Discovery of the avian sarcoma virus',\n",
       "   'S3_1',\n",
       "   'no_sub_id',\n",
       "   8): 'In early s Peyton Rous working Rockefeller Institute New York showed that type of sarcoma affecting chickens was transmissible homogenate filtrates that could only contain viruses Years later causative virus was isolated and named RSV This discovery marks beginning of research tumour viruses',\n",
       "  ('Transformation in cell cultures',\n",
       "   'S3_2',\n",
       "   'no_sub_id',\n",
       "   9): 'During s Harry Rubin and Howard Temin managed establish new experimental model study tumour viruses California Institute of Technology It consisted of infection of fibroblasts culture The infection caused radical changes phenotype of cells which acquired capacities characteristic of tumour cells such as reduced dependence on growth factors immortality anchorageindependent growth motility invasiveness loss of contact inhibition metabolic reprogramming and ability form tumours syngeneic or immunosuppressed mice These changes were called cellular transformation new experimental system ushered new era tumour virus research  ',\n",
       "  ('Discovery of DNA tumour viruses',\n",
       "   'S3_3',\n",
       "   'no_sub_id',\n",
       "   10): 'In Rockefeller Institute New York Richard Shope identified virus that causes papillomas rabbits Papillomas are benign tumours that rarely progress squamous cell carcinomas of skin Unlike Rous Sarcoma Virus whose genetic material is RNA papillomaviruses are made of DNA There are currently more human papillomaviruses HPV described discovery of HPV was followed discovery of more tumour viruses whose genetic material is DNA including i Polyomavirus which when infecting mice caused tumours of various origins hence its name ii  SV which is lytic virus some primate cell types and silent rodent cells and is therefore called nonpermissive nonpermissive cells SV produces cellular transformation although very low frequency ',\n",
       "  ('Discovery of DNA tumour viruses',\n",
       "   'S3_3',\n",
       "   'no_sub_id',\n",
       "   11): 'Papillomavirus polyomavirus and SV are known as papovaviruses Their DNA is small circular molecule',\n",
       "  ('Discovery of DNA tumour viruses',\n",
       "   'S3_3',\n",
       "   'no_sub_id',\n",
       "   12): 'Other viruses oncogenic capabilities include i Adenovirus which infects airways and can produce tumours when it infects hamster cells ii Herpesvirus which produces different tumours human cells iii Epstein Barr Virus EBV which can produce Burkitts lymphomas or nasopharyngeal carcinomas Compared papovaviruses latter three are very large',\n",
       "  ('Integration of the virus into the host cell genome',\n",
       "   'S3_4',\n",
       "   'no_sub_id',\n",
       "   13): 'Several lines of evidence showed that tumour viruses had remain active tumour cells maintain transformed phenotype inactivation of virus produced return normal cellular state',\n",
       "  ('Integration of the virus into the host cell genome',\n",
       "   'S3_4',\n",
       "   'no_sub_id',\n",
       "   14): 'Different viruses use different mechanisms keep tumour cells dividing division Some EBV or HPV become integrated becoming part of cell genome Almost all cervical tumours are produced HPVs which make up part of their genome necessary cell transformation E and E oncogenes ',\n",
       "  ('Integration of the virus into the host cell genome',\n",
       "   'S3_4',\n",
       "   'no_sub_id',\n",
       "   15): 'Herpesviruses use two strategies perpetuate their genome tumour cells Some such as human herpesvirus HHV integrate telomeric regions of chromosomes which are transcriptionally silenced making virus able remain latent long periods of time Others such as herpesvirus that produces Kaposis sarcoma HHV replicate episodically ie extrachromosomally but are able bind chromosomes temporarily ensure replication',\n",
       "  ('Integration of the virus into the host cell genome',\n",
       "   'S3_4',\n",
       "   'no_sub_id',\n",
       "   16): 'While DNA virus integration solved how they could remain tumour cells it created seemingly unsolvable problem How did RNA viruses Rous Sarcoma Virus remain solution this problem led one of most surprising discoveries biology retrotranscription Howard Temin and David Baltimore showed that RNA viruses copy their genome doublestranded DNA which integrates host cells genome Retrotranscription violated dogma proposed Francis Crick which flow of biological information follows DNARNAProtein direction fact retrotranscription is mandatory step life cycle of retrovirusesas RNA viruses that undergo this process are called contrast integration of DNA viruses is very rare event infections',\n",
       "  ('Identifying the first of a long list of oncogenes',\n",
       "   'S3_5',\n",
       "   'no_sub_id',\n",
       "   17): 'Rous Sarcoma Virus most retroviruses has reduced genome ~ kb it are encoded genes necessary its retrotranscription and integration as well as proteins that form part of its capsid This simplicity made them very useful tools identifying elements required cell transformation comparing viral variants capable of replication but not transformation variants capable of transformation but not replication it was concluded that single gene called src was responsible cell transformation',\n",
       "  ('Identifying the first of a long list of oncogenes',\n",
       "   'S3_5',\n",
       "   'no_sub_id',\n",
       "   18): 'Characterising src oncogene Harold Varmus and Michael Bishop working University of California San Francisco obtained totally unexpected result  They found copies of src cells that had not been transformed Rous Sarcoma Virus Actually src is gene present totally normal cells that was hijacked tumour virus Rous Sarcoma Virus This result was authentic revolution and led several conclusions that have revolutionised way we think cancer some of which are detailed below',\n",
       "  ('Identifying the first of a long list of oncogenes',\n",
       "   'S3_5',\n",
       "   'no_sub_id',\n",
       "   19): 'The discovery of src initiated race identify oncogenes carried retroviruses which led characterisation of oncogenes involved pathogenesis of numerous tumours These are two examples',\n",
       "  ('Identifying the first of a long list of oncogenes',\n",
       "   'S3_5',\n",
       "   'no_sub_id',\n",
       "   20): 'Currently list of oncogenes associated retroviruses exceeds two dozen ',\n",
       "  ('QUESTION: AT PRESENT, WHAT PROPORTION OF MALIGNANT TUMOURS IN GENERAL HAVE A PROVEN OR PROBABLE CAUSALITY IN A VIRAL INFECTION?',\n",
       "   'S4',\n",
       "   'no_sub_id',\n",
       "   21): 'It is accepted that one of six tumours world is probably associated infection It is important highlight that series published on this subject sources of information and criteria detecting infectious agents are heterogeneous and this conditions reliable approach subject',\n",
       "  ('QUESTION: AT PRESENT, WHAT PROPORTION OF MALIGNANT TUMOURS IN GENERAL HAVE A PROVEN OR PROBABLE CAUSALITY IN A VIRAL INFECTION?',\n",
       "   'S4',\n",
       "   'no_sub_id',\n",
       "   22): 'The International Agency Research on Cancer IARC Lyon Epidemiology and Infections Group has made significant contributions that underpin some of current knowledge this area study Plummer et al  published data it is established that of million new cases of cancer per year  million  were attributed infections Excluding one bacterium cases which proved be predominant next four most important infectious agents worldwide were HPV  Hepatitis B Virus HBV  Hepatitis C Virus HCV  and EBV  Furthermore subSaharan Africa Kaposis Sarcoma caused HHV emerged as second largest contributor cancer burden there were  million deaths this type of tumour Twothirds of these deaths occur poor countries these can be added role of certain retroviruses linked oncogenic capabilities such as HTLV and Human Immunodeficiency Viruses HIV ',\n",
       "  ('QUESTION: AT PRESENT, WHAT PROPORTION OF MALIGNANT TUMOURS IN GENERAL HAVE A PROVEN OR PROBABLE CAUSALITY IN A VIRAL INFECTION?',\n",
       "   'S4',\n",
       "   'no_sub_id',\n",
       "   23): 'It should be noted that role of virus as aetiological agent of tumours is conditioned its prevalence its detection methods and estimation of attributable risk exposed populations accuracy of measurement of exposure is critical as it ensures that different methods calculating attributable risk provide results that are compatible reality experience of Global burden of cancers attributable liver flukes group shows that infections capable of becoming carcinogenic have demonstrated that biomarkers that are sensitive and capable of distinguishing highrisk lowrisk infections are essential elucidating true strength of their role cancer  ',\n",
       "  ('QUESTION: AT PRESENT, WHAT PROPORTION OF MALIGNANT TUMOURS IN GENERAL HAVE A PROVEN OR PROBABLE CAUSALITY IN A VIRAL INFECTION?',\n",
       "   'S4',\n",
       "   'no_sub_id',\n",
       "   24): 'In light of contributions made this regard it seems appropriate refer assessment of cancer burden France attributable infectious agents authors conduct systematic review of representative series on prevalence of infectious agents main associated cancer types They tracked original studies published up September PubMed and performed randomeffects metaanalysis Cancer incidence data were obtained French Network of Cancer Registries allowing calculation of national incidence estimates accordance validated methods Of new cancer cases France of all new cancer cases were attributable infectious agents largest contribution infectious agents was represented HPV and  responsible and  new tumour cases  and  of all new cancer cases respectively',\n",
       "  ('QUESTION: AT PRESENT, WHAT PROPORTION OF MALIGNANT TUMOURS IN GENERAL HAVE A PROVEN OR PROBABLE CAUSALITY IN A VIRAL INFECTION?',\n",
       "   'S4',\n",
       "   'no_sub_id',\n",
       "   25): 'An additional aspect that supports robustness of contributions is that three main groups of infectious agents and cancer modalities were used estimation of tumours attributable infection Firstly cancer sites where infectious agents are assumed contribute almost  of all cases cervical cancer due highrisk HPV Secondly cancer sites attributable infection whenever infectious agent is detected tumour tissue using sensitive and validated detection methods oral oropharyngeal anal laryngeal vulvar vaginal and penile cancers due highrisk HPV nasopharyngeal cancers Hodgkins and nonHodgkins lymphomas due EBV and  although it is bacterial infection  gastric MALT lymphoma due Thirdly cancer cases where infectious agents increase risk of developing tumour but are not responsible all new cancer cases even when antibodies infectious agent are detected serum',\n",
       "  ('QUESTION: AT PRESENT, WHAT PROPORTION OF MALIGNANT TUMOURS IN GENERAL HAVE A PROVEN OR PROBABLE CAUSALITY IN A VIRAL INFECTION?',\n",
       "   'S4',\n",
       "   'no_sub_id',\n",
       "   26): 'The proportion of new cancer cases France associated infectious agents is comparable that of other highincome countries estimates of this study are overall slightly higher those of specific analyses United Kingdom  and Australia where gender categorisation showed that  and  of all new cancer cases men were attributable infectious agents both countries respectively and  and  of all new cancer cases women were also attributable infectious agents These differences previous studies are due part differences risk of infection areas as well as differences what is considered gold standard measuring prevalence of infection association specific cancers ',\n",
       "  ('QUESTION: AT PRESENT, WHAT PROPORTION OF MALIGNANT TUMOURS IN GENERAL HAVE A PROVEN OR PROBABLE CAUSALITY IN A VIRAL INFECTION?',\n",
       "   'S4',\n",
       "   'no_sub_id',\n",
       "   27): 'There are important global differences depending on health and sociocultural conditions how these infections are responsible tumour genesis Thus Australia and New Zealand infectious origin of cancer is of cases compared in SubSaharan Africa  Improving quality and quantity of knowledge seems essential so as prioritise preventive programmes and reduce disease burden',\n",
       "  ('QUESTION: WHICH ARE THE TUMOURS WITH THE MOST CLEARLY DEMONSTRATED VIRAL AETIOLOGY?',\n",
       "   'S5',\n",
       "   'no_sub_id',\n",
       "   28): 'Infections certain microorganisms viruses bacteria and parasites are risk factors developing certain cancers According latest update of IARC monograph on biological agents associated cancer following microorganisms were classified as carcinogenic group  ',\n",
       "  ('QUESTION: WHICH ARE THE TUMOURS WITH THE MOST CLEARLY DEMONSTRATED VIRAL AETIOLOGY?',\n",
       "   'S5',\n",
       "   'no_sub_id',\n",
       "   29): 'In estimate of burden of cancers associated infectious agents was published this estimate number of new cases diagnosed attributed infections previously described table country was calculated combining incidence rates of different cancers estimates of attributable fractions of different infectious agents attributable fractions each infection are calculated infection prevalence cancer cases and relative risk These attributable fractions are highly variable depending on infectious agent and country Of  million new cancer cases diagnosed according GLOBOCAN   million  were attributable infections This percentage varies greatly region in USA Canada Australia and some European countries over some SubSaharan African countries most important infectious agents were  cases HPV  cases HBV  cases HCV  cases and EBV  cases many of these infectionscancers there are clearly effective preventive strategies such as vaccines and early detection programmes Vaccination and early detection programmes treatment should be established reduce incidence of these cancers associated infections',\n",
       "  ('QUESTION: IS IT POSSIBLE TO BROADLY UNDERSTAND THE PATHOGENESIS OF VIRUS-MEDIATED ONCOGENESIS? WHAT ARE BRADFORD HILL’S PRINCIPLES OF CAUSALITY?',\n",
       "   'S6',\n",
       "   'no_sub_id',\n",
       "   30): 'As described viruses can transform normal cells tumour cells activating oncogenes some cases such as Rous Sarcoma Virus virus itself contains oncogene others such as EBV virus causes proliferation of lymphoid cells that eventually remodel their genome so that expression of cMyc oncogene becomes aberrantly high HPVs integrate pieces of their genome randomly cells When these pieces include oncogenes E and E they transform cells as happens vast majority of cervical and some oropharyngeal tumours    ',\n",
       "  ('QUESTION: IS IT POSSIBLE TO BROADLY UNDERSTAND THE PATHOGENESIS OF VIRUS-MEDIATED ONCOGENESIS? WHAT ARE BRADFORD HILL’S PRINCIPLES OF CAUSALITY?',\n",
       "   'S6',\n",
       "   'no_sub_id',\n",
       "   31): 'In  Sir Austin Bradford Hill  listed nine principles that must be demonstrated epidemiologically order establish causal relationship event and observed effect Bradford Hills principles of causality have been used frequently public health research None of principles proves causal relationship more principles are fulfilled more notion of causal relationship is strengthened Of particular relevance was application of Bradford Hill principles demonstration of causal relationship tobacco use and cancer',\n",
       "  ('QUESTION: IS IT POSSIBLE TO BROADLY UNDERSTAND THE PATHOGENESIS OF VIRUS-MEDIATED ONCOGENESIS? WHAT ARE BRADFORD HILL’S PRINCIPLES OF CAUSALITY?',\n",
       "   'S6',\n",
       "   'no_sub_id',\n",
       "   32): 'The following is list of principles and how they demonstrate recently proposed causeandeffect relationship HPV and oropharyngeal tumours ',\n",
       "  ('QUESTION: HOW COULD THE INVOLVEMENT OF HPV IN GENITAL TUMOURS BE SUMMED UP IN FIGURES?',\n",
       "   'S7',\n",
       "   'no_sub_id',\n",
       "   33): 'HPV is one of main causative agents of cancer as it is implicated cases of all new cancer cases worldwide each year  women  men It is estimated that it caused more half of all cancers attributable infections women  cases vast majority of HPVrelated neoplasms develop anogenital tract primarily cancer of cervix and less frequently cancer of vagina vulva and anus',\n",
       "  ('QUESTION: HOW COULD THE INVOLVEMENT OF HPV IN GENITAL TUMOURS BE SUMMED UP IN FIGURES?',\n",
       "   'S7',\n",
       "   'no_sub_id',\n",
       "   34): 'Cervical cancer is fourth most common cancer women and fourth leading cause of cancer death worldwide second women aged number of new cases was estimated and number of deaths More of cases are diagnosed developing countries agestandardised incidence rate is  cases and mortality rate is  deaths per  women year large variations geographical regions and countries especially depending on extent of screening',\n",
       "  ('QUESTION: HOW COULD THE INVOLVEMENT OF HPV IN GENITAL TUMOURS BE SUMMED UP IN FIGURES?',\n",
       "   'S7',\n",
       "   'no_sub_id',\n",
       "   35): 'All other anogenital cancers that affect both women and men have lower incidence Worldwide  cases are diagnosed of which  are attributable HPV men  cases are diagnosed anus and penis and women  cases anus vulva and vagina both penis and vulva there is clear distinction basaloid or warty tumours clearly causally related HPV and keratinizing tumours that are seen older ages and are not related HPV Moreover these locations it is also more difficult establish which cases HPV is attributable factor this sense most studies accept addition detection of DNAHPV tumour other transforming activity markers such as presence of E or E mRNA or p Based on these data it is estimated that cases attributable HPV are approximately  of anal cancer  of penile cancer  of vaginal cancer and and  of vulvar cancer ',\n",
       "  ('QUESTION: HOW COULD THE INVOLVEMENT OF HPV IN GENITAL TUMOURS BE SUMMED UP IN FIGURES?',\n",
       "   'S7',\n",
       "   'no_sub_id',\n",
       "   36): 'Data on burden of HPVrelated neoplastic disease countries Europe have recently been published estimated number of new cases per year cervical cancer is  cases countries as whole assuming that HPV is causative practically  of cases vulvar cancer there are estimated  cases  if we take account fraction attributable HPV of vaginal cancer there are estimated  cases  if we have fraction attributable HPV anal cancer  cases fraction attributable HPV of  Finally penile cancer  cases  cases fraction attributable HPV of  ',\n",
       "  ('QUESTION: HOW COULD THE INVOLVEMENT OF HPV IN GENITAL TUMOURS BE SUMMED UP IN FIGURES?',\n",
       "   'S7',\n",
       "   'no_sub_id',\n",
       "   37): 'Although anogenital premalignant lesions are much more frequent cancer their lack of recording makes it very difficult estimate their prevalence recent analysis provides data on Europe It is estimated that and  cases of grade  cervical intraepithelial neoplasia CIN are diagnosed annually  cases women and  cases men of grade  anal intraepithelial neoplasia AIN and  cases of grade  and  vulvar intraepithelial neoplasia VIN and and  cases of grade  and  vaginal intraepithelial neoplasia VaIN',\n",
       "  ('QUESTION: HOW COULD THE INVOLVEMENT OF HPV IN GENITAL TUMOURS BE SUMMED UP IN FIGURES?',\n",
       "   'S7',\n",
       "   'no_sub_id',\n",
       "   38): 'High quality cancer incidence data are essential Such information is currently only available small fraction of worlds population absence of this information may lead misinterpretation of actual disease burden as well as possible delay or neglect implementation of preventive measures or impossibility evaluate such measures',\n",
       "  ('QUESTION: WHAT WOULD BE THE IMPACT OF HPV AS A CAUSAL AGENT OF EXTRAGENITAL TUMOURS?',\n",
       "   'S8',\n",
       "   'no_sub_id',\n",
       "   39): 'Beyond anogenital locations HPV is associated head and neck cancer term head and neck cancer has been widely adopted recent literature include lesions several anatomical sites lip oral cavity nose and sinuses nasopharynx oropharynx hypopharynx and larynx HPV is predominantly associated oropharyngeal cancer and that tonsil cancer',\n",
       "  ('QUESTION: WHAT WOULD BE THE IMPACT OF HPV AS A CAUSAL AGENT OF EXTRAGENITAL TUMOURS?',\n",
       "   'S8',\n",
       "   'no_sub_id',\n",
       "   40): 'The classic risk factors head and neck cancer are tobacco and alcohol use but recent decades have seen increase proportion of HPVassociated oropharyngeal cancer cases This increase may be due changes sexual behaviour as well as decrease prevalence of smoking',\n",
       "  ('QUESTION: WHAT WOULD BE THE IMPACT OF HPV AS A CAUSAL AGENT OF EXTRAGENITAL TUMOURS?',\n",
       "   'S8',\n",
       "   'no_sub_id',\n",
       "   41): 'Annually  new cases of HPVassociated oropharyngeal cancer are diagnosed men and women  Globally proportion of HPVassociated cases oropharyngeal cancer is  and of tonsil with large difference depending on countriesregions being more in countries such as USA or Northern Europe and less in countries Africa or other regions   HPV  is most prevalent type found more of HPVpositive tumours It should be noted that HPVrelated oropharyngeal cancers differ unrelated cancers both epidemiological and clinical and molecular characteristics Patients positive HPV tumours appear have better overall and diseasespecific survival compared negative group Laryngeal squamous cell papilloma and recurrent respiratory papillomatosis are well established HPVinduced tumours primarily  and ',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   42): 'Within natural history of chronic hepatitis of viral origin chronic hepatitiscirrhosiscancer sequence has been well known decades This incontrovertible data allows us pose different questions of great relevance such as whether it is possible know epidemiological impact of this association',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   43): 'The question is not simple unlike unidirectional and almost linear relationship other types of viral infection and development of cancer oncogenic capacity of hepatotropic viruses is modulated different factors as listed below',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   44): '',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   45): 'A differential and characteristic data of hepatocellular carcinoma is that more of cases it occurs liver affected cirrhosis Strikingly it is common find hepatocellular carcinoma patients cirrhosis of nonviral cause such as alcoholism and particularly metabolic fatty liver disease This fact besides having marked influence on treatment strategy indicates that mechanisms associated development of cirrhosis inflammation angiogenesis fibrogenesis etc generate microenvironment its own oncogenic potential independent of viral infection itself',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   46): '',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   47): 'Regardless of relatively similar natural history of chronic hepatitis associated virus B and virus C both viruses are very different terms of their own character DNA or RNA virus their replicative cycle or integration host cell genome and different degrees of production of necrosis oxidative stress expression of viral proteins etc Furthermore relationship intensity of viral replication and risk of cancer is clearly different while it is clear virus B it does not exist case of virus C   Finally possibility of liver cancer patients cirrhosis is markedly more frequent patients hepatitis B especially Asia',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   48): '',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   49): 'The contribution of different risk factors linked development of hepatocellular carcinoma has clear geographical differences that are related most frequent causes of cirrhosis each area Thus incidence of hepatocellular carcinoma Europe is mostly associated patients cirrhosis due virus C while Asia this association is virus B ',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   50): '',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   51): 'It is well known that progression of chronic liver disease is affected different factors that are often present patients viral origin chronic liver disease such as alcohol consumption presence of metabolic syndrome or tobacco use It should be noted that they are all wellknown cofactors involved development of cancer Therefore precise contribution of each of factors involved viral and nonviral development of liver neoplasms is difficult define ',\n",
       "  ('QUESTION: IS IT POSSIBLE TO MEASURE THE IMPACT OF THE HEPATITIS B AND C VIRUSES ON THE INCIDENCE OF LIVER TUMOURS?',\n",
       "   'S9',\n",
       "   'no_sub_id',\n",
       "   52): 'In any case there is no doubt that both direct and indirect mechanisms presence of cirrhosis as mentioned association hepatotropic viruses and liver cancer is of unquestionable relevance being possibly responsible more of primary liver tumours',\n",
       "  ('Human T lymphotropic virus type 1 (HTLV-1)',\n",
       "   'S10_1',\n",
       "   'no_sub_id',\n",
       "   53): 'HTLV infects  million people worldwide and its main geographical distribution is Japan Caribbean South America and subSaharian Africa Only  of infected people develop disease and conditions that it causes are adult Tcell leukaemialymphoma ATL and HTLVassociated myelopathy or tropical spastic paraparesis ',\n",
       "  ('Human T lymphotropic virus type 1 (HTLV-1)',\n",
       "   'S10_1',\n",
       "   'no_sub_id',\n",
       "   54): 'People HTLV positive serology have risk of developing ATL over their lifetime risk is greater males and typically appears  decades infection subjects who acquire it childhood rare occurrence those who become infected adulthood ',\n",
       "  ('Human T lymphotropic virus type 1 (HTLV-1)',\n",
       "   'S10_1',\n",
       "   'no_sub_id',\n",
       "   55): 'The HTLV genome is composed of single strand of RNA that is integrated cell It then expresses  oncogenic proteins transcriptional transactivator protein Tax and HBZ protein Both proteins Tax and HBZ are specifically and directly involved oncogenesis Tax being initiator of tumour genesis and HBZ being charge of maintenance ',\n",
       "  ('Human T lymphotropic virus type 1 (HTLV-1)',\n",
       "   'S10_1',\n",
       "   'no_sub_id',\n",
       "   56): 'ATL is characterised clonal proliferation of CD T cells HTLV integrated These cells morphologically have dentate nucleus dense chromatin and basophilic flowerlike cytoplasm There are  clinical forms characteristics if which are summarised Treatment is not very effective any of stages and although aggressive cases there is initial response chemotherapy early relapses fatal outcomes occur short periods of time combination of AZT interferon has been used some patients variable results',\n",
       "  ('Human Immunodeficiency Virus (HIV)',\n",
       "   'S10_2',\n",
       "   'no_sub_id',\n",
       "   57): 'The origin of tumour diseases patients HIV infection is multifactorial most important factors being HIV itself immunosuppression coinfection oncogenic viruses and increased survival due use of antiretroviral treatment ART  HIV is necessary but not sufficient condition as it is not strictly considered oncogenic virus However fragments of its genome have been found some patients NHL and tat gene appears be involved growth of Kaposis sarcoma cells all these reasons it is considered essential agent but not only one development of tumours that appear these patients ',\n",
       "  ('Human Immunodeficiency Virus (HIV)',\n",
       "   'S10_2',\n",
       "   'no_sub_id',\n",
       "   58): 'Immunosuppression and uncontrolled HIV viremia increase risk of developing neoplasms such that undetectable viral load and CD lymphocytes  per mm are factors that protect development of some tumours which explains why decrease number of AIDSdefining malignancies ADM has been observed use of ART On other hand paradoxically there is increase nonAIDSdefining malignancies NADM due part increased survival of patients as result of use of ART which prolongs life completely restoring immune function  All of this conditions greater exposure environmental carcinogens tobacco ultraviolet light greater possibility of superinfection oncogenic viruses and increase possibilities of genetic mutations appearing patients family history of cancer giving rise appearance of neoplasms that other times did not develop due early mortality of patients   ',\n",
       "  ('Human Immunodeficiency Virus (HIV)',\n",
       "   'S10_2',\n",
       "   'no_sub_id',\n",
       "   59): 'Another important point is that presence of HIV causes persistent stimulation of B lymphocytes which alters antitumour immunity facilitates expression of oncogenic genes and allows superinfection viruses oncogenic capacity such as EBV HVH HBV HCV or HPV All ADM are associated viral diseases as well as most frequent ones NADM except pulmonary carcinoma directly related smoking  ',\n",
       "  ('Human Immunodeficiency Virus (HIV)',\n",
       "   'S10_2',\n",
       "   'no_sub_id',\n",
       "   60): 'shows differences and similarities HTLV and HIV',\n",
       "  ('QUESTION: WHAT PROPORTION OF HIV PATIENTS WHO DIE DO SO BECAUSE OF AN HIV-ASSOCIATED NEOPLASM?',\n",
       "   'S11',\n",
       "   'no_sub_id',\n",
       "   61): 'Since introduction of ART mortality people living HIV PLHIV has decreased significantly  so that people died while initial years of epidemic numbers were much higher reaching  deaths However immune reconstitution is generally not complete so patients are exposed effects of chronic inflammation and persistent immune activation Both processes favour appearance of socalled nonAIDS diseases whose importance has progressively increased recent years and which are one of main causes of morbidity and mortality PLHIV This broad group of diseases includes most comorbidities which some cases become more important HIV infection itself other processes cardiovascular pathology renal disease osteoporosis and bone fractures neurocognitive impairment and tumour pathology stand out',\n",
       "  ('QUESTION: WHAT PROPORTION OF HIV PATIENTS WHO DIE DO SO BECAUSE OF AN HIV-ASSOCIATED NEOPLASM?',\n",
       "   'S11',\n",
       "   'no_sub_id',\n",
       "   62): 'Malignant neoplasms are major cause of hospitalisation and death PLHIV as result of ART use and decrease opportunistic infections Today cancer can be diagnosed of patients and while preART era only  of deaths were of tumour origin now up are our environment according data CORIS cohort neoplasms were most frequent cause of death nonAIDS diseases and this same study it is important note that  of tumours diagnosed were AIDSdefining malignancies ADM and  were nonAIDSdefining malignancies NADM  ',\n",
       "  ('QUESTION: WHAT PROPORTION OF HIV PATIENTS WHO DIE DO SO BECAUSE OF AN HIV-ASSOCIATED NEOPLASM?',\n",
       "   'S11',\n",
       "   'no_sub_id',\n",
       "   63): 'At EACS Congress results obtained review of neoplasms diagnosed to Spanish centre were communicated of  patients  suffered least one neoplasm NADM increased over time decrease ADMNADM ratio   patients  died due tumour progression higher mortality NADM  vs ADM  p highest mortality was seen tumours of pancreas  lung  and colon ',\n",
       "  ('QUESTION: WHAT PROPORTION OF HIV PATIENTS WHO DIE DO SO BECAUSE OF AN HIV-ASSOCIATED NEOPLASM?',\n",
       "   'S11',\n",
       "   'no_sub_id',\n",
       "   64): 'Another Spanish group  analysed mortality PLHIV and found that  deaths were directly related AIDS and  of them  were due ADM same series another  deaths occurred due nonAIDS related processes and   were as result of NADM Therefore overall mortality due neoplasm this series was ',\n",
       "  ('QUESTION: WHAT PROPORTION OF HIV PATIENTS WHO DIE DO SO BECAUSE OF AN HIV-ASSOCIATED NEOPLASM?',\n",
       "   'S11',\n",
       "   'no_sub_id',\n",
       "   65): 'In other series outside our scope results are similar Thus Engels et al  found that approximately  of deaths PLHIV receiving ART period were due neoplasm progressive increase over time large proportion of deaths were due nonHodgkins lymphomas lung cancer and hepatocellular carcinoma As our environment it is observed that deaths due NADM are increasing importance while there is decrease number of deaths due AIDS itself',\n",
       "  ('QUESTION: WHAT PROPORTION OF HIV PATIENTS WHO DIE DO SO BECAUSE OF AN HIV-ASSOCIATED NEOPLASM?',\n",
       "   'S11',\n",
       "   'no_sub_id',\n",
       "   66): 'All these studies show decrease mortality AIDSindicating diseases and predominance of deaths nonAIDS diseases recent years neoplasms being one of most frequent causes all series even though patients are on ART and virologically suppressed',\n",
       "  ('QUESTION: WHAT PROPORTION OF HIV PATIENTS WHO DIE DO SO BECAUSE OF AN HIV-ASSOCIATED NEOPLASM?',\n",
       "   'S11',\n",
       "   'no_sub_id',\n",
       "   67): 'In we see reflected importance of death of tumour origin PLHIV other series different those described text',\n",
       "  ('QUESTION: WHAT IS THE INVOLVEMENT OF HERPESVIRUS IN THE CAUSALITY OF CANCER?',\n",
       "   'S12',\n",
       "   'no_sub_id',\n",
       "   68): 'The human herpes virus HHV group includes herpes simplex virus HSV  and  varicella zoster virus VZV cytomegalovirus CMV Epstein Barr Virus EBV HHV  and general they are characterised producing primary infection early age and subsequently establishing latency different tissues which they are able reactivate producing clinical manifestations again we have summarised their most frequent clinical manifestations including tumour processes which they have been associated',\n",
       "  ('QUESTION: WHAT IS THE INVOLVEMENT OF HERPESVIRUS IN THE CAUSALITY OF CANCER?',\n",
       "   'S12',\n",
       "   'no_sub_id',\n",
       "   69): 'Involvement tumour processes is well established EBV and HHV and we will devote most of our review them rest of herpes viruses are not considered directly cause any type of cancer although their role as cofactors is discussed example there is some evidence suggest that HSV may increase risk of cervical cancer HPV infection and that it may play role tumour genesis of serous ovarian carcinoma and some prostate tumours  Associations HHV and different tumours have also been sought but these have not yet been confirmed',\n",
       "  ('QUESTION: WHAT IS THE INVOLVEMENT OF HERPESVIRUS IN THE CAUSALITY OF CANCER?',\n",
       "   'S12',\n",
       "   'no_sub_id',\n",
       "   70): 'We will focus on EBV is primary agent of infectious mononucleosis It establishes latency asymptomatically virtually all adults B cells T cells epithelial cells and myocytes and usually does not cause cytopathic effect However it shows clear ability transform cells and is associated development of Bcell lymphomas Tcell lymphomas Hodgkins lymphomas and nasopharyngeal and other head and neck carcinomas transplant recipients it produces Posttransplant lymphoproliferative disease PTLD that can be very aggressive ',\n",
       "  ('QUESTION: WHAT IS THE INVOLVEMENT OF HERPESVIRUS IN THE CAUSALITY OF CANCER?',\n",
       "   'S12',\n",
       "   'no_sub_id',\n",
       "   71): '',\n",
       "  ('QUESTION: WHAT IS THE INVOLVEMENT OF HERPESVIRUS IN THE CAUSALITY OF CANCER?',\n",
       "   'S12',\n",
       "   'no_sub_id',\n",
       "   72): 'The treatment of all these tumours does not include administration of antivirals cells are not lytic cycle which is necessary Acyclovir be effective usefulness of cell therapy specific cytotoxic Tlymphocytes EBV and Rituximab is being studied',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   73): 'Kaposis sarcoma KS is angioproliferative tumour and one of clearest examples of tumour that requires infection virus and that is also modulated patients immune status pathogenesis of tumour requires infection human herpesvirus  HHV also called Kaposis sarcoma associated herpesvirus KSHV It is named Moritz Kaposi Hungarian dermatologist who first described entity ',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   74): 'Before briefly describing some of characteristics of KS it should be noted that HHV also causes two other tumours  Cavity lymphoma is Bcell nonHodgkins lymphoma that has preference peritoneal pleural and pericardial spaces Castlemans disease is also very rare lymphoproliferative disorder that causes fever splenomegaly hepatomegaly and lymphadenopathy and can affect both HIVnegative and HIVpositive patients',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   75): 'KS is characterised vessel proliferation angiogenesis accompanied inflammation and proliferation of spindle cells HHV infects cells and gene products of virus influence both regulation of cell cycle and control of apoptosis infection induces disordered proliferation of cells that mostly do not express lytic cycle but latent infection addition function of tumour suppressor genes is interrupted and recognition host immune system is prevented thus promoting tumour growth performing PCR biopsy it is possible amplify viral DNA sequences and also identify using immunohistochemistry latent viral antigen spindle cells membrane proteins',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   76): 'are recognised depending on type of patients affected  Classic or sporadic KS which corresponds form originally described Kaposi and which is extraordinarily rare  per year HIVpositive males over Mediterranean area It usually occurs males over  years of age and mainly affects people Mediterranean area Sardinia Sicily etc or Jewish ancestry  Endemic KS prevalent subSaharan Africa AIDS epidemic It affects children and adults and it is believed that continuous exposure certain types of soil facilitates appearance of disease  iatrogenic KS associated use of immunosuppressants and described mainly solid organ transplant recipients  finally AIDSassociated KS epidemic KS better control of AIDS epidemic incidence US has dropped rates that reached  cases per year per million people then Kaposis sarcoma has become less common producing cases per million people each year different epidemiological and clinical aspects of these four types are summarised ',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   77): 'Infection HHV virus is necessary condition development of KS but not sufficient other cofactors are required its appearance such as genetic predisposition sporadic form and all immunosuppression either iatrogenic organ transplant or due HIV infection Thus prevalence of seropositivity population is much higher that of Kaposis sarcoma',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   78): 'The most common of KS especially early stages of tumour is lesions It is characterised appearance of raised violet lesions that mainly affect lower extremities face especially nose oral mucosa and genitals They may be accompanied significant oedema reflecting vascular obstruction lymphadenopathy or action of cytokines involved pathogenesis of tumour Oral lesions appear onethird of patients and mainly affect gums and palate and may interfere nutrition and speech It is important remember that KS can also have  mainly advanced stages affecting mainly gastrointestinal and respiratory tracts gastrointestinal system is now less frequently affected Its diagnosis is difficult absence of concomitant skin lesions Clinical manifestations of gastrointestinal KS include weight loss abdominal pain nausea and vomiting gastrointestinal bleeding malabsorption intestinal obstruction and diarrhoea As lung disease it can appear highly variable radiological findings including nodules single or multiple interstitial or alveolar infiltrates pleural effusion adenopathy or solitary nodules diagnosis is based on characteristic appearance of lesions endoscopy or bronchoscopy and is confirmed biopsy',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   79): 'The incidence of KS is  and represents approximately  of posttransplant tumours excluding skin cancer This incidence is much higher that of general population and is justified chronic immunosuppression required transplant patients Although KS is mostly described HIVpositive patients primary infection transplantation has been shown be most important risk factor our environment  This primary infection can be acquired transplanted organ or administration of blood products or other routes half of KS diagnosed transplant recipients respond only reducing immunosuppression or switching Sirolimus Rapamycin which has antitumour and antiangiogenic effects ',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   80): ' KS has been described all risk groups although higher incidence homosexual or bisexual men relation higher seropositivity rate these patients close KS rates some studies reached   years diagnosis of HIV infection if CD figure was  cellsmm  However although rate of HHV infection has not changed early and effective antiretroviral treatment has significantly reduced frequency of this tumour standardised incidence rate SIR Kaposis sarcoma compared general population was  and declined with widespread use of antiretroviral treatment ',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   81): 'Some HIV patients Kaposis sarcoma present KICS that is characterised fever gastrointestinal respiratory and neurological manifestations and is associated elevated KSHV tumour load',\n",
       "  ('QUESTION: WHAT IS THE RELATIONSHIP BETWEEN KAPOSI’S SARCOMA AND HERPES VIRUS?',\n",
       "   'S13',\n",
       "   'no_sub_id',\n",
       "   82): 'depends on extent of tumour and its location and symptoms As solid organ transplant recipients HIVpositive patients may respond immune recovery initiation of highly active antiretroviral therapy HAART although others may also require local or systemic chemotherapy It has also been observed that KS is less frequent patients who have received Ganciclovir or Foscarnet demonstrating relative sensitivity of virus these antivirals relative survival over five years is over ',\n",
       "  ('Cancer-related bacteria',\n",
       "   'S14_1',\n",
       "   'no_sub_id',\n",
       "   83): ' is helical bacillus that lives exclusively human gastric epithelium infection can cause inflammation of gastric mucosa that can progress leading peptic ulcers and mucousassociated lymphoid tissue  Because of its spiral shape it can literally screw itself to colonize stomach epithelium addition having urease that allows it neutralise its acidic environment bacteria generates free radicals injects cytotoxin known as CagA that alters structure of cells lining stomach and generates locally high levels of molecules signalling inflammation such as TNFalpha or interleukin  that could induce mutation of epithelial cells of stomach  another bacteria digestive tract that causes Whipples disease may be associated similar way neoplasms',\n",
       "  ('Cancer-related bacteria',\n",
       "   'S14_1',\n",
       "   'no_sub_id',\n",
       "   84): 'has been linked hepatobiliary and gall bladder tumours and  and have been linked lung cancer',\n",
       "  ('Cancer-related bacteria',\n",
       "   'S14_1',\n",
       "   'no_sub_id',\n",
       "   85): 'Chronic Bacterial Osteomyelitis and hidradenitis suppurativa are associated squamous cell carcinoma of skin also ',\n",
       "  ('Cancer-related parasites',\n",
       "   'S14_2',\n",
       "   'no_sub_id',\n",
       "   86): 'Millions of people world especially those living tropics suffer some form of parasitic disease oncogenic role of certain parasites has been known many decades Three parasites trematode helminths cause urinary or hepatobiliary tumours  ',\n",
       "  ('Cancer-related parasites',\n",
       "   'S14_2',\n",
       "   'no_sub_id',\n",
       "   87): 'But how can parasite cause cancer Adult helminths are constantly moving burrowing and laying eggs that secrete toxic proteins host tries get rid of them which induces chronic inflammation that can eventually degenerate metaplasia',\n",
       "  ('Cancer-related parasites',\n",
       "   'S14_2',\n",
       "   'no_sub_id',\n",
       "   88): 'However some parasites may be protective tumour genesis inducing apoptosis phenomena and inhibiting signals of inflammatory regulation and angiogenesis Certain proteins excreted and are capable of inhibiting tumour cell growth  and may be used as anticancer therapy future',\n",
       "  ('QUESTION: COULD THE CONCEPTS OF ONCOGEN AND ONCOPROTEINS BE SUMMARISED? AND THE CONCEPT OF GENOMIC INSTABILITY?',\n",
       "   'S15',\n",
       "   'no_sub_id',\n",
       "   89): 'Studies on chicken sarcoma first decade of th century suggested that origin of tumours was viral example pioneering studies Peyton Rous showed how filtering pulverized chicken sarcoma sieve that did not allow cells pass only viruses then injecting extract transmitted sarcoma recipient chicken Throughout almost two thirds of century this viral theory of origin of cancer was main driving force cancer research and fact good number of viruses capable of triggering tumour processes were found As oncologist Ludwik Gross said However some observations did not fit this model example trying explain high incidence of tumours miners Japanese pathologist Katsaburo Yamagiwa  observed that repeated exposure of skin charcoal induced sarcomas rabbits This suggested that carbon must have some chemical agent that induced change animals skin cells and made them grow of control but how',\n",
       "  ('QUESTION: COULD THE CONCEPTS OF ONCOGEN AND ONCOPROTEINS BE SUMMARISED? AND THE CONCEPT OF GENOMIC INSTABILITY?',\n",
       "   'S15',\n",
       "   'no_sub_id',\n",
       "   90): 'The answer finally came s discovery of concept of oncogenes derives presence of genes that are mutated tumour cells and which are responsible transforming them malignant ones',\n",
       "  ('QUESTION: COULD THE CONCEPTS OF ONCOGEN AND ONCOPROTEINS BE SUMMARISED? AND THE CONCEPT OF GENOMIC INSTABILITY?',\n",
       "   'S15',\n",
       "   'no_sub_id',\n",
       "   91): 'These genes perform normal functions cell such as stimulating growth increasing survival or defining identity However presence of certain mutations them means that once translated protein they have altered capacity capable of transforming normal cell malignant one genes that once mutated give rise oncogenes are called  and proteins that are generated these are called discovery of first oncogene was published by  independent laboratories those directed doctors Robert Weinberg Michael Wigler and Spaniard Mariano Barbacid  who managed sequence transforming oncogenes isolated bladder cancer cells ',\n",
       "  ('QUESTION: COULD THE CONCEPTS OF ONCOGEN AND ONCOPROTEINS BE SUMMARISED? AND THE CONCEPT OF GENOMIC INSTABILITY?',\n",
       "   'S15',\n",
       "   'no_sub_id',\n",
       "   92): 'The first oncogene discovered was  which we know today is family of genes whose function is regulate cell growth response growth factors Many others were later discovered notable cases such as or cyclin E  which as case of  control cell growth We now know that many of oncogenes are related genes that control cell growth such way that oncogenic mutations promote uncontrolled proliferation characteristic of tumours While several decades it was thought that most oncogenes were related cell proliferation or their increased survival tumour genome sequencing studies revealed not surprise that fact class of genes most represented oncogenes are those related chromatin and epigenetics Although many cases we still do not fully understand how these alterations epigeneticrelated genes can trigger tumour processes most accepted idea is that these mutations change identity of cells and generate undifferentiated states This undifferentiated cell which has lost its identity is one that subsequently and thanks also other mutations that promote its growth gives rise tumours As expected oncogenic mutations are often targets of tumour treatments and development of drugs that target all types of oncogenes including those epigeneticrelated genes is currently very active field drug development and new antitumour therapies',\n",
       "  ('QUESTION: COULD THE CONCEPTS OF ONCOGEN AND ONCOPROTEINS BE SUMMARISED? AND THE CONCEPT OF GENOMIC INSTABILITY?',\n",
       "   'S15',\n",
       "   'no_sub_id',\n",
       "   93): 'In addition presence of oncogenes another characteristic present practically all tumour cells is genomic instability First described Teodor Boveri beginning of th century  genomic instability is defined as presence of genomes multiple chromosomal aberrations tumour cells such as gain or loss of entire chromosomes chromosomal translocations or loss or duplication of regions of one or more chromosomes Genomic instability is caused failures DNA replication  or distribution of chromosomes mitosis processes that are often involved tumour cells Furthermore it has recently been discovered that oncogenes are also source of genomic instability as they promote abnormal replication that leads DNA damage Fortunately all cells have mechanisms that suppress genomic instability and normal cells keep their genome stable fact that genomic instability is distinctive feature of tumour cells has opened door antitumour strategies based on selectively killing cells genomic instability One known example is polyADPribose polymerase PARP inhibitors that have been shown be effective killing tumour cells deficiencies DNA repair breast ovarian and prostate tumours  Another alternative that is now being clinically studied and which laboratory of one of us played important role is that of ATR kinase inhibitors which are mainly responsible type of genomic instability initiated oncogenes ',\n",
       "  ('QUESTION: WHAT PROPORTION OF CANCER DEATHS CAUSED BY VIRUSES COULD BE PREVENTED BY EXISTING VACCINES?',\n",
       "   'S16',\n",
       "   'no_sub_id',\n",
       "   94): 'Cancer mortality series offer uneven picture regions of world due multiplicity of factors involved their genesis global approach estimates that million cancer deaths could be avoided annually if underlying infections that led development of tumour were prevented or treated ',\n",
       "  ('QUESTION: WHAT PROPORTION OF CANCER DEATHS CAUSED BY VIRUSES COULD BE PREVENTED BY EXISTING VACCINES?',\n",
       "   'S16',\n",
       "   'no_sub_id',\n",
       "   95): 'A pioneering contribution this area is that of Catherine de Martel et al  who published their analysis of incidence of  types of cancer countries Lancet Oncology describing fact that two thirds of these deaths occur less developed countries These authors carried analysis estimate proportion of cancers globally that could be attributed infections and have calculated categorising planet eight regions population that could be affected new tumours and which could have been prevented specific intervention exposure They point that of million new cancers worldwide about  million were attributable infections and of these  million  were developing countries Of million deaths that occurred attributable oncological process estimated  million were due potentially preventable and treatable infections upwardly weighted estimate of  deaths worldwide could be prevented every hour tumours caused infectious agents potentially preventable immunisation',\n",
       "  ('QUESTION: WHAT PROPORTION OF CANCER DEATHS CAUSED BY VIRUSES COULD BE PREVENTED BY EXISTING VACCINES?',\n",
       "   'S16',\n",
       "   'no_sub_id',\n",
       "   96): 'There are significant contrasts different areas of planet how these infections are responsible oncogenesis Thus Australia and New Zealand infectious origin of cancer is identified of cases compared in SubSaharan Africa women cervical cancer accounted approximately half of cancer burden related infection men liver and gastric cancers accounted more About  of cases attributable infections occur people In smaller scope Spanish group has been able describe series of  cervical smears collected and women screened Human Papillomavirus HPV Castilla y León that its prevalence foreign women was  significantly higher in Spanish women  p  and that presence of morphological changes foreign women was also higher ',\n",
       "  ('QUESTION: WHAT PROPORTION OF CANCER DEATHS CAUSED BY VIRUSES COULD BE PREVENTED BY EXISTING VACCINES?',\n",
       "   'S16',\n",
       "   'no_sub_id',\n",
       "   97): 'The application of preventive public health methods which already exist such as vaccines or antiinfective treatments another conceptual framework could have significant effect on global burden of cancer future specific field of viral agents it is worth noting that we already have vaccines proven effectiveness HPV and Hepatitis B Virus HBV  Increasing vaccine coverage should be priority health systems highburden countries as G Danaei  states editorial accompanying aforementioned study ',\n",
       "  ('QUESTION: WHAT PROPORTION OF CANCER DEATHS CAUSED BY VIRUSES COULD BE PREVENTED BY EXISTING VACCINES?',\n",
       "   'S16',\n",
       "   'no_sub_id',\n",
       "   98): 'A significant proportion of cancer cases attributable infections can be prevented improvements vaccination and screening programmes Expansion of vaccination HBV and HPV screening and treatment programmes eg Hepatitis C Virus HCV could greatly reduce mortality due them',\n",
       "  ('QUESTION: WHAT PROPORTION OF CANCER DEATHS CAUSED BY VIRUSES COULD BE PREVENTED BY EXISTING VACCINES?',\n",
       "   'S16',\n",
       "   'no_sub_id',\n",
       "   99): 'An additional aspect of vaccination programmes is describe their acceptance population carry economic assessment studies that verify their suitability and availability perspective of social funder and establish their accessibility',\n",
       "  ('QUESTION: WHAT PROPORTION OF CANCER DEATHS CAUSED BY VIRUSES COULD BE PREVENTED BY EXISTING VACCINES?',\n",
       "   'S16',\n",
       "   'no_sub_id',\n",
       "   100): 'In developed countries context of patients coinfected Human Immunodeficiency Virus HIV very suggestive lines of work have been established De Martel and Plummers own group  These authors indicate that although HPV and hepatotropic viruses such as HBV and HCV do not represent differentiated weight this category of patients USA they do constitute Human Herpesrvirus HHV expense of its aetiological involvement Kaposis Sarcoma and EpsteinBarr Virus EBV due its causal relationship lymphoid pathology There is no doubt that research applied vaccines that can be extended family will represent decisive impulse towards minimising their impact on patients coinfected HIV',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   101): 'Vaccines human papillomavirus HPV induce elevated production of antibodies capable of neutralising virus and preventing infection of anogenital tract and therefore possible development of precancerous lesions and cancer Given natural history of infection which requires years or decades initiation development of cancer protection persistent infection and premalignant lesions is considered surrogate marker of protection cancer',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   102): 'More years commercialisation of HPV vaccines many studies provide data on their effectiveness effectiveness general population and real life fact that there is reduction prevalence of vaccine genotypes or reduction rate of premalignant lesions vaccinated population is certainly indicative of protection cancer',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   103): 'A recent systematic review and metaanalysis assesses populationlevel impact of vaccine effectiveness realworld setting total of  countries and territories have initiated vaccination programmes WHO expanded recommendation favour of promoting vaccination of multiple cohorts of girls over singlecohort vaccination analysis of  potential articles allowed final inclusion of  articles carried in  highincome countries  articles assess HPV infection anogenital warts and CIN lesions This metaanalysis of over  million individuals and  years of postvaccination followup provides compelling evidence of substantial impact of vaccination programmes on reducing HPV infection and diagnosis of anogenital warts and CIN lesions ',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   104): 'Specifically prevalence of HPV  and  decreased significantly RR   CI •–• girls aged  and  RR   CI •–• women aged  Also prevalence of HPV   and  decreased significantly RR   CI •–• girls aged  years Five nine years vaccination diagnosis of CIN lesions decreased significantly RR   CI •–• girls aged  years and RR •  CI •–• women aged  years',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   105): 'This metaanalysis demonstrates stronger and faster direct impact as well as herd effect countries high coverage and which included multiple vaccine cohorts Therefore these realworld data confirm that both cause highrisk HPV infection and immediate precancer condition CIN are decreasing significantly vaccinated populations and therefore vaccine is effective preventing cervical and other HPVrelated cancers ',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   106): 'Another recent study US assessed type of HPV present cytology samples women aged  years assessed Kaiser Permanente Northwest and two periods of vaccine era  and prevalence of vaccine HPV types went in in years introduction of vaccine prevalence of HPV vaccine types decreased among  years old and among  years old This decrease was observed both vaccinated and unvaccinated women which is evidence of both direct and herd protection ',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   107): 'In same vein data Scotland nine cohorts of women aged  years have been published evaluate effectiveness of bivalent vaccine preventing precancerous lesions analysis confirms reduction prevalent CIN reduction CIN and reduction CIN vaccinated women born and  compared unvaccinated women born Unvaccinated women also showed lower prevalence of CIN lesions supporting herd protection effect Because of this effect reduction HPV  infections would not only impact women themselves but also overall network of sexual relationships men and women fact that vaccination programme reduced all types of CIN lesions and not only those related types  and  included bivalent vaccine indicates strong crossprotection other common oncogenic types such as HPV accordance previous clinical trials ',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   108): 'Finally data registries showing decrease cervical cancer are still very early stage Specifically Finland monitoring of cancer registries vaccinated women clinical trials and their comparison unvaccinated cohorts period  confirms that not single case was diagnosed vaccinated cohort versus  cases of HPVrelated cancer unvaccinated cohort  cases of cervical cancer one vulvar cancer and one oropharyngeal cancer However this analysis vaccinated and unvaccinated cohorts were not comparable which limits interpretation of data ',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   109): 'Another study of annual incidence of invasive cervical cancer United States compares four years prior introduction of vaccine – vaccine era – There was significant  reduction average annual incidence rates study period  versus  per  people rate ratio =   CI women aged years and  lower women years these years vaccine coverage increased in younger cohorts Although incidence rates had already declined prior introduction of vaccine these strongly declining data suggest that it may be partly attributable introduction of HPV vaccine ',\n",
       "  ('QUESTION: WHAT IMPACT IN NUMBERS HAS HPV VACCINATION HAD ON REDUCING FEMALE GENITAL CANCER?',\n",
       "   'S17',\n",
       "   'no_sub_id',\n",
       "   110): 'In relation impact on nongenital tumours case of both anal and oropharyngeal cancer more of HPVassociated cases are caused HPV and more by least one of types currently available vaccines would have very high reduction impact on these two types of cancer',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   111): 'The question posed is interesting epidemiologyfiction exercise of great future importance and of enormous potential value terms of public health',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   112): 'The theoretical substrate of question is essentially based on fact that there is no reservoir other human beings viruses B and C which encourages logical hope that their elimination implantation of universal vaccination or means of antiviral treatment applied all possible patients would be capable of clearly attenuating even its disappearance liver diseases associated chronic viral infection including primary liver cancer This attractive concept would be particularly true ideal scenario of no new patients hepatitis B due vaccination although risk of cancer would persist those patients already infected whom screening would still be essential',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   113): 'However there are several elements that mitigate undoubted potential impact on incidence of hepatocellular carcinoma',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   114): '',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   115): 'Different studies have clearly shown that sustained viral response patients treated direct antivirals has marked effect on progression of liver disease patients early stages of infection and that it reduces risk of complications patients more advanced disease However patients significant portal hypertension over  mmHg ie those more advanced disease and risk of developing complications of cirrhosis antiviral treatment fails lower portal pressure risk threshold significant proportion of patients higher it is greater degree of deterioration Therefore risk of developing hepatocellular carcinoma clearly influenced presence of cirrhosis severe portal hypertension is not eliminated despite elimination of virus patients advanced disease',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   116): 'Therefore as long as there are patients treated whom there is basically advanced fibrosis risk of developing hepatocellular carcinoma is not zero There are no data however quantify safe threshold of fibrosis which screening would not be necessary',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   117): 'ii',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   118): 'This is very controversial issue arising observation Spanish multicentre study of increased frequency of hepatocellular carcinoma recurrence and its severity patients hepatocellular carcinoma treated radical intent and who immediately afterwards received antiviral treatment hepatitis C researchers speculated possible impact of abrupt suppression of chronic immune response associated cure of C virus infection loss of antitumour surveillance mediated immune system cells Information and this hypothesis has emerged this study general it can be considered that antiviral treatment does not per se increase risk of developing hepatocellular carcinoma patients cirrhosis no known tumour However delaying attempt eradicate virus patients recently treated hepatocellular carcinoma is recommended ',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   119): 'iii',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   120): 'As discussed previous questions presence of cirrhosis per se regardless of its cause is prooncogenic factor This is extremely important patients who are carriers of fatty metabolic liver disease which is real epidemic Western world Strikingly this disease whose pathogenic complexity and systemic inflammatory substrate are widely known has its own prooncogenic mechanisms epidemiological point of view it is important note that patients hepatocellular carcinoma associated fatty metabolic liver disease are more frequently observed in other noncirrhotic liver aetiologies are diagnosed more advanced stages and are therefore less likely receive treatment curative intent future impact terms of increased incidence of hepatocellular carcinoma associated this disease is not known certainty but if forecasts of increased prevalence worldwide are true dramatic increase can be expected medium term fact recent studies  clearly reinforce this trend',\n",
       "  ('QUESTION: IN AN IDEAL WORLD IN WHICH HEPATITIS C IS ERADICATED, COULD WE ESTIMATE THE DECREASE IN MORTALITY ATTRIBUTABLE TO LIVER TUMOURS? WHAT WOULD BE THE IMPACT ON TUMOUR MORTALITY IN A WORLD WHERE HEPATITIS B VACCINATION WAS UNIVERSAL?',\n",
       "   'S18',\n",
       "   'no_sub_id',\n",
       "   121): 'Ultimately impact of universal elimination of hepatotropic viruses on development of liver cancer would be of great importance although it would not completely eliminate this dreaded disease',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   122): 'The relationship viruses and cancer is clearly underestimated and little known both professional level and population level despite such strong data as fact that second carcinogen demonstrated worldwide present is virus HPV ',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   123): 'Successful and widespread vaccines have been achieved HBV and HPV but widespread vaccine EBV remains elusive EBV as already mentioned is oncogenic virus as proven its association Burkitts lymphoma and its ability transform B cells vitro expression of EpsteinBarr nuclear antigens EBNA and latent membrane protein LMP EBVinfected cells are also capable of withstanding cellular lysis of acute infection and this also contributes neoplastic development',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   124): 'The lifelong persistence of EBV humans is complex multistep process that begins infection of oropharynx and culminates maintenance of EBV circulating memory B cells EBV probably uses normal Bcell differentiation pathway achieve persistence because it is able implement various latency and lytic transcription programmes assuming different antigenic states infected individuals However despite wide variety of antigens that predominate throughout EBV life cycle EBV candidate vaccines have traditionally focused on only limited number of EBV antigens ',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   125): 'Both therapeutic and prophylactic vaccines have been explored',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   126): 'Therapeutic vaccines aim enhance and maintain immune response patients EBVassociated disorders and have been studied mainly nasopharyngeal carcinoma using dendritic cells specific CD epitopes LMP and using MVA Modified Vaccinia Ankara platform including LMP and EBNA  antigens data suggests that tumour growth can be controlled immune system  These studies have led trials different therapeutic vaccines that have been well tolerated and results of phase I and II trials are encouraging but suggest that they are not themselves solution nasopharyngeal carcinoma main carcinoma on which these types of vaccines have been tested as they have effect on only low proportion of patients and on temporary basis ',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   127): 'The largest number of studies have focused on prophylactic vaccines',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   128): 'In first test was performed recombinant attenuated virus itself and did not induce antibodies seropositive adults experts faced these results decided that vaccination was not appropriate approach control this virus',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   129): 'Over past two decades trials have been based on glycoprotein  which led phase II trial sample size of  people threedose protocol antibodies remained months and incidence of infectious mononucleosis was reduced but vaccine did not reduce risk of acquiring EBV infection ',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   130): 'Work has also been done vaccine based on glycoprotein its prekidney transplant application children that was not very immunogenic ',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   131): 'Similar data were obtained Phase II trial vaccine using toxoid conjugated EBNA nuclear antigen designed elicit specific Tcell responses EBV but it also failed prevent EBV infection It should be noted that this vaccine is very simple perform due simplicity of antigen ',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   132): 'Antigenantibody conjugates or antigenarmed antibodies AgAbs which specifically deliver antigenic peptides antigenic cells  have also been used as vaccine candidates conclusive results',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   133): 'EBV antigens have also been introduced viruslike particles   and selfassembling nanoparticles These platforms allow monomeric antigens be similar EBV but as they lack DNA they are not infectious Chimeric viruses are also achieved fusion of EBV antigens structural proteins of Newcastle disease virus these structures example gp induces greater response vaccination  ',\n",
       "  ('QUESTION: IS THERE A PROSPECT FOR AN EPSTEIN-BARR VIRUS VACCINATION?',\n",
       "   'S19',\n",
       "   'no_sub_id',\n",
       "   134): 'All these studies leave us long way achieving effective vaccine EBV and its primary diseases and more importantly its ability induce tumour processes',\n",
       "  ('QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM?',\n",
       "   'S20',\n",
       "   'no_sub_id',\n",
       "   135): 'An oncolytic virus is virus that preferentially infects and kills cancer cells As infected cancer cells are destroyed oncolysis releases new viral particles that help destroy remaining tumour',\n",
       "  ('QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM?',\n",
       "   'S20',\n",
       "   'no_sub_id',\n",
       "   136): 'The potential of viruses as anticancer agents was first discovered early th century although coordinated research efforts did not begin s Several viruses including adenovirus reovirus measles virus HVS Newcastle disease virus and others have been clinically tested as oncolytic agents',\n",
       "  ('QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM?',\n",
       "   'S20',\n",
       "   'no_sub_id',\n",
       "   137): 'Most current oncolytic viruses are designed be selective tumour cells although there are naturally occurring examples such as Reovirus and Senecavirus that have been used clinical trials',\n",
       "  ('QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM?',\n",
       "   'S20',\n",
       "   'no_sub_id',\n",
       "   138): 'The acquisition of virus selectivity tumour cell can be obtained modifying proteins of viral capsid giving it high selectivity tumour cells It can also be achieved modifying virus genome so that replication only takes place inside tumour cell This is achieved either modifying transcription target cell or attenuation which involves introducing deletions viral genome favour its entry tumour cells and eliminate its ability penetrate healthy cells It is also possible introduce genes oncolytic viruses that encode synthesis of endostatin and angiostatin natural proteins that inhibit angiogenesis consequent necrosis of tumour',\n",
       "  ('QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM?',\n",
       "   'S20',\n",
       "   'no_sub_id',\n",
       "   139): 'Oncolytic viruses not only cause direct destruction of tumour cells but also stimulate hosts antitumour immune system responses Most are genetically modified increase tumour tropism and reduce virulence nonneoplastic host cells  Thus they can stimulate proinflammatory environment improving antigen releaserecognition and subsequent immune activation counteract immune evasion malignant cells fact oncological tic viruses also aim take advantage of tumours tolerance mechanisms which can facilitate viral infection and death of cells that are not protected immune system This allows theoretical domino effect involving chained viral transfer neoplastic cells and increased immune activation',\n",
       "  ('QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM?',\n",
       "   'S20',\n",
       "   'no_sub_id',\n",
       "   140): 'There are currently numerous viral species different stages of research immunooncological use Possibly best studied so far are herpes viruses of which some strains have been found have tropism natural tumour cells while others have been designed improve selectivity  Initial scans using herpes have shown promising results murine glioblastoma Additional efficacy has been seen prostate cancer using recombinant smallpoxvaccine virus capable of regulating prostatespecific antigen and expression of three costimulating factors involved presence of antigen and activation of T cells addition several strains of recombinant vaccine virus have shown promise as antineoplastic agents One strain has antitumour angiogenesis another has shown efficacy hepatocellular carcinoma animal models and third improves recognition of tumour cells  Other viruses have been or are being explored as possible vehicles of immunomodulation cancer such as Newcastle disease virus coxsackievirus reovirus and even measles virus ',\n",
       "  ('QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM?',\n",
       "   'S20',\n",
       "   'no_sub_id',\n",
       "   141): 'Among those approved treatment FDA is Talimogene laherparepvec OncoVEX GMCSF also known as Tvec Amgen which successfully completed phase III trials advanced melanoma March October US Food and Drug Administration approved Tvec brand name Imlygic® treatment of melanoma patients inoperable tumours becoming first approved oncolytic agent Western world It is based on Herpes simplex virus HSV It has also been tested Phase I trial pancreatic cancer and Phase III trial head and neck cancer with chemotherapy and radiotherapy cisplatin',\n",
       "  ('QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM?',\n",
       "   'S20',\n",
       "   'no_sub_id',\n",
       "   142): 'Oncolytic viruses are generally associated therapeutically other therapeutic strategies such as association checkpoint inhibitors Ipilimumab Pembrolizumab Atezolizumab antitumour lymphocytes CART or associations of oncolytic viruses tumour epitopes vaccines',\n",
       "  ('QUESTION: WHAT ARE ONCOLYTIC VIRUSES? WHAT ARE THE PROSPECTS FOR TREATMENT WITH THEM?',\n",
       "   'S20',\n",
       "   'no_sub_id',\n",
       "   143): 'Clinical trials oncolytic viruses entities as different as colorectal cancer glioblastoma tumours widespread metastases pancreatic cancer bladder cancer ovarian cancer or primary tumours of peritoneum are underway and represent hope therapeutic future of these malignancies',\n",
       "  ('QUESTION: WHAT IS THE COST TO HEALTH CARE SYSTEMS OF TUMOURS DUE TO VIRUSES THAT COULD HAVE BEEN AVOIDED? WHAT ROLE SHOULD HEALTH AUTHORITIES PLAY IN APPROACHING THIS ISSUE?',\n",
       "   'S21',\n",
       "   'no_sub_id',\n",
       "   144): 'In addition human cost of cancer financial cost is considerable Direct costs include treatment expenses as well as cost of care and rehabilitation Indirect costs include loss of economic output due work lost and premature death There are also costs that are difficult quantify such as nonmedical costs exact global cost of cancer is unknown but is expected increase due increase number of new cancer cases as well as rising cost of cancer therapies ',\n",
       "  ('QUESTION: WHAT IS THE COST TO HEALTH CARE SYSTEMS OF TUMOURS DUE TO VIRUSES THAT COULD HAVE BEEN AVOIDED? WHAT ROLE SHOULD HEALTH AUTHORITIES PLAY IN APPROACHING THIS ISSUE?',\n",
       "   'S21',\n",
       "   'no_sub_id',\n",
       "   145): 'The health authorities must act on this issue fundamentally modifying prevention of risk factors and implementing preventive strategies',\n",
       "  ('QUESTION: WHAT IS THE COST TO HEALTH CARE SYSTEMS OF TUMOURS DUE TO VIRUSES THAT COULD HAVE BEEN AVOIDED? WHAT ROLE SHOULD HEALTH AUTHORITIES PLAY IN APPROACHING THIS ISSUE?',\n",
       "   'S21',\n",
       "   'no_sub_id',\n",
       "   146): 'The risk factors most immediate intervention are decrease genital HPV infections where other means it is possible intervene vaccines and vaccination and treatment of hepatitis virus infections ',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   147): 'Over last ten years press and media have reduced resources spaces and personnel dedicated generating producing and writing health and medical content as result of economic crisis that affected them both closure of companies and newspaper titles as well as financial adjustments and staff cuts',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   148): 'Training and specialisation levels have also been reduced health sanitation and science sections same reasons',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   149): 'Despite variability of economic crisis media have not recovered lost ground and continue be immersed situations of weakness and economicfinancial fragility',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   150): 'The impact of new technologies no longer so new and possibilities they have offered opening up publication of content society as well as appearance of new communication channels have posed risk media and threat of loss or dissolution of their preponderant role as central and principal reference of information society having compete platforms such as internet its broadest facet of distribution of all kinds of products social networks and socalled citizen journalism',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   151): 'Despite these circumstances press and media have placed cancer and everything related this disease forefront of relevance and interest respect health and healthcare issues and content giving it media prominence other diseases broad and compact informative approach that considers angles and approaches ranging health policy variety of tumours role of patients research and scientific advances work of medicalscientific societies and oncology sector activity of health or pharmaceutical centres and companies commemoration of World Days etc',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   152): 'Journalism loves cancer would be quick and easy headline',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   153): 'Having thus explained and exposed prominence of cancer press and media broad diversified and comprehensive scope it must also be said that viruses infections their prognosis their effects and their medical and social impact as public health issue are also subject of strong media coverage such as flu AIDS and hepatitis',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   154): 'However  and here we have paradox of two related worlds that are disconnected both media and society  despite many studies and evidence that link and concatenate viruses cancer information dissemination knowledge and content provided media their health and cancer information society hardly connect these two aspects unlike others such as cancersmoking or cancerageing',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   155): 'The role of vaccines time when antivaccine movements are rearming and advancing first on social networks and then society is also decisive this issue and while big question popular imagination continues be whether cancer vaccine will ever be discovered medicine has some that serve curb certain tumours',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   156): 'Thus press and media neither transmit nor have great knowledge binomial subject of study of this Symposium they do not dedicate special time space resources or contents informative or educational this specific angle of many news stories they publish cancer',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   157): 'We suggest therefore some measures media report on cancer and viruses',\n",
       "  ('QUESTION: IS THE PRESS AWARE OF THIS ISSUE? WHAT ROLE SHOULD IT PLAY?',\n",
       "   'S22',\n",
       "   'no_sub_id',\n",
       "   158): '',\n",
       "  ('QUESTION: HOW IS THE VIRUS CANCER RELATIONSHIP EXPERIENCED, FROM THE PERSPECTIVE OF THE SPANISH PATIENTS WITH CANCER GROUP, GEPAC?',\n",
       "   'S23',\n",
       "   'no_sub_id',\n",
       "   159): 'The Virus and Cancer association is little known population and information cancer patient associations is also partial and deficient this respect Therefore great deal of educational and informative work remains be done this area This absence often forces one turn Doctor Google information which can lead misinformation one does not know which sites are reliable or does not have sufficient knowledge fully understand and interpret data that appear',\n",
       "  ('QUESTION: HOW IS THE VIRUS CANCER RELATIONSHIP EXPERIENCED, FROM THE PERSPECTIVE OF THE SPANISH PATIENTS WITH CANCER GROUP, GEPAC?',\n",
       "   'S23',\n",
       "   'no_sub_id',\n",
       "   160): 'Probably what resonates most patients families and society large are associations such as HPV HBV or HIV and cancer According US National Cancer Institute Certain infectious germs including viruses bacteria and parasites can cause cancer or increase risk of tumour formation Also some infections weaken immune system making body less able fight other infections that cause cancer Some viruses bacteria and parasites also cause chronic inflammation that can lead cancer ',\n",
       "  ('QUESTION: HOW IS THE VIRUS CANCER RELATIONSHIP EXPERIENCED, FROM THE PERSPECTIVE OF THE SPANISH PATIENTS WITH CANCER GROUP, GEPAC?',\n",
       "   'S23',\n",
       "   'no_sub_id',\n",
       "   161): 'With no knowledge of these basic facts it should not be surprising that social demand and requirement patients and associations adequate vaccines when they exist is also not of appropriate intensity It is often ignored that protection condom is not always sufficient prevention of all types of sexually transmitted viruses addition limiting sexual partners',\n",
       "  ('QUESTION: HOW IS THE VIRUS CANCER RELATIONSHIP EXPERIENCED, FROM THE PERSPECTIVE OF THE SPANISH PATIENTS WITH CANCER GROUP, GEPAC?',\n",
       "   'S23',\n",
       "   'no_sub_id',\n",
       "   162): 'GEPAC wants highlight need sex education prevention of STDs teach safe sexual practices care personal health and our sexual partners If we are informed we know all ways of contagion and we are aware of importance of medical checkups if we live dangerous situations we can reduce number of people affected this type of illness',\n",
       "  ('QUESTION: HOW IS THE VIRUS CANCER RELATIONSHIP EXPERIENCED, FROM THE PERSPECTIVE OF THE SPANISH PATIENTS WITH CANCER GROUP, GEPAC?',\n",
       "   'S23',\n",
       "   'no_sub_id',\n",
       "   163): 'It should be noted that most of viruses that can pose cancer risk can be transmitted certain body fluids or blood And not only that this type of virus and thus disease addition health problems they entail are linked psychological repercussions that will depend on severity of your situation symptoms and treatment received',\n",
       "  ('QUESTION: HOW IS THE VIRUS CANCER RELATIONSHIP EXPERIENCED, FROM THE PERSPECTIVE OF THE SPANISH PATIENTS WITH CANCER GROUP, GEPAC?',\n",
       "   'S23',\n",
       "   'no_sub_id',\n",
       "   164): 'In addition it can lead anxiety depression or feelings of guilt or fear of criticism due social stigma Perhaps guilt is most difficult emotion handle situation where contraction of virus seems be linked risky sexual practices',\n",
       "  ('QUESTION: HOW IS THE VIRUS CANCER RELATIONSHIP EXPERIENCED, FROM THE PERSPECTIVE OF THE SPANISH PATIENTS WITH CANCER GROUP, GEPAC?',\n",
       "   'S23',\n",
       "   'no_sub_id',\n",
       "   165): 'For all these reasons we can conclude that only educating young people and working groups most risk will we be able have informed adults future and thus reduce cases of infection',\n",
       "  ('QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE?',\n",
       "   'S24',\n",
       "   'no_sub_id',\n",
       "   166): 'Classical medical training one we received medical schools has been and is victim of bias that vitiates many of our approaches issues such as one raised here that of relationship viruses and cancer It is bias that did not exist classical medicine but has become invasive early th century advances experimental research made it possible that moment on describe great precision pathognomonic symptoms of some diseases almost same time as their causal agents were found Think example of microorganisms that were identified dozens late th century and which led utopia of thinking that each morbid species would be produced specific agent meningitis meningococcus pneumonia pneumococcus etc On other hand advances experimental pharmacology allowed identification of first specific drugs that acted aetiological agents that produced diseases leaving all other organic structures unharmed It was dream of Béchamps atoxyl and Ehrlichs magic bullets',\n",
       "  ('QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE?',\n",
       "   'S24',\n",
       "   'no_sub_id',\n",
       "   167): 'At heart of all this was unconscious presupposition that of specificity Diseases were species those botany and zoology catalogue of diseases similar Linnaeuss Systema Naturæ catalogue of morbid species could therefore be drawn up Each of them would have specific aetiology which example microbiology would discover and specific therapeutics would also begin be found which attacking cause of disease would restore state of health It was therefore linear process starting specific cause continuing clinical picture of morbid species and ending application of specific treatment It was chain of specificity role of medicine was find remedies usually pharmacological that would act on specific agent and allow restitutio ad integrum paradigmatic example of this is pulmonary tuberculosis clinical picture of this disease which was very common time of industrial revolution was described great precision great masters of anatomical clinical method including Laënnec Koch identified bacillus that caused it and later midth century first specific treatment streptomycin was developed that moment on every doctor knew what he had do use that antibiotic and tuberculosis and TB drugs that came soon to kill Koch bacillus and thus cure disease',\n",
       "  ('QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE?',\n",
       "   'S24',\n",
       "   'no_sub_id',\n",
       "   168): 'But example of tuberculosis is very illustrative of limitations of this way of understanding disease I still remember debates tuberculosis my time as medical student s Could it be said that TB was caused Kochs bacillus Wasnt it also true that pauperism malnutrition poor hygiene etc played role What was cause of tuberculosis Was it just one or was it many And how articulate them',\n",
       "  ('QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE?',\n",
       "   'S24',\n",
       "   'no_sub_id',\n",
       "   169): 'I have brought this example mind because it is very illustrative of way which school medicine has understood illness and because it expresses very well socalled chain of specificity TB is caused Kochs bacillus If we eradicated it there would be no pulmonary tuberculosis even pauperism malnutrition etc These on other hand are not strictly medical issues but social ones',\n",
       "  ('QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE?',\n",
       "   'S24',\n",
       "   'no_sub_id',\n",
       "   170): 'Let us now turn our problem that of viruses and cancer It is clear that cancer is result of genetic dysregulation This alteration is produced various agents including viruses If we were able eliminate these or correct alterations they produce genome means of gene editing techniques some if not all of important types of cancer would disappear That is goal of medicine and that is aim of research being done today It is again linear scheme chain of specificity',\n",
       "  ('QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE?',\n",
       "   'S24',\n",
       "   'no_sub_id',\n",
       "   171): 'Things are however more complex There is no single causal factor fact this term should disappear our vocabulary or least become discreet second term Cause is what necessarily produces effect so that even if all concomitant factors were disappear effect would be produced it alone Something impossible affirm empirical world What we know are not causes even if they seem be but functional correlations fact all experimental research aims identify them as precisely as possible They are correlations not causes And these correlations there is no doubt that Koch bacillus plays important role but so do immunity and environmental conditions etc fact not every person infected Kochs bacillus develops tuberculosis',\n",
       "  ('QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE?',\n",
       "   'S24',\n",
       "   'no_sub_id',\n",
       "   172): 'Rather establishing linear relationship cause clinical picture and therapy it is necessary make use of more complex schemes of circular or least spiral nature genesis of cancer endogenous factors intervene such as genome we have but also exogenous factors fact is that viruses are some of those exogenous factors that infect cells and alter their genetic information There are many other exogenous factors that produce similar results Think of radiation example or tobacco These are factors that can be called direct But there are many other indirect factors Thus tobacco is direct agent case of certain lung cancers but acts as indirect agent hepatocellular carcinoma And with tobacco and alcohol place sexual habits case of infection human papillomavirus food habits fatty liver and increased likelihood of liver cancer etc',\n",
       "  ('QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE?',\n",
       "   'S24',\n",
       "   'no_sub_id',\n",
       "   173): 'The conclusion of all this already long journey is that life habits are important factors genesis of cancer some cases indirectly viruses and others directly This seems elementary but it is far clear not only population but even doctors We believe that what is important is control of gene alterations that trigger uncontrolled cell reproduction and that other is not question of medicine And we lose sight of fact that rather being curative medicine should be preventative dizzying increase its therapeutic capacity is making us forget this primary truth primary role of physician is not cure but prevention health education is preferable Otherwise we arrive absurdity that we live and suffer every day This is case of diabetic who eats cakes because this can be fixed increasing dose of insulin or loss of respect HIV because we already have effective therapies',\n",
       "  ('QUESTION: WHAT ARE THE REFLECTIONS ON THE VIRUS CANCER RELATIONSHIP FROM AN ETHICAL PERSPECTIVE?',\n",
       "   'S24',\n",
       "   'no_sub_id',\n",
       "   174): 'Prevention or rather health education is not just information That is one of great mistakes that have become almost universal Educating is far more difficult and complicated informing Education is always knowing how manage ones own life autonomously and prudently Its knowing how make right decisions Or put it another way its making choices we have make And heres ethics aim of this discipline is none other to teach us how make decisions right decisions so that we do what we have do big question of ethics is always same what should I do And there can only be one answer all possible courses of action given situation only decision that leads optimal course is good or correct that is one which adheres values stake most and injures them least Only optimum course is good Everything else is bad good surgeon is one who performs best possible operation and good judge is one who passes best possible sentence etc know how do this and do it well is be educated This is not easy because human mind is full of dark areas those that Freud called unconscious that skew our decisions us noticing Good education is art of managing all these factors properly so that our decisions are best they can possibly be This and no other is goal of ethics'},\n",
       " {('1. Introduction',\n",
       "   'sec1-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   0): 'Breast BCa and gynecological GCa cancers constitute group of female neoplasms ICD C C– that has significant contribution cancer morbidity and mortality worldwide Despite advances screening and treatment of cancer  BCa is still most frequent malignancy accounting more of all cases and leading cause of cancer death females globally  Gynecological cancers GCa or neoplasms of female genital organs ICD C–C include cervical ovarian endometrial vaginal vulvar and fallopian tube cancers which cervical cancer CCa and ovarian cancer OCa are most common cancers females  Tumorigenesis of these cancers is intricate process that is influenced both environmental and genetic factors ranging carcinogens and reproductive factors genetic components  Accumulating evidences supports role genetic predisposition factors epidemiology of BCa and GCa Recently extensive research stressed role of noncoding RNAs especially microRNAs miRNAs carcinogenesis and susceptibility several cancers including BCa and GCa ',\n",
       "  ('1. Introduction',\n",
       "   'sec1-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   1): 'miRNAs are short noncoding RNAs that are involved negatively regulating expression of most proteincoding genes posttranscriptional level  They are engaged complex networks that are responsible tight regulation of important cellular processes that are often altered carcinogenesis utility of miRNAs as early detectors of different cancers is active research Increasing evidence suggest that single nucleotide polymorphisms SNPs influencing miRNA function ie miRNA polymorphisms can provide useful information predict risk of female neoplasms  Recent studies reported several miRNArelated polymorphisms that can play pivotal roles prediction of BCa and GCa risk development and emphasized their utility as reliable genetic markers predicting potential cancer risk  Therefore genetic screening miRNA polymorphisms even childhood or adolescence holds great promise and offers opportunity better define genetic risk female neoplasms exploiting these early predictors of future malignancies However inconsistent findings found literature should be detected and resolved facilitate use of miRNA polymorphisms diagnostics as predictors of future malignancies',\n",
       "  ('1. Introduction',\n",
       "   'sec1-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   2): 'This study represents comprehensive systematic review and metaanalysis of risk of female neoplasms that are associated miRNA polymorphisms We were interested finding which miRNA polymorphisms are hypothesized modify risk of female neoplasms including breast and gynecological cancers literature whether there are sufficient data draw robust conclusions regarding role of miRNA polymorphisms susceptibility different female neoplasms whether miRNA polymorphisms pose ethnicspecific effects susceptibility female neoplasms',\n",
       "  ('2.1. Study Characteristics',\n",
       "   'sec2dot1-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   3): 'shows process of identifying eligible studies total of  records were identified literature search removing duplicate records titles and abstracts of remaining  records were screened and  records were excluded following reasons not genetic association study   review articles   abstracts or conference papers   studying other genes or polymorphisms   studying other diseases   systematic reviews or metaanalyses   and not written English full texts of remaining  records were evaluated and  articles were excluded following reasons insufficient reported data    studying other genes or polymorphisms    not casecontrol design    and duplicate study    Finally total of  articles remained  Taken together association of  miRNA polymorphisms risk of female neoplasms either BCa or GCa was evaluated these articles Metaanalyses were performed miRNA polymorphisms which number of studies per SNP was more one summarizes main characteristics of studies that were included final metaanalysis',\n",
       "  ('2.1. Study Characteristics',\n",
       "   'sec2dot1-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   4): 'The metaanalyses were performed remaining  miRNA polymorphisms These include miRa rs  studies  cases and  controls miRa rs  studies  cases and  controls miRa rs  studies  cases and  controls miR rs  studies  cases and  controls miR rs nine studies  cases and  controls miR rs six studies  cases and  controls miR rs five studies  cases and  controls miR rs five studies  cases and  controls miR rs six studies  cases and  controls miR rs four studies  cases and  controls miR rs four studies  cases and  controls miRbc rs four studies  cases and  controls miRa rs two studies  cases and  controls miR rs two studies  cases and  controls and miR rs two studies  cases and  controls',\n",
       "  ('2.2. miR-146a rs2910164 and the Risk of Female Neoplasms',\n",
       "   'sec2dot2-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   5): 'Twentyeight association studies total of  cases and  controls were included metaanalysis of miRa rs and risk of female neoplasms  and these there were studies that were carried among Asians   Caucasians   Africans   or South Americans genotype counts control group of six studies deviated HardyWeinberg Equilibrium HWE expectations metaanalysis pooling ORGs found no significant association rs and female neoplasms  and  topleft panel ORG CI  –   This result was also confirmed metaanalysis assuming genetic models  Significant heterogeneity was present all genetic models most heterogeneous model being homozygote contrast  Metaregression showed that type of cancers ie BCa or GCa significantly explains part of heterogeneity observed ORG model R test of moderators  No statistical or visual evidence asymmetry of funnel plots was observed All     topleft panel Subgroup analyses  showed that miRa rs might not be associated female cancers Asians Caucasians or Africans Moreover this polymorphism was associated risk of BCa neither Asians nor Caucasians GCa subgroup pooling ORGs of studies yielded significant association  ORG CI  – This indicates that C allele being mutant and G being reference mutational load of miRa rs is associated lower risk of GCa Concordantly recessive model also yielded significant association GCa subgroup  which suggests that women carrying CC genotype of studied polymorphism had lower risk of gynecological cancers those carrying atleast one G allele subgroup analysis that was based on quality of studies showed no difference highquality or lowquality studies which confirms that results of overall analysis might not be influenced lowquality studies Moreover potential influence of excluding HWEdeviated studies was evaluated and results showed that excluding such studies did not alter main conclusions of metaanalysis ORG CI all studies  – HWE studies  – ORG method has shown superior power detecting association when there is deviation HWE  Using approach that was described methods section overall ORG model was screened and study Mashayekhi  was identified as potential influential study exclusion of this study led reduction of heterogeneity tau to  However conclusion of overall ORG model did not alter ORG CI exclusion  – exclusion  –   Moreover this study  was also identified as contributor heterogeneity of BCa subgroup and its exclusion led significant reduction heterogeneity tau to no effect on conclusion ORG CI exclusion  –    I exclusion     I ',\n",
       "  ('2.2. miR-146a rs2910164 and the Risk of Female Neoplasms',\n",
       "   'sec2dot2-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   6): 'Rs substitutes C nucleotide ′ arm of hsamiRa precursor MI G nucleotide  This substitution induces mispairing precursor structure and it affects third base of seed region of hsamiRap MIMAT Accumulating evidence suggests that rs might influence maturation and expression of miRa context dependent paradigm which true effect of either allele might depend on cell type and disease status  Observations that support this paradigm include discrepancies pathological and normal samples terms of miRa genotypeexpression correlation  and opposite effects of rs alleles on miRa expression different cell types or diseases  Moreover miRNAmediated regulation of gene expression has been shown be highly influenced celltype specific conditions  Therefore further functional studies on specific diseasecelltype should be carried to further elucidate rsinduced changes and their effects on disease susceptibility and progress Apart disease susceptibility miRa and rs have also been shown influence proliferation disease progression and survival of cancer patients Tissue overexpression of miRap has been shown contribute proliferation BCa patients  Moreover basallike BCa cells overexpression of miRa confers enhanced tumorigenic potential association altered p status  Triple negative BCa patients higher expression of miRa have lower survival rate and poorer prognosis  As expression of miRNAs is tight regulation different candidate mechanisms may explain upregulation of miRa BCa patients It is not yet clear what extent rs might contribute disturbed regulation of miRa Apart its effect on miRa expression rs may potentially influence repertoire of target genes of miRap  However most studies have focused on leading mature miRNA originated ′ arm of corresponding hairpin and importance of ′ arm miRNAs is just beginning emerge  Future experiments may shed more lights on possible role of miRap or miRa pp ratio development of female neoplasms and influence of rs on miRa function',\n",
       "  ('2.3. miR-196a2 rs11614913 and the Risk of Female Neoplasms',\n",
       "   'sec2dot3-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   7): 'Overall  association studies including  studies on BCa six studies on GCa and one study on both BCa and GCa were included article Linhares et al  is composed of two studies on separate ethnicities these there were studies that were carried among Asians   Caucasians   Africans   South Americans   or nonCaucasian Brazilians genotype counts control group of nine studies deviated HWE expectations metaanalysis of association miRa rs and risk of female neoplasms was carried while using thirtyone studies including  cases and  controls and results revealed significant associations  and  topright panel pooled ORG CI  – results were also significant while assuming homozygote and recessive models  indicating that women carrying TT genotype had lower risk of female neoplasms those carrying atleast one C allele No statistical or visual evidence asymmetry of funnel plots was observed All     topright panel When subgrouped ethnicity modelfree and genetic model approach both concordantly indicated significant association miRa rs and risk of female neoplasms Asians but not Caucasians  When subgrouped based on cancer type only significant association was identified GCa subgroup as shown summary ORG ORG CI  – This polymorphism was not associated BCa either Asians or Caucasians ',\n",
       "  ('2.3. miR-196a2 rs11614913 and the Risk of Female Neoplasms',\n",
       "   'sec2dot3-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   8): 'Excluding lowquality studies led reduction of betweenstudy heterogeneity all contrasts  However results of overall analyses were still significant both modelfree ORG analysis and genetic contrasts  which indicates that inclusion of lowquality studies had no dramatic effect on conclusion of overall metaanalysis Moreover excluding HWEdeviated studies had no dramatic effect on conclusion all studies pooled ORG CI  – HWE studies pooled ORG CI  – Influential analysis  indicated that study  ie study Thakur  might introduce some additional residual heterogeneity ORG model as removing this study would yield considerably smaller estimates of τ Moreover as shown plot of Cook′s distances  this study has considerable influence on fit of model results of ORG model and homozygote model were not stable excluding study number  ORG CI exclusion  – exclusion  –   However recessive model was not affected exclusion of mentioned study and result was still significant while assuming this model OR CI exclusion  –   I  tau exclusion  –   I  tau ',\n",
       "  ('2.3. miR-196a2 rs11614913 and the Risk of Female Neoplasms',\n",
       "   'sec2dot3-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   9): 'The precursor miRNA originated hsamira locus generates two mature miRNAs miRap and miRap studied polymorphism which resided miRap can affect expression and targeting ability of miRa There is kcalmol difference minimum free energy of thermodynamic predicted structure of premiRa either T or C allele suggesting that T allele might reduce stability of premiRa  Indeed experimentations have shown that T allele may diminish processing of premiRNA its mature form and reduce expression of miRa as compared C allele MCF BCa cells transfection of premiraC led higher mature mira expression as compared cells that were transfected premiraT vector  Although rs is resided outside of seed region of miRap studies have shown that this polymorphism might affect binding of this mature miRNA and alter repertoire of target genes of miRa  Expression microarray analysis of MCF BCa cells that were transfected either C or T allele suggested that rs might influence repertoire of target genes of miRa  Similar results were obtained other cancers ',\n",
       "  ('2.4. miR-27a rs895819 and the Risk of Female Neoplasms',\n",
       "   'sec2dot4-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   10): 'Thirteen association studies total of  cases and  controls were included metaanalysis of miRa rs and risk of female neoplasms included studies there were studies that were carried among Asians   Caucasians   Africans   or South Americans   Most of studies evaluated risk of BCa and only one study assessed GCa one study genotype distribution of control group deviated HWE metaanalysis pooling ORGs revealed as significant association miRa rs and female neoplasms  and  bottomleft panel ORG CI  –   However results of pooling effect sizes genetic models showed no significant association  There were significant heterogeneities all analyzed genetic models No statistical or visual evidence asymmetry of funnel plots was observed All     bottomleft panel When subgrouped ethnicity significant associations miRa rs and female neoplasms were observed Caucasians but not Asians  This finding suggests protective role of rsG allele as compared A allele Caucasians and it indicates that Caucasian women carrying atleast one G allele have lower risk of female neoplasms those carrying AA genotype  MiRa rs was also associated risk of BCa both modelfree analysis and genetic contrasts  When BCa studies were subgrouped according ethnicity significant association miRa rs and BCa risk was only observed Caucasians but not Asians  This might indicate ethnicdependent effect of miRa rs on BCa risk However it should be noted that Caucasian studies recruited larger sample sizes relative Asian studies  three Caucasian studies samples relative seven Asian studies samples Therefore association studies recruiting larger samples are needed confirm findings Asians Excluding lowquality studies did not alter results of genetic contrasts  However pooled ORG was borderline nonsignificant excluding lowquality studies pooled ORG CI all studies  – high quality studies  – Excluding HWEdeviated studies did not influence significance of summary ORG pooled ORG CI all studies  – HWE studies  – No individual study was identified as being influential',\n",
       "  ('2.5. miR-499 rs3746444 and the Risk of Female Neoplasms',\n",
       "   'sec2dot5-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   11): 'Eighteen studies containing  cases and  controls were included metaanalysis of association miR rs and risk of female neoplasms  As genotype distributions were not reported manuscript study Kabirizadeh et al was only included allele contrast included studies there were studies that were carried among Asians   Caucasians   Africans   or South Americans   Moreover most studies   evaluated risk of BCa and only few studies   focused on GCa four studies genotype distributions of control group significantly deviated HWE expectations study Kabirizadeh et al computation of HWE test statistics were not possible due insufficient reported data summary ORG was significant ORG CI  –   which indicates that C allele being mutant and T allele being reference mutational load of miR rs is implicated increased susceptibility female neoplasms pooling of effect sizes genetic models revealed that rs was associated risk of female neoplasms while assuming homozygote CC vs TT and allelic models C vs T  suggesting that rsC allele increases risk of female neoplasms as compared T allele No statistical or visual evidence asymmetry of funnel plots was observed All   and  bottomright panel Moreover miR rs was found be associated female neoplasms Asians  ORG CI  – C vs T OR CI  – According summary ORGs miR rs was associated slightly increased risk of BCa  – but not risk of GCa  – association rs and BCa risk did not remain significant excluding few nonAsian studies BCa Asians ORG CI  – exclusion of nonAsian studies led significant reduction total number of cases and controls studies Qian  and Catucci  are two largescale studies carried among nonAsians Africans and Caucasians respectively This might indicate that subtle effect that is imposed rs on risk of BCa is difficult identify when sample size decreases Therefore sufficient data are not available judge possible ethnicspecific effects of rs on risk of BCa More largescale association studies are needed elucidating influence of miR rs on risk of BCa different ethnicities',\n",
       "  ('2.5. miR-499 rs3746444 and the Risk of Female Neoplasms',\n",
       "   'sec2dot5-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   12): 'In sensitivity analysis excluding lowquality studies led significant diminution of heterogeneity all modes of inheritance especially homozygote and recessive models  Excluding lowquality studies did not dramatically influence summary ORG ORG CI all studies  – highquality studies  – Moreover subset of highquality studies miR rs was associated female neoplasms dominant and recessive models addition homozygote and allele contrasts  These results suggest that summary ORG was more robust terms of sensitivity inclusion of lowquality studies when compared genetic models Excluding HWEdeviated studies did not influence magnitude or significance of summary ORG pooled ORG CI all studies  – HWE studies  – No individual study was identified be influential',\n",
       "  ('2.5. miR-499 rs3746444 and the Risk of Female Neoplasms',\n",
       "   'sec2dot5-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   13): 'Members of human miR precursor family hsapremira and hsamirb are encoded opposite strands of intronic region of gene  According miRBase database  four mature miRNAs namely miRbp miRbp miRap and miRap are generated this region two each precursor Recent studies have provided evidence supporting functional role of mature miRNAs originating both arms of precursor miRNA  While most studies focused on function of miRap evidence supporting importance of miRap are beginning emerge  Given that rs overlaps seed region of miRap on forward strand and ′ portion of miRbp on reverse strand it might influence processing andor pp balance of both precursors It has been shown that rs C allele might lead lower miRap expression breast tissues  which suggests mechanism increased BCa risk associated this allele However it is not yet clear whether rs interfere miRap targeting and what implications of these changes female neoplasms',\n",
       "  ('2.6. miR-423 rs6505162 and the Risk of Female Neoplasms',\n",
       "   'sec2dot6-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   14): 'Nine studies containing  cases and  controls were included metaanalysis of association miR rs and risk of female neoplasms included studies there were studies carried among Asians   Caucasians   Africans   or South Americans   Eight studies explored association of rs and BCa and one study evaluated both BCa and GCa one study genotype distributions of control group significantly deviated HWE expectations  Metaanalysis using summary ORG and summary OR different genetic models showed no evidence of association miR rs and female neoplasms  and  topleft panel Significant heterogeneity was present all models except recessive model subgroup analysis revealed no significant associations BCa and Asians subgroups Moreover excluding HWEdeviated study did not dramatically alter summary ORG pooled ORG CI all studies  – HWE studies  –',\n",
       "  ('2.7. miR-149 rs2292832 and the Risk of Female Neoplasms',\n",
       "   'sec2dot7-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   15): 'Six studies containing  cases and  controls were included metaanalysis of association miR rs and risk of female neoplasms included studies there were studies that were carried among Asians   or Caucasians   Five studies explored association of miR rs and BCa and one study evaluated both BCa and GCa two studies genotype distributions of control group significantly deviated HWE expectations  Metaanalysis using summary ORG and summary OR different genetic models showed no evidence of association miR rs and female neoplasms  and  topright panel Significant heterogeneity was present homozygote τ recessive τ  and allelic τ  models  all   Moreover excluding HWEdeviated study did not alter significance of summary ORG pooled ORG CI all studies  – HWE studies  –',\n",
       "  ('2.8. miR-605 rs2043556 and the Risk of Female Neoplasms',\n",
       "   'sec2dot8-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   16): 'Five studies containing  cases and  controls were included metaanalysis included studies there were studies that were carried among Asians   Africans   or South Americans   All of studies explored association miR rs and BCa three studies genotype distributions of control group significantly deviated HWE expectations  Metaanalysis using ORG and OR different genetic models showed that miR rs was not associated BCa overall studies  and  bottomleft panel or BCa Asians  Although ORG method has been shown be less sensitive HWEdeviation  it should be noted that limited number of studies and high proportion of HWEdeviated studies might prevent drawing robust conclusion addition this study did not identify any association study exploring role of miR rs susceptibility gynecological cancers Therefore more studies are needed clarify potential contribution of rs female neoplasms',\n",
       "  ('2.9. miR-608 rs4919510 and the Risk of Female Neoplasms',\n",
       "   'sec2dot9-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   17): 'Five studies containing  cases and  controls were included metaanalysis included studies there were studies that were carried among Asians   or South Americans   All of studies explored association miR rs and BCa Metaanalysis using ORG and OR different genetic models showed that miR rs was not associated BCa all studies  and  bottomright or BCa Asians  However it should be noted that limited number of studies might prevent drawing robust conclusion addition this study did not identify any association study exploring role of rs susceptibility gynecological cancers Therefore more studies are needed clarify potential contribution of miR rs female neoplasms',\n",
       "  ('2.10. miR-100 rs1834306 and the Risk of Female Neoplasms',\n",
       "   'sec2dot10-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   18): 'Six studies containing  cases and  controls were included metaanalysis article Yao et al is composed of two studies on separate ethnicities  Two studies were only included recessive model as sufficient data calculating effect size other models were not provided articles included studies there were studies that were carried among Asians   AfricaAmericans   or EuropeanAmericans   Four studies explored association of miR rs and BCa and two studies evaluated GCa According quality scores  all of studies were considered be high quality one studies genotype distributions of control group significantly deviated HWE expectations  Metaanalysis using ORG and OR different genetic models showed that miR rs was not associated female neoplasms  and  topleft panel Moreover excluding HWEdeviated study did not alter significance of summary ORG pooled ORG CI all studies  – HWE studies  – It should be noted that more association studies are needed enable drawing robust conclusion',\n",
       "  ('2.11. miR-124 rs531564 and the Risk of Female Neoplasms',\n",
       "   'sec2dot11-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   19): 'Four studies containing  cases and  controls were included metaanalysis  All of studies were performed Asians Two studies explored association rs and BCa and two studies evaluated GCa cervical cancer According quality scores  three of four studies were considered be high quality summary ORG revealed no evidence association miR rs and female neoplasms ORG CI  – However summary ORs were significant while assuming homozygote  topright panel and recessive models  which suggests that women GG genotype had lower risk of female neoplasms as compared those carrying CC genotype  –   or compared women carrying least one C allele   –   Excluding lowquality study did not influence conclusion and results remained significant homozygote and recessive models  Future experiments may benefit performing genetic association studies nonAsian ethnicities and exploring contribution of rs risk of other types of female neoplasms More studies are needed draw definite conclusions regarding contribution of this polymorphism susceptibility female neoplasms',\n",
       "  ('2.12. miR-218 rs11134527 and the Risk of Female Neoplasms',\n",
       "   'sec2dot12-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   20): 'Four studies containing  cases and  controls were included metaanalysis  All of studies were carried among Asians One study explored association miR rs and BCa and three studies evaluated GCa cervical cancer According quality scores  all of studies were considered be highquality metaanalysis using ORG revealed no evidence association rs and female neoplasms  and  bottomleft panel ORG CI  – Consistently summary ORs assuming genetic models were not significant  which suggests that this polymorphism does not contribute risk of female neoplasms When three studies on cervical cancer were pooled no significant association was observed  Given that only one study was focused on BCa definite conclusion regarding association miR rs and BCa might not be drawn this metaanalysis Moreover all of studies were carried among Asians and there are no data regarding possible involvement of miR rs susceptibility female neoplasms other ethnicities Although current data suggest lack of association rs and female neoplasms especially cervical cancer Asians performing more genetic association studies is necessary obtain more robust conclusion',\n",
       "  ('2.13. miR-34b/c rs4938723 and the Risk of Female Neoplasms',\n",
       "   'sec2dot13-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   21): 'Four studies containing  cases and  controls were included metaanalysis article Bensen et al is composed of two studies on separate ethnicities  There were studies carried among Asians   Caucasians   and AfricanAmericans   Three studies explored association miRbc rs and BCa and one study evaluated GCa ie cervical cancer metaanalysis using ORG revealed no evidence association miRbc rs and female neoplasms  and  bottomright panel ORG CI  – Consistently summary ORs assuming genetic models were not significant  which suggests that this polymorphism does not contribute risk of female neoplasms Excluding lowquality study did not influence overall results highquality studies ORG CI  – I  No significant association was observed when three studies on BCa were pooled  Given that only three studies were focused on BCa definite conclusion regarding association miRbc rs and BCa might not be drawn this metaanalysis Although current data suggest lack of association miRbc rs and female neoplasms especially cervical cancer performing more genetic association studies is necessary obtaining more robust conclusion',\n",
       "  ('2.14. miR-26a-1 rs7372209, miR-373 rs12983273, miR-618 rs2682818 and the Risk of Female Neoplasms',\n",
       "   'sec2dot14-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   22): 'Two studies were included metaanalysis of association each of these miRNA polymorphisms and risk of female neoplasms  rs  rs  rs each case included studies were compatible HWE expectations and considered be highquality according quality scores metaanalyses using either summary ORGs or summary ORs genetic models yielded no significant association these polymorphisms and female neoplasms  and  It should be noted that heterogeneity might not be precisely estimated presence of limited number of studies Therefore results should be treated caution Future association studies may shed more lights on contribution of these miRNA polymorphisms risk of female neoplasms',\n",
       "  ('2.14. miR-26a-1 rs7372209, miR-373 rs12983273, miR-618 rs2682818 and the Risk of Female Neoplasms',\n",
       "   'sec2dot14-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   23): 'In conclusion this study systematically identified  miRNA polymorphisms that were evaluated possible contribution risk of female neoplasms ie breast cancer and gynecological cancers majority of studied polymorphisms   sufficient data performing metaanalysis were not available and therefore no conclusion regarding contribution of these polymorphisms risk of female neoplasms was drawn current study following conclusions may be obtained based on results of this study concerning  miRNA polymorphisms that were included metaanalysis most miRNA polymorphisms breast cancer was most studied cancer followed cervical or ovarian cancer studies that were included metaanalysis Only few studies were focused on other types of gynecological cancers and different types of gynecological cancers were less studied breast cancer Moreover it should be noted that this study did not adjust covariates age and gender or interaction environmental factors and it was based on unadjusted summary effects of original studies Designing flexible platform data harmonization might provide feasibility of performing metaanalysis of individual patient data which allows testing of interactions covariates results of this metaanalysis suggest that miRa rs is implicated susceptibility gynecological cancers load of rsC allele could be associated decreased risk of gynecological cancers This study also suggests that miRa rsT allele has moderate protective effect development of female neoplasms Asians but not Caucasians This moderate effect vanishes breast cancer subgroup possibly due reduction of sample size ie total number of cases and controls load of miRa rsT allele could be associated decreased risk of gynecological cancers Regarding miRa rs G allele might pose protective effect female neoplasms especially breast cancer Caucasians C allele of miR rs may slightly increase risk of female neoplasms especially breast cancer G allele of miR rs might be associated lower risk of female neoplasms homozygote and recessive models However larger samples are needed confirm this finding current evidences do not support association of remaining polymorphisms and risk of female neoplasms ie miR rs miR rs miR rs miR rs miR rs miR rs miRbc rs miRa rs miR rs and miR rs',\n",
       "  ('3.1. Search Strategy ',\n",
       "   'sec3dot1-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   24): 'Embase PubMed ScienceDirect and Scopus were searched according specific search tips of each database identify all potentially eligible publications databases last search  March following keywords or MeSH terms were used Cervical Cancer OR Uterine Cervical Neoplasms OR Cervix Uteri Cancer OR Ovarian Cancer OR Fallopian Tube Neoplasms OR Endometrial Neoplasms OR Uterine Neoplasms OR Uterine Serous Carcinoma OR Corpus Uteri Cancer OR Vaginal Neoplasms OR Vulvar Neoplasms OR Breast Cancer OR Breast Carcinoma OR Breast Neoplasms AND miRNA OR microRNA OR premir OR miR AND Single nucleotide polymorphism OR SNP OR variant OR variation OR polymorphism OR mutation OR locus References of previous metaanalysis review articles or other relevant articles were also manually screened identify potentially eligible articles This metaanalysis was carried in accordance Preferred Reporting Items Systematic Reviews and MetaAnalyses PRISMA statement ',\n",
       "  ('3.2. Inclusion and Exclusion Criteria',\n",
       "   'sec3dot2-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   25): 'Studies meeting all of following criteria were included casecontrol study evaluating association polymorphism any miRNA gene and susceptibility female neoplasms ICD C C–C including breast cancer ICD C and tumors of female genital tract  availability of genotype count data estimating odds ratio OR and its  confidence interval CI fulltext article is written English and minimum of two studies per each miRNA polymorphism should be met include polymorphism metaanalysis Studies that met any of following criteria were excluded  metaanalysis review articles or abstracts  duplicate publications  studies on animals or celllines  studies casecontrol design  studies that did not report genotype counts or allele frequencies  studies investigating survival progression or severity of disease and article was not written English',\n",
       "  ('3.3. Data Extraction and Quality Assessment',\n",
       "   'sec3dot3-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   26): 'Each eligible study was screened and following items were recorded first author publication year country ethnicity cancer type source of controls miRNA name polymorphism ID genotyping method genotype counts each SNP and number of cases and controls recruited quality of each study was assessed while using modified version of quality assessment criteria genetic association studies used elsewhere  that scores lowest highest Studies that were scored equal or less eight were regarded low quality while those scores of nine or higher were regarded high quality',\n",
       "  ('3.4. Data Analysis',\n",
       "   'sec3dot4-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   27): 'Associations of miRNA polymorphisms female neoplasms are represented pooling odds ratios ORs and their  confidence intervals  CIs assuming five genetic models homozygote BB vs AA heterozygote AB vs AA dominant BBAB vs AA recessive BB vs AAAB and allelic B vs Moreover generalized odds ratio ORG which is modelfree measure of genetic risk effect was also used evaluate association miRNA polymorphisms and female neoplasms ORG expresses association estimating overall risk effect while considering complete genotype distribution and it indicates whether mutational load of polymorphism is involved disease susceptibility chisquared based Q test and I were used assess significance of heterogeneity and Z test was performed assess significance of pooled ORs    was considered be statistically significant Considerable heterogeneity was expected studies because of differences sources of control group and other sample characteristics Therefore randomeffects model RE DerSimionian–Laird estimator was used calculate summary effects all cases case of genetic models method Hartung and Knapp was used adjusting test statistics and confidence intervals ',\n",
       "  ('3.4. Data Analysis',\n",
       "   'sec3dot4-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   28): 'Univariate metaregression was carried to identify potential sources of heterogeneity Subgroup analyses that were based on cancer type ethnicity and study quality were also performed When examining and interpreting asymmetry of funnel plots recommendations of other investigators have been followed  As statistical tests of funnel plot asymmetry have low test power distinguish chance real asymmetry when there are fewer studies metaanalysis such tests were only performed metaanalysis of ≥ studies method that was proposed Harbord et al  which is weighted linear regression test utilizing efficient score and score variance was used assess asymmetry funnel plots when estimated heterogeneity variance of log odds ratios τ was ie absence of substantial heterogeneity presence of substantial heterogeneity ie when τ method that was proposed Rücker et al arcsine test that explicitly models betweenstudy heterogeneity was employed prevent issues regarding false positive results that may raise presence of high heterogeneity Funnel plots were visually inspected further assist interpretation of mentioned statistical tests',\n",
       "  ('3.4. Data Analysis',\n",
       "   'sec3dot4-ijms-20-05088',\n",
       "   'no_sub_id',\n",
       "   29): 'Genotype frequencies of polymorphisms control group of each study were assessed departure HWE expectations while using exact goodness of fit test following approach was employed deal studies which genotype counts control groups deviated HWE expectations ie HWEdeviated studies HWEdeviated studies were not excluded metaanalyses However sensitivity analysis was performed evaluate possible influence of excluding HWEdeviated studies on pooled ORG and corresponding  CIs When more ten studies were included metaanalysis influential study diagnostics modelfree approach were computed using metafor package R following diagnostic measures were computed and plotted externally standardized residuals rstudent DFFITS values Cook′s distances cookd covariance ratios covr DFBETAS values estimates of τ when each study is removed turn test statistics residual heterogeneity when each study is removed turn diagonal elements of hat matrix and weights that are given observed outcomes model fitting DIFFITS value of study represents how much predicted pooled effect changes excluding this study  Cook′s distance measures effect of deleting given observation calculating distance value once study is included as compared when it is excluded covariance ration is determinant of variancecovariance matrix of parameter estimates when study is removed divided determinant of variancecovariance matrix of parameter estimates when full dataset is considered study was considered be probably influential if least one of following was true  i absolute DFFITS value is larger √pkp where p is number of model coefficients and k is number of studies ii lower tail area of chisquare distribution p degrees of freedom cut off Cook′s distance is larger iii hat value is larger pk iv Any DFBETAS value is larger ORG and its  CI were calculated using ORGGASMA   All other statistical analyses were carried while using Meta package R R version  '},\n",
       " {('INTRODUCTION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   0): 'The burden of noncommunicable diseases NCDs continues show strongly disproportionate growth relative population size irrespective of global efforts WHO estimated that  of million global deaths were due NCDs of which  million  were premature deaths majority of these premature deaths are estimated have occurred Africa where NCDs are associated higher mortality in highincome countries disability burden of NCDs subSaharan Africa to  showed increase disabilityadjusted lifeyears DALYs million DALYs to  million DALYs It is estimated that of all deaths Africa will be attributed NCDs Ghana NCDs accounted of all deaths Cancers particular show increased numbers globally as well Ghana Ghana recorded  incident cancer cases corresponding mortality of more two thirds  of incident cases Unfortunately GLOBOCAN estimates used only data one of two cancer registries Ghana which could have affected their estimates Additionally reported mortality estimates were based on modeling of mortality incidence cancer registry data neighboring countries Maintaining cancer registry nationwide coverage comes high cost low and middleincome countries LMICs alternative already existing data source gain information on cancer burden is routine health care data on hospitalizations',\n",
       "  ('INTRODUCTION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   1): 'Because of increasing burden of NCDs it is imperative that health services plan and allocate resources accordinglyboth treatment and prevention measures However this requires accurate and reliable estimates of future burden of disease Routine health service delivery data are increasingly available but have been widely underused research purposes especially LMICs potential benefits gained using these routinely collected health data sets health services include morbidity and mortality estimation specific geographic regions planning of resource allocation and acquisition and distribution of essential medical drugs beds and consumables Administrative health data can also support research aiding public health and health care decisions and policy Ghana Statistical Service data on vital statistics and population data and Ghana Health Service GHS District Health Information Management System  DHIMS database are two examples of databases that contain nationwide information on vital statistics and patient health records',\n",
       "  ('INTRODUCTION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   2): 'Cancer continues be second leading cause of NCD morbidity and mortality globally accounting million  annual deaths about  million  of these deaths LMICs Cancer is estimated account annual deaths Ghana Several small and nonrepresentative hospitalbased studies have indicated that cancer of breast prostate and cervix are leading neoplasms responsible hospital admissions However reliable nationwide data Ghana are missing such that there is large uncertainty future cancerrelated morbidity mortality and hospitalizations Similar previous data sets used estimating NCD burden DHIMS data set is promising candidate but has not yet been applied detail situation Ghana Hence our study aimed provide reliable nationwide age sex and regionspecific estimates of current and future burden of hospitalization because of neoplasms Ghana',\n",
       "  ('Study Setting and Data Sources',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   3): 'This study was based on data two sources First inpatient data on neoplasms were extracted GHS DHIMS database DHIMS is based on District Health Information System  developed University of Oslo Norway which is widely used LMICs It covers inpatient data entered more users over  universityteaching regional district and missionprivate hospitals Ghana Clinicians or data entry staff are supposed code patient diagnoses DHIMS according WHO International Statistical Classification of Diseases and Related Health Problems International Classification of Diseases th Revision ICD classification However this is not always case as some of diagnoses are captured as free text ICD codes DHIMS is improvement of DHIMS which lacks ICD codes and is not user friendly Ghana neoplasmrelated diagnoses vary considerably different types of hospitals instance benign and malignant excisions are done medical officers district hospitals and sent histopathology another hospital or laboratory capacity do test Although benign tumors are managed local hospitals malignant tumors generally are referred larger and teaching hospitals regional hospitals which serve as referral points district hospitals neoplasms requiring excisions are treated surgeons histopathology and management either done hospital or referred specialized center Ghana does not have national cancer registry and two populationbased registries are either not well defined or limited scope in most LMICs DHIMS is one of few nationwide data sources diseasespecific hospitalizations globally Hence our study  variables on hospital admission and discharge including sociodemographic characteristics were extracted national data manager assistance principal investigator Second Ghana Statistical Service provided past and future projected counts countrys population region age and sex',\n",
       "  ('Study Population',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   4): 'The study participants included patients hospitalized all types of neoplasms hospitals and  recorded DHIMS database Patients missing data on age sex or date of admission were excluded as these could be described as missing random',\n",
       "  ('Statistical Analysis',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   5): 'All neoplasms were defined principal diagnosis hospitalization according ICD neoplasm codes CD Missing ICD codes captured as free text approximately  were manually assigned on basis of free text where possible Hospitalization duration was defined as difference date of admission and discharge plus one Each episode of hospitalization was treated as unique record as our data did not distinguish multiple visits per patient sociodemographic characteristics of patients were stratified malignancy category that is malignant CC benign DD and neoplasms of uncertain or unknown behaviors DD We modeled rate of hospitalizations because of neoplasms and  using Poisson regression robust sandwich estimator account overdispersion Our choice of Poisson regression is report empirical and predict future rates of neoplasm hospitalizations as count data compared other models Modeling future hospitalization rates is useful hospital managers and policymakers resource allocation three malignancy groups malignant benign and neoplasms of uncertain or unknown behaviors were treated as categorical outcomes three separate models Covariates model included calendaryear quantitative reference year  age categorized year age groups age  years as reference group sex reference group male region  categories Greater Accra region as reference group as well as interaction term age and sex Log population count was used as offset This model was used predict future hospitalization counts three broad groups of neoplasms on basis of projected population data',\n",
       "  ('Statistical Analysis',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   6): 'For predictions we assumed no effect of calendar year beyond  This assumption implies that any previous secular trend health care delivery or diagnostic quality associated neoplasmrelated hospitalization rates reached plateau assumption also implied that potential risk factors neoplasm incidence not included regression model would remain constant Hence only variables accommodated future changes associated neoplasm hospitalization rate were projected population counts per region age and sex We assessed how well model fits our data using visual inspection of Pearson residual plot each group of neoplasms',\n",
       "  ('Statistical Analysis',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   7): 'We report empirical  and predicted  hospitalization counts CIs and corresponding values as well as relative rates RRs CI and values Wald tests',\n",
       "  ('Statistical Analysis',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   8): 'Data cleaning analysis and predictions were performed using Stata v Stata codes as well as GHS patient and Ghana Statistical Service population data sets can be obtained principal investigator request',\n",
       "  ('Statistical Analysis',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   9): 'The study was approved GHS Ethics Review Committee GHSERC ',\n",
       "  ('Participants',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   10): 'A total of  inpatient records were identified to excluding all cases other diagnoses n =  records incomplete data n = \\u202c and duplicate records n = study population comprised  records of hospitalization neoplasms Fig overall sociodemographic characteristics of patients are presented Table  and detailed breakdowns of all neoplasms are shown Appendix Table A',\n",
       "  ('Description of Patients Hospitalized for Neoplasms',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   11): 'From Table of hospitalization records analyzed this study   were due malignant disease   due benign neoplasms and   due neoplasms of unknown or uncertain behaviors DD median age patients malignancies was  years interquartile range IQR  years patients benign neoplasms was  years IQR  years and patients neoplasms of uncertain or unknown behaviors was  years IQR  years median duration of hospitalization was  days irrespective of malignancy status However IQR patients malignancies ranged to  days and that of patients benign disease ranged to median duration of stay was  days patients neoplasms of unknown or uncertain behaviors patients malignant and benign diseases annual number of hospitalizations increased and to   and respectively Although there was increase hospitalization because of neoplasms of unknown or uncertain behaviors DD to  it kept fluctuating subsequent years',\n",
       "  ('Description of Patients Hospitalized for Neoplasms',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   12): 'The regional hospitalization rates showed that Volta region recorded highest proportions of admissions both malignant   and benign disease   admissions patients neoplasms of unknown or uncertain behaviors most of records were Greater Accra region   Most of patients any of neoplasms either had no education   or completed primary education   Unemployment and health insurance ownership were reported majority of patients   and   Comorbidity   and case fatality   were highest patients malignancies lowest comorbidity proportion was patients neoplasms of uncertain or unknown behaviors   and lowest case fatality patients benign disease this was nationwide study hospitals classified as districtgovernmentmunicipal   or regional   accounted most hospitalizations especially those because of benign neoplasms six universityteaching hospitals included study recorded more neoplasms of uncertain or unknown behaviors   malignant   and benign remaining sections of results focus on malignant neoplasms as benign tumors could be described as mainly precancerous lesions',\n",
       "  ('Modeling Past Hospitalizations (2012-2017)',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   13): 'The Poisson regression hospitalization because of any neoplasm showed annual RR of   CI overall rate of female patients was three times compared that of male patients RR   CI modified age agesexspecific strata females age groups  years years have higher RRs and  compared males other age groups females have lower agesexspecific strata RRs and  compared males remaining overall results are shown Figure and Appendix Table A',\n",
       "  ('Modeling Past Hospitalizations (2012-2017)',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   14): 'The annual RR hospitalization because of malignant neoplasms CC was   CI For malignant neoplasms RR female patients compared male patients was   CI = ',\n",
       "  ('Modeling Past Hospitalizations (2012-2017)',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   15): 'Compared patients age  years diagnosed malignant younger patients had lower hospitalization rates and older patients had higher hospitalization rates younger patients malignant diagnoses RRs ranged to  years RR   CI to  years RR   CI whereas much higher rates were observed older patients range of RR   CI from years RR   CI among patients age  years RRs each neoplasm category increased age especially highrisk group compared patients age  years Fig and Appendix Table A',\n",
       "  ('Modeling Past Hospitalizations (2012-2017)',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   16): 'All regions except Eastern Region showed statistically significant RR compared Greater Accra region reference region highest RR   CI =  and lowest RR   CI for hospitalization because of malignant neoplasms were Volta and Upper West regions respectively',\n",
       "  ('Modeling Past Hospitalizations (2012-2017)',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   17): 'The RRs age and sex interaction were significantly lower females   years and those years malignancies Rates other neoplasms are shown Figure and Appendix Table A',\n",
       "  ('Predicting Future Neoplastic Hospitalizations (2022-2032)',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   18): 'We present predictions of malignant neoplasms CC here whereas predictions of benign and neoplasm of uncertain or unknown behaviors are shown Appendix Figures and A',\n",
       "  ('Predicting Future Neoplastic Hospitalizations (2022-2032)',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   19): 'The visual inspection of Pearson residual plot each group of neoplasms showed no variation observed and fitted values according Appendix Figures AAAC',\n",
       "  ('Predicting Future Neoplastic Hospitalizations (2022-2032)',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   20): 'From annual number of hospitalizations males were   malignant malignant and females   malignant malignant We predict that yearly number of hospitalizations of male patients malignant neoplasm will be   CI corresponding increase compared For females we predict   CI hospitalizations representing increase compared For projected number of hospitalizations of male patients malignant neoplasm is   CI corresponding increase compared For females prediction is   CI representing increase compared In corresponding predictions are   CI for males and   CI for females Fig and Table  representing and  increase males and females respectively compared ',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   21): 'We demonstrated usefulness of routinely collected health data estimating current and future burden because of hospitalizations neoplasms Ghana absence of national populationbased cancer registry our knowledge our study is first provide nationwide estimate of hospitalizations all different neoplasms different hospital types Ghana documented annual number of all hospitalizations of patients neoplasms increased in  years increase was largely influenced benign tumors This large increase could partly be explained ambitious efforts GHS improve its health information system It should be noted that only hospitalization rates are available national level as no national cancer registry currently exists Additionally cancers and other NCDs subSaharan Africa are estimated increase',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   22): 'The burden because of hospitalization of women neoplasms was three times higher that of men consistent results smaller studies on demographics of patients cancer However rates hospitalization of female patients malignant disease were twice that men whereas hospitalization rates of women benign disease were six times those of their male counterparts higher proportion of female patients neoplasms was obvious regions of Ghana which could probably be explained high cervical and breast neoplasms This distribution is also consistent different hospital types involved study Patients malignancies were decade older other patients our study contrast previous smaller studies Ghana On basis of regional population distribution one would expect that highest number of all neoplasms would have been recorded Greater Accra and Ashanti regions However this was not case highest number of hospitalizations both malignant and benign neoplasms was Volta region Presumably this could be due specialized hospital foreign assistance caring patients fibroid making hospital accessible whole country especially people of Greater Accra region and Republic of Togo Also probable reason low number of hospitalizations two biggest regions Greater Accra and Ashanti could be due teaching hospitals associated cancer registries these two regions which do not contribute data DHIMS',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   23): 'The overall high increase observed and predicted burden of different neoplasms could be plausibly because of high burden of leiomyoma of uterus unspecified and female malignant neoplasm of breast cervix uteri prostate and ovary compared other neoplasms',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   24): 'The Poisson regression model showed RR  increase annual rates malignant neoplasm admissions over years Volta region recorded highest RRs of patients malignancies stronger increase hospitalization rates of patients ages  and  years malignant neoplasm and neoplasms of uncertain or unknown behaviors reflects general age distribution of cancer incidence previously reported some teaching hospitals Ghana',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   25): 'We predicted number of neoplasticrelated hospitalizations over  years on basis of available population forecast this time period Nevertheless limiting prediction shorter time interval is preferred because of large uncertainties very longterm population estimates our predictions we estimated that  and  male and female patients malignant cancers would be hospitalized Subsequently yeartoyear relative increase number of predicted hospitalization counts increases in in  and doubles for patients malignancies Hospitalizations of male patients were predicted slightly increase compared for females These estimates were made assuming that same level of health care delivery is maintained as is doctortopatient ratio health education and availability of health facilities and lifestyle risk factors remain unchanged year  was chosen as reference year as DHIMS database had incomplete data Assuming constant external factors on hospitalization because of neoplasms leaving only demographic development driving change hospitalization rates onward represents conservative compromise given large uncertainty making specific predictions relevant individual influences It aims balance possibly increasing trend health care availability possible success of prevention efforts reducing all neoplasm incidence We also did not provide predictions years because this period elapsed while our study was ongoing',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   26): 'In line similar global estimates we extended our predictions years although this increases uncertainty Our longterm predictions aim raise awareness of expected increase burden of all neoplasms inpatients different regions and corresponding challenges health services planning Our predictions will also allow future comparison studies observed data benchmark and validate attempts use administrative health data future resource planning',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   27): 'The overall increase estimated burden of different neoplasms hospitalized patients is consistent globally estimated cancer burden',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   28): 'It should be noted that we were not able calculate incidence rates and that hospitalization may only be partly correlated incidence major limitation of this study is fact that most of neoplasms especially malignancies were diagnosed as unspecified addition two biggest teaching hospitals Ghana do not contribute data on neoplasms DHIMS database However majority of inpatients these two hospitals also receive medical care majority of hospitals involved this study patient referral Also of benign cases teaching hospitals are referred district and regional hospitals minimizing effect further However effect on our estimates regards hospitalization because of malignant neoplasms may be moderate Further limitations are implied unavailability of modifiable risk factors DHIMS database our study population This could bias prediction case of drastic change these factors Another important fact consider is dominance of fibroid breast cervical and prostate cancers which when detected early can reduce overall number of hospitalizations',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   29): 'The interpretation of our predictions must be done caution as future changes diagnostic therapeutic and preventive conditions could result higher or lower hospitalization rates Our prediction of neoplasmrelated hospitalization rates Ghana is essential support public health measures planning hospitals capacity admit increasing number of neoplastic patients and estimate national burden of all neoplasms hospitalized patients',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   30): 'In conclusion reported study has three major implications resource allocation improved data on all neoplasmrelated hospitalizations and neoplasmrelated policies Ghana and usefulness of routine health databases First projected nationwide hospitalization trend malignant cancers benign and neoplasms of uncertain or unknown behavior could be used efficient health care planning resource allocation and hospital management Second data this study are strong contribution body of knowledge on types of neoplasms Ghana and usefulness of DHIMS database Finally empirical and estimated hospitalizations because of neoplasms could possibly be used prioritizing neoplasmrelated policies such as early detection measures prevention programs and outpatient management',\n",
       "  ('DISCUSSION',\n",
       "   'no_id',\n",
       "   'no_sub_id',\n",
       "   31): 'Although not all private hospitals admitting patients neoplasms contribute data GHS database we believe that all regional district mission and private hospitals on DHIMS platform are adequate us generalize our findings cover whole country evidence our study also paves way future nationwide studies assessing diagnostic treatment and management capacities of various hospitals other teaching hospitals which neoplastic patients seek care'}]"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5ec2aaae",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3.10 (biomed)",
   "language": "python",
   "name": "biomed"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
